0001193125-22-106907.txt : 20220415 0001193125-22-106907.hdr.sgml : 20220415 20220415171118 ACCESSION NUMBER: 0001193125-22-106907 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220415 DATE AS OF CHANGE: 20220415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALPHA HEALTHCARE ACQUISITION CORP III CENTRAL INDEX KEY: 0001842939 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40228 FILM NUMBER: 22830585 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 646-494-3296 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 10-K 1 d268885d10k.htm FORM 10-K Form 10-K
falseFY0001842939falseAn aggregate of 4,312,500 shares of Class B common stock were originally issued, of which 562,500 shares were subject to forfeiture depending on whether the over-allotment option was exercised in full or in part by the underwriters during the 45-day option period. As a result of a partial over-allotment option exercise by the underwriters, an aggregate of 451,474 shares were forfeited at the end of the 45-day option period. 0001842939 2021-01-21 2021-12-31 0001842939 2021-12-31 0001842939 2021-06-30 0001842939 2021-09-09 2021-09-09 0001842939 2021-08-03 2021-08-03 0001842939 2021-01-20 0001842939 us-gaap:CommonClassBMember 2021-12-31 0001842939 us-gaap:CommonClassAMember 2021-12-31 0001842939 us-gaap:CommonClassBMember us-gaap:OverAllotmentOptionMember 2021-12-31 0001842939 us-gaap:IPOMember 2021-12-31 0001842939 us-gaap:OverAllotmentOptionMember alpau:PrivatePlacementWarrantsMember 2021-12-31 0001842939 alpau:SponsorMember us-gaap:CommonClassAMember 2021-12-31 0001842939 alpau:SponsorMember alpau:PromissoryNoteMember 2021-12-31 0001842939 alpau:WorkingCapitalLoanMember 2021-12-31 0001842939 alpau:UnderwritingAgreementMember us-gaap:OverAllotmentOptionMember 2021-12-31 0001842939 us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember 2021-12-31 0001842939 alpau:FounderMember us-gaap:CommonClassAMember 2021-12-31 0001842939 us-gaap:WarrantMember 2021-12-31 0001842939 alpau:RedemptionOfWarrantsBelowUsDollarNinePointTwoZeroMember 2021-12-31 0001842939 alpau:RedemptionOfWarrantsEqualsOrExceedsUsDollarEighteenPointZeroZeroMember 2021-12-31 0001842939 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001842939 us-gaap:PrivatePlacementMember 2021-12-31 0001842939 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001842939 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001842939 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001842939 us-gaap:DomesticCountryMember 2021-12-31 0001842939 us-gaap:WarrantMember 2021-01-21 2021-12-31 0001842939 us-gaap:CapitalUnitsMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-01-21 2021-12-31 0001842939 us-gaap:AdditionalPaidInCapitalMember 2021-01-21 2021-12-31 0001842939 us-gaap:PrivatePlacementMember 2021-01-21 2021-12-31 0001842939 us-gaap:PrivatePlacementMember us-gaap:AdditionalPaidInCapitalMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassAMember us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2021-01-21 2021-12-31 0001842939 alpau:ClassACommonStockSubjectToPossibleRedemptionMember us-gaap:CommonStockMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassAMember 2021-01-21 2021-12-31 0001842939 alpau:PublicWarrantsMember 2021-01-21 2021-12-31 0001842939 alpau:PrivatePlacementWarrantsMember alpau:SponsorMember 2021-01-21 2021-12-31 0001842939 us-gaap:IPOMember 2021-01-21 2021-12-31 0001842939 alpau:PublicWarrantsMember alpau:ClassACommonStockSubjectToPossibleRedemptionMember 2021-01-21 2021-12-31 0001842939 alpau:ClassACommonStockSubjectToPossibleRedemptionMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassAMember alpau:SponsorMember 2021-01-21 2021-12-31 0001842939 alpau:OfficeSpaceAdministrativeAndSupportServicesMember 2021-01-21 2021-12-31 0001842939 alpau:SponsorMember 2021-01-21 2021-12-31 0001842939 us-gaap:OverAllotmentOptionMember alpau:UnderwritingAgreementMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassAMember alpau:RedemptionOfWarrantsEqualsOrExceedsUsDollarEighteenPointZeroZeroMember 2021-01-21 2021-12-31 0001842939 alpau:RedemptionOfWarrantsEqualsOrExceedsUsDollarEighteenPointZeroZeroMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassBMember 2021-01-21 2021-12-31 0001842939 us-gaap:AdditionalPaidInCapitalMember alpau:PublicWarrantsMember 2021-01-21 2021-12-31 0001842939 us-gaap:RetainedEarningsMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-01-21 2021-12-31 0001842939 alpau:ClassACommonStockSubjectToPossibleRedemptionMember us-gaap:IPOMember 2021-01-21 2021-12-31 0001842939 us-gaap:MeasurementInputExpectedTermMember 2021-01-21 2021-12-31 0001842939 alpau:OverallotmentLiabilityMember 2021-01-21 2021-12-31 0001842939 alpau:ForwardPurchaseAgreementMember 2021-01-21 2021-12-31 0001842939 alpau:RiskIncentivePrivateSharesMember us-gaap:IPOMember alpau:SponsorMember alpau:FounderMember 2021-07-29 2021-07-29 0001842939 alpau:NonriskIncentivePrivateSharesMember us-gaap:IPOMember alpau:SponsorMember alpau:FounderMember 2021-07-29 2021-07-29 0001842939 srt:MaximumMember us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember 2021-07-29 2021-07-29 0001842939 us-gaap:IPOMember us-gaap:CommonClassAMember 2021-07-29 2021-07-29 0001842939 us-gaap:IPOMember 2021-07-29 2021-07-29 0001842939 alpau:FounderSharesMember alpau:SponsorMember alpau:NonriskIncentivePrivateSharesMember us-gaap:IPOMember 2021-07-29 2021-07-29 0001842939 alpau:FounderSharesMember alpau:SponsorMember us-gaap:IPOMember alpau:RiskIncentivePrivateSharesMember 2021-07-29 2021-07-29 0001842939 us-gaap:OverAllotmentOptionMember alpau:UnderwritingAgreementMember 2021-07-29 2021-07-29 0001842939 us-gaap:CommonClassAMember 2021-07-29 2021-07-29 0001842939 alpau:SponsorMember alpau:NonriskIncentivePrivateSharesMember 2021-07-29 2021-07-29 0001842939 us-gaap:IPOMember us-gaap:CommonClassAMember 2021-07-29 0001842939 us-gaap:IPOMember 2021-07-29 0001842939 us-gaap:IPOMember alpau:SponsorMember alpau:FounderSharesMember alpau:NonriskIncentivePrivateSharesMember 2021-07-29 0001842939 us-gaap:IPOMember alpau:SponsorMember alpau:FounderMember alpau:NonriskIncentivePrivateSharesMember 2021-07-29 0001842939 alpau:RiskIncentivePrivateSharesMember us-gaap:IPOMember alpau:SponsorMember alpau:FounderMember 2021-07-29 0001842939 alpau:PrivatePlacementWarrantsMember us-gaap:OverAllotmentOptionMember 2021-08-03 2021-08-03 0001842939 us-gaap:OverAllotmentOptionMember alpau:UnderwritingAgreementMember 2021-08-03 2021-08-03 0001842939 alpau:FounderSharesMember alpau:UnderwritingAgreementMember 2021-08-03 2021-08-03 0001842939 us-gaap:OverAllotmentOptionMember alpau:FounderSharesMember 2021-08-03 2021-08-03 0001842939 us-gaap:OverAllotmentOptionMember 2021-08-03 2021-08-03 0001842939 us-gaap:MeasurementInputExpectedTermMember 2021-08-03 2021-08-03 0001842939 us-gaap:CommonClassBMember 2021-08-03 0001842939 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-08-03 0001842939 us-gaap:MeasurementInputExpectedDividendRateMember 2021-08-03 0001842939 us-gaap:MeasurementInputPriceVolatilityMember 2021-08-03 0001842939 alpau:FounderSharesMember 2021-01-21 2021-01-21 0001842939 alpau:FounderSharesMember 2021-01-21 0001842939 alpau:FounderSharesMember 2021-01-25 2021-01-25 0001842939 us-gaap:OverAllotmentOptionMember us-gaap:CommonStockMember 2021-01-25 2021-01-25 0001842939 alpau:FounderSharesMember 2021-01-25 0001842939 alpau:PromissoryNoteMember alpau:SponsorMember 2021-01-25 0001842939 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2021-01-25 0001842939 us-gaap:CommonClassBMember 2021-03-01 2021-03-01 0001842939 us-gaap:CommonClassBMember 2021-03-01 0001842939 us-gaap:CommonClassAMember 2021-03-01 0001842939 us-gaap:PreferredStockMember 2021-03-01 0001842939 us-gaap:OverAllotmentOptionMember alpau:UnderwritingAgreementMember 2021-07-26 2021-07-26 0001842939 us-gaap:OverAllotmentOptionMember alpau:UnderwritingAgreementMember 2021-08-06 2021-08-06 0001842939 alpau:SponsorMember srt:MaximumMember alpau:NonriskIncentivePrivateSharesMember 2021-07-14 0001842939 alpau:SponsorMember srt:MinimumMember alpau:RiskIncentivePrivateSharesMember 2021-07-14 0001842939 us-gaap:OverAllotmentOptionMember 2021-09-30 2021-09-30 0001842939 alpau:DarleneDeRemerMember alpau:SponsorMember alpau:FounderSharesMember 2021-07-27 2021-07-27 0001842939 alpau:EugenePodsiadloMember alpau:SponsorMember alpau:FounderSharesMember 2021-07-27 2021-07-27 0001842939 alpau:WilliamWoodwardMember alpau:SponsorMember alpau:FounderSharesMember 2021-07-27 2021-07-27 0001842939 alpau:ThreeIndependentDirectorNomineesMember us-gaap:CommonClassBMember alpau:SponsorMember 2021-07-27 2021-07-27 0001842939 us-gaap:CommonClassBMember 2022-04-15 0001842939 us-gaap:CommonClassAMember 2022-04-15 0001842939 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-01-20 0001842939 us-gaap:RetainedEarningsMember 2021-01-20 0001842939 us-gaap:AdditionalPaidInCapitalMember 2021-01-20 0001842939 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-01-20 0001842939 alpau:ClassACommonStockSubjectToPossibleRedemptionMember us-gaap:CommonStockMember 2021-01-20 0001842939 us-gaap:CommonStockMember alpau:ClassACommonStockSubjectToPossibleRedemptionMember 2021-12-31 0001842939 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-12-31 0001842939 us-gaap:RetainedEarningsMember 2021-12-31 0001842939 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001842939 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001842939 alpau:OverallotmentLiabilityMember 2021-01-20 0001842939 alpau:OverallotmentLiabilityMember 2021-12-31 iso4217:USD xbrli:shares utr:Day xbrli:pure utr:Year utr:Month iso4217:USD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 10-K
 
 
(Mark One)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended December 31, 2021
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period from
                    
to
                    
Commission File Number:
001-40228
 
 
Alpha Healthcare Acquisition Corp. III
(Exact name of Registrant as specified in its charter)
 
 
 
Delaware
 
85-1645738
(State or Other Jurisdiction of
Incorporation or Organization)
 
(I.R.S. Employer
Identification Number)
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
(646)
494-3296
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
symbol(s)
 
Name of each exchange
on which registered
Units, each consisting of one share of Class A Common Stock and
one-fourth
of one Redeemable Warrant
 
ALPAU
 
The Nasdaq Stock Market LLC
Class A Common Stock, par value $0.0001 per share
 
ALPA
 
The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
 
ALPAW
 
The Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None
 
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.     Yes  ☐    No  ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  ☐    No  ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in
Rule 12b-2
of the Exchange Act.
 
Large Accelerated Filer      Accelerated Filer  
       
Non-accelerated Filer      Smaller Reporting Company  
       
         Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act  
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2
of the Exchange Act.)    Yes      No  ☐
As of December 31, 2021, the last day of the registrant’s most recently completed fiscal quarter, the aggregate market value of the Class A common stock held by
non-affiliates
of the registrant was approximately $157.17 million based on the closing price of the registrant’s Class A common stock on December 31, 2021. The calculation excludes shares of the registrant’s common stock held by current executive officers, directors and stockholders that the registrant has concluded are affiliates of the registrant. This determination of affiliate status is not a determination for other purposes.
As of
April 15
, 2022, there were 15,907,985 shares of Class A common stock and 3,861,026 shares of Class B common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
None.
 
 
 

TABLE OF CONTENTS
 
    
Page
 
     7  
Item 1
  Business      7  
     26  
Item 1A
  Risk Factors      26  
Item 1B
  Unresolved Staff Comments      59  
Item 2
  Properties      60  
Item 3
  Legal Proceedings      60  
Item 4
  Mine Safety Disclosures      60  
     60  
Item 5
  Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities      60  
Item 6
  Reserved.      61  
Item 7
  Management’s Discussion and Analysis of Financial Condition and Results of Operations.      61  
Item 7A
  Quantitative and Qualitative Disclosures About Market Risk      66  
Item 8
  Financial Statements and Supplementary Data      66  
Item 9
  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure      66  
Item 9A
  Controls and Procedures      66  
Item 9B.
  Other Information      67  
Item 9C.
  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.      67  
         67  
Item 10
  Directors, Executive Officers and Corporate Governance      67  
Item 11
  Executive Compensation      76  
Item 12
  Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters      76  
Item 13
  Certain Relationships and Related Transactions, and Director Independence      80  
Item 14
  Principal Accountant Fees and Services      81  
Item 15
  Exhibits, Financial Statement Schedules      82  
Item 16
  Form 10-K Summary      84  
 
 
-i-

CERTAIN TERMS
Unless otherwise stated in this Annual Report on Form
10-K
or the context otherwise requires, references to:
 
 
 
“common stock” are to our Class A common stock and our Class B common stock, collectively;
 
 
 
“founder shares” are to shares of our Class B common stock initially purchased by our sponsor in a private placement prior to our initial public offering, and the shares of our Class A common stock issuable upon the conversion thereof;
 
 
 
“initial public offering” are to our initial public offering of 15,000,000 units, at $10.00 per unit, which closed on July 29, 2021, and the partial over-allotment exercise of 444,103 units, at $10.00 per unit, which closed on August 3, 2021;
 
 
 
“initial stockholders” are to our sponsor and any other holders of our founder shares prior to our initial public offering (or their permitted transferees);
 
 
 
“management” or our “management team” are to our officers and directors;
 
 
 
“placement units” are to the units purchased by our sponsor in the private placement concurrent with our initial public offering, each placement unit consisting of one placement share and
one-fourth of
one placement warrant;
 
 
 
“placement shares” are to the shares of our common stock included within the placement units purchased by our sponsor in the private placement concurrent with our initial public offering;
 
 
 
“placement warrants” are to the warrants included within the placement units purchased by our sponsor in the private placement concurrent with our initial public offering;
 
 
 
“private placement” are to the private placement of 463,882 placement units at a price of $10.00 per unit, for an aggregate purchase price of $4,638,820, which occurred simultaneously with the completion of our initial public offering;
 
 
 
“public shares” are to shares of our Class A common stock sold as part of the units in our initial public offering;
 
 
 
“public stockholders” are to the holders of our public shares, including our initial stockholders and management team to the extent our initial stockholders and/or members of our management team purchase public shares, provided that each initial stockholder’s and member of our management team’s status as a “public stockholder” shall only exist with respect to such public shares;
 
 
 
“public warrants” are to our redeemable warrants sold as part of the units in our initial public offering;
 
 
 
“sponsor” are to AHAC Sponsor LLC, a Delaware limited liability company;
 
 
 
“warrants” are to our redeemable warrants, which includes the public warrants as well as the placement warrants and any warrants issued upon conversion of working capital loans; and
 
 
 
“we,” “us,” “company” or “our company” are to Alpha Healthcare Acquisition Corp. III
 
2

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some of the statements contained in this Annual Report on Form
10-K
may constitute “forward-looking statements” for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Annual Report on Form
10-K
may include, for example, statements about:
 
   
our ability to select an appropriate target business or businesses in the healthcare industry;
 
   
our ability to complete our initial business combination in the healthcare industry;
 
   
our expectations around the performance of the prospective target business or businesses in the healthcare industry;
 
   
our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;
 
   
our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination, as a result of which they would then receive expense reimbursements;
 
   
our potential ability to obtain additional financing to complete our initial business combination;
 
   
our pool of prospective target businesses in the healthcare industry;
 
   
our ability to consummate an initial business combination due to the uncertainty resulting from the recent
COVID-19 pandemic;
 
   
the ability of our officers and directors to generate a number of potential business combination opportunities;
 
   
our public securities’ potential liquidity and trading;
 
   
the lack of a market for our securities;
 
   
the use of proceeds not held in the trust account or available to us from interest income on the trust account balance;
 
   
the trust account not being subject to claims of third parties; or
 
   
our financial performance following our initial public offering.
The forward-looking statements contained in this Annual Report on Form
10-K
are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors.” Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
 
3

SUMMARY OF MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS
An investment in our securities involves a high degree of risk. You should consider carefully all of the risks described below, together with the other information contained in this Annual Report on Form
10-K,
before making a decision to invest in our units. The occurrence of one or more of the events or circumstances described in the section titled “Risk Factors,” alone or in combination with other events or circumstances, may materially adversely affect our business, financial condition and operating results. In that event, the trading price of our securities could decline, and you could lose all or part of your investment. Such risks include, but are not limited to:
 
   
We are a recently incorporated company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.
 
   
Our public stockholders may not be afforded an opportunity to vote on our proposed initial business combination, which means we may complete our initial business combination even though a majority of our public stockholders do not support such a combination.
 
   
Your only opportunity to affect the investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash.
 
   
If we seek stockholder approval of our initial business combination, our sponsor has agreed to vote in favor of such initial business combination, regardless of how our public stockholders vote.
 
   
The ability of our public stockholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into our initial business combination with a target.
 
   
The ability of our public stockholders to exercise redemption rights with respect to a large number of our shares may not allow us to complete the most desirable business combination or optimize our capital structure.
 
   
Redeeming stockholders may be unable to sell their securities when they wish to in the event that the proposed business combination is not approved.
 
   
In connection with any meeting held to approve an initial business combination, we will offer each public stockholder the option to vote in favor of the proposed business combination and still seek redemption of their shares.
 
   
Our search for a business combination, and any target business with which we ultimately consummate a business combination, may be materially adversely affected by the recent
COVID-19
coronavirus pandemic and the status of debt and equity markets.
 
   
If we do not consummate an initial business combination within 24 months from the closing of our initial public offering, our public stockholders may be forced to wait beyond such 24 months before redemption from our trust account.
 
   
We may not be able to complete our initial business combination within the prescribed time frame, in which case we would cease all operations except for the purpose of winding up and we would redeem our public shares and liquidate, in which case our public stockholders may only receive $10.00 per share, or less than such amount in certain circumstances, and our warrants will expire worthless.
 
   
We may attempt to complete our initial business combination with a private company about which little information is available, which may result in a business combination with a company that is not as profitable as we suspected, if at all.
 
   
We may seek acquisition opportunities in industries or sectors which may or may not be outside of our founders’ area of expertise.
 
   
We may only be able to complete one business combination with the proceeds of our initial public offering, which will cause us to be solely dependent on a single business, which may have a limited number of products or services. This lack of diversification may negatively impact our operations and profitability.
 
4

   
Changes in the market for directors and officers liability insurance could make it more difficult and more expensive for us to negotiate and complete an initial business combination.
 
   
Past performance by our sponsor or their affiliates, including our management team, may not be indicative of future performance of an investment in us.
 
   
We may seek business combination opportunities with a high degree of complexity that require significant operational improvements, which could delay or prevent us from achieving our desired results.
 
   
Our executive officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests.
 
   
We may engage in a business combination with one or more target businesses that have relationships with entities that may be affiliated with our sponsor, executive officers, directors or existing holders which may raise potential conflicts of interest.
 
   
You will not be entitled to protections normally afforded to investors of many other blank check companies.
 
   
You will not have any rights or interests in funds from the trust account, except under certain limited circumstances. To liquidate your investment, therefore, you may be forced to sell your public shares or warrants, potentially at a loss.
 
   
Nasdaq may delist our securities from trading on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions.
 
   
If third parties bring claims against us, the proceeds held in the trust account could be reduced and the
per-share
redemption amount received by stockholder may be less than $10.00 per public share.
 
   
We are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of
non-compliance.
 
   
We are an “emerging growth company” and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our securities less attractive to investors.
 
   
Compliance obligations under the Sarbanes-Oxley Act of 2002 may make it more difficult for us to effectuate our initial business combination, require substantial financial and management resources, and increase the time and costs of completing an acquisition.
 
   
If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to complete our initial business combination.
 
   
Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss.
 
   
An investment in our securities, and certain subsequent transactions with respect to our securities, may result in uncertain or adverse U.S. federal income tax consequences.
 
   
We may effect our initial business combination with a company located outside of the United States.
 
   
Social unrest, acts of terrorism, regime changes, changes in laws and regulations, political upheaval, or policy changes or enactments may occur in a country in which we may operate after we effect our initial business combination.
 
   
Many countries have difficult and unpredictable legal systems and underdeveloped laws and regulations that are unclear and subject to corruption and inexperience.
 
   
If relations between the United States and foreign governments deteriorate, it could cause potential target businesses or their goods and services to become less attractive.
 
   
If our management following our initial business combination is unfamiliar with United States securities laws, they may have to expend time and resources becoming familiar with such laws.
 
5

   
Currency policies may cause a target business’ ability to succeed in the international markets to be diminished.
 
   
Because foreign law could govern our material agreements, we may not be able to enforce our rights within such jurisdiction or elsewhere.
 
6

PART I
 
Item 1
Business
Our Company
We are a blank check company formed under the laws of the State of Delaware on January 21, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this annual report as our initial business combination. To date, our efforts have been limited to organizational activities as well as activities related to our initial public offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We have generated no operating revenues to date and we do not expect that we will generate operating revenues until we consummate our initial business combination.
While we may pursue an acquisition opportunity in any business industry or sector, we intend to capitalize on our management team’s differentiated ability to source, acquire and manage a business in the healthcare industry in the United States. Our management team has an extensive track record of creating value for stockholders by acquiring attractive businesses at disciplined valuations, investing in growth while fostering financial discipline and ultimately improving financial results.
On July 29, 2021, the Company sold 15,000,000 Units at $10.00 per Unit in its initial public offering, generating gross proceeds of $150.0 million. Each unit consists of one share of Class A common stock and
one-fourth
of one redeemable warrant. Only whole warrants are exercisable. Each whole warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share.
Simultaneously with the closing of the initial public offering, the Company consummated the sale of 455,000 Units at a price of $10.00 per Unit to the Sponsor, generating gross proceeds of $4,550,000. In connection with the IPO, the Company also granted the underwriters a
45-day
option to purchase an additional 2,250,000 Public Units at the initial public offering price. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units for the total amount of $4,441,030, received on August 6, 2021. Resulting from the partial over-allotment exercise, the Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds.
A total of $154,441,030, composed of the proceeds of the Initial Public Offering, including from the exercise of the over-allotment option by the Underwriters, and the sale of the Private Placement Units, including $5,250,000 of the underwriters’ deferred discount, was placed in the Trust Account.
We paid a total of $3,000,000 in underwriting discounts and commissions and $461,151 for other costs and expenses related to the Initial Public Offering. In addition, the Company also included in offering costs the fair value of $1,186,448 of the Founders Shares transferred by the Sponsor to certain investors as a compensation for their commitment to purchase the Public Units sold in the IPO. In addition, the underwriters agreed to defer $5,250,000 in underwriting discounts and commissions. Transaction costs related to the Underwriters’ partial over-allotment exercise amounted to $92,070, consisting of $88,820 of underwriting fees and $3,250 of other offering costs. The Company has also accrued underwriting fees of $155,435 that will be paid only if a business combination is entered into.
Our Management Team
Our management team is led by Rajiv Shukla, our Chairman and Chief Executive Officer, and Patrick A. Sturgeon, our Chief Financial Officer.
Rajiv Shukla has been our Chairman and Chief Executive Officer since inception and has two decades of buyouts, investments and operations experience in the healthcare industry. Since August 2021, Mr. Shukla has served as a director of Humacyte, Inc. (“HUMA”). Mr. Shukla also served as Chairman and Chief Executive Officer of Constellation Alpha Capital Corp. (“CNAC”), a Nasdaq-listed special purpose acquisition company, from June 2017 to August 2019. CNAC raised $144 million in proceeds from a Nasdaq initial public offering and successfully closed its initial business combination with DermTech, Inc., or DermTech, in August 2019. DermTech is a molecular dermatology company that develops and markets
non-invasive diagnostic
tests. The transaction was financed in part with proceeds from a private placement transaction with investors including Farallon Capital, Victory RS Science and Technology Fund, Irwin Jacobs, RTW and HLM Venture Partners.
 
7

Since August 2019, Mr. Shukla has served as an independent director on the board of directors of InflammX Therapeutics, formerly known as Ocunexus Therapeutics, a clinical stage biotech company. From June 2013 to May 2015, Mr. Shukla served as Chief Executive Officer of Pipavav Defence & Offshore Engineering Company (now Reliance Naval and Engineering Ltd.), an Indian listed shipbuilding and defense manufacturing company. In this role, he successfully implemented an extensive financial restructuring project and sold control to the Reliance ADA Group. Between 2008 and 2013, Mr. Shukla worked as an investor at ICICI Venture, Morgan Stanley Investment Management and Citi Venture Capital International. Throughout his investment career, Mr. Shukla has been involved with numerous investments in healthcare companies. As a private equity investor, Mr. Shukla was involved with numerous control and minority healthcare investments including a hospital
roll-up platform
comprising multiple control investments and significant minority stakes in tertiary care hospitals and outpatient treatment centers, a
roll-up of
specialty chemicals and animal health businesses, a U.S. based clinical research organization, a vaccine company, and three specialty pharma companies. From 2001 to 2006, Mr. Shukla served as Senior Director at Pfizer, Inc. (NYSE: PFE). In this role, he played a key role in several acquisitions including Pharmacia in 2003, Meridica in 2004, Vicuron Pharmaceuticals and Idun Pharmaceuticals in 2005, and Rinat Neuroscience in 2006. Mr. Shukla also led the operational integration of these organizations into Pfizer across multiple sites around the world. Mr. Shukla graduated from Harvard University with a Masters in Healthcare Management and Policy and received a Bachelors in Pharmaceutics from the Indian Institute of Technology.
Patrick A. Sturgeon has been our Chief Financial Officer since inception and has nearly two decades of experience with M&A and equity capital market transactions in the healthcare and other sectors. Mr. Sturgeon serves as Chief Financial Officer of Brookline Capital Acquisition Corp., a Nasdaq-listed special purpose acquisition company which raised $50 million in its initial public offering in January 2021. He has also served as a Managing Director at Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”) since March 2016. At Brookline, Mr. Sturgeon focuses on mergers and acquisitions, public financing, private capital raising, secondary offerings, and capital markets. On the public financing front, he focuses on SPAC transactions, primarily underwritten initial public offerings and initial business combinations. From July 2013 to February 2016, Mr. Sturgeon served as a Managing Director at Axiom Capital Management. He worked at Freeman & Co. from October 2002 to November 2011, where he focused on mergers and acquisitions in the financial services sector. Mr. Sturgeon received his B.S. in Economics from the University of Massachusetts, Amherst and his M.B.A. in Finance from New York University.
We believe our management team’s operating and transaction experience and relationships with companies will provide us with a substantial number of potential business combination targets. Over the course of their careers, the members of our management team have developed a broad network of contacts and corporate relationships in the healthcare industry. This network has grown through the activities of our management team sourcing, acquiring and financing businesses, our management team’s relationships with sellers, financing sources and target management teams and the experience of our management team in executing transactions under varying economic and financial market conditions.
We also believe that potential sellers of target businesses will view the fact that our management team has already successfully closed an initial business combination with CNAC and HUMA as positive factors in considering whether or not to enter into a business combination with us. However, past performance by our management team is not a guarantee of success with respect to any business combination we may consummate.
Industry Opportunity
While we may acquire a business in any industry, our focus will be on the healthcare industry in the United States. We believe the healthcare industry is attractive for a number of reasons:
Large Target Market.
The healthcare industry represents a significant target market, with total annual U.S. national health expenditure reaching $3.8 trillion in 2019. The Center for Medicare and Medicaid Services has estimated that total healthcare expenditures are projected to grow at an annualized pace of approximately 5.4% from 2020 through 2028 to reach $6.2 trillion in 2028, which will constitute approximately 20% of total U.S. Gross Domestic Product.
 
8

Broad Universe of Potential Targets.
We intend to focus our investment effort broadly across the healthcare industry, which encompasses services, therapeutics, devices, diagnostics, healthcare technology and animal health. We intend to concentrate on venture capital and private equity-backed target companies in the healthcare industry with an enterprise value range between $250 million and $3 billion. We estimate that there are approximately 406 healthcare companies that currently meet this criteria, based on data from Pitchbook. We believe that our investment and operating expertise in healthcare across multiple industry verticals will give us a large, addressable universe of potential targets. The diversity of the target universe and the number of largely uncorrelated
sub-sectors maximizes
the likelihood that the management team will be able to identify and execute an attractive transaction.
Favorable Trends.
Total global healthcare expenditure has grown at a pace substantially above the rate of inflation in recent years, and this growth is projected to continue over the years to come, driven by factors such as an aging population, increased prevalence of chronic disease and improved access to healthcare. While the size of healthcare spending has grown and will continue to grow, this expense has put significant pressure on payors, including federal and state governments as well as individuals. This dynamic has offered opportunities to services companies that can both control cost and improve the overall quality of healthcare. An area of focus that we believe will continue to be of strong interest is diagnostics — both manufacturing and testing facilities. According to a 2021 KPMG LLP healthcare report, 63% of respondents believe deal volume to continue to increase, perpetuated by demand created from
COVID-19.
In addition, beyond the demand created by
COVID-19,
the other three main areas of focus favorable to M&A activity in the subsector are
point-of-care testing,
liquid biopsy, and next-generation sequencing (NGS). Telehealth is another sector where there are strong positive investment trends. According to a 2020 McKinsey & Company report, after
COVID-19,
an estimated $250 billion of U.S. healthcare spending could go towards virtual health and telemedicine sectors. With the disruption caused by
COVID-19 effecting
in-person diagnostic,
evaluation and in some cases treatment, we see more investment and technological development continue in the sector.
Competitive Differentiation
Our mission is to create attractive risk-adjusted returns for our stockholders. We intend to capitalize on the ability of our management team to identify, acquire and operate a business that will benefit from their involvement by utilizing the following differentiating factors to our advantage:
 
   
Industry Expertise:
Healthcare is a broad, diverse and truly local industry comprised of numerous
sub-sectors that
each require unique institutional knowledge to be properly analyzed. Our management team has the ability to draw on vast experience to drive value creation for stockholders.
 
   
Sourcing:
Our management team has an extensive network of relationships with Private Equity funds, industry executives, private owners, advisors and other intermediaries that we believe will generate deal-sourcing opportunities.
 
   
Execution:
The members of our management team have collectively executed or advised on some of the largest and most impactful healthcare M&A transactions over the course of their careers. We believe this experience will allow for compelling structuring solutions that create true alignment between management and stockholders, as well as efficient negotiations and pricing.
 
   
Investment Expertise:
Our management team and their affiliates have considerable experience with public market healthcare investments and exits. We believe this experience will allow our team to effectively position the target company with public market investors. Additionally, the ability to effectively access the capital markets to either fund growth or
right-size a
company’s balance sheet provides management teams with additional flexibility while running a business.
 
   
Operational
Value-Add:
The members of our management team have decades of diverse experience operating businesses and driving value creation. The team has successfully led businesses in various stages of their lifecycle including
pre-revenue startups,
growth businesses,
roll-ups and
restructurings. We believe this will allow for a diverse set of acquisition targets to be evaluated.
 
9

We believe the collective experience of our management team and their affiliates will lead to many potential acquisition opportunities.
Acquisition Criteria
Consistent with our strategy, we have identified the following general criteria and guidelines that we believe are important in evaluating prospective target businesses. We will use these criteria and guidelines in evaluating acquisition opportunities, but we may decide to enter into our initial business combination with a target business that does not meet these criteria and guidelines. We intend to filter our opportunities based on the following criteria:
 
   
Opportunities for organic growth and
add-on
 acquisitions
. We will seek targets that we believe we can grow both organically and through acquisitions. We intend to leverage the industry experience and financial acumen of our management team to identify additional operational improvement opportunities for the target business. In addition, we believe that we can utilize our extensive networks to source opportunities and execute additional transactions that will drive growth for our business combination target.
 
   
Offers an unrecognized value proposition
. We will conduct due diligence with respect to potential business combination targets, with a goal of identifying value that has been unrecognized and would allow us to invest in companies and buy assets at prices that we believe to be below intrinsic value. In the case of turnaround opportunities, we expect to only acquire companies where we can utilize our operating experience, industry networks and capital to implement a turnaround plan that addresses key aspects of underperformance. The ideal turnaround candidates are those that may require a recapitalization, improvements in working capital management, operational improvements that result in margin expansion, or those that could benefit from the application of new technology that could improve productivity or result in new business orders.
 
   
History of, or potential for, free cash flow generation
. We will seek one or more businesses or assets that have a history of, or potential for, strong, stable free cash flow generation, with predictable and recurring revenue streams.
 
   
Experienced and motivated management team
. We will target one or more businesses or assets that have strong, experienced management teams or those that provide a platform for us to assemble an effective and experienced management team. We will focus on management teams with a track record of driving revenue growth, enhancing profitability and creating value for their stockholders.
These criteria are not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant, on these general guidelines as well as other considerations, factors and criteria that our management team may deem relevant. In the event that we decide to enter into our initial business combination with a target business that does not meet the above criteria and guidelines, we will disclose that the target business does not meet the above criteria in our stockholder communications related to our initial business combination, which, as discussed in this annual report, would be in the form of proxy solicitation materials or tender offer documents that we would file with the U.S. Securities and Exchange Commission.
We may need to obtain additional financing either to complete our initial business combination or because we become obligated to redeem a significant number of our public shares upon completion of our initial business combination. We intend to acquire a company with an enterprise value significantly above the net proceeds of our initial public offering and the sale of the placement units. Depending on the size of the transaction or the number of public shares we become obligated to redeem, we may potentially utilize several additional financing sources, including but not limited to the issuance of additional securities to the sellers of a target business, debt issued by banks or other lenders or the owners of the target, a private placement to raise additional funds, or a combination of the foregoing. If we are unable to complete our initial business combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the trust account. In addition, following our initial business combination, if cash on hand is insufficient to meet our obligations or our working capital needs, we may need to obtain additional financing.
 
10

Initial Business Combination
Nasdaq rules and our certificate of incorporation require that we complete one or more business combinations having an aggregate fair market value of at least 80% of the assets held in the trust account (excluding the amount of deferred underwriting discounts held in trust and taxes payable on the interest earned on the trust account) at the time of signing the agreement to enter into the initial business combination. If our board of directors is not able to independently determine the fair market value of the target business or businesses, or we are considering an initial business combination with an affiliated entity, we will obtain an opinion from an independent investment banking firm that is a member of the Financial Industry Regulatory Authority (FINRA), or an independent valuation or accounting firm with respect to the satisfaction of such criteria.
We anticipate structuring our initial business combination either (i) in such a way so that the post-transaction company in which our public stockholders own shares will own or acquire 100% of the equity interests or assets of the target business or businesses, or (ii) in such a way so that the post-transaction company owns or acquires less than 100% of such interests or assets of the target business in order to meet certain objectives of the target management team or stockholders, or for other reasons. However, we will only complete an initial business combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended. Even if the post-transaction company owns or acquires 50% or more of the voting securities of the target, our stockholders prior to the initial business combination may collectively own a minority interest in the post-transaction company, depending on valuations ascribed to the target and us in the initial business combination. For example, we could pursue a transaction in which we issue a substantial number of new shares in exchange for all of the outstanding capital stock of a target. In this case, we would acquire a 100% controlling interest in the target. However, as a result of the issuance of a substantial number of new shares, our stockholders immediately prior to our initial business combination could own less than a majority of our outstanding shares subsequent to our initial business combination. If less than 100% of the equity interests or assets of a target business or businesses are owned or acquired by the post-transaction company, the portion of such business or businesses that is owned or acquired is what will be taken into account for purposes of the 80% of net assets test. If the initial business combination involves more than one target business, the 80% of net assets test will be based on the aggregate value of all of the target businesses and we will treat the target businesses together as the initial business combination for purposes of a tender offer or for seeking stockholder approval, as applicable.
Our Business Combination Process
In evaluating prospective business combinations, we expect to conduct a thorough due diligence review process that will encompass, among other things, a review of historical and projected financial and operating data, meetings with management and their advisors (if applicable),
on-site inspection
of facilities and assets, discussion with customers and suppliers, legal reviews and other reviews as we deem appropriate. We will also seek to utilize the expertise of our management team in analyzing healthcare companies and evaluating operating projections, financial projections and determining the appropriate return expectations given the risk profile of the target business.
We are not prohibited from pursuing an initial business combination or subsequent transaction with a company that is affiliated with our sponsor, founders, officers, or directors, or a company in which any of the foregoing may have a direct or indirect interest. In the event we seek to complete our initial business combination with a company that is affiliated with our sponsor or any of our founders, officers or directors, we, or a committee of independent directors, will obtain an opinion from an independent investment banking firm which is a member of FINRA or an independent valuation or accounting firm that such initial business combination or transaction is fair to our company from a financial point of view.
Members of our board of directors own founder shares and placement units and, accordingly, may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. Further, each of our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers or directors were to be included by a target business as a condition to any agreement with respect to our initial business combination.
 
11

We currently do not have any specific business combination under consideration. Our officers and directors have neither individually selected nor considered a target business nor have they had any substantive discussions regarding possible target businesses among themselves or with our underwriters or other advisors. We have not (nor has anyone on our behalf) contacted any prospective target business or had any substantive discussions, formal or otherwise, with respect to a business combination transaction with our company. We have not (nor have any of our agents or affiliates) been approached by any candidates (or representative of any candidates) with respect to a possible acquisition transaction with our company. Additionally, we have not, nor has anyone on our behalf, taken any substantive measure, directly or indirectly, to select or locate any suitable acquisition candidate for us, nor have we engaged or retained any agent or other representative to select or locate any such acquisition candidate.
Our sponsor and our officers and directors may sponsor or form other special purpose acquisition companies similar to ours or may pursue other business or investment ventures during the period in which we are seeking an initial business combination. Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination.
Each of our officers and directors presently has, and any of them in the future may have additional, fiduciary, contractual or other obligations to other entities pursuant to which such persons is or will be required to present a business combination opportunity. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which such person has then-current fiduciary, contractual or other obligations to present such opportunity to such entity, such person will honor such fiduciary, contractual or other obligations to present such opportunity to such entity, in which case such opportunity will likely not be made available to the company. Further, each of our officers and directors have duties and obligations with respect to confidentiality to other entities and may in the future agree to additional such duties or obligations, which may prevent such officers and directors from disclosing such information to the company. Our officers and directors will comply with such duties and obligations of confidentiality to such other entities, in which case, the company may not have access to such information. Our amended and restated certificate of incorporation provides that we renounce our interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of our company and such opportunity is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue, and to the extent the director or officer is permitted to refer that opportunity to us without violating another legal obligation.
Members of our management team are not obligated to devote any specific number of hours to our matters but they intend to devote as much of their time as they, in the exercise of their respective business judgement, deem necessary to our affairs until we have completed our initial business combination. The amount of time that any member of our management team will devote in any time period will vary based on whether a target business has been selected for our initial business combination and the current stage of the business combination process. We do not have an employment agreement with any member of our management team.
Any past experience and performance of our management team is not a guarantee either: (1) that we will be able to successfully identify a suitable candidate for our initial business combination; or (2) of any results with respect to any initial business combination we may consummate. You should not rely on the historical record of our management team’s performance as indicative of the future performance of an investment in us or the returns we will, or are likely to, generate going forward. Additionally, in the course of their respective careers, members of our management team have been involved in businesses and deals that were unsuccessful.
Status as a Public Company
We believe our structure will make us an attractive business combination partner to target businesses. As an existing public company, we offer a target business an alternative to the traditional initial public offering through a merger or other business combination with us. In a business combination transaction with us, the owners of the target business may, for example, exchange their shares of stock in the target business for our shares of Class A common stock (or shares of a new holding company) or for a combination of our shares of Class A common stock and cash, allowing us to tailor the consideration to the specific needs of the sellers. We believe target businesses will find this method a more expeditious and cost effective method to become a public company than the typical initial public offering. The typical initial public offering process takes a significantly longer period of time than the typical business combination transaction process, and there are significant expenses in the initial public offering process, including underwriting discounts and commissions, that may not be present to the same extent in connection with a business combination with us.
 
12

Furthermore, once a proposed business combination is completed, the target business will have effectively become public, whereas an initial public offering is always subject to the underwriters’ ability to complete the initial public offering, as well as general market conditions, which could prevent the initial public offering from occurring. Once public, we believe the target business would then have greater access to capital, an additional means of providing management incentives consistent with stockholders’ interests and the ability to use its shares as currency for acquisitions. Being a public company can offer further benefits by augmenting a company’s profile among potential new customers and vendors and aid in attracting talented employees.
While we believe that our structure and our management team’s backgrounds will make us an attractive business partner, some potential target businesses may view our status as a blank check company, such as our lack of an operating history and our ability to seek stockholder approval of any proposed initial business combination, negatively.
We are an “emerging growth company,” as defined in the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a
non-binding advisory
vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the prices of our securities may be more volatile.
In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period.
We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our shares of Class A common stock that is held by
non-affiliates exceeds
$700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in
non-convertible debt
during the prior three-year period.
Additionally, we are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation
S-K.
Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common stock held by
non-affiliates exceeds
$250 million as of the prior June 30, or (2) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common stock held by
non-affiliates exceeds
$700 million as of the prior June 30.
Financial Position
With funds held in the trust account and available for a business combination in the amount of $149,043,685 after future payment of $5,405,436 in deferred underwriting fees, we offer a target business a variety of options such as creating a liquidity event for its owners, providing capital for the potential growth and expansion of its operations or strengthening its balance sheet by reducing its debt ratio. Because we are able to complete our initial business combination using our cash, debt or equity securities, or a combination of the foregoing, we have the flexibility to use the most efficient combination that will allow us to tailor the consideration to be paid to the target business to fit its needs and desires. However, we have not taken any steps to secure third party financing and there can be no assurance it will be available to us.
 
13

Effecting Our Initial Business Combination
We are not presently engaged in, and we will not engage in, any operations for an indefinite period of time. We intend to effectuate our initial business combination using cash from the proceeds of our initial public offering, the private placements of the placement units, our equity, debt or a combination of these as the consideration to be paid in our initial business combination. We may seek to complete our initial business combination with a company or business that may be financially unstable or in its early stages of development or growth, which would subject us to the numerous risks inherent in such companies and businesses.
If our initial business combination is paid for using equity or debt securities, or not all of the funds released from the trust account are used for payment of the consideration in connection with our initial business combination or used for redemptions of our shares of Class A common stock, we may apply the balance of the cash released to us from the trust account for general corporate purposes, including for maintenance or expansion of operations of the post-transaction company, the payment of principal or interest due on indebtedness incurred in completing our initial business combination, to fund the purchase of other companies or for working capital.
We have not selected any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions with any business combination target. Additionally, we have not engaged or retained any agent or other representative to select or locate any suitable acquisition candidate, to conduct any research or take any measures, directly or indirectly, to locate or contact a target business, other than our officers and directors. Although our management will assess the risks inherent in a particular target business with which we may combine, we cannot assure you that this assessment will result in our identifying all risks that a target business may encounter. Furthermore, some of those risks may be outside of our control, meaning that we can do nothing to control or reduce the chances that those risks will adversely affect a target business.
We may need to obtain additional financing to complete our initial business combination, either because the transaction requires more cash than is available from the proceeds held in our trust account, or because we become obligated to redeem a significant number of our public shares upon completion of the business combination, in which case we may issue additional securities or incur debt in connection with such business combination. There are no prohibitions on our ability to issue securities or incur debt in connection with our initial business combination. We are not currently a party to any arrangement or understanding with any third party with respect to raising any additional funds through the sale of securities, the incurrence of debt or otherwise.
Sources of Target Businesses
Certain members of our management team have spent significant portions of their careers working with businesses in the healthcare industry and have developed a wide network of professional services contacts and business relationships in that industry. The members of our board of directors also have significant executive management and public company experience with healthcare companies. Our process of identifying acquisition targets will leverage our management team’s industry experiences, demonstrated deal sourcing capabilities and broad and deep network of relationships, including executives and management teams, private equity groups and other institutional investors, large business enterprises, lenders, investment bankers and other investment market participants, restructuring advisers, consultants, attorneys and accountants, which we believe should provide us with a number of business combination opportunities. We expect that the collective experience, capability and network of our founders, directors and officers, combined with their individual and collective reputations in the investment community, will help to create prospective business combination opportunities.
In addition, we anticipate that target business candidates may be brought to our attention from various unaffiliated sources, including investment bankers and private investment funds. Target businesses may be brought to our attention by such unaffiliated sources as a result of being solicited by us through calls or mailings. These sources may also introduce us to target businesses in which they think we may be interested on an unsolicited basis, since many of these sources will have read this annual report and know what types of businesses we are targeting. Our officers and directors, as well as their affiliates, may also bring to our attention target business candidates of which they become aware through their business contacts as a result of formal or informal inquiries or discussions they may have, as well as attending trade shows or conventions.
 
14

While we do not presently anticipate engaging the services of professional firms or other individuals that specialize in business acquisitions on any formal basis, we may engage these firms or other individuals in the future, in which event we may pay a finder’s fee, consulting fee or other compensation to be determined in an arm’s length negotiation based on the terms of the transaction. We will engage a finder only to the extent our management determines that the use of a finder may bring opportunities to us that may not otherwise be available to us or if finders approach us on an unsolicited basis with a potential transaction that our management determines is in our best interest to pursue. Payment of a finder’s fee is customarily tied to completion of a transaction, in which case any such fee will be paid out of the funds held in the trust account. In no event, however, will our sponsor or any of our existing officers or directors, or any entity with which they are affiliated, be paid any finder’s fee, consulting fee or other compensation by the company prior to, or for any services they render in order to effectuate, the completion of our initial business combination (regardless of the type of transaction that it is). None of our sponsor, executive officers or directors, or any of their respective affiliates, will be allowed to receive any compensation, finder’s fees or consulting fees from a prospective business combination target in connection with a contemplated acquisition of such target by us.
We are not prohibited from pursuing an initial business combination with a business combination target that is affiliated with our sponsor, officers or directors, or from making the acquisition through a joint venture or other form of shared ownership with our sponsor, officers or directors. Although we will not be specifically focusing on, or targeting, any transactions with affiliated entities, we would pursue such a transaction if we determined that such affiliated entity met our criteria for a business combination as set forth below and such transaction was approved by a majority of our independent and disinterested directors. In the event we seek to complete our initial business combination with a business combination target that is affiliated with our sponsor, executive officers or directors, we, or a committee of independent directors, would obtain an opinion from an independent investment banking which is a member of FINRA or an independent valuation or accounting firm, that such an initial business combination is fair to our company from a financial point of view. We are not required to obtain such an opinion in any other context.
If any of our executive officers becomes aware of a business combination opportunity that falls within the line of business of any entity, to which he or she has
pre-existing fiduciary
or contractual obligations, he or she may be required to present such business combination opportunity to such entity prior to presenting such business combination opportunity to us. All of our executive officers currently have certain relevant fiduciary duties or contractual obligations that may take priority over their duties to us. Our amended and restated certificate of incorporation provides that we renounce our interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of our company and such opportunity is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue.
Evaluation of a Target Business and Structuring of Our Initial Business Combination
In evaluating a prospective target business, we expect to conduct a thorough due diligence review which may encompass, among other things, meetings with incumbent management and employees, document reviews, interviews of customers and suppliers, inspection of facilities, as well as a review of financial, operational, legal and other information which will be made available to us. If we determine to move forward with a particular target, we will proceed to structure and negotiate the terms of the business combination transaction.
The time required to select and evaluate a target business and to structure and complete our initial business combination, and the costs associated with this process, are not currently ascertainable with any degree of certainty. Any costs incurred with respect to the identification and evaluation of, and negotiation with, a prospective target business with which our initial business combination is not ultimately completed will result in our incurring losses and will reduce the funds we can use to complete another business combination. The company will not pay any consulting fees to members of our management team, or any of their respective affiliates, for services rendered to or in connection with our initial business combination.
Lack of Business Diversification
For an indefinite period of time after the completion of our initial business combination, the prospects for our success may depend entirely on the future performance of a single business. Unlike other entities that have the resources to complete business combinations with multiple entities in one or several industries, it is probable that we will not have the resources to diversify our operations and mitigate the risks of being in a single line of business. By completing our initial business combination with only a single entity, our lack of diversification may:
 
15

   
subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination; and
 
   
cause us to depend on the marketing and sale of a single product or limited number of products or services.
Limited Ability to Evaluate the Target’s Management Team
Although we intend to closely scrutinize the management of a prospective target business when evaluating the desirability of effecting our initial business combination with that business, our assessment of the target business’s management may not prove to be correct. In addition, the future management may not have the necessary skills, qualifications or abilities to manage a public company. Furthermore, the future role of members of our management team, if any, in the target business cannot presently be stated with any certainty. The determination as to whether any of the members of our management team will remain with the combined company will be made at the time of our initial business combination. While it is possible that one or more of our directors will remain associated in some capacity with us following our initial business combination, it is unlikely that any of them will devote their full efforts to our affairs subsequent to our initial business combination. Moreover, we cannot assure you that members of our management team will have significant experience or knowledge relating to the operations of the particular target business.
We cannot assure you that any of our key personnel will remain in senior management or advisory positions with the combined company. The determination as to whether any of our key personnel will remain with the combined company will be made at the time of our initial business combination.
Following a business combination, we may seek to recruit additional managers to supplement the incumbent management of the target business. We cannot assure you that we will have the ability to recruit additional managers, or that additional managers will have the requisite skills, knowledge or experience necessary to enhance the incumbent management.
Stockholders May Not Have the Ability to Approve Our Initial Business Combination
We may conduct redemptions without a stockholder vote pursuant to the tender offer rules of the SEC subject to the provisions of our amended and restated certificate of incorporation. However, we will seek stockholder approval if it is required by law or applicable stock exchange rule, or we may decide to seek stockholder approval for business or other legal reasons.
Under Nasdaq’s listing rules, stockholder approval would be required for our initial business combination if, for example:
 
   
we issue (other than in a public offering for cash) common stock that will either (a) be equal to or in excess of 20% of the number of shares of Class A common stock then outstanding or (b) have voting power equal to or in excess of 20% of the voting power then outstanding;
 
   
any of our directors, officers or substantial stockholders (as defined by Nasdaq rules) has a 5% or greater interest (or such persons collectively have a 10% or greater interest), directly or indirectly, in the target business or assets to be acquired or otherwise and the present or potential issuance of common stock could result in an increase in outstanding common stock or voting power of 5% or more; or
 
   
the issuance or potential issuance of common stock will result in our undergoing a change of control.
The decision as to whether we will seek stockholder approval of a proposed business combination in those instances in which stockholder approval is not required by law will be made by us, solely in our discretion, and will be based on business and legal reasons, which include a variety of factors, including, but not limited to:
 
16

   
the timing of the transaction, including in the event we determine stockholder approval would require additional time and there is either not enough time to seek stockholder approval or doing so would place the company at a disadvantage in the transaction or result in other additional burdens on the Company;
 
   
the expected cost of holding a stockholder vote;
 
   
the risk that the stockholders would fail to approve the proposed business combination;
 
   
other time and budget constraints of the company; and
 
   
additional legal complexities of a proposed business combination that would be time-consuming and burdensome to present to stockholders.
Permitted Purchases of our Securities
If we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor, directors, executive officers, advisors or their affiliates may purchase shares or public warrants in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination. However, they have no current commitments, plans or intentions to engage in such transactions and have not formulated any terms or conditions for any such transactions. None of the funds in the trust account will be used to purchase shares or public warrants in such transactions. If they engage in such transactions, they will not make any such purchases when they are in possession of any material
non-public information
not disclosed to the seller or if such purchases are prohibited by Regulation M under the Exchange Act.
In the event that our sponsor, directors, officers, advisors or their affiliates purchase shares in privately negotiated transactions from stockholders who have already elected to exercise their redemption rights, such selling stockholders would be required to revoke their prior elections to redeem their shares. We do not currently anticipate that such purchases, if any, would constitute a tender offer subject to the tender offer rules under the Exchange Act or a going-private transaction subject to the going-private rules under the Exchange Act; however, if the purchasers determine at the time of any such purchases that the purchases are subject to such rules, the purchasers will comply with such rules.
The purpose of any such purchases of shares could be to (i) vote such shares in favor of the business combination and thereby increase the likelihood of obtaining stockholder approval of the business combination or (ii) to satisfy a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain amount of cash at the closing of our initial business combination, where it appears that such requirement would otherwise not be met. The purpose of any such purchases of public warrants could be to reduce the number of public warrants outstanding or to vote such warrants on any matters submitted to the warrant holders for approval in connection with our initial business combination. Any such purchases of our securities may result in the completion of our initial business combination that may not otherwise have been possible.
In addition, if such purchases are made, the public “float” of our shares of Class A common stock or public warrants may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange.
Our sponsor, officers, directors and/or their affiliates anticipate that they may identify the stockholders with whom our sponsor, officers, directors or their affiliates may pursue privately negotiated purchases by either the stockholders contacting us directly or by our receipt of redemption requests submitted by stockholders (in the case of shares of Class A common stock) following our mailing of proxy materials in connection with our initial business combination. To the extent that our sponsor, officers, directors, advisors or their affiliates enter into a private purchase, they would identify and contact only potential selling stockholders who have expressed their election to redeem their shares for a pro rata share of the trust account or vote against our initial business combination, whether or not such stockholder has already submitted a proxy with respect to our initial business combination but only if such shares have not already been voted at the stockholder meeting related to our initial business combination. Our sponsor, executive officers, directors, advisors or any of their affiliates will select which stockholders to purchase shares from based on the negotiated price and number of shares and any other factors that they may deem relevant, and will only purchase shares if such purchases comply with Regulation M under the Exchange Act and the other federal securities laws.
 
17

Our sponsor, officers, directors and/or their affiliates will not make purchases of shares if the purchases would violate Section 9(a)(2) or
Rule 10b-5 of
the Exchange Act. Any such purchases will be reported pursuant to Section 13 and Section 16 of the Exchange Act to the extent such purchasers are subject to such reporting requirements.
Redemption Rights for Public Stockholders upon Completion of our Initial Business Combination
We will provide our stockholders with the opportunity to redeem all or a portion of their shares of Class A common stock upon the completion of our initial business combination at a
per-share price,
payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of the initial business combination, including interest (net of taxes payable), divided by the number of then outstanding public shares, subject to the limitations described herein. The amount in the trust account is initially anticipated to be $10.00 per public share. The per share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions we will pay to the underwriters. The redemption rights will include the requirement that a beneficial holder must identify itself in order to validly redeem its shares. Our sponsor has entered into an agreement with us, pursuant to which it has agreed to (i) waive its redemption rights with respect to its founder shares and (ii) waive its rights to liquidating distributions from the trust account with respect to its founder shares if we fail to consummate an initial business combination within 24 months from the closing of our initial public offering. Our sponsor and our directors and executive officers have also agreed (A) that they will not propose any amendment to our amended and restated certificate of incorporation that would modify the substance or timing of our obligation to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering or with respect to any other material provisions relating to stockholders’ rights or
pre-initial business
combination activity, unless we provide our public stockholders with the opportunity to redeem their shares and (B) to waive their redemption rights with respect to their founder shares and any public shares they may acquire during or after our initial public offering in connection with the completion of our initial business combination. However, if our sponsor or members of our management team acquire public shares in or after our initial public offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to consummate an initial business combination within 24 months from the closing of our initial public offering.
Limitations on Redemptions
Our amended and restated certificate of incorporation provides that in no event will we redeem our public shares in an amount that would cause our net tangible assets to be less than $5,000,001 (so that we are not subject to the SEC’s “penny stock” rules). However, the proposed business combination may require: (i) cash consideration to be paid to the target or its owners, (ii) cash to be transferred to the target for working capital or other general corporate purposes or (iii) the retention of cash to satisfy other conditions in accordance with the terms of the proposed business combination. In the event the aggregate cash consideration we would be required to pay for all shares of Class A common stock that are validly submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed business combination exceed the aggregate amount of cash available to us, we will not complete the business combination or redeem any shares, and all shares of Class A common stock submitted for redemption will be returned to the holders thereof.
Manner of Conducting Redemptions
We will provide our stockholders with the opportunity to redeem all or a portion of their shares of Class A common stock upon the completion of our initial business combination either (i) in connection with a stockholder meeting called to approve the business combination or (ii) by means of a tender offer. The decision as to whether we will seek stockholder approval of a proposed business combination or conduct a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require us to seek stockholder approval under applicable law or stock exchange listing requirement or whether we were deemed to be a foreign private issuer (which would require a tender offer rather than seeking stockholder approval under SEC rules). Asset acquisitions and stock purchases would not typically require stockholder approval while direct mergers with our company where we do not survive and any transactions where we issue more than 20% of our outstanding common stock or seek to amend our amended and restated certificate of incorporation would require stockholder approval. We currently intend to conduct redemptions in connection with a stockholder vote unless stockholder approval is not required by applicable law or stock exchange listing requirement and we choose to conduct redemptions pursuant to the tender offer rules of the SEC for business or other legal reasons.
 
18

If we held a stockholder vote to approve our initial business combination, we will, pursuant to our amended and restated certificate of incorporation:
 
   
conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules; and
 
   
file proxy materials with the SEC.
In the event that we seek stockholder approval of our initial business combination, we will distribute proxy materials and, in connection therewith, provide our stockholders with the redemption rights described above upon completion of the initial business combination.
If we seek stockholder approval, we will complete our initial business combination only if a majority of the shares of Class A common stock voted, on an as converted basis, are voted in favor of the business combination. In such case, our sponsor has agreed to vote the founder shares and any public shares purchased by our sponsor during or after our initial public offering in favor of our initial business combination. As a result, in addition to our sponsor’s founder shares, we would need 3,915,000, or 26.1%, of the 15,000,000 public shares sold in our initial public offering to be voted in favor of an initial business combination in order to have our initial business combination approved. Each stockholder may elect to redeem their public shares irrespective of whether they vote for or against the proposed transaction. In addition, our sponsor and our directors and executive officers have entered into agreements with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares and public shares in connection with the completion of a business combination.
If we conduct redemptions pursuant to the tender offer rules of the SEC, we will, pursuant to our amended and restated certificate of incorporation:
 
   
conduct the redemptions pursuant to
Rule 13e-4 and
Regulation 14E of the Exchange Act, which regulate issuer tender offers; and
 
   
file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies.
Upon the public announcement of our initial business combination, we or our sponsor will terminate any plan established in accordance with
Rule 10b5-1 to
purchase shares of Class A common stock in the open market if we elect to redeem our public shares through a tender offer, to comply with
Rule 14e-5 under
the Exchange Act.
In the event we conduct redemptions pursuant to the tender offer rules, our offer to redeem will remain open for at least 20 business days, in accordance with
Rule 14e-1(a)
under the Exchange Act, and we will not be permitted to complete our initial business combination until the expiration of the tender offer period. In addition, the tender offer will be conditioned on stockholders not tendering more than the number of public shares we are permitted to redeem. If stockholders tender more shares than we have offered to purchase, we will withdraw the tender offer and not complete the initial business combination.
 
19

Limitation on Redemption upon Completion of Our Initial Business Combination If We Seek Stockholder Approval
If we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our amended and restated certificate of incorporation provides that a stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to Excess Shares. We believe this restriction will discourage stockholders from accumulating large blocks of shares, and subsequent attempts by such holders to use their ability to exercise their redemption rights against a proposed business combination as a means to force us or our management to purchase their shares at a significant premium to the then-current market price or on other undesirable terms. Absent this provision, a public stockholder holding more than an aggregate of 15% of the shares sold in our initial public offering could threaten to exercise its redemption rights if such holder’s shares are not purchased by us, our sponsor or our management at a premium to the then-current market price or on other undesirable terms. By limiting our stockholders’ ability to redeem no more than 15% of the shares sold in our initial public offering without our prior consent, we believe we will limit the ability of a small group of stockholders to unreasonably attempt to block our ability to complete our initial business combination, particularly in connection with a business combination with a target that requires as a closing condition that we have a minimum net worth or a certain amount of cash.
However, we would not be restricting our stockholders’ ability to vote all of their shares (including Excess Shares) for or against our initial business combination.
Tendering Share Certificates in Connection with Redemption Rights or a Tender Offer
Public stockholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in “street name,” will be required to either tender their certificates (if any) to our transfer agent prior to the date set forth in the proxy solicitation or tender offer materials, as applicable, mailed to such holders, or to deliver their shares to the transfer agent electronically using The Depository Trust Company’s DWAC (Deposit/ Withdrawal At Custodian) System, at the holder’s option, in each case up to two business days prior to the initially scheduled vote to approve the business combination. The proxy solicitation or tender offer materials, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will indicate the applicable delivery requirements, which will include the requirement that a beneficial holder must identify itself in order to validly redeem its shares. Accordingly, a stockholder would have from the time we send out our tender offer materials up to two days prior to the vote on the business combination to tender its shares if it wishes to seek to exercise its redemption rights. Given the relatively short period in which to exercise redemption rights, it is advisable for stockholders to use electronic delivery of their public shares.
There is a nominal cost associated with the above-referenced tendering process and the act of certificating the shares or delivering them through the DWAC System. The transfer agent will typically charge the tendering broker a fee of approximately $80.00 and it would be up to the broker whether or not to pass this cost on to the redeeming holder. However, this fee would be incurred regardless of whether or not we require holders seeking to exercise redemption rights to tender their shares. The need to deliver shares is a requirement of exercising redemption rights regardless of the timing of when such delivery must be effectuated.
The foregoing is different from the procedures used by many blank check companies. In order to perfect redemption rights in connection with their business combinations, many blank check companies would distribute proxy materials for the stockholders’ vote on an initial business combination, and a holder could simply vote against a proposed business combination and check a box on the proxy card indicating such holder was seeking to exercise their redemption rights. After the business combination was approved, the company would contact such stockholder to arrange for them to deliver their certificate to verify ownership. As a result, the stockholder then had an “option window” after the completion of the business combination during which he or she could monitor the price of the company’s shares in the market. If the price rose above the redemption price, they could sell their shares in the open market before actually delivering their shares to the company for cancellation. As a result, the redemption rights to which stockholders were aware they needed to commit before the stockholder meeting, would become “option” rights surviving past the completion of the business combination until the redeeming holder delivered its certificate. The requirement for physical or electronic delivery prior to the meeting ensures that a redeeming stockholder’s election to redeem is irrevocable once the business combination is approved.
Any request to redeem such shares, once made, may be withdrawn at any time up to two business days prior to the vote on the proposal to approve the business combination, unless otherwise agreed to by us. Furthermore, if a holder of a public share delivered its certificate in connection with an election of redemption rights and subsequently decides prior to the applicable date not to elect to exercise such rights, such holder may simply request that the transfer agent return the certificate (physically or electronically). It is anticipated that the funds to be distributed to holders of our public shares electing to redeem their shares will be distributed promptly after the completion of our initial business combination.
 
20

If our initial business combination is not approved or completed for any reason, then our stockholders who elected to exercise their redemption rights would not be entitled to redeem their shares for the applicable pro rata share of the trust account. In such case, we will promptly return any certificates delivered by public holders who elected to redeem their shares.
If our initial proposed business combination is not completed, we may continue to try to complete a business combination with a different target until 24 months from the closing of our initial public offering.
Redemption of Public Shares and Liquidation If No Initial Business Combination
Our amended and restated certificate of incorporation provides that we will have only 24 months from the closing of our initial public offering to consummate an initial business combination. If we are unable to consummate an initial business combination within 24 months from the closing of our initial public offering, we will: (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a
per-share price,
payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest (less up to $100,000 of interest to pay dissolution expenses and net of taxes payable), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii) to our obligations to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to our warrants, which will expire worthless if we fail to consummate an initial business combination within 24 months from the closing of our initial public offering.
Our sponsor has entered into an agreement with us, pursuant to which it has waived its rights to liquidating distributions from the trust account with respect to its founder shares if we fail to consummate an initial business combination within 24 months from the closing of our initial public offering. However, if our sponsor or members of our management team acquire public shares in or after our initial public offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to consummate an initial business combination within 24 months from the closing of our initial public offering.
Our sponsor had agreed, pursuant to a written agreement with us, that they it not propose any amendment to our amended and restated certificate of incorporation to modify the substance or timing of our obligation to redeem 100% of our public shares if we do not consummate an initial business combination within 24 months from the closing of our initial public offering or with respect to any other material provisions relating to stockholders’ rights or
pre-initial business
combination activity, unless we provide our public stockholders with the opportunity to redeem their public shares upon approval of any such amendment at a
per-share price,
payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest (net of taxes payable), divided by the number of then outstanding public shares. However, we may not redeem our public shares in an amount that would cause our net tangible assets to be less than $5,000,001 (so that we are not subject to the SEC’s “penny stock” rules). If this optional redemption right is exercised with respect to an excessive number of public shares such that we cannot satisfy the net tangible asset requirement, we would not proceed with the amendment or the related redemption of our public shares at such time. This redemption right shall apply in the event of the approval of any such amendment, whether proposed by our sponsors, any executive officer, director, or any other person.
We expect that all costs and expenses associated with implementing our plan of dissolution, as well as payments to any creditors, will be funded from the remaining $774,192 of proceeds held outside the trust account as of December 31, 2021, although we cannot assure you that there will be sufficient funds for such purpose. However, if those funds are not sufficient to cover the costs and expenses associated with implementing our plan of dissolution, we may request the trustee to release to us an additional amount of up to $100,000 of such accrued interest to pay those costs and expenses.
 
21

If we were to expend all of the net proceeds of our initial public offering, other than the proceeds deposited in the trust account, and without taking into account interest, if any, earned on the trust account, the
per-share redemption
amount received by stockholders upon our dissolution would be approximately $10.00. The proceeds deposited in the trust account could, however, become subject to the claims of our creditors which would have higher priority than the claims of our public stockholders. We cannot assure you that the actual
per-share redemption
amount received by stockholders will not be less than $10.00. While we intend to pay such amounts, if any, we cannot assure you that we will have funds sufficient to pay or provide for all creditors’ claims.
Although we will seek to have all vendors, service providers (excluding our independent registered public accounting firm), prospective target businesses and other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust account for the benefit of our public stockholders, there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from bringing claims against the trust account including but not limited to fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain an advantage with respect to a claim against our assets, including the funds held in the trust account. If any third party refuses to execute an agreement waiving such claims to the monies held in the trust account, our management will perform an analysis of the alternatives available to it and will only enter into an agreement with a third party that has not executed a waiver if management believes that such third party’s engagement would be significantly more beneficial to us than any alternative. Examples of possible instances where we may engage a third party that refuses to execute a waiver include the engagement of a third party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a waiver. The underwriters will not execute agreements with us waiving such claims to the monies held in the trust account. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not seek recourse against the trust account for any reason. In order to protect the amounts held in the trust account, our sponsor has agreed that it will be liable to us if and to the extent any claims by a vendor for services rendered or products sold to us, or a prospective target business with which we have discussed entering into a transaction agreement, reduce the amounts in the trust account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account if less than $10.00 per share due to reductions in the value of the trust assets, in each case less taxes payable, provided that such liability will not apply to any claims by a third party who executed a waiver of any and all rights to seek access to the trust account nor will it apply to any claims under our indemnity of the underwriters of initial public offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, our sponsor will not be responsible to the extent of any liability for such third party claims. However, we have not asked our sponsor to reserve for such indemnification obligations, nor have we independently verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and we believe that our sponsor’s only assets are securities of our company. Therefore, we cannot assure you that our sponsor would be able to satisfy those obligations. None of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective target businesses.
In the event that the proceeds in the trust account are reduced below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account if less than $10.00 per share due to reductions in the value of the trust assets, in each case less taxes payable, and our sponsor asserts that it is unable to satisfy its indemnification obligations or that it has no indemnification obligations related to a particular claim, our independent directors would determine whether to take legal action against our sponsor to enforce its indemnification obligations. While we currently expect that our independent directors would take legal action on our behalf against our sponsor to enforce its indemnification obligations to us, it is possible that our independent directors in exercising their business judgment may choose not to do so in any particular instance. Accordingly, we cannot assure you that due to claims of creditors the actual value of the
per-share redemption
price will not be less than $10.00 per share.
 
22

We will seek to reduce the possibility that our sponsor will have to indemnify the trust account due to claims of creditors by endeavoring to have all vendors, service providers (excluding our independent registered public accounting firm), prospective target businesses or other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to monies held in the trust account. Our sponsor will also not be liable as to any claims under our indemnity of the underwriters of our initial public offering against certain liabilities, including liabilities under the Securities Act. As of December 31, 2021, we had $774,192 with which to pay any such potential claims (including costs and expenses incurred in connection with our liquidation, currently estimated to be no more than approximately $100,000). In the event that we liquidate and it is subsequently determined that the reserve for claims and liabilities is insufficient, stockholders who received funds from our trust account could be liable for claims made by creditors.
If we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy law and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our stockholders. To the extent any bankruptcy claims deplete the trust account, we cannot assure you we will be able to return $10.00 per share to our public stockholders. Additionally, if we file a bankruptcy petition or an involuntary bankruptcy petition is filed against us that is not dismissed, any distributions received by stockholders could be viewed under applicable debtor/creditor and/or bankruptcy laws as either a “preferential transfer” or a “fraudulent conveyance.” As a result, a bankruptcy court could seek to recover some or all amounts received by our stockholders. Furthermore, our board of directors may be viewed as having breached its fiduciary duty to our creditors and/or may have acted in bad faith, and thereby exposing itself and our company to claims of punitive damages, by paying public stockholders from the trust account prior to addressing the claims of creditors. We cannot assure you that claims will not be brought against us for these reasons.
Our public stockholders will be entitled to receive funds from the trust account only (i) in the event of the redemption of our public shares if we do not consummate an initial business combination within 24 months from the closing of our initial public offering, (ii) in connection with a stockholder vote to amend our amended and restated certificate of incorporation to modify the substance or timing of our obligation to redeem 100% of our public shares if we do not consummate an initial business combination within 24 months from the closing of our initial public offering or with respect to any other material provisions relating to stockholders’ rights or
pre-initial business
combination activity or (iii) if they redeem their respective shares for cash upon the completion of the initial business combination. In no other circumstances will a stockholder have any right or interest of any kind to or in the trust account. In the event we seek stockholder approval in connection with our initial business combination, a stockholder’s voting in connection with the business combination alone will not result in a stockholder’s redeeming its shares to us for an applicable pro rata share of the trust account. Such stockholder must have also exercised its redemption rights described above. These provisions of our amended and restated certificate of incorporation, like all provisions of our amended and restated certificate of incorporation, may be amended with a stockholder vote.
Comparison of Redemption or Purchase Prices in Connection with Our Initial Business Combination and If We Fail to Complete Our Initial Business Combination
The following table compares the redemptions and other permitted purchases of public shares that may take place in connection with the completion of our initial business combination and if we are unable to consummate an initial business combination within 24 months from the closing of our initial public offering.
 
23

    
REDEMPTIONS IN
CONNECTION WITH OUR
INITIAL BUSINESS
COMBINATION
  
OTHER PERMITTED
PURCHASES OF PUBLIC
SHARES BY OUR AFFILIATES
  
REDEMPTIONS IF WE FAIL
TO COMPLETE AN INITIAL
BUSINESS COMBINATION
Calculation of redemption price
   Redemptions at the time of our initial business combination may be made in connection with a stockholder vote or pursuant to a tender offer. The redemption price will be the same whether we conduct redemptions pursuant to a tender offer or in connection with a stockholder vote. In either case, our stockholders may redeem their public shares for cash equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of the initial business combination (which is initially anticipated to be $10.00 per share), including interest (net of taxes payable), divided by the number of then outstanding public shares, subject to the limitation that no redemptions will take place if all of the redemptions would cause our net tangible assets to be less than $5,000,001 and any limitations (including but not limited to cash requirements) agreed to in connection with the negotiation of terms of a proposed business combination.    If we seek stockholder approval of our initial business combination, our sponsor, directors, officers, advisors or their affiliates may purchase shares in privately negotiated transactions or in the open market either prior to or following completion of our initial business combination. There is no limit to the prices that our sponsor, directors, officers, advisors or their affiliates may pay in these transactions. If they engage in such transactions, they will not make any such purchases when they are in possession of any material nonpublic information not disclosed to the seller or if such purchases are prohibited by Regulation M under the Securities Exchange Act of 1934, as amended, or the Exchange Act. We do not currently anticipate that such purchases, if any, would constitute a tender offer subject to the tender offer rules under the Exchange Act or a going-private transaction subject to the going-private rules under the Exchange Act; however, if the purchasers determine at the time of any such purchases that the purchases are subject to such rules, the purchasers will comply with such rules.    If we are unable to consummate an initial business combination within 24 months from the closing of our initial public offering, we will redeem all public shares at a per share price, payable in cash, equal to the aggregate amount, then on deposit in the trust account (which is initially anticipated to be $10.00 per share), including interest (less up to $100,000 of interest to pay dissolution expenses and net of taxes payable) divided by the number of then outstanding public shares.
       
Impact to remaining stockholders
   The redemptions in connection with our initial business combination will reduce the book value per share for our remaining stockholders, who will bear the burden of the deferred underwriting commissions and taxes payable.    If the permitted purchases described above are made, there would be no impact to our remaining stockholders because the purchase price would not be paid by us.    The redemption of our public shares if we fail to complete our initial business combination will reduce the book value per share for the shares held by our sponsor, who will be our only remaining stockholder after such redemptions.
 
24

Competition
In identifying, evaluating and selecting a target business for our initial business combination, we may encounter intense competition from other entities having a business objective similar to ours, including other blank check companies, private equity groups and leveraged buyout funds, public companies, operating businesses seeking strategic acquisitions. Many of these entities are well established and have extensive experience identifying and effecting business combinations directly or through affiliates. Moreover, many of these competitors possess greater financial, technical, human and other resources than us. Our ability to acquire larger target businesses will be limited by our available financial resources. This inherent limitation gives others an advantage in pursuing the acquisition of a target business. Furthermore, our obligation to pay cash in connection with our stockholders who exercise their redemption rights may reduce the resources available to us for our initial business combination and our outstanding warrants, and the future dilution they potentially represent, may not be viewed favorably by certain target businesses. Either of these factors may place us at a competitive disadvantage in successfully negotiating an initial business combination.
Facilities
We currently maintain our executive offices at 1177 Avenue of the Americas, 5
th
 Floor, New York, New York 10036. We will reimburse an affiliate of our sponsor for office space, secretarial and administrative services provided to us in the amount of $10,000 per month. We consider our current office space adequate for our current operations.
Employees
We currently have two executive officers. These individuals are not obligated to devote any specific number of hours to our matters, but they intend to devote as much of their time as they deem necessary to our affairs until we have completed our initial business combination. The amount of time they will devote in any time period will vary based on whether a target business has been selected for our initial business combination and the stage of the business combination process we are in. We do not intend to have any full-time employees prior to the completion of our initial business combination.
Periodic Reporting and Financial Information
We have registered our units, Class A common stock and warrants under the Exchange Act and have reporting obligations, including the requirement that we file annual, quarterly and current reports with the SEC. In accordance with the requirements of the Exchange Act, our annual reports will contain financial statements audited and reported on by our independent registered public accountants.
We will provide stockholders with audited financial statements of the prospective target business as part of the tender offer materials or proxy solicitation materials sent to stockholders to assist them in assessing the target business. In all likelihood, these financial statements will need to be prepared in accordance with, or reconciled to, GAAP, or IFRS, depending on the circumstances, and the historical financial statements may be required to be audited in accordance with the standards of the PCAOB. These financial statement requirements may limit the pool of potential targets we may conduct an initial business combination with because some targets may be unable to provide such statements in time for us to disclose such statements in accordance with federal proxy rules and complete our initial business combination within the prescribed time frame. We cannot provide any assurance that any particular target business identified by us as a potential business combination candidate will have financial statements prepared in accordance with GAAP or that the potential target business will be able to prepare its financial statements in accordance with the requirements outlined above. To the extent that these requirements cannot be met, we may not be able to acquire the proposed target business. While this may limit the pool of potential business combination candidates, we do not believe that this limitation will be material.
 
25

We will be required to evaluate our internal control procedures for the fiscal year ending December 31, 2022 as required by the Sarbanes-Oxley Act. Only in the event we are deemed to be a large accelerated filer or an accelerated filer, and no longer qualify as an emerging growth company, will we be required to have our internal control procedures audited. A target company may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy of their internal controls. The development of the internal controls of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the time and costs necessary to complete any such business combination. We have filed a Registration Statement on
Form 8-A with
the SEC to voluntarily register our securities under Section 12 of the Exchange Act. As a result, we are subject to the rules and regulations promulgated under the Exchange Act. We have no current intention of filing a Form 15 to suspend our reporting or other obligations under the Exchange Act prior or subsequent to the consummation of our initial business combination.
We are an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a
non-binding advisory
vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the prices of our securities may be more volatile.
In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period.
We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our shares of Class A common stock that are held by
non-affiliates exceeds
$700 million as of the prior June 30
th
, and (2) the date on which we have issued more than $1.0 billion in
non-convertible debt
during the prior three-year period. References herein to “emerging growth company” will have the meaning associated with it in the JOBS Act.
Additionally, we are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation
S-K.
Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common stock held by
non-affiliates equals
or exceeds $250 million as of the end of that year’s second fiscal quarter, or (2) our annual revenues equaled or exceeded $100 million during such completed fiscal year and the market value of our common stock held by
non-affiliates exceeds
$700 million as of the end of that year’s second fiscal quarter.
PART II
Item 1A. Risk Factors
An investment in our securities involves a high degree of risk. Careful consideration should be given to all of the risks described below, together with the other information contained in this Annual Report on Form
10-K,
before making a decision to invest in our securities. If any of the following events occur, our business, financial condition and operating results may be materially adversely affected. In that event, the trading price of our securities could decline, and our stockholders could lose all or part of their investment.
 
26

Risks Related to Our Business and Financial Position
We are a blank check company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.
We are a blank check company with no operating results, and we will not commence operations until obtaining funding through the initial public offering and consummating our initial business combination. Because we lack an operating history, you have no basis upon which to evaluate our ability to achieve our business objective of completing our initial business combination with one or more target businesses. We have no plans, arrangements or understandings with any prospective target business concerning our initial business combination and may be unable to complete our initial business combination. If we fail to complete our initial business combination, we will never generate any operating revenues.
Our independent registered public accounting firm’s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going concern.”
As of December 31, 2021, the Company had cash outside the Trust Account of $774,192, available for working capital needs, and net working capital of $643,168. Further, we have incurred and expect to continue to incur significant costs in pursuit of our financing and acquisition plans. Management’s plans to address this need for capital through the proceeds from the initial public offering and the working capital loans from the Sponsor are discussed in the section of this annual report titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” We cannot assure you that our plans to raise capital or to consummate an initial business combination will be successful. These factors, among others, raise substantial doubt about our ability to continue as a going concern. The financial statements contained elsewhere in this annual report do not include any adjustments that might result from our inability to consummate the initial public offering or our inability to continue as a going concern.
We may be unable to obtain additional financing to complete our initial business combination or to fund the operations and growth of a partner business, which could compel us to restructure or abandon a particular business combination. If we are unable to complete our initial business combination, our public stockholders may receive only approximately $10.00 per public share, or less in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless.
Because we have not yet selected any prospective partner business we cannot ascertain the capital requirements for any particular transaction. If the net proceeds of our initial public offering and the sale of the placement units prove to be insufficient, either because of the size of our initial business combination, the depletion of the available net proceeds in search of a partner business, the obligation to redeem for cash a significant number of shares from stockholders who elect redemption in connection with our initial business combination or the terms of negotiated transactions to purchase shares in connection with our initial business combination, we may be required to seek additional financing or to abandon the proposed business combination. Such financing may not be available on acceptable terms, if at all. The current economic environment may make difficult for companies to obtain acquisition financing. To the extent that additional financing proves to be unavailable when needed to complete our initial business combination, we would be compelled to either restructure the transaction or abandon that particular business combination and seek an alternative partner business candidate. If we do not complete our initial business combination within the required time period, our public stockholders may receive only approximately $10.00 per public share, or less in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless. In addition, even if we do not need additional financing to complete our initial business combination, we may require such financing to fund the operations or growth of the partner business. The failure to secure additional financing could have a material adverse effect on the continued development or growth of the partner business. None of our officers, directors or stockholders is required to provide any financing to us in connection with or after our initial business combination.
We may issue notes or other debt securities, or otherwise incur substantial debt, to complete our initial business combination, which may adversely affect our financial condition and thus negatively impact the value of our stockholders’ investment in us.
Although we have no commitments to issue any notes or other debt securities, or to otherwise incur outstanding debt, we may choose to incur substantial debt to complete our initial business combination. If we incur any indebtedness without a waiver from the lender of any right, title, interest or claim of any kind in or to any monies held in the trust account, the incurrence of debt could have a variety of negative effects, including:
 
 
27

   
default and foreclosure on our assets if our operating revenues after our initial business combination are insufficient to repay our debt obligations;
 
   
acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;
 
   
our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;
 
   
our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding;
 
   
our inability to pay dividends on our shares of common stock;
 
   
using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our shares of common stock if declared, expenses, capital expenditures, acquisitions and other general corporate purposes;
 
   
limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;
 
   
increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and
 
   
limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt.
If the net proceeds of our initial public offering and the sale of the placement units not being held in the trust account are insufficient to allow us to operate for the 24 months following the closing of our initial public offering, it could limit the amount available to fund our search for a partner business or businesses and complete our initial business combination, and we will depend on loans from our sponsor to fund our search and to complete our initial business combination.
As of December 31, 2021, the Company had cash outside the Trust Account of $774,192 available for working capital needs. We believe that, the funds available to us outside of the trust account, together with funds available from loans from our sponsor or any of their affiliates will be sufficient to allow us to operate for at least the 24 months following the closing of our initial public offering; however, our estimate may not be accurate, and our sponsor or any of their affiliates are under no obligation to advance funds to us in such circumstances. Of the funds available to us, we expect to use a portion of the funds available to us to pay fees to consultants to assist us with our search for a partner business. We could also use a portion of the funds as a down payment or to fund a
“no-shop”
provision (a provision in letters of intent designed to keep partner businesses from “shopping” around for transactions with other companies or investors on terms more favorable to such partner businesses) with respect to a particular proposed business combination, although we do not have any current intention to do so. If we entered into a letter of intent where we paid for the right to receive exclusivity from a partner business and were subsequently required to forfeit such funds (whether as a result of our breach or otherwise), we might not have sufficient funds to continue searching for, or conduct due diligence with respect to, a partner business.
 
28

If we are required to seek additional capital, we would need to borrow funds from our sponsor or any of their affiliates or other third parties to operate or may be forced to liquidate. Neither our sponsor nor any of their affiliates is under any obligation to advance funds to us in such circumstances. Any such advances may be repaid only from funds held outside the trust account or from funds released to us upon completion of our initial business combination. Up to $1,500,000 of such loans may be convertible into placement units of the post-business combination entity at a price of $10.00 per placement unit at the option of the lender. The placement units would be identical to the units. Prior to the completion of our initial business combination, we do not expect to seek loans from parties other than our sponsor or any of their affiliates as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account. If we do not complete our initial business combination within the required time period because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the trust account. Consequently, our public stockholders may only receive an estimated $10.00 per public share, or possibly less, on our redemption of our public shares, and our warrants will expire worthless.
Risks Related to Our Proposed Initial Business Combination
Our public stockholders may not be afforded an opportunity to vote on our proposed initial business combination, which means we may complete our initial business combination even though a majority of our public stockholders do not support such a combination.
We may choose not to hold a stockholder vote to approve our initial business combination unless the initial business combination would require stockholder approval under applicable law or stock exchange listing requirements or if we decide to hold a stockholder vote for business or other legal reasons. Except as required by applicable law or stock exchange requirements, the decision as to whether we will seek stockholder approval of a proposed initial business combination or will allow stockholders to sell their shares to us in a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors, such as the timing of the transaction and whether the terms of the transaction would otherwise require us to seek stockholder approval. Accordingly, we may complete our initial business combination even if holders of a majority of our public shares do not approve of the initial business combination we complete. Please see the section of this annual report entitled “Proposed Business — Stockholders May Not Have the Ability to Approve Our Initial Business Combination” for additional information.
Your only opportunity to affect the investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash.
At the time of your investment in us, you will not be provided with an opportunity to evaluate the specific merits or risks of one or more target businesses. Because our board of directors may consummate our initial business combination without seeking stockholder approval, public stockholders may not have the right or opportunity to vote on the business combination. Accordingly, your only opportunity to affect the investment decision regarding a potential business combination may be limited to exercising your redemption rights within the period of time (which will be at least 20 business days) set forth in our tender offer documents mailed to our public stockholders in which we describe our business combination.
If we seek stockholder approval of our initial business combination, our sponsor has agreed to vote in favor of such initial business combination, regardless of how our public stockholders vote.
Our sponsor owns, on an
as-converted basis,
20% of our outstanding common stock following our initial public offering. Our sponsor also may from time to time purchase shares of Class A common stock prior to our initial business combination. Our amended and restated certificate of incorporation provides that, if we seek stockholder approval of an initial business combination, such initial business combination will be approved if we receive the affirmative vote of a majority of the shares voted at such meeting, including the founder shares. As a result, in addition to our sponsor’s founder shares, we would need 3,915,000, or 26.1%, of the 15,000,000 public shares sold in our initial public offering to be voted in favor of an initial business combination in order to have our initial business combination approved. Accordingly, if we seek stockholder approval of our initial business combination, the agreement by our sponsor to vote in favor of our initial business combination will increase the likelihood that we will receive the requisite stockholder approval for such initial business combination. In addition, in the event that our anchor investors purchase all of the approximately $100 million of units that they collectively have expressed an interest in purchasing in our initial public offering and vote their public shares in favor of our initial business combination, no affirmative votes from other public stockholders would be required to approve our initial business combination. However, because our anchor investors are not obligated to continue owning any public shares following the closing and are not obligated to vote any public shares in favor of our initial business combination, we cannot assure you that any of these anchor investors will be stockholders at the time our stockholders vote on our initial business combination, and, if they are stockholders, we cannot assure you as to how such anchor investors will vote on any business combination.
 
29

The ability of our public stockholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into our initial business combination with a target.
We may enter into a transaction agreement with a prospective target that requires as a closing condition that we have a minimum net worth or a certain amount of cash. If too many public stockholders exercise their redemption rights, we may not be able to meet such closing condition, and as a result, would not be able to proceed with the business combination. Furthermore, in no event will we redeem our public shares in an amount that would cause our net tangible assets to be less than $5,000,001. Consequently, if accepting all properly submitted redemption requests would cause our net tangible assets to be less than $5,000,001 or such greater amount necessary to satisfy a closing condition as described above, we would not proceed with such redemption and the related business combination and may instead search for an alternate business combination. Prospective targets would be aware of these risks and, thus, may be reluctant to enter into our initial business combination transaction with us.
The ability of our public stockholders to exercise redemption rights with respect to a large number of our shares may not allow us to complete the most desirable business combination or optimize our capital structure.
At the time we enter into an agreement for our initial business combination, we will not know how many stockholders may exercise their redemption rights, and therefore will need to structure the transaction based on our expectations as to the number of shares that will be submitted for redemption.
If a large number of shares are submitted for redemption, we may need to restructure the transaction to reserve a greater portion of the cash in the trust account or arrange for additional third party financing. Raising additional third party financing may involve dilutive equity issuances or the incurrence of indebtedness at higher than desirable levels. The above considerations may limit our ability to complete the most desirable business combination available to us or optimize our capital structure. The amount of the deferred underwriting commissions payable to the underwriters will not be adjusted for any shares that are redeemed in connection with an initial business combination. The
per-share amount
we will distribute to stockholders who properly exercise their redemption rights will not be reduced by the deferred underwriting commission and after such redemptions, the amount held in trust will continue to reflect our obligation to pay the entire deferred underwriting commissions.
We will require public stockholders who wish to redeem their shares of common stock in connection with a proposed business combination, or an amendment to our certificate of incorporation to effect the substance or timing of their redemption obligation if we fail to timely complete a business combination, to comply with specific requirements for redemption that may make it more difficult for them to exercise their redemption rights prior to the deadline for exercising their rights.
We will require our public stockholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in “street name,” to either (i) tender their certificates to our transfer agent prior to the expiration date set forth in the tender offer documents mailed to such holders, or in the event we distribute proxy materials, up to two business days prior to the vote on the proposal to approve the business combination or amendment to our certificate of incorporation to modify the substance or timing of our redemption obligation to redeem all public shares if we cannot complete an initial business combination or with respect to any other material provisions relating to stockholders’ rights or
pre-initial business
combination activity, or (ii) deliver their shares to the transfer agent electronically using Depository Trust Company’s DWAC (Deposit/Withdrawal At Custodian) System, at the holder’s option. In order to obtain a physical stock certificate, a stockholder’s broker and/or clearing broker, DTC and our transfer agent will need to act to facilitate this request. It is our understanding that stockholders should generally allot at least two weeks to obtain physical certificates from the transfer agent. However, because we do not have any control over this process or over the brokers or DTC, it may take significantly longer than two weeks to obtain a physical stock certificate. While we have been advised that it takes a short time to deliver shares through the DWAC System, this may not be the case. Under our certificate of incorporation, we are required to provide at least 10 days advance notice of any stockholder meeting, which would be the minimum amount of time a stockholder would have to determine whether to exercise redemption rights. Accordingly, if it takes longer than we anticipate for stockholders to deliver their shares, stockholders who wish to redeem may be unable to meet the deadline for exercising their redemption rights and thus may be unable to redeem their shares.
 
30

Redeeming stockholders may be unable to sell their securities when they wish to in the event that the proposed business combination is not approved.
We will require public stockholders who wish to redeem their shares of common stock in connection with any proposed business combination to comply with the delivery requirements discussed above for redemption. If such proposed business combination is not consummated, we will promptly return such certificates to the tendering public stockholders. Accordingly, investors who attempted to redeem their shares in such a circumstance will be unable to sell their securities after the failed acquisition until we have returned their securities to them. The market price for our shares of common stock may decline during this time and you may not be able to sell your securities when you wish, even while other stockholders that did not seek redemption may be able to sell their securities.
In connection with any meeting held to approve an initial business combination, we will offer each public stockholder the option to vote in favor of the proposed business combination and still seek redemption of their shares.
In connection with any meeting held to approve an initial business combination, we will offer each public stockholder (but not our sponsor, officers or directors) the right to have their shares of common stock redeemed for cash regardless of whether such stockholder votes for or against such proposed business combination; provided that a stockholder must in fact vote for or against a proposed business combination in order to have their shares of common stock redeemed for cash. If a stockholder fails to vote for or against a proposed business combination, that stockholder would not be able to have their shares of common stock so redeemed. We will consummate our initial business combination only if we have net tangible assets of at least $5,000,001 upon such consummation and a majority of the outstanding shares of common stock voted are voted in favor of the business combination. This is different than other similarly structured blank check companies where stockholders are offered the right to redeem their shares only when they vote against a proposed business combination. This threshold and the ability to seek redemption while voting in favor of a proposed business combination may make it more likely that we will consummate our initial business combination.
The ability of our public stockholders to exercise redemption rights with respect to a large number of our shares could increase the probability that our initial business combination would be unsuccessful and that you would have to wait for liquidation in order to redeem your shares.
If our initial business combination agreement requires us to use a portion of the cash in the trust account to pay the purchase price or requires us to have a minimum amount of cash at closing, the probability that our initial business combination would be unsuccessful is increased. If our initial business combination is unsuccessful, you would not receive your pro rata portion of the funds in the trust account until we liquidate the trust account. If you are in need of immediate liquidity, you could attempt to sell your shares in the open market; however, at such time our shares may trade at a discount to the pro rata amount per share in the trust account. In either situation, you may suffer a material loss on your investment or lose the benefit of funds expected in connection with our redemption until we liquidate or you are able to sell your shares in the open market.
The requirement that the target business or businesses that we acquire must collectively have a fair market value equal to at least 80% of the balance of the funds in the trust account (excluding any taxes payable) at the time of the execution of a definitive agreement for our initial business combination may limit the type and number of companies with which we may complete such a business combination.
Nasdaq rules and our certificate of incorporation require that the target business or businesses that we acquire must collectively have a fair market value equal to at least 80% of the balance of the funds in the trust account (excluding any taxes payable) at the time of the execution of a definitive agreement for our initial business combination. This restriction may limit the type and number of companies that we may complete a business combination with. If we are unable to locate a target business or businesses that satisfy this fair market value test, we may be forced to liquidate and you will only be entitled to receive your pro rata portion of the funds in the trust account, which may be less than $10.00 per share.
 
31

The requirement that we consummate an initial business combination within 24 months after the closing of our initial public offering may give potential target businesses leverage over us in negotiating a business combination and may limit the time we have in which to conduct due diligence on potential business combination targets, in particular as we approach our dissolution deadline, which could undermine our ability to complete our initial business combination on terms that would produce value for our stockholders.
Any potential target business with which we enter into negotiations concerning a business combination will be aware that we must consummate an initial business combination within 24 months from the closing of our initial public offering. Consequently, such partner business may obtain leverage over us in negotiating a business combination, knowing that if we do not complete our initial business combination within the required time period with that particular partner business, we may be unable to complete our initial business combination with any partner business. This risk will increase as we get closer to the timeframe described above. In addition, we may have limited time to conduct due diligence and may enter into our initial business combination on terms that we would have rejected upon a more comprehensive investigation.
Our search for a business combination, and any target business with which we ultimately consummate a business combination, may be materially adversely affected by the recent
COVID-19
coronavirus pandemic and the status of debt and equity markets.
In December 2019, a novel strain of coronavirus was reported to have surfaced, which has and is continuing to spread throughout the world, including the United States. On January 30, 2020, the World Health Organization declared the outbreak of the
COVID-19 coronavirus
disease a “Public Health Emergency of International Concern.” On January 31, 2020, U.S. Health and Human Services Secretary Alex M. Azar II declared a public health emergency for the United States to aid the U.S. healthcare community in responding to
COVID-19,
and on March 11, 2020, the World Health Organization characterized the outbreak as a “pandemic.” The
COVID-19 outbreak
has resulted in, and a significant outbreak of other infectious diseases could result in, a widespread health crisis that could materially and adversely affect the economies and financial markets worldwide, and the operations and financial position of any potential target business with which we consummate a business combination could be materially and adversely affected. Furthermore, we may be unable to complete a business combination if continued concerns relating to
COVID-19 restrict
travel, limit the ability to have meetings with potential investors, if the target company’s personnel, vendors and service providers are unavailable to negotiate and consummate a transaction in a timely manner, or if
COVID-19 causes
a prolonged economic downturn. The extent to which
COVID-19 impacts
our search for a business combination will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of
COVID-19 and
the actions to contain
COVID-19 or
treat its impact, among others. If the disruptions posed by
COVID-19 or
other matters of global concern continue for an extensive period of time, our ability to consummate a business combination, or the operations of a target business with which we ultimately consummate a business combination, may be materially adversely affected.
In addition, our ability to consummate a business combination may be dependent on the ability to raise equity and debt financing which may be impacted by
COVID-19 and
other events, including as a result of increased market volatility, decreased market liquidity and third-party financing being unavailable on terms acceptable to us or at all.
 
32

If we do not consummate an initial business combination within 24 months from the closing of our initial public offering, our public stockholders may be forced to wait beyond such 24 months before redemption from our trust account.
If we are unable to consummate our initial business combination within 24 months from the closing of our initial public offering, we will, as promptly as reasonably possible but not more than five business days thereafter (subject to our certificate of incorporation and applicable law), distribute the aggregate amount then on deposit in the trust account (net of taxes payable), pro rata to our public stockholders by way of redemption and cease all operations except for the purposes of winding up of our affairs by way of a voluntary liquidation, as further described herein. Any redemption of public stockholders from the trust account shall be effected as required by our certificate of incorporation prior to our commencing any voluntary liquidation. Except as otherwise described herein, we have no obligation to return funds to investors prior to the date of any redemption required as a result of our failure to consummate our initial business combination within the period described above or our liquidation, unless we consummate our initial business combination prior thereto and only then in cases where investors have sought to redeem their shares of common stock. Only upon any such redemption of public shares as we are required to effect, or any liquidation, will public stockholders be entitled to distributions if we are unable to complete our initial business combination.
We may not be able to complete our initial business combination within the prescribed time frame, in which case we would cease all operations except for the purpose of winding up and we would redeem our public shares and liquidate, in which case our public stockholders may only receive $10.00 per share, or less than such amount in certain circumstances, and our warrants will expire worthless.
Our amended and restated certificate of incorporation provides that we must complete our initial business combination within 24 months from the closing of our initial public offering. We may not be able to find a suitable target business and complete our initial business combination within such time period. Our ability to complete our initial business combination may be negatively impacted by general market conditions, volatility in the capital and debt markets and the other risks described herein. For example, if the outbreak of
COVID-19 continues
to grow both in the U.S. and globally and, while the extent of the impact of the outbreak on us will depend on future developments, it could limit our ability to complete our initial business combination, including as a result of increased market volatility, decreased market liquidity and third-party financing being unavailable on terms acceptable to us or at all. Additionally, the outbreak of
COVID-19 may
negatively impact businesses we may seek to acquire.
If we have not completed our initial business combination within such time period, we will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a
per-share price,
payable in cash, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in the case of clauses (ii) and (iii) above to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. In such case, our public stockholders may only receive $10.00 per share, and our warrants will expire worthless. In certain circumstances, our public stockholders may receive less than $10.00 per share on the redemption of their shares.
We may attempt to complete our initial business combination with a private company about which little information is available, which may result in a business combination with a company that is not as profitable as we suspected, if at all.
In pursuing our acquisition strategy, we may seek to effectuate our initial business combination with a privately held company. By definition, very little public information exists about private companies, and we could be required to make our decision on whether to pursue a potential initial business combination on the basis of limited information, which may result in our initial business combination with a company that is not as profitable as we suspected, if at all.
 
33

Because of our limited resources and the significant competition for business combination opportunities, it may be more difficult for us to complete our initial business combination. If we do not complete our initial business combination within the required time period, our public stockholders may receive only approximately $10.00 per public share, or less in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless.
In recent years, the number of special purpose acquisition companies that have been formed has increased substantially. Many companies have entered into business combinations with special purpose acquisition companies, and there are still many special purpose acquisition companies seeking targets for their initial business combination, as well as many additional special purpose acquisition companies currently in registration. As the number of special purpose acquisition companies increases, there may be more competition to find an attractive target for an initial business combination. This could increase the costs associated with completing our initial business combination and may result in our inability to find a suitable target for our initial business combination.
We also expect to encounter intense competition from other entities having a business objective similar to ours, including private investors (which may be individuals or investment partnerships) and other entities, domestic and international, competing for the types of businesses we intend to acquire. Many of these individuals and entities are well-established and have extensive experience in identifying and effecting, directly or indirectly, acquisitions of companies operating in or providing services to various industries. Many of these competitors possess greater technical, human and other resources or more local industry knowledge than we do and our financial resources will be relatively limited when contrasted with those of many of these competitors. While we believe there are numerous partner businesses we could potentially acquire with the net proceeds of our initial public offering and the sale of the placement units, our ability to compete with respect to the acquisition of certain partner businesses that are sizable will be limited by our available financial resources. This inherent competitive limitation gives others an advantage in pursuing the acquisition of certain partner businesses.
Furthermore, we are obligated to offer holders of our public shares the right to redeem their shares for cash at the time of our initial business combination in conjunction with a stockholder vote or via a tender offer. Partner companies will be aware that this may reduce the resources available to us for our initial business combination. Any of these obligations may place us at a competitive disadvantage in successfully negotiating a business combination. If we have not consummated our initial business combination within the required time period, our public stockholders may receive only approximately $10.00 per public share, or less in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless.
We may engage one or more of the underwriters or their affiliates to provide additional services to us after our initial public offering, which may include acting as financial advisor in connection with an initial business combination or as placement agent in connection with a related financing transaction. The underwriters are entitled to receive deferred commissions that will be released from the Trust Account only on a completion of an initial business combination. These financial incentives may cause the underwriters to have potential conflicts of interest in rendering any such additional services to us after our initial public offering, including, for example, in connection with the sourcing and consummation of an initial business combination.
We may engage one or more of the underwriters or their affiliates to provide additional services to us after our initial public offering, including, for example, identifying potential targets, providing financial advisory services, acting as a placement agent in a private offering or arranging debt financing. We may pay the underwriters or their affiliates fair and reasonable fees or other compensation that would be determined at that time in an arm’s length negotiation. The underwriters are also entitled to receive deferred commissions that are conditioned on the completion of an initial business combination. The fact that the underwriters or their affiliates’ financial interests are tied to the consummation of a business combination transaction may give rise to potential conflicts of interest in providing any such additional services to us, including potential conflicts of interest in connection with the sourcing and consummation of an initial business combination.
Subsequent to our consummation of our initial business combination, we may be required to take write-downs or write-offs, restructuring and impairment or other charges.
Even if we conduct thorough due diligence on a target business with which we combine, this diligence may not surface all material issues that may be present inside a particular target business. And, regardless of how comprehensive our diligence may be, factors outside of the target business and outside of our control may arise later. As a result of these factors, we may be forced to later write-down or
write-off assets,
restructure our operations, or incur impairment or other charges that could result in our reporting losses. Even if our due diligence successfully identifies certain risks, unexpected risks may arise and previously known risks may materialize in a manner not consistent with our preliminary risk analysis. Even though these charges may be
non-cash items
and not have an immediate impact on our liquidity, the fact that we report charges of this nature could contribute to negative market perceptions about us or our securities. In addition, charges of this nature may cause us to violate net worth or other covenants to which we may be subject as a result of assuming
pre-existing debt
held by a target business or by virtue of our obtaining post-combination debt financing.
 
34

Accordingly, any holders who choose to retain their securities following the business combination could suffer a reduction in the value of their securities.
Such holders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws that the proxy solicitation or tender offer materials, as applicable, relating to the business combination contained an actionable material misstatement or material omission.
Our directors may decide not to enforce indemnification obligations against our sponsor, resulting in a reduction in the amount of funds in the trust account available for distribution to our public stockholders.
In the event that the proceeds in the trust account are reduced below $10.00 per share (whether or not the underwriters’ overallotment option is exercised in full) and our sponsor asserts that it is unable to satisfy its obligations or that it has no indemnification obligations related to a particular claim, our independent directors would determine on our behalf whether to take legal action against our sponsor to enforce its indemnification obligations. While we currently expect that our independent directors would take legal action on our behalf against our sponsor to enforce its indemnification obligations to us, it is possible that our independent directors in exercising their business judgment may choose not to do so in any particular instance. If our independent directors choose not to enforce these indemnification obligations on our behalf, the amount of funds in the trust account available for distribution to our public stockholders may be reduced below $10.00 per share.
If, after we distribute the proceeds in the trust account to our public stockholders, we file a bankruptcy or insolvency petition or an involuntary bankruptcy or insolvency petition is filed against us that is not dismissed, a bankruptcy or insolvency court may seek to recover such proceeds, and the members of our board of directors may be viewed as having breached their fiduciary duties to our creditors, thereby exposing the members of our board of directors and us to claims of punitive damages.
If, after we distribute the proceeds in the trust account to our public stockholders, we file a bankruptcy or insolvency petition or an involuntary bankruptcy or insolvency petition is filed against us that is not dismissed, any distributions received by stockholders could be viewed under applicable debtor/ creditor and/or bankruptcy laws as either a “preferential transfer” or a “fraudulent conveyance.” As a result, a bankruptcy or insolvency court could seek to recover some or all amounts received by our stockholders. In addition, our board of directors may be viewed as having breached its fiduciary duty to our creditors and/or having acted in bad faith, thereby exposing itself and us to claims of punitive damages, by paying public stockholders from the trust account prior to addressing the claims of creditors.
If, before distributing the proceeds in the trust account to our public stockholders, we file a bankruptcy or insolvency petition or an involuntary bankruptcy or insolvency petition is filed against us that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of our stockholders and the
per-
share amount that would otherwise be received by our stockholders in connection with our liquidation may be reduced.
If, before distributing the proceeds in the trust account to our public stockholders, we file a bankruptcy or insolvency petition or an involuntary bankruptcy or insolvency petition is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our stockholders. To the extent any bankruptcy claims deplete the trust account, the
per-share amount
that would otherwise be received by our stockholders in connection with our liquidation may be reduced.
 
35

Our sponsor paid an aggregate of $25,000 for the founder shares, or approximately $0.00579 per founder share (after taking into account the 1:1.2 stock split on March 1, 2021). As a result of this low initial price, our sponsor, its affiliates and our management team stand to make a substantial profit even if an initial business combination subsequently declines in value or is unprofitable for our public stockholders.
As a result of the low acquisition cost of our founder shares, our sponsor, its affiliates and our management team could make a substantial profit even if we select and consummate an initial business combination with an acquisition target that subsequently declines in value or is unprofitable for our public stockholders. Thus, such parties may have more of an economic incentive for us to enter into an initial business combination with a riskier, weaker-performing or financially unstable business, or an entity lacking an established record of revenues or earnings, than would be the case if such parties had paid the full offering price for their founder shares.
Unlike some other similarly structured special purpose acquisition companies, our sponsor will receive additional shares of Class A common stock if we issue certain shares to consummate an initial business combination.
The founder shares will automatically convert into shares of Class A common stock concurrently with or immediately following the consummation of our initial business combination on a
one-for-one basis,
subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional shares of Class A common stock or equity-linked securities are issued or deemed issued in connection with our initial business combination, the number of shares of Class A common stock issuable upon conversion of all founder shares will equal, in the aggregate, on an as converted basis, 20% of the total number of shares of Class A common stock outstanding after such conversion (after giving effect to any redemptions of shares of Class A common stock by public stockholders). This amount will include the total number of shares of Class A common stock issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial business combination, but will exclude any shares of Class A common stock or equity-linked securities or rights exercisable for or convertible into shares of Class A common stock issued, or to be issued, to any seller in the initial business combination and any placement units issued to our sponsor, officers or directors upon conversion of working capital loans, provided that such conversion of founder shares will never occur on a less than
one-for-one basis.
This is different than some other similarly structured special purpose acquisition companies in which the initial stockholders will only be issued an aggregate of 20% of the total number of shares to be outstanding prior to our initial business combination.
Because we are neither limited to evaluating a partner business in a particular industry sector nor have we selected any specific partner businesses with which to pursue our initial business combination, you will be unable to ascertain the merits or risks of any particular partner business’s operations.
We may pursue business combination opportunities in any sector, except that we will not, under our amended and restated certificate of incorporation, be permitted to effectuate our initial business combination solely with another blank check company or similar company with nominal operations. Because we have not yet selected or approached any specific partner business with respect to a business combination, there is no basis to evaluate the possible merits or risks of any particular partner business’s operations, results of operations, cash flows, liquidity, financial condition or prospects. To the extent we complete our initial business combination, we may be affected by numerous risks inherent in the business operations with which we combine. For example, if we combine with a financially unstable business or an entity lacking an established record of sales or earnings, we may be affected by the risks inherent in the business and operations of a financially unstable or a development stage entity. Although our officers and directors will endeavor to evaluate the risks inherent in a particular partner business, we may not properly ascertain or assess all of the significant risk factors or that we will have adequate time to complete due diligence. Furthermore, some of these risks may be outside of our control and leave us with no ability to control or reduce the chances that those risks will adversely impact a partner business. An investment in our units may not ultimately prove to be more favorable to investors than a direct investment, if such opportunity were available, in a business combination target. Accordingly, any holders who choose to retain their securities following our initial business combination could suffer a reduction in the value of their securities. Such holders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws that the proxy solicitation or tender offer materials, as applicable, relating to the business combination contained an actionable material misstatement or material omission.
 
36

We may seek acquisition opportunities in industries or sectors which may or may not be outside of our founders’ area of expertise.
We will consider a business combination outside of our founders’ area of expertise if a business combination target is presented to us and we determine that such candidate offers an attractive acquisition opportunity for our company. Although our sponsor will endeavor to evaluate the risks inherent in any particular business combination target, we may not adequately ascertain or assess all of the significant risk factors. We also cannot assure you that an investment in our units will not ultimately prove to be less favorable to investors in our initial public offering than a direct investment, if an opportunity were available, in a business combination target. In the event we elect to pursue an acquisition outside of the areas of our founders’ expertise, our founders’ expertise may not be directly applicable to its evaluation or operation, and the information contained in this annual report regarding the areas of our founders’ expertise would not be relevant to an understanding of the business that we elect to acquire. As a result, our sponsor may not be able to adequately ascertain or assess all of the significant risk factors. Accordingly, any holders who choose to retain their securities following our initial business combination could suffer a reduction in the value of their securities. Such holders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws that the proxy solicitation or tender offer materials, as applicable, relating to the business combination contained an actionable material misstatement or material omission.
Although we have identified general criteria that we believe are important in evaluating prospective partner businesses, we may enter into our initial business combination with a partner that does not meet such criteria, and as a result, the partner business with which we enter into our initial business combination may not have attributes entirely consistent with our general criteria.
Although we have identified general criteria for evaluating prospective partner businesses, it is possible that a partner business with which we enter into our initial business combination will not have all of these positive attributes. If we complete our initial business combination with a partner that does not meet some or all of these criteria, such combination may not be as successful as a combination with a business that does meet all of our general criteria. In addition, if we announce a prospective business combination with a partner that does not meet our general criteria, a greater number of stockholders may exercise their redemption rights, which may make it difficult for us to meet any closing condition with a partner business that requires us to have a minimum net worth or a certain amount of cash. In addition, if stockholder approval of the transaction is required by applicable law or stock exchange rule, or we decide to obtain stockholder approval for business or other reasons, it may be more difficult for us to attain stockholder approval of our initial business combination if the partner business does not meet our general criteria. If we do not complete our initial business combination within the required time period, our public stockholders may receive only approximately $10.00 per public share, or less in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless.
We may only be able to complete one business combination with the proceeds of our initial public offering, which will cause us to be solely dependent on a single business, which may have a limited number of products or services. This lack of diversification may negatively impact our operations and profitability.
The net proceeds from our initial public offering, partial overallotment exercise, and the sale of the placement units provided us $150,121,192, that we may use to complete our initial business combination.
 
37

We may effectuate our initial business combination with a single target business or multiple target businesses simultaneously. However, we may not be able to effectuate our initial business combination with more than one target business because of various factors, including the existence of complex accounting issues and the requirement that we prepare and file pro forma financial statements with the SEC that present operating results and the financial condition of several target businesses as if they had been operated on a combined basis. By consummating our initial business combination with only a single entity, our lack of diversification may subject us to numerous economic, competitive and regulatory developments. Further, we would not be able to diversify our operations or benefit from the possible spreading of risks or offsetting of losses, unlike other entities, which may have the resources to complete several business combinations in different industries or different areas of a single industry. Accordingly, the prospects for our success may be solely dependent upon the performance of a single business, property or asset, or dependent upon the development or market acceptance of a single or limited number of products or services. This lack of diversification may subject us to numerous economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact upon the particular industry in which we may operate subsequent to our initial business combination.
We may attempt to simultaneously consummate business combinations with multiple prospective targets, which may hinder our ability to consummate our initial business combination and give rise to increased costs and risks that could negatively impact our operations and profitability.
If we determine to simultaneously acquire several businesses that are owned by different sellers, we will need for each of such sellers to agree that our purchase of its business is contingent on the simultaneous closings of the other business combinations, which may make it more difficult for us, and delay our ability, to complete the initial business combination. With multiple business combinations, we could also face additional risks, including additional burdens and costs with respect to possible multiple negotiations and due diligence investigations (if there are multiple sellers) and the additional risks associated with the subsequent assimilation of the operations and services or products of the acquired companies in a single operating business. If we are unable to adequately address these risks, it could negatively impact our profitability and results of operations.
Management’s flexibility in identifying and selecting a prospective acquisition candidate, along with our management’s financial interest in consummating our initial business combination, may lead management to enter into an acquisition agreement that is not in the best interest of our stockholders.
Subject to the requirements in Nasdaq rules and our certificate of incorporation that we must complete one or more business combinations having an aggregate fair market value of at least 80% of the value of the trust account (excluding any taxes payable) at the time of the agreement to enter into such initial business combination, we will have virtually unrestricted flexibility in identifying and selecting a prospective acquisition candidate. Investors will be relying on management’s ability to identify business combinations, evaluate their merits, conduct or monitor diligence and conduct negotiations. Management’s flexibility in identifying and selecting a prospective acquisition candidate, along with management’s financial interest in consummating our initial business combination, may lead management to enter into an acquisition agreement that is not in the best interest of our stockholders, which would be the case if the trading price of our shares of common stock after giving effect to such business combination was less than the
per-share trust
liquidation value that our stockholders would have received if we had dissolved without consummating our initial business combination.
We do not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for us to complete our initial business combination with which a substantial majority of our stockholders or warrant holders do not agree.
Our amended and restated certificate of incorporation does not provide a specified maximum redemption threshold, except that in no event will we redeem our public shares in an amount that would cause our net tangible assets to be less than $5,000,001. In addition, our proposed initial business combination may impose a minimum cash requirement for: (i) cash consideration to be paid to the target or its owners, (ii) cash for working capital or other general corporate purposes or (iii) the retention of cash to satisfy other conditions. As a result, we may be able to complete our initial business combination even though a substantial majority of our public stockholders do not agree with the transaction and have redeemed their shares or, if we seek stockholder approval of our initial business combination and do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, have entered into privately negotiated agreements to sell their shares to our sponsor, officers, directors, advisors or any of their affiliates. In the event the aggregate cash consideration we would be required to pay for all shares of Class A common stock that are validly submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed business combination exceed the aggregate amount of cash available to us, we will not complete the business combination or redeem any shares in connection with such initial business combination, all shares of Class A common stock submitted for redemption will be returned to the holders thereof, and we instead may search for an alternate business combination.
 
38

We are not required to obtain an opinion from an independent investment banking firm, and consequently, an independent source may not confirm that the price we are paying for the business is fair to our stockholders from a financial point of view.
Unless we consummate our initial business combination with an affiliated entity, we are not required to obtain an opinion from an independent investment banking firm that the price we are paying is fair to our stockholders from a financial point of view. If no opinion is obtained, our stockholders will be relying on the judgment of our board of directors, who will determine fair market value based on standards generally accepted by the financial community. Such standards used will be disclosed in our tender offer documents or proxy solicitation materials, as applicable, related to our initial business combination.
Resources could be wasted in researching acquisitions that are not completed, which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. If we do not complete our initial business combination within the required time period, our public stockholders may receive only approximately $10.00 per public share, or less in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless.
We anticipate that the investigation of each specific target business and the negotiation, drafting, and execution of relevant agreements, disclosure documents, and other instruments will require substantial management time and attention and substantial costs for accountants, attorneys and others. If we decide not to complete a specific initial business combination, the costs incurred up to that point for the proposed transaction likely would not be recoverable. Furthermore, if we reach an agreement relating to a specific target business, we may fail to consummate our initial business combination for any number of reasons including those beyond our control. Any such event will result in a loss to us of the related costs incurred, which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. If we are unable to complete our initial business combination, our public stockholders may only receive $10.00 per share or even less on our redemption, and our warrants will expire worthless.
There are risks related to the healthcare industry to which we may be subject.
Business combinations with companies with operations in the healthcare industry entail special considerations and risks. If we are successful in completing a business combination with a target business with operations in the healthcare industry, we will be subject to, and possibly adversely affected by, the following risks, including but not limited to:
 
   
Competition could reduce profit margins.
 
   
Our inability to comply with governmental regulations affecting the healthcare industry could negatively affect our operations.
 
   
An inability to license or enforce intellectual property rights on which our business may depend.
 
   
The success of our planned business following consummation of our initial business combination may depend on maintaining a well-secured business and technology infrastructure.
 
   
If we are required to obtain governmental approval of our products, the production of our products could be delayed and we could be required to engage in a lengthy and expensive approval process that may not ultimately be successful.
 
   
Continuing government and private efforts to contain healthcare costs, including through the implementation of legal and regulatory changes, may reduce our future revenue and our profitability following such business combination.
 
   
Changes in the healthcare related wellness industry and markets for such products affecting our customers or retailing practices could negatively impact customer relationships and our results of operations.
 
39

   
The healthcare industry is susceptible to significant liability exposure. If liability claims are brought against us following a business combination, it could materially adversely affect our operations.
 
   
Dependence of our operations upon third-party suppliers, manufacturers or contractors whose failure to perform adequately could disrupt our business.
 
   
A disruption in supply could adversely impact our business.
Any of the foregoing could have an adverse impact on our operations following a business combination. However, our efforts in identifying prospective target businesses will not be limited to the healthcare industry. Accordingly, if we acquire a target business in another industry, these risks will likely not affect us and we will be subject to other risks attendant with the specific industry in which we operate or target business which we acquire, none of which can be presently ascertained.
Changes in the market for directors and officers liability insurance could make it more difficult and more expensive for us to negotiate and complete an initial business combination.
 
   
In recent months, the market for directors and officers liability insurance for special purpose acquisition companies has changed in ways adverse to us and our management team. Fewer insurance companies are offering quotes for directors and officers liability coverage, the premiums charged for such policies have generally increased and the terms of such policies have generally become less favorable. These trends may continue into the future.
 
   
The increased cost and decreased availability of directors and officers liability insurance could make it more difficult and more expensive for us to negotiate and complete an initial business combination. In order to obtain directors and officers liability insurance or modify its coverage as a result of becoming a public company, the post-business combination entity might need to incur greater expense and/or accept less favorable terms. Furthermore, any failure to obtain adequate directors and officers liability insurance could have an adverse impact on the post-business combination’s ability to attract and retain qualified officers and directors.
 
   
In addition, after completion of any initial business combination, our directors and officers could be subject to potential liability from claims arising from conduct alleged to have occurred prior to such initial business combination. As a result, in order to protect our directors and officers, the post-business combination entity may need to purchase additional insurance with respect to any such claims
(“run-off insurance”).
The need for
run-off insurance
would be an added expense for the post-business combination entity and could interfere with or frustrate our ability to consummate an initial business combination on terms favorable to our investors.
Risks Related to Our Operations
Past performance by our sponsor or their affiliates, including our management team, may not be indicative of future performance of an investment in us.
Information regarding performance by, or businesses associated with, our sponsor or their affiliates is presented for informational purposes only. Any past experience of and performance by our sponsor or their affiliates, is not a guarantee either: (1) that we will be able to successfully identify a suitable candidate for our initial business combination; or (2) of any results with respect to any initial business combination we may consummate. You should not rely on the historical record of our sponsor or any of their affiliates’ as indicative of the future performance of an investment in us or the returns we will, or are likely to, generate going forward.
 
40

Our sponsor may not be able to maintain control of a partner business after our initial business combination. Upon the loss of control of a partner business, new management may not possess the skills, qualifications or abilities necessary to profitably operate such business.
We may structure our initial business combination to acquire less than 100% of the equity interests or assets of a target business, but we will only consummate such business combination if we will become the majority stockholder of the target (or control the target through contractual arrangements in limited circumstances for regulatory compliance purposes) or are otherwise not required to register as an investment company under the Investment Company Act or to the extent permitted by law we may acquire interests in a variable interest entity, in which we may have less than a majority of the voting rights in such entity, but in which we are the primary beneficiary. Even though we may own a majority interest in the target, our stockholders prior to the business combination may collectively own a minority interest in the post business combination company, depending on valuations ascribed to the target and us in the business combination transaction. For example, we could pursue a transaction in which we issue a substantial number of new shares in exchange for all of the outstanding capital stock of a target. In this case, we acquire a 100% controlling interest in the target. However, as a result of the issuance of a substantial number of new shares, our stockholders immediately prior to such transaction could own less than a majority of our outstanding shares subsequent to such transaction. In addition, other minority stockholders may subsequently combine their holdings resulting in a single person or group obtaining a larger share of the company’s stock than we initially acquired. Accordingly, this may make it more likely that we will not be able to maintain our control of the target business.
We may seek business combination opportunities with a high degree of complexity that require significant operational improvements, which could delay or prevent us from achieving our desired results.
We may seek business combination opportunities with large, highly complex companies that we believe would benefit from operational improvements. While we intend to implement such improvements, to the extent that our efforts are delayed or we are unable to achieve the desired improvements, the business combination may not be as successful as we anticipate.
To the extent we complete our initial business combination with a large complex business or entity with a complex operating structure, we may also be affected by numerous risks inherent in the operations of the business with which we combine, which could delay or prevent us from implementing our strategy. Although our sponsor will endeavor to evaluate the risks inherent in a particular partner business and its operations, we may not be able to properly ascertain or assess all of the significant risk factors until we complete our business combination. If we are not able to achieve our desired operational improvements, or the improvements take longer to implement than anticipated, we may not achieve the gains that we anticipate. Furthermore, some of these risks and complexities may be outside of our control and leave us with no ability to control or reduce the chances that those risks and complexities will adversely impact a partner business. Such combination may not be as successful as a combination with a smaller, less complex organization.
We are dependent upon our executive officers and directors and their loss could adversely affect our ability to operate.
Our operations are dependent upon a relatively small group of individuals and, in particular, our executive officers and directors. We believe that our success depends on the continued service of our officers and directors, at least until we have completed our initial business combination. In addition, our executive officers and directors are not required to commit any specified amount of time to our affairs and, accordingly, will have conflicts of interest in allocating their time among various business activities, including identifying potential business combinations and monitoring the related due diligence. We do not have an employment agreement with, or
key-man insurance
on the life of, any of our directors or executive officers. The unexpected loss of the services of one or more of our directors or executive officers could have a detrimental effect on us.
Our ability to successfully effect our initial business combination and to be successful thereafter will be largely dependent upon the efforts of our officers, directors and key personnel, some of whom may join us following our initial business combination. The loss of key personnel could negatively impact the operations and profitability of our post- combination business.
Our ability to successfully effect our initial business combination is dependent upon the efforts of our key personnel. The role of our key personnel in the partner business, however, cannot presently be ascertained. Although some of our key personnel may remain with the partner business in senior management or advisory positions following our initial business combination, it is likely that some or all of the management of the partner business will remain in place. While we intend to closely scrutinize any individuals we engage after our initial business combination, we cannot assure you that our assessment of these individuals will prove to be correct. These individuals may be unfamiliar with the requirements of operating a company regulated by the SEC, which could cause us to have to expend time and resources helping them become familiar with such requirements.
 
41

Our key personnel may negotiate employment or consulting agreements with a partner business in connection with a particular business combination, and a particular business combination may be conditioned on the retention or resignation of such key personnel. These agreements may provide for them to receive compensation following our initial business combination and as a result, may cause them to have conflicts of interest in determining whether a particular business combination is the most advantageous.
Our key personnel may be able to remain with our company after the completion of our initial business combination only if they are able to negotiate employment or consulting agreements in connection with the business combination. Such negotiations would take place simultaneously with the negotiation of the business combination and could provide for such individuals to receive compensation in the form of cash payments and/or our securities for services they would render to us after the completion of the business combination. Such negotiations also could make such key personnel’s retention or resignation a condition to any such agreement. The personal and financial interests of such individuals may influence their motivation in identifying and selecting a partner business.
We may have a limited ability to assess the management of a prospective target business and, as a result, may effectuate our initial business combination with a target business whose management may not have the skills, qualifications or abilities to manage a public company.
When evaluating the desirability of effecting our initial business combination with a prospective target business, our ability to assess the target business’ management may be limited due to a lack of time, resources or information. Our assessment of the capabilities of the target’s management, therefore, may prove to be incorrect and such management may lack the skills, qualifications or abilities we suspected. Should the target’s management not possess the skills, qualifications or abilities necessary to manage a public company, the operations and profitability of the post-combination business may be negatively impacted.
Accordingly, any holders who choose to retain their securities following our initial business combination could suffer a reduction in the value of their securities. Such holders are unlikely to have a remedy for such reduction in value.
The officers and directors of an acquisition candidate may resign upon consummation of our initial business combination. The loss of an acquisition target’s key personnel could negatively impact the operations and profitability of our post-combination business.
The role of an acquisition candidate’s key personnel upon the consummation of our initial business combination cannot be ascertained at this time. Although we contemplate that certain members of an acquisition candidate’s management team will remain associated with the acquisition candidate following our initial business combination, it is possible that some members of the management team of an acquisition candidate will not wish to remain in place.
Our executive officers and directors will allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on our ability to complete our initial business combination.
Our executive officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial business combination. Each of our executive officers is engaged in several other business endeavors for which he may be entitled to substantial compensation, and our executive officers are not obligated to contribute any specific number of hours per week to our affairs. Our independent directors also serve as officers and board members for other entities. If our executive officers’ and directors’ other business affairs require them to devote substantial amounts of time to such affairs in excess of their current commitment levels, it could limit their ability to devote time to our affairs which may have a negative impact on our ability to complete our initial business combination. For a complete discussion of our executive officers’ and directors’ other business affairs, please see “Management — Officers and Directors.”
 
42

Our officers and directors presently have, and any of them in the future may have additional, fiduciary or contractual or other obligations to other entities and, accordingly, may have conflicts of interest in determining to which entity a particular business opportunity should be presented.
Until we consummate our initial business combination, we intend to engage in the business of identifying and combining with one or more businesses. Each of our officers and directors presently has, and any of them in the future may have, additional fiduciary, contractual or other obligations to other entities. Any of the foregoing may engage in businesses that are competitive to a prospective or actual target for the Company’s initial business acquisition. Accordingly, they may have conflicts of interest in determining to which entity a particular business opportunity should be presented. These conflicts may not be resolved in our favor and a potential target business may be presented to another entity prior to its presentation to us. Our amended and restated certificate of incorporation provides that we renounce our interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of the company and such opportunity is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue, and to the extent the director or officer is permitted to refer that opportunity to us without violating another legal obligation. In addition, our sponsor and our officers and directors may sponsor or form other special purpose acquisition companies similar to ours or may pursue other business or investment ventures during the period in which we are seeking an initial business combination. Any such companies, businesses or ventures may present additional conflicts of interest in pursuing an initial business combination. However, we do not believe that any such potential conflicts would materially affect our ability to complete our initial business combination. For a complete discussion of our executive officers’ and directors’ business affiliations and the potential conflicts of interest that you should be aware of, please see “Management — Officers and Directors,” “Management — Conflicts of Interest” and “Certain Relationships and Related Party Transactions.”
Our executive officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests.
We have not adopted a policy that expressly prohibits our directors, executive officers, security holders or affiliates from having a direct or indirect pecuniary or financial interest in any investment to be acquired or disposed of by us or in any transaction to which we are a party or have an interest. In fact, we may enter into a business combination with a target business that is affiliated with our sponsor, our directors or executive officers or a target business in which any of the foregoing have an interest, although we do not intend to do so. Nor do we have a policy that expressly prohibits any such persons from engaging for their own account in business activities of the types conducted by us. Accordingly, such persons or entities may have a conflict between their interests and ours. In particular, our sponsor is focused on investments in the healthcare. As a result, there may be substantial overlap between companies that would be a suitable business combination for us and companies that would make an attractive target for our sponsor. In addition, our amended and restated certificate of incorporation provides that we renounce our interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of our company and such opportunity is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue, and to the extent the director or officer is permitted to refer that opportunity to us without violating another legal obligation.
The personal and financial interests of our directors and officers may influence their motivation in timely identifying and selecting a target business and completing a business combination or in determining the outcome of any conflicts of interest that may arise as a result of such personal and financial interests. Consequently, our directors’ and officers’ discretion in identifying and selecting a suitable target business may result in a conflict of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate and in our stockholders’ best interest. If this were the case, it would be a breach of their fiduciary duties to us as a matter of Delaware law and we or our stockholders might have a claim against such individuals for infringing on our stockholders’ rights. However, we might not ultimately be successful in any claim we may make against them for such reason.
 
43

We may engage in a business combination with one or more target businesses that have relationships with entities that may be affiliated with our sponsor, executive officers, directors or existing holders which may raise potential conflicts of interest.
In light of the involvement of our sponsor, officers and directors with other entities, we may decide to acquire one or more businesses affiliated with our sponsor, officers or directors. Our directors also serve as officers and board members for other entities, including, without limitation, those described under the section of this annual report entitled “Management — Conflicts of Interest.” Such entities may compete with us for business combination opportunities. Our sponsor, officers and directors are not currently aware of any specific opportunities for us to complete our business combination with any entities with which they are affiliated, and there have been no preliminary discussions concerning a business combination with any such entity or entities. Although we will not be specifically focusing on, or targeting, any transaction with any affiliated entities, we would pursue such a transaction if we determined that such affiliated entity met our criteria for a business combination as set forth in the section of this annual report entitled “Proposed Business — Sources of Target Businesses” and such transaction was approved by a majority of our disinterested directors. Despite our agreement to obtain an opinion from an independent investment banking firm that is a member of FINRA, or from an independent accounting firm, regarding the fairness to our company from a financial point of view of a business combination with one or more domestic or international businesses affiliated with our officers, directors or existing holders, potential conflicts of interest still may exist and, as a result, the terms of the business combination may not be as advantageous to our public stockholders as they would be absent any conflicts of interest.
Since our sponsor, officers and directors will lose their entire investment in us if our business combination is not completed, a conflict of interest may arise in determining whether a particular business combination target is appropriate for our initial business combination.
On January 21, 2021, our sponsor subscribed to purchase 3,593,750 shares of our common stock. On January 25, 2021, our sponsor paid $25,000, or approximately $0.00696 per share, for certain expenses on behalf of us in exchange for issuance of the founder shares. On March 1, 2021, we effected a 1:1.2 stock split of our common stock which resulted in 3,593,750 shares of our common stock being converted into 4,312,500 shares of our Class B common stock. Prior to the initial investment in the company of $25,000 by the sponsor, the company had no assets, tangible or intangible. The per share price of the founder shares was determined by dividing the amount contributed to the company by the number of founder shares issued. The founder shares will be worthless if we do not complete an initial business combination. In addition, our sponsor purchased an aggregate of 455,000 placement units, at a purchase price of $4,550,000, in a private placement that closed simultaneously with the closing of our initial public offering. If we do not consummate an initial business within 24 months from the closing of our initial public offering, the placement units (and the underlying securities) will expire worthless. The personal and financial interests of our executive officers and directors may influence their motivation in identifying and selecting a partner business combination, completing an initial business combination and influencing the operation of the business following the initial business combination. This risk may become more acute as the
24-month anniversary
of the closing of our initial public offering nears, which is the deadline for our consummation of an initial business combination.
Certain shares beneficially owned by our officers and directors will not participate in liquidating distributions and, therefore, our officers and directors may have a conflict of interest in determining whether a particular target business is appropriate for our initial business combination.
Our sponsor has agreed to (i) waive its redemption rights with respect to its founder shares and (ii) waive its rights to liquidating distributions from the trust account with respect to its founder shares if we fail to consummate an initial business combination within 24 months from the closing of our initial public offering. Our sponsor and our directors and executive officers have entered into agreements with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares and any public shares they may acquire during or after our initial public offering in connection with the completion of our initial business combination. However, if our sponsor, directors or executive officers acquire public shares in or after our initial public offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to consummate an initial business combination within 24 months from the closing of our initial public offering. Accordingly, the founder shares will be worthless if we do not consummate our initial business combination. Any warrants they hold, like those held by the public, will also be worthless if we do not consummate an initial business combination. The personal and financial interests of our directors and officers may influence their motivation in timely identifying and selecting a target business and completing a business combination. Consequently, our directors’ and officers’ discretion in identifying and selecting a suitable target business may result in a conflict of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate and in our stockholders’ best interest.
 
44

Our sponsor controls a substantial interest in us and thus may exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not support.
Our sponsor (and its transferees/designees, if any) collectively owns 20% of our issued and outstanding shares of common stock. Accordingly, they may exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not support, including amendments to our certificate of incorporation.
Our sponsor paid an aggregate of $25,000, or approximately $0.00579 per founder share (after taking into account the 1:1.2 stock split on March 1, 2021) and, accordingly, you will experience immediate and substantial dilution from the purchase of our shares of common stock.
The difference between the public offering price per share (allocating all of the unit purchase price to the shares of common stock included in the unit and none to the warrants included in the unit) and the net tangible book value per share after our initial public offering constitutes the dilution to you and the other investors in our initial public offering. Our sponsor acquired the founder shares at a nominal price, significantly contributing to this dilution. Upon closing of our initial public offering, you and the other public stockholders incurred an immediate and substantial dilution of approximately 90.2% or $9.02 per share (the difference between the pro forma net tangible book value per share of $0.98 and the initial offering price of $10.00 per share immediately upon the closing of our initial public offering).
If we seek stockholder approval of our initial business combination, our sponsor, directors, executive officers, advisors and their affiliates may elect to purchase public shares or warrants, which may influence a vote on a proposed business combination.
If we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor, directors, executive officers, advisors or their affiliates may purchase public shares or warrants in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination, although they are under no obligation to do so. However, other than as expressly stated herein, they have no current commitments, plans or intentions to engage in such transactions and have not formulated any terms or conditions for any such transactions. None of the funds in the trust account will be used to purchase public shares or warrants in such transactions.
In the event that our sponsor, directors, executive officers, advisors or their affiliates purchase shares in privately negotiated transactions from public stockholders who have already elected to exercise their redemption rights, such selling stockholders would be required to revoke their prior elections to redeem their shares. The purpose of any such transaction could be to (1) vote in favor of the business combination and thereby increase the likelihood of obtaining stockholder approval of the business combination, (2) reduce the number of public warrants outstanding or vote such warrants on any matters submitted to the warrant holders for approval in connection with our initial business combination or (3) satisfy a closing condition in an agreement with a partner that requires us to have a minimum net worth or a certain amount of cash at the closing of our initial business combination, where it appears that such requirement would otherwise not be met. Any such purchases of our securities may result in the completion of our initial business combination that may not otherwise have been possible.
Any such purchases will be reported pursuant to Section 13 and Section 16 of the Exchange Act to the extent such purchasers are subject to such reporting requirements.
 
45

Purchases of shares of common stock in the open market or in privately negotiated transactions by our sponsor, directors, officers, advisors or their affiliates may make it difficult for us to maintain the listing of our shares on a national securities exchange following the consummation of an initial business combination.
If our sponsor, directors, officers, advisors or their affiliates purchase shares of common stock in the open market or in privately negotiated transactions, the public “float” of our shares of common stock and the number of beneficial holders of our securities would both be reduced, possibly making it difficult to maintain the listing or trading of our securities on a national securities exchange following consummation of the business combination.
The requirement that we maintain a minimum net worth or retain a certain amount of cash could increase the probability that we cannot consummate our business combination and that you would have to wait for liquidation in order to redeem your shares.
If, pursuant to the terms of our proposed business combination, we are required to maintain a minimum net worth or retain a certain amount of cash in trust in order to consummate the business combination and regardless of whether we proceed with redemptions under the tender offer or proxy rules, the probability that we cannot consummate our business combination is increased. If we do not consummate our business combination, you would not receive your pro rata portion of the trust account until we liquidate. If you are in need of immediate liquidity, you could attempt to sell your shares in the open market; however, at such time our shares may trade at a discount to the pro rata amount in our trust account. In either situation, you may suffer a material loss on your investment or lose the benefit of funds expected in connection with our redemption until we liquidate or you are able to sell your shares in the open market.
Risks Related to Our Corporate Governance and Stockholder Rights
We may not hold an annual meeting of stockholders until after the consummation of our initial business combination, which could delay the opportunity for our stockholders to elect directors.
In accordance with Nasdaq corporate governance requirements, we are not required to hold an annual meeting until no later than one year after our first fiscal year end following our listing on Nasdaq. Under Section 211(b) of the DGCL, we are, however, required to hold an annual meeting of stockholders for the purposes of electing directors in accordance with our bylaws unless such election is made by written consent in lieu of such a meeting. We may not hold an annual meeting of stockholders to elect new directors prior to the consummation of our initial business combination, and thus we may not be in compliance with Section 211(b) of the DGCL, which requires an annual meeting. Therefore, if our stockholders want us to hold an annual meeting prior to the consummation of our initial business combination, they may attempt to force us to hold one by submitting an application to the Delaware Court of Chancery in accordance with Section 211(c) of the DGCL.
In order to effectuate an initial business combination, blank check companies have, in the recent past, amended various provisions of their charters and other governing instruments, including their warrant agreements. We cannot assure you that we will not seek to amend our amended and restated certificate of incorporation or governing instruments in a manner that will make it easier for us to complete our initial business combination that our stockholders may not support.
In order to effectuate an initial business combination, blank check companies have, in the recent past, amended various provisions of their charters and modified governing instruments, including their warrant agreements. For example, blank check companies have amended the definition of business combination, increased redemption thresholds and extended the time to consummate an initial business combination and, with respect to their warrants, amended their warrant agreements to require the warrants to be exchanged for cash and/or other securities. Amending our amended and restated certificate of incorporation requires the approval of holders of 65% of our common stock, and amending our warrant agreement will require a vote of holders of at least a majority of the public warrants (which may include public warrants acquired by our sponsor or its affiliates in our initial public offering or thereafter in the open market). In addition, our amended and restated certificate of incorporation requires us to provide our public stockholders with the opportunity to redeem their public shares for cash if we propose an amendment to our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or certain amendments to our charter prior thereto or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering or (B) with respect to any other provision relating to stockholders’ rights or
pre-initial business
combination activity.
 
46

To the extent any such amendments would be deemed to fundamentally change the nature of any securities of the Company, we would register, or seek an exemption from registration for, the affected securities. We cannot assure you that we will not seek to amend our charter or governing instruments or extend the time to consummate an initial business combination in order to effectuate our initial business combination.
The provisions of our amended and restated certificate of incorporation that relate to our
pre-business
combination activity (and corresponding provisions of the agreement governing the release of funds from our trust account), including an amendment to permit us to withdraw funds from the trust account such that the per share amount investors will receive upon any redemption or liquidation is substantially reduced or eliminated, may be amended with the approval of holders of at least 65% of our common stock, which is a lower amendment threshold than that of some other blank check companies. It may be easier for us, therefore, to amend our amended and restated certificate of incorporation and the trust agreement to facilitate the completion of an initial business combination that some of our stockholders may not support.
Our amended and restated certificate of incorporation provides that any of its provisions related to
pre-initial business
combination activity (including the requirement to deposit proceeds of our initial public offering and the sale of the placement units into the trust account and not release such amounts except in specified circumstances, and to provide redemption rights to public stockholders as described herein and including to permit us to withdraw funds from the trust account such that the per share amount investors will receive upon any redemption or liquidation is substantially reduced or eliminated) may be amended if approved by holders of at least 65% of our common stock entitled to vote thereon, and corresponding provisions of the trust agreement governing the release of funds from our trust account may be amended if approved by holders of at least 65% of our common stock entitled to vote thereon. In all other instances, our amended and restated certificate of incorporation may be amended by holders of a majority of our outstanding common stock entitled to vote thereon, subject to applicable provisions of the DGCL or applicable stock exchange rules. We may not issue additional securities that can vote on amendments to our amended and restated certificate of incorporation. Our initial stockholders will participate in any vote to amend our amended and restated certificate of incorporation and/or trust agreement and will have the discretion to vote in any manner they choose. As a result, we may be able to amend the provisions of our amended and restated certificate of incorporation which govern our
pre-initial business
combination behavior more easily than some other blank check companies, and this may increase our ability to complete an initial business combination with which you do not agree. Our stockholders may pursue remedies against us for any breach of our amended and restated certificate of incorporation.
Our sponsor, officers and directors have agreed, pursuant to a written agreement with us, that they will not propose any amendment to our amended and restated certificate of incorporation (i) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or certain amendments to our charter prior thereto or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering or (ii) with respect to any other provision relating to stockholders’ rights or
pre-initial business
combination activity, unless we provide our public stockholders with the opportunity to redeem their shares of Class A common stock upon approval of any such amendment at a
per-share price,
payable in cash, equal to the aggregate amount then on deposit in the trust account, divided by the number of then outstanding public shares. These agreements are contained in a letter agreement that we have entered into with our sponsor, officers and directors. Our stockholders are not parties to, or third-party beneficiaries of, these agreements and, as a result, will not have the ability to pursue remedies against our sponsor, officers or directors for any breach of these agreements. As a result, in the event of a breach, our stockholders would need to pursue a stockholder derivative action, subject to applicable law.
 
47

We may amend the terms of the warrants in a manner that may be adverse to holders of public warrants with the approval by the holders of at least 50% of the then outstanding public warrants. As a result, the exercise price of your warrants could be increased, the exercise period could be shortened and the number of our Class A common stock purchasable upon exercise of a warrant could be decreased, all without your approval.
Our warrants were issued in registered form under a warrant agreement between Continental Stock Transfer & Trust Company, as warrant agent, and us. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, including to conform the provisions of the warrant agreement to the description of the terms of the warrants and the warrant agreement, but requires the approval by the holders of at least 50% of the then-outstanding public warrants to make any change that adversely affects the interests of the registered holders of public warrants. Accordingly, we may amend the terms of the warrants in a manner adverse to a holder if holders of at least 50% of the then-outstanding public warrants approve of such amendment. Although our ability to amend the terms of the warrants with the consent of at least 50% of the then-outstanding public warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, convert the warrants into cash, shorten the exercise period or decrease the number of Class A common stock purchasable upon exercise of a warrant. We may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.
A provision of our warrant agreement may make it more difficult for us to consummate an initial business combination.
Unlike most blank check companies, if (x) we issue additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to our initial stockholders or their affiliates, without taking into account any founder shares held by our initial stockholders or such affiliates, as applicable, prior to such issuance including any transfer or reissuance of such shares) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination, and (z) the volume weighted average trading price of our shares of Class A common stock during the 20 trading day period starting on the trading day prior to the day on which we consummate our initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price of the warrants will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, respectively. This may make it more difficult for us to consummate an initial business combination with a target business.
Provisions in our amended and restated certificate of incorporation and Delaware law may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our Class A common stock and could entrench management.
Our amended and restated certificate of incorporation contains provisions that may discourage unsolicited takeover proposals that stockholders may consider to be in their best interests. These provisions include a staggered board of directors and the ability of the board of directors to designate the terms of and issue new series of preferred shares, which may make the removal of management more difficult and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities.
We are also subject to anti-takeover provisions under Delaware law, which could delay or prevent a change of control. Together these provisions may make the removal of management more difficult and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities.
The grant of registration rights to our sponsor may make it more difficult to complete our initial business combination, and the future exercise of such rights may adversely affect the market price of our shares of common stock.
Our sponsor (and/or our sponsor’s designees) and their permitted transferees can demand that we register the founder shares, the placement shares, the placement warrants, the underlying securities and any securities issued upon conversion of working capital loans. We will bear the cost of registering these securities. The registration and availability of such a significant number of securities for trading in the public market may have an adverse effect on the market price of our shares of common stock. In addition, the existence of the registration rights may make our initial business combination more costly or difficult to conclude. This is because the stockholder of the target business may increase the equity stake they seek in the combined entity or ask for more cash consideration to offset the negative impact on the market price of our shares of common stock that is expected to occur when the securities owned by our sponsor, holders of our placement units or their respective permitted transferees are registered.
 
48

Risks Related to Ownership of Our Securities
You will not have any rights or interests in funds from the trust account, except under certain limited circumstances. To liquidate your investment, therefore, you may be forced to sell your public shares or warrants, potentially at a loss.
Our public stockholders will be entitled to receive funds from the trust account only upon the earliest to occur of: (i) our completion of an initial business combination, and then only in connection with those shares of Class A common stock that such stockholder properly elected to redeem, subject to the limitations described herein, (ii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or certain amendments to our charter prior thereto or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering or (B) with respect to any other provision relating to stockholders’ rights or
pre-initial business
combination activity and (iii) the redemption of our public shares if we are unable to complete an initial business combination within 24 months from the closing of our initial public offering, subject to applicable law and as further described herein. In no other circumstances will a public stockholder have any right or interest of any kind in the trust account. Holders of warrants will not have any right to the proceeds held in the trust account with respect to the warrants. Accordingly, to liquidate your investment, you may be forced to sell your public shares or warrants, potentially at a loss.
Nasdaq may delist our securities from trading on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions.
Our units, Class A Common Stock and warrants are listed on Nasdaq. In order to continue listing our securities on Nasdaq prior to our initial business combination, we must maintain certain financial, distribution and stock price levels. Generally, we must maintain a minimum amount in stockholders’ equity (generally $2,500,000) and a minimum number of holders of our securities (generally 300 public holders). Additionally, in connection with our initial business combination, we will be required to demonstrate compliance with Nasdaq’s initial listing requirements, which are more rigorous than Nasdaq’s continued listing requirements, in order to continue to maintain the listing of our securities on Nasdaq. For instance, our stock price would generally be required to be at least $4.00 per share, our stockholders’ equity would generally be required to be at least $5.0 million and we would be required to have a minimum of 300 round lot holders (with at least 50% of such round lot holders holding securities with a market value of at least $2,500) of our securities. We cannot assure you that we will be able to meet those initial listing requirements at that time.
If Nasdaq delists our securities from trading on its exchange and we are not able to list our securities on another national securities exchange, we expect our securities could be quoted on an
over-the-counter market.
If this were to occur, we could face significant material adverse consequences, including:
 
   
a limited availability of market quotations for our securities;
 
   
reduced liquidity for our securities;
 
   
a determination that our Class A common stock is a “penny stock” which will require brokers trading in our Class A common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;
 
   
a limited amount of news and analyst coverage; and
 
   
a decreased ability to issue additional securities or obtain additional financing in the future.
 
49

The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as “covered securities.” Although the states are preempted from regulating the sale of our securities, the federal statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. While we are not aware of a state having used these powers to prohibit or restrict the sale of securities issued by blank check companies, other than the State of Idaho, certain state securities regulators view blank check companies unfavorably and might use these powers, or threaten to use these powers, to hinder the sale of securities of blank check companies in their states. Further, if we were no longer listed on Nasdaq, our securities would not be covered securities and we would be subject to regulation in each state in which we offer our securities, including in connection with our initial business combination.
If a stockholder fails to receive notice of our offer to redeem our public shares in connection with our initial business combination, or fails to comply with the procedures for tendering its shares, such shares may not be redeemed.
We will comply with the proxy rules or tender offer rules, as applicable, when conducting redemptions in connection with our initial business combination. Despite our compliance with these rules, if a stockholder fails to receive our proxy solicitation or tender offer materials, as applicable, such stockholder may not become aware of the opportunity to redeem its shares. In addition, the proxy solicitation or tender offer materials, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will describe the various procedures that must be complied with in order to validly redeem or tender public shares. In the event that a stockholder fails to comply with these procedures, its shares may not be redeemed. See “Business — Effecting Our Initial Business Combination — Tendering Share Certificates in Connection with a Tender Offer or Redemption Rights.”
If we seek stockholder approval of our business combination and we do not conduct redemptions pursuant to the tender offer rules, and if you or a “group” of stockholders are deemed to hold in excess of 15% of our shares of common stock, you will lose the ability to redeem all such shares in excess of 15% of our shares of common stock.
If we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our business combination pursuant to the tender offer rules, our certificate of incorporation provides that a public stockholder, individually or together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to more than an aggregate of 15% of the shares sold in our initial public offering. Your inability to redeem more than an aggregate of 15% of the shares sold in our initial public offering will reduce your influence over our ability to consummate our initial business combination and you could suffer a material loss on your investment in us if you sell such excess shares in open market transactions. As a result, you will continue to hold that number of shares exceeding 15% and, in order to dispose of such shares, you would be required to sell your shares in open market transaction, potentially at a loss.
We may issue additional common stock or preferred stock to complete our initial business combination or under an employee incentive plan after completion of our initial business combination. We may also issue shares of Class A common stock upon the conversion of the Class B common stock at a ratio greater than
one-to-one
at the time of the consummation of our initial business combination as a result of the anti-dilution provisions contained in our amended and restated certificate of incorporation. Any such issuances would dilute the interest of our stockholders and likely present other risks.
Our amended and restated certificate of incorporation authorizes the issuance of up to 100,000,000 shares of Class A common stock, par value $0.0001 per share, 10,000,000 shares of Class B common stock, par value $0.0001 per share, and 1,000,000 shares of preferred stock, par value $0.0001 per share. There are 84,092,015 and 6,138,974 authorized but unissued shares of Class A common stock and Class B common stock, respectively, available for issuance, which amount includes the shares of Class A common stock reserved for issuance upon exercise of outstanding warrants or the shares of Class A common stock issuable upon conversion of Class B common stock. Shares of Class B common stock are convertible into shares of our Class A common stock initially at a
one-for-one ratio
but subject to adjustment as set forth herein, including in certain circumstances in which we issue Class A common stock or equity-linked securities related to our initial business combination.
 
50

We may issue a substantial number of additional shares of common or preferred stock to complete our initial business combination or under an employee incentive plan after completion of our initial business combination (although our amended and restated certificate of incorporation provides that we may not issue securities that can vote with common stockholders on matters related to our
pre-initial business
combination activity). We may also issue shares of Class A common stock upon conversion of the Class B common stock at a ratio greater than
one-to-one at
the time of the consummation of our initial business combination as a result of the anti-dilution provisions contained in our amended and restated certificate of incorporation. However, our amended and restated certificate of incorporation provides, among other things, that prior to our initial business combination, we may not issue additional shares of capital stock that would entitle the holders thereof to (i) receive funds from the trust account or (ii) vote on any initial business combination. These provisions of our amended and restated certificate of incorporation, like all provisions of our amended and restated certificate of incorporation, may be amended with the approval of our stockholders. However, our executive officers and directors have agreed, pursuant to a written agreement with us, that they will not propose any amendment to our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or certain amendments to our charter prior thereto or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering or (B) with respect to any other provision relating to stockholders’ rights or
pre-initial business
combination activity, unless we provide our public stockholders with the opportunity to redeem their shares of common stock upon approval of any such amendment at a
per-share price,
payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest (which interest shall be net of taxes payable), divided by the number of then outstanding public shares.
The issuance of additional shares of common or preferred stock:
 
   
may significantly dilute the equity interest of investors in our initial public offering, which dilution would increase if the anti-dilution provisions in the Class B common stock resulted in the issuance of Class A shares on a greater than
one-to-one basis
upon conversion of the Class B common stock;
 
   
may subordinate the rights of holders of our common stock if preferred stock is issued with rights senior to those afforded our common stock;
 
   
could cause a change of control if a substantial number of shares of our common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors;
 
   
may have the effect of delaying or preventing a change of control of us by diluting the stock ownership or voting rights of a person seeking to obtain control of us; and
 
   
may adversely affect prevailing market prices for our units, Class A common stock and/or warrants.
We may redeem unexpired warrants prior to their exercise at a time that is disadvantageous to the warrant holders.
We have the ability to redeem outstanding warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant, if, among other things, the Reference Value equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a
30-trading day
period ending on the third trading day prior to proper notice of such redemption. Please see “Description of Securities — Warrants — Redemption of Warrants When the Price Per Share of Class A Common Stock Equals or Exceeds $18.00.” We will not redeem the warrants unless an effective registration statement under the Securities Act covering the shares of Class A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A common stock is available throughout the
30-day redemption
period. If and when the warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws.
The value received upon exercise of the warrants (1) may be less than the value the holders would have received if they had exercised their warrants at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of the warrants. We will not redeem the warrants unless an effective registration statement under the Securities Act covering the shares of Class A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A common stock is available throughout the
30-day redemption
period, except if the warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act. If and when the warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws.
 
51

Redemption of the outstanding warrants could force you to (i) exercise your warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so, (ii) sell your warrants at the then-current market price when you might otherwise wish to hold your warrants or (iii) accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, is likely to be substantially less than the Market Value of your warrants.
Because each unit contains
one-fourth
of one warrant and only a whole warrant may be exercised, the units may be worth less than units of other blank check companies.
Each unit contains
one-fourth of
one warrant. Pursuant to the warrant agreement, no fractional warrants will be issued upon separation of the units, and only whole units will trade. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number the number of Class A common stock to be issued to the warrant holder. This is different from other offerings similar to ours whose units include one common stock and one warrant to purchase one whole share. We have established the components of the units in this way in order to reduce the dilutive effect of the warrants upon completion of a business combination since the warrants will be exercisable in the aggregate for
one-fourth of
the number of shares compared to units that each contain a whole warrant to purchase one share, thus making us, we believe, a more attractive merger partner for partner businesses. Nevertheless, this unit structure may cause our units to be worth less than if it included a warrant to purchase one whole share.
If we do not maintain a current and effective prospectus relating to the shares of common stock issuable upon exercise of the warrants, public holders will only be able to exercise such warrants on a “cashless basis” which would result in a fewer number of shares being issued to the holder than had such holder exercised the warrants for cash.
If we do not maintain a current and effective prospectus relating to the shares of common stock issuable upon exercise of the public warrants at the time that holders wish to exercise such warrants, they will only be able to exercise them on a “cashless basis” provided that an exemption from registration is available. As a result, the number of shares of common stock that a holder will receive upon exercise of its public warrants will be fewer than it would have been had such holder exercised its warrant for cash. Further, if an exemption from registration is not available, holders would not be able to exercise their warrants on a cashless basis and would only be able to exercise their warrants for cash if a current and effective prospectus relating to the shares of common stock issuable upon exercise of the warrants is available. Under the terms of the warrant agreement, we have agreed to use our commercially reasonable efforts to meet these conditions and to maintain a current and effective prospectus relating to the shares of common stock issuable upon exercise of the warrants until the expiration of the warrants. However, we cannot assure you that we will be able to do so. If we are unable to do so, the potential “upside” of the holder’s investment in us may be reduced or the warrants may expire worthless. Notwithstanding the foregoing, the placement warrants may be exercisable for unregistered shares of common stock for cash even if the prospectus relating to the shares of common stock issuable upon exercise of the warrants is not current and effective.
We have no obligation to net cash settle the warrants.
In no event will we have any obligation to net cash settle the warrants. Accordingly, the warrants may expire worthless.
Our management’s ability to require holders of our warrants to exercise such warrants on a cashless basis will cause holders to receive fewer shares of common stock upon their exercise of the warrants than they would have received had they been able to exercise their warrants for cash.
If we call our warrants for redemption when the price per share of Class A common stock equals or exceeds $18.00 after the criteria for such redemption have been satisfied, our management will have the option to require any holders that wishes to exercise their warrant to do so on a “cashless basis.” If our management chooses to require holders to exercise their warrants on a cashless basis, the number of shares of common stock received by a holder upon exercise will be fewer than it would have been had such holder exercised their warrant for cash. This will have the effect of reducing the potential “upside” of the holder’s investment in our company.
 
52

An investor will only be able to exercise a warrant for cash if the issuance of common stock upon such exercise has been registered or qualified or is deemed exempt under the securities laws of the state of residence of the holder of the warrants.
No public warrants will be exercisable for cash and we will not be obligated to issue shares of common stock unless the shares of common stock issuable upon such exercise have been registered or qualified or deemed to be exempt under the securities laws of the state of residence of the holder of the warrants. At the time that the warrants become exercisable, we expect to continue to be listed on a national securities exchange, which would provide an exemption from registration in every state. However, we cannot assure you of this fact. If the common shares issuable upon exercise of the warrants are not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, the warrants may be deprived of any value, the market for the warrants may be limited and they may expire worthless if they cannot be sold.
Holders of warrants will not participate in liquidating distributions if we are unable to complete an initial business combination within the required time period.
If we are unable to complete an initial business combination within the required time period and we liquidate the funds held in the trust account, the warrants will expire and holders will not receive any of such proceeds with respect to the warrants. The foregoing may provide a financial incentive to public stockholders to vote in favor of any proposed initial business combination as each of their warrants would entitle the holder to receive or purchase additional shares of common stock, resulting in an increase in their overall economic stake in us. If a business combination is not approved, the warrants will expire and will be worthless.
Because we must furnish our stockholders with target business financial statements prepared in accordance with U.S. generally accepted accounting principles or international financial reporting standards, we may lose the ability to complete an otherwise advantageous initial business combination with some prospective target businesses.
The federal proxy rules require that a proxy statement with respect to a vote on a business combination meeting certain financial significance tests include historical and/or pro forma financial statement disclosure in periodic reports. These financial statements may be required to be prepared in accordance with, or be reconciled to, accounting principles generally accepted in the United States of America, or GAAP, or international financial reporting standards, or IFRS, as issued by the International Accounting Standards Board or the IASB, depending on the circumstances. Historical financial statements may be required to be audited in accordance with the standards of the Public Company Accounting Oversight Board (United States), or PCAOB. We will include substantially the same financial statement disclosure in connection with any tender offer documents we use, whether or not they are required under the tender offer rules. These financial statement requirements may limit the pool of potential target businesses with which we consummate our initial business combination, because some targets may be unable to provide such statements in time for us to disclose such statements in accordance with federal proxy rules, and hence we may be unable to complete our initial business combination within the prescribed time frame.
The securities in which we invest the funds held in the trust account could bear a negative rate of interest, which could reduce the value of the assets held in trust such that the
per-share
redemption amount received by public stockholders may be less than $10.00 per share.
The proceeds held in the trust account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under
Rule 2a-7 under
the Investment Company Act, which invest only in direct U.S. government treasury obligations. While short-term U.S. government treasury obligations currently yield a positive rate of interest, they have briefly yielded negative interest rates in recent years. Central banks in Europe and Japan pursued interest rates below zero in recent years, and the Open Market Committee of the Federal Reserve has not ruled out the possibility that it may in the future adopt similar policies in the United States. In the event that we are unable to complete our initial business combination or make certain amendments to our amended and restated certificate of incorporation, our public stockholders are entitled to receive their prorate share of the proceeds held in the trust account, plus any interest income, net of taxes paid or payable (less, in the case we are unable to complete our initial business combination, $100,000 of interest). Negative interest rates could reduce the value of the assets held in trust such that the
per-share redemption
amount received by public stockholders may be less than $10.00 per share.
 
53

If third parties bring claims against us, the proceeds held in the trust account could be reduced and the
per-share
redemption amount received by stockholder may be less than $10.00 per public share.
Our placing of funds in the trust account may not protect those funds from third party claims against us. Although we will seek to have all vendors, service providers (excluding our independent registered public accounting firm), prospective partner businesses and other entities with which we do business execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust account for the benefit of our public stockholders, such parties may not execute such agreements, or even if they execute such agreements, they may not be prevented from bringing claims against the trust account, including, but not limited to, fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain advantage with respect to a claim against our assets, including the funds held in the trust account. If any third party refuses to execute an agreement waiving such claims to the monies held in the trust account, our founders will perform an analysis of the alternatives available to it and will only enter into an agreement with a third party that has not executed a waiver if our sponsor believes that such third party’s engagement would be significantly more beneficial to us than any alternative.
Examples of possible instances where we may engage a third party that refuses to execute a waiver include the engagement of a third party consultant whose particular expertise or skills are believed by our sponsor to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where our sponsor is unable to find a service provider willing to execute a waiver. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not seek recourse against the trust account for any reason. Upon redemption of our public shares, if we have not consummated an initial business combination within 24 months from the closing of our initial public offering or upon the exercise of a redemption right in connection with our initial business combination, we will be required to provide for payment of claims of creditors that were not waived that may be brought against us within the 10 years following redemption. Accordingly, the per share redemption amount received by public stockholder could be less than the $10.00 per public share initially held in the trust account, due to claims of such creditors. Pursuant to the letter agreement, our sponsor has agreed that it will be liable to us if and to the extent any claims by a third party owning, holding or trading “investment securities” constituting more than 40% of our assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. Our business will be to identify and complete a business combination and thereafter to operate the post-business combination business or assets for the long term. We do not plan to buy businesses or assets with a view to resale or profit from their resale. We do not plan to buy unrelated businesses or assets or to be a passive investor.
We do not believe that our anticipated principal activities will subject us to the Investment Company Act. To this end, the proceeds held in the trust account may only be invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under
Rule 2a-7 promulgated
under the Investment Company Act which invest only in direct U.S. government treasury obligations. Pursuant to the trust agreement, the trustee is not permitted to invest in other securities or assets. By restricting the investment of the proceeds to these instruments, and by having a business plan targeted at acquiring and growing businesses for the long term (rather than on buying and selling businesses in the manner of a merchant bank or private equity fund), we intend to avoid being deemed an “investment company” within the meaning of the Investment Company Act. Our initial public offering was not intended for persons who are seeking a return on investments in government securities or investment securities. The trust account is intended as a holding place for funds pending the earliest to occur of either: (i) the completion of our initial business combination; (ii) the redemption of any public shares properly tendered in connection with a stockholder vote to amend our amended and restated certificate of incorporation(A) to modify the substance or timing of our obligation to provide holders of shares of our Class A common stock the right to have their shares redeemed in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering or (B) with respect to any other provision relating to the rights of holders of shares of our Class A common stock, and (iii) the redemption of our public shares if we have not consummated an initial business within 24 months from the closing of our initial public offering, subject to applicable law and as further described herein. If we do not invest the proceeds as discussed above, we may be deemed to be subject to the Investment Company Act. If we were deemed to be subject to the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses for which we have not allotted funds and may hinder our ability to complete a business combination. If we do not complete our initial business combination within the required time period, our public stockholders may receive only approximately $10.00 per public share, or less in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless.
 
54

General Risk Factors
We are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of
non-compliance.
We are subject to rules and regulations by various governing bodies, including, for example, the SEC, which are charged with the protection of investors and the oversight of companies whose securities are publicly traded, and to new and evolving regulatory measures under applicable law. Our efforts to comply with new and changing laws and regulations have resulted in and are likely to continue to result in, increased general and administrative expenses and a diversion of management time and attention from seeking a business combination target.
Moreover, because these laws, regulations and standards are subject to varying interpretations, their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our disclosure and governance practices. If we fail to address and comply with these regulations and any subsequent changes, we may be subject to penalty and our business may be harmed.
We are an “emerging growth company” and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our securities less attractive to investors.
We are an “emerging growth company,” as defined in the JOBS Act. We will remain an “emerging growth company” for up to five years. However, if either our
non-convertible debt
issued within a three-year period, or our revenues exceed $1.07 billion, or the market value of our shares of common stock that are held by
non-affiliates exceeds
$700 million on the last day of the second fiscal quarter of any given fiscal year, we would cease to be an emerging growth company as of the following fiscal year. As an emerging growth company, we (i) are not required to comply with the auditor attestation requirements of section 404 of the Sarbanes-Oxley Act, (ii) have reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and (iii) are exempt from the requirements of holding a nonbinding advisory vote on executive compensation and obtaining stockholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging growth
companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, will not adopt the new or revised standard until the time private companies are required to adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accountant standards used.
 
55

We cannot predict if investors will find our shares less attractive because we may rely on these provisions. If some investors find our shares less attractive as a result, there may be a less active trading market for our shares and our share price may be more volatile.
Compliance obligations under the Sarbanes-Oxley Act of 2002 may make it more difficult for us to effectuate our initial business combination, require substantial financial and management resources, and increase the time and costs of completing an acquisition.
Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, requires that we evaluate and report on our system of internal controls beginning with our Annual Report on
Form 10-K for
the year ending December 31, 2021. The fact that we are a blank check company makes compliance with the requirements of the Sarbanes-Oxley Act particularly burdensome on us as compared to all public companies because a target company with which we seek to complete our initial business combination may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy of its internal controls. The development of the internal controls of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the time and costs necessary to complete any such acquisition.
If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to complete our initial business combination.
If we are deemed to be an investment company under the Investment Company Act, our activities may be restricted, including restrictions on the nature of our investments and restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial business combination. In addition, we may have imposed upon us burdensome requirements, including registration as an investment company, adoption of a specific form of corporate structure and reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations. If we were deemed to be subject to the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses for which we have not allotted funds and may hinder our ability to consummate our initial business combination.
In order not to be regulated as an investment company under the Investment Company Act, unless we can qualify for an exclusion, we must ensure that we are engaged primarily in a business other than investing, reinvesting or trading of securities and that our activities do not include investing, reinvesting, owning, holding or trading “investment securities” constituting more than 40% of our assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. Our business will be to identify and complete a business combination and thereafter to operate the post-business combination business or assets for the long term. We do not plan to buy businesses or assets with a view to resale or profit from their resale. We do not plan to buy unrelated businesses or assets or to be a passive investor.
We do not believe that our anticipated principal activities will subject us to the Investment Company Act. To this end, the proceeds held in the trust account may only be invested in U.S. “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under
Rule 2a-7 promulgated
under the Investment Company Act which invest only in direct U.S. government treasury obligations. Pursuant to the trust agreement, the trustee is not permitted to invest in other securities or assets. By restricting the investment of the proceeds to these instruments, and by having a business plan targeted at acquiring and growing businesses for the long term (rather than on buying and selling businesses in the manner of a merchant bank or private equity fund), we intend to avoid being deemed an “investment company” within the meaning of the Investment Company Act. Our initial public offering was not intended for persons who are seeking a return on investments in government securities or investment securities. The trust account is intended as a holding place for funds pending the earliest to occur of either: (i) the completion of our initial business combination; (ii) the redemption of any public shares properly tendered in connection with a stockholder vote to amend our amended and restated certificate of incorporation (A) to modify the substance or timing of our obligation to provide holders of our Class A common stock the right to have their shares redeemed in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering or (B) with respect to any other provision relating to the rights of holders of our Class A common stock or
pre-initial business
combination activity, and (iii) the redemption of our public shares if we have not consummated an initial business within 24 months from the closing of our initial public offering, subject to applicable law and as further described herein. If we do not invest the proceeds as discussed above, we may be deemed to be subject to the Investment Company Act. If we were deemed to be subject to the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses for which we have not allotted funds and may hinder our ability to complete a business combination. If we do not complete our initial business combination within the required time period, our public stockholders may receive only approximately $10.00 per public share, or less in certain circumstances, on the liquidation of our trust account and our warrants will expire worthless.
 
56

Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss.
We depend on digital technologies, including information systems, infrastructure and cloud applications and services, including those of third parties with which we may deal. Sophisticated and deliberate attacks on, or security breaches in, our systems or infrastructure, or the systems or infrastructure of third parties or the cloud, could lead to corruption or misappropriation of our assets, proprietary information and sensitive or confidential data. As an early stage company without significant investments in data security protection, we may not be sufficiently protected against such occurrences. We may not have sufficient resources to adequately protect against, or to investigate and remediate any vulnerability to, cyber incidents. It is possible that any of these occurrences, or a combination of them, could have adverse consequences on our business and lead to financial loss.
An investment in our securities, and certain subsequent transactions with respect to our securities, may result in uncertain or adverse U.S. federal income tax consequences.
An investment in our securities, and certain subsequent transactions with respect to our securities, may result in uncertain or adverse U.S. federal income tax consequences. For instance, because there are no authorities that directly address instruments similar to the units we issued in our initial public offering, the allocation an investor makes with respect to the purchase price of a unit between the share of Class A common stock and the
one-fourth of
one redeemable warrant to purchase one share of our Class A common stock included in each unit could be challenged by the U.S. Internal Revenue Service, or the IRS, or the courts. Furthermore, the U.S. federal income tax consequences of a cashless exercise of warrants included in the units we issued in our initial public offering is unclear under current law, and the adjustment to the exercise price and/or redemption price of the warrants could give rise to dividend income to investors without a corresponding payment of cash. In addition, it is unclear whether the redemption rights with respect to our shares of Class A common stock suspend the running of a U.S. holder’s holding period for purposes of determining whether any gain or loss realized by such holder on the sale or exchange of Class A common stock is long-term capital gain or loss and for determining whether any dividend we pay would be eligible for favorable U.S. federal income tax treatment.
Furthermore, if we are determined to be a personal holding company for U.S. federal income tax purposes in a given taxable year, certain portions of our taxable income in such taxable year would be subject to an additional 20% tax, which would reduce the net
after-tax amount
of interest income earned on the funds placed in our trust account. We would generally be classified as a personal holding company for U.S. federal income tax purposes in a given taxable year if (i) at any time during the last half of such taxable year, five or fewer individuals (without regard to their citizenship or residency and including as individuals for this purpose certain entities such as certain
tax-exempt organizations,
pension funds and charitable trusts) own or are deemed to own (pursuant to certain constructive ownership rules) more than 50% of the outstanding stock of the corporation by value and (ii) at least 60% of the corporation’s adjusted ordinary gross income, as determined for U.S. federal income tax purposes, for such taxable year consists of personal holding company income (which includes, among other things, dividends, interest, certain royalties, annuities and, under certain circumstances, rents). See the section titled “U.S. Federal Income Tax Considerations” for a summary of certain U.S. federal income tax considerations generally applicable to an investment in our securities. Prospective investors are urged to consult with and rely solely upon their tax advisors with respect to these and other tax considerations applicable to their specific circumstances when acquiring, holding or disposing of our securities.
 
57

Risks Associated with Acquiring and Operating a Business outside of the United States
We may effect our initial business combination with a company located outside of the United States.
If we effect our initial business combination with a company located outside of the United States, we would be subject to any special considerations or risks associated with companies operating in the target business’ home jurisdiction, including any of the following:
 
 
rules and regulations or currency redemption or corporate withholding taxes on individuals;
 
 
laws governing the manner in which future business combinations may be effected;
 
 
exchange listing and/or delisting requirements;
 
 
tariffs and trade barriers;
 
 
regulations related to customs and import/export matters;
 
 
longer payment cycles;
 
 
tax issues, limits on our ability to change our tax residence from the United States, complex withholding and other tax regimes that may apply in connection with our business combination or to our structure following our business combination, such as tax law changes and variations in tax laws as compared to the United States;
 
 
currency fluctuations and exchange controls;
 
 
rates of inflation or deflation;
 
 
challenges in collecting accounts receivable;
 
 
cultural and language differences;
 
 
employment regulations;
 
 
crime, strikes, riots, civil disturbances, terrorist attacks, pandemics and wars; and
 
 
deterioration of political relations with the United States. We may not be able to adequately address these additional risks. If we were unable to do so, our operations might suffer.
Social unrest, acts of terrorism, regime changes, changes in laws and regulations, political upheaval, or policy changes or enactments may occur in a country in which we may operate after we effect our initial business combination.
Political events in another country may significantly affect our business, assets or operations. Social unrest, acts of terrorism, regime changes, changes in laws and regulations, political upheaval, pandemics and policy changes or enactments could negatively impact our business in a particular country.
Many countries have difficult and unpredictable legal systems and underdeveloped laws and regulations that are unclear and subject to corruption and inexperience.
Our ability to seek and enforce legal protections, including with respect to intellectual property and other property rights, or to defend ourselves with regard to legal actions taken against us in a given country, may be difficult or impossible, which could adversely impact our operations, assets or financial condition.
Rules and regulations in many countries are often ambiguous or open to differing interpretation by responsible individuals and agencies at the municipal, state, regional and federal levels. The attitudes and actions of such individuals and agencies are often difficult to predict and inconsistent.
Delay with respect to the enforcement of particular rules and regulations, including those relating to customs, tax, environmental and labor, could cause serious disruption to operations abroad and negatively impact our results.
 
58

If relations between the United States and foreign governments deteriorate, it could cause potential target businesses or their goods and services to become less attractive.
The relationship between the United States and foreign governments could be subject to sudden fluctuation and periodic tension. For instance, the United States may announce its intention to impose quotas on certain imports. Such import quotas may adversely affect political relations between the two countries and result in retaliatory countermeasures by the foreign government in industries that may affect our ultimate target business. Changes in political conditions in foreign countries and changes in the state of U.S. relations with such countries are difficult to predict and could adversely affect our operations or cause potential target businesses or their goods and services to become less attractive. Because we are not limited to any specific industry, there is no basis for investors in our initial public offering to evaluate the possible extent of any impact on our ultimate operations if relations are strained between the United States and a foreign country in which we acquire a target business or move our principal manufacturing or service operations.
If our management following our initial business combination is unfamiliar with United States securities laws, they may have to expend time and resources becoming familiar with such laws.
Following our initial business combination, our management may resign from their positions as officers or directors of the company and the management of the target business at the time of the business combination will remain in place. Management of the target business may not be familiar with United States securities laws. If new management is unfamiliar with our laws, they may have to expend time and resources becoming familiar with such laws. This could be expensive and time-consuming and could lead to various regulatory issues, which may adversely affect our operations.
Currency policies may cause a target business’ ability to succeed in the international markets to be diminished.
In the event we acquire a
non-U.S.
target, all revenues and income would likely be received in a foreign currency, the dollar equivalent of our net assets and distributions, if any, could be adversely affected by reductions in the value of the local currency. The value of the currencies in our target regions fluctuate and are affected by, among other things, changes in political and economic conditions. Any change in the relative value of such currency against our reporting currency may affect the attractiveness of any target business or, following consummation of our initial business combination, our financial condition and results of operations. Additionally, if a currency appreciates in value against the dollar prior to the consummation of our initial business combination, the cost of a target business as measured in dollars will increase, which may make it less likely that we are able to consummate such transaction.
Because foreign law could govern our material agreements, we may not be able to enforce our rights within such jurisdiction or elsewhere.
Foreign law could govern our material agreements. The target business may not be able to enforce any of its material agreements and remedies may not be available outside of such foreign jurisdiction’s legal system. The system of laws and the enforcement of existing laws and contracts in such jurisdiction may not be as certain in implementation and interpretation as in the United States. The judiciaries in certain foreign countries may be relatively inexperienced in enforcing corporate and commercial law, leading to a higher than usual degree of uncertainty as to the outcome of any litigation. Any such jurisdictions may not favor outsiders or could be corrupt. As a result, the inability to enforce or obtain a remedy under any of our future agreements could result in a significant loss of business and business opportunities.
We have identified a material weakness in our internal control over financial reporting. If we are unable to develop and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us and materially and adversely affect our business and operating results.
As described elsewhere in this Annual Report on Form 10-K, we have identified a material weakness in our internal control over financial reporting related to the Company’s accounting and reporting of complex financial instruments. We have taken a number of measures to remediate the material weakness described herein. However, if we are unable to remediate our material weakness in a timely manner or we identify additional material weaknesses, we may be unable to provide required financial information in a timely and reliable manner and we may incorrectly report financial information. Likewise, if our financial statements are not filed on a timely basis, we could be subject to sanctions or investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities. The existence of a material weakness in internal control over financial reporting could adversely affect our reputation or investor perceptions of us, which could have a negative effect on the trading price of our securities. We can give no assurance that the measures we have taken and plan to take in the future will remediate the material weakness identified or that any additional material weaknesses or restatements of financial results will not arise in the future due to a failure to implement and maintain adequate internal control over financial reporting or circumvention of these controls. Even if we are successful in strengthening our controls and procedures, in the future those controls and procedures may not be adequate to prevent or identify irregularities or errors or to facilitate the fair presentation of our financial statements.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis.
Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. We continue to evaluate steps to remediate the material weakness. These remediation measures may be time consuming and costly and there is no assurance that these initiatives will ultimately have the intended effects.
If we identify any new material weaknesses in the future, any such newly identified material weakness could limit our ability to prevent or detect a misstatement of our accounts or disclosures that could result in a material misstatement of our annual or interim financial statements. In such case, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting and the price of our securities may decline as a result. We cannot assure you that any measures we may take in the future, will be sufficient to avoid potential future material weaknesses.
 
Item 1B.
Unresolved Staff Comments
None.
 
59

Item 2
Properties
We currently maintain our executive offices at 1177 Avenue of the Americas, 5
th
 Floor, New York, New York 10036. We will reimburse an affiliate of our sponsor for office space, secretarial and administrative services provided to us in the amount of $10,000 per month. We consider our current office space adequate for our current operations.
 
Item 3
Legal Proceedings
To the knowledge of our management, there is no litigation currently pending or contemplated against us, any of our officers or directors in their capacity as such or against any of our property.
 
Item 4
Mine Safety Disclosures
Not applicable.
PART II
 
Item  5
Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities
 
 
(a)
Market Information
Our units, Class A common stock and warrants are each traded on the Nasdaq Capital Market under the symbols “ALPAU,” “ALPA” and “ALPAW,” respectively. Our units commenced public trading on July 29, 2021. Our Class A common stock and warrants began separate trading on or about September 15, 2021.
 
 
(b)
Holders
On December 31, 2021, there were 6 holders of record of our units, 1 holder of record of our Class A common stock, 5 holders of record of our Class B common stock and 1 holder of record of our warrants. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners whose securities are held in the names of various security brokers, dealers, and registered clearing agencies.
 
 
(c)
Dividends
We have not paid any cash dividends on our common stock to date and do not intend to pay cash dividends prior to the completion of our initial business combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of our initial business combination. Further, if we incur any indebtedness in connection with our initial business combination, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith.
 
 
(d)
Securities Authorized for Issuance Under Equity Compensation Plans
None.
 
 
(e)
Performance Graph
Not applicable.
 
 
(f)
Recent Sales of Unregistered Securities; Use of Proceeds from Registered Offerings
On July 29, 2021, we consummated our Initial Public Offering of 15,000,000 Units at a price of $10.00 per Unit, generating total gross proceeds of $150,000,000. BofA Securities Inc. and PJT Partners LP acted as book-running managers. The securities sold in the initial public offering were registered under the Securities Act on a registration statement on
Form S-1
(No. 333-253876).
The registration statements became effective on July 26, 2021.
Simultaneously with the consummation of the Initial Public Offering, we consummated a private placement of 455,000 Private Placement Units to our Sponsor at a price of $10.00 per Private Placement Unit, generating total proceeds of $4,550,000. Such securities were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.
 
60

On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units for the total amount of $4,441,030. Resulting from the partial over-allotment exercise, the Company issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds.
A total of $154,441,030, composed of the proceeds of the Initial Public Offering, including from the exercise of the over-allotment option by the Underwriters, and the sale of the Private Placement Units, including $5,405,436 of the underwriters’ deferred discount, was placed in the Trust Account.
We paid a total of $3,000,000 in underwriting discounts and commissions and $461,151 for other costs and expenses related to the Initial Public Offering. In addition, the Company also included in offering costs the fair value of $1,186,448 of Founders Shares transferred by the Sponsor to certain investors as a compensation for their commitment to purchase the Public Units sold in our initial public offering. In addition, the underwriters agreed to defer $5,250,000 in underwriting discounts and commissions. Transaction costs related to the Underwriters’ partial over-allotment exercise amounted to $92,070, consisting of $88,820 of underwriting fees and $3,250 of other offering costs. The Company has also accrued underwriting fees of $5,405,436 that will be paid only if a business combination is entered into.
 
 
(g)
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None.
 
Item  6
Reserved.
Not Applicable.
 
Item  7
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
References to the “Company,” “our,” “us” or “we” refer to Alpha Healthcare Acquisition Corp. III. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the audited financial statements and the notes thereto contained elsewhere in this Annual Report on Form
10-K.
Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.
Cautionary Note Regarding Forward-Looking Statements
This Annual Report on Form
10-K
includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Such statements include, but are not limited to, possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this Form
10-K.
Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other Securities and Exchange Commission (“SEC”) filings.
Overview
We are a blank check company incorporated on January 21, 2021 as a Delaware corporation for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. We have not selected any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We intend to effectuate our initial business combination using cash from the proceeds of our Initial Public Offering and the private placement of the Private Placement Units, our shares, debt or a combination of cash, equity and debt.
We expect to incur significant costs in the pursuit of our initial Business Combination. We cannot assure you that our plans to raise capital or to complete our initial Business Combination will be successful.
 
61

Results of Operations and Known Trends or Future Events
We have neither engaged in any operations nor generated any revenues to date. Our only activities since inception have been organizational activities, activities necessary to prepare for and complete our Initial Public Offering, and activities related to identifying a potential target for an initial business combination. Since our Initial Public Offering, we have not generated any operating revenues, and do not expect to generate any operating revenues, until after completion of our initial business combination. $8,091 of dividend and interest income has been earned in the Trust Account through December 31, 2021. We will continue to
generate non-operating income
in the form of dividend and interest income on cash and cash equivalents held in the Trust Account. As a result of being a public company, we have incurred, and will continue to incur, legal, financial reporting, accounting and auditing compliance expenses, as well as due diligence expenses related to potential targets.
For the period from January 21, 2021 (inception) through December 31, 2021, we had a net loss of $329,382, which consisted of formation and general and administrative costs.
Liquidity, Capital Resources and Going Concern
Until the consummation of the Initial Public Offering, our only source of liquidity was an initial purchase of Class B common stock by the Sponsor and loans from our Sponsor.
On July 29, 2021, we consummated the Initial Public Offering of 15,000,000 Units at a price of $10.00 per Unit, generating gross proceeds of $150,000,000. Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 455,000 Private Placement Units to the Sponsor at a price of $10.00 per Private Placement Unit generating gross proceeds of $4,550,000. We incurred $9,897,599 in transaction costs, including $3,000,000 of underwriting fees, $1,186,448 representing the fair value of the Founder Shares transferred from the Sponsor to certain investors as an incentive to purchase the Units, underwriting fees of $5,250,000 that will be paid only if a business combination is entered into, and $461,151 of other offering costs.
On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units for the total amount of $4,441,030 resulting from the partial over-allotment exercise. The Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds. Transaction costs related to the Underwriters’ partial over-allotment exercise amounted to $247,506, consisting of $88,820 of underwriting fees, deferred underwriting fees of $155,436 that will be paid only if a business combination is entered into, and $3,250 of other offering costs.
Following our initial public offering, the sale of the Private Placement Units and the exercise of the over-allotment option, a total of $154,441,030 was placed in the Trust Account, and we had $1,550,000 of cash held outside of the Trust Account, after payment of costs related to the Initial Public Offering, and available for working capital purposes. As of December 31, 2021, the Company had cash outside the Trust Account of $774,192 available for working capital needs.
We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account, excluding deferred underwriting commissions, to complete our Business Combination. We may withdraw interest from the Trust Account to pay taxes, if any. To the extent that our share capital or debt is used, in whole or in part, as consideration to complete a Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.
We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, structure, negotiate and complete a Business Combination.
 
62

In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete a Business Combination, we may repay such loaned amounts out of the proceeds of the Trust Account released to us. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into placement units of the post-business combination entity at a price of $10.00 per placement unit at the option of the lender. The placement units would be identical to the units.
We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than an agreement to pay an affiliate of the Sponsor a monthly fee of $10,000 for office space, secretarial and administrative services provided to the Company. We began incurring these fees on July 26, 2021 and will continue to incur these fees monthly until the earlier of the completion of a Business Combination and the Company’s liquidation.
The underwriters are entitled to a deferred fee of $0.35 per unit, or $5,405,436.05 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement.
For the period from January 21, 2021 (inception) through December 31, 2021, we had a net loss of $329,382, which consisted of formation and general and administrative costs.
The $774,192 held outside of the Trust Account as of December 31, 2021, may not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company may need to raise additional capital through loans or additional investments from its Sponsor, stockholders, officers, directors, or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern, assuming a Business Combination is not consummated. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
The Company believes that the proceeds raised in the initial public offering and the funds potentially available from loans from the sponsor or any of their affiliates will be sufficient to allow the Company to meet the expenditures required for operating its business. However, if the estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to the initial Business Combination. Moreover, the Company may need to obtain additional financing either to complete the Business Combination or because the Company becomes obligated to redeem a significant number of public shares upon completion of the Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination.
Related Party Transactions
Founder Shares
On January 21, 2021, the Sponsor subscribed to purchase 3,593,750 shares of the Company’s common stock, par value $0.0001 per share (the “Founder Shares”) for an aggregate price of $25,000. On January 25, 2021, the Sponsor paid $25,000, or approximately $0.00696 per share, to cover for certain offering and formation costs in consideration for 3,593,750 Founder Shares. On March 1, 2021, the Company effected a 1:1.2 stock split of its common stock which resulted in an aggregate of 4,312,500 shares of Class B common stock outstanding. All shares and associated amounts have been retroactively restated to reflect the stock split. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units out of the total 2,250,000 available under the over-allotments and the forfeiture provisions lapsed for 111,026 Founder Shares. The remaining 451,464 Founder Shares were forfeited upon the expiration of
the 45-day period
reserved for the exercise of over-allotment option.
At the date of our initial public offering, the Sponsor also transferred to certain investors a total of 225,000 of Founders shares as a compensation for their commitment to purchase the Public Units sold in our initial public offering. The Company estimated the aggregate fair value of these shares to be $1,186,448, or $5.27 per share. The fair value of the
Non-Risk
Incentive Private Shares was determined to be a contribution from the Sponsor for offering costs in accordance with Staff Accounting Bulletin Topic 5T. These offering costs were allocated to the Units and charged to shareholder’s equity upon the completion of the Initial Public Offering.
At the date of our initial public offering, the Sponsor also transferred to certain other investors the total of 600,900 of Founders shares (“Risk Incentive Private Shares”) as a compensation for their commitment to acquire at least 9.9% of the Units sold in our initial public offering. These Risk Incentive Private Shares are subject to forfeiture if the investors sell their Units prior to the closing of the initial Business Combination. The fair value of these Risk Incentive Private Shares is equal to the fair value of the
Non-Risk
Incentive Private Shares. Due to the high probability of forfeiture, the fair value of these Risk Incentive Private Shares will be recorded as a capital contribution from the Sponsor upon the closing of the initial Business Combination The Sponsor, directors and executive officers have agreed not to transfer, assign or sell (i) any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Company’s shares of Class A common stock equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within
any 30-trading day
period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of its public shareholders having the right to exchange their common stock for cash, securities or other property, and (ii) any of their Private Placement Units, placement shares, Private Placement Warrants and Class A common stock issued upon conversion or exercise thereof until 30 days after the completion of the initial Business Combination
(the “Lock-up”). Any
permitted transferees will be subject to the same restrictions and other agreements of the Sponsor and directors and executive officers with respect to any Founder Shares, Private Placement Units, placement shares, Private Placement Warrants and Class A common stock issued upon conversion or exercise thereof.
 
63

Private Placement
Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased 455,000 placement units, at a purchase price of $4,550,000, in a private placement. Each Private Placement Unit is identical to the Units sold in the Initial Public Offering except as described below. A portion of the proceeds from the Private Placement Units was added to the proceeds from the Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law).
Resulting from the partial over-allotment exercise on August 3, 2021, the Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds.
On January 25, 2021, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $300,000 to be used for a portion of the expenses of the Proposed Public Offering. This loan
is non-interest bearing,
unsecured, and due at the earlier of (i) the date on which the Company consummates the initial public offering and (ii) the date on which the Company determines not to conduct an initial public offering of its securities, upon request from the Company the Sponsor. Any loan balances were to be repaid upon the closing of the Proposed Public Offering out of the initial public offering proceeds not held in the Trust Account. The Company made no borrowings under the promissory note.
Due to Related Party
The balance of $2,275 as of December 31, 2021, represents general and administrative costs paid by the Sponsor on behalf the Company.
Administrative Service Fee
The Company has agreed, commencing on the date that the Company’s securities are first listed on the Nasdaq, to pay an affiliate of the Sponsor a monthly fee of an aggregate of $10,000 for office space, administrative and support services. For the period from January 21, 2021 (inception) through December 31, 2021, administrative fees incurred and paid to the Sponsor totaled $51,000. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees.
 
64

Related Party Loans
In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon consummation of a Business Combination into warrants at a price of $1.50 per warrant. The warrants will be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of December 31, 2021, there were no written agreements in place for the Working Capital Loans.
Commitments and Contingencies
Registration Rights
The holders of the founder shares, placement units (including securities contained therein) and units (including securities contained therein) that may be issued upon conversion of working capital loans, and any shares of Class A common stock issuable upon the exercise of the placement warrants and any shares of Class A common stock and warrants (and underlying Class A common stock) that may be issued upon conversion of the units issued as part of the working capital loans and Class A common stock issuable upon conversion of the founder shares, will be entitled to registration rights pursuant to the registration rights agreement requiring us to register such securities for resale (in the case of the founder shares, only after conversion to our Class A common stock). The holders of the majority of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of an initial business combination and rights to require us to register for resale such securities pursuant to Rule 415 under the Securities Act. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering our securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Contractual Obligations
We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than the underwriters are entitled to a deferred fee of $5,405,436 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a business combination, subject to the terms of the underwriting agreement.
JOBS Act
The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company” and under the JOBS Act will be allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for
non-emerging
growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.
Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of
non-emerging
growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our initial public offering or until we are no longer an “emerging growth company,” whichever is earlier.
Critical Accounting Policies and Estimates
The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. There were no critical accounting policies that contained significant judgment or estimates. Refer to Note 2 for the Company’s accounting policies.
Recent Accounting Standards
Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our financial statements.
 
65

Item 7A
Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined by Rule
12b-2
of the Exchange Act and are not required to provide the information otherwise required under this item.
 
Item  8
Financial Statements and Supplementary Data
This information appears following Item 16 of this Report and is incorporated herein by reference.
 
Item  9
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
 
Item 9A
Controls and Procedures
Disclosure Controls and Procedures
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
Evaluation of Disclosure Controls and Procedures
As required by Rules
13a-15
and
15d-15
under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2021. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that during the period covered by this report, our disclosure controls and procedures were not effective due to a material weakness in internal controls over financial reporting related to the accounting for complex financial instruments. Management identified errors in its historical financial statements related to the accounting for the Class A common stock subject to redemption. Because the Class A common stock issued in the Initial Public Offering can be redeemed or become redeemable subject to the occurrence of future events considered outside of the Company’s control, the Company should have classified all of these redeemable shares in temporary equity. In addition, errors were identified related to the overallotment liability, which was not recorded in the three months ended September 30, 2021, or in the audited balance sheet as of July 29, 2021, and was corrected in the financial statements as of December 31, 2021 included in this annual report.
To address this material weakness, management has devoted, and plans to continue to devote, significant effort and resources to the remediation and improvement of its internal control over financial reporting and to provide processes and controls over the internal communications within the Company, financial reporting advisors and independent registered public accounting firm. While we have processes to identify and appropriately apply applicable accounting requirements, we plan to enhance these processes to better evaluate our research and understanding of the nuances of the complex accounting standards that apply to our financial reporting requirements by utilizing the expertise of outside financial reporting advisors to support the Company in evaluating these transactions. We can offer no assurance that these initiatives will ultimately have the intended effects. Other than this issue, our disclosure controls and procedures were effective at a reasonable assurance level and, accordingly, provided reasonable assurance that the information required to be disclosed by us in reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.
Changes in Internal Control Over Financial Reporting
Other than changes that have resulted from the material weakness remediation activities noted above, there has been no change in our internal control over financial reporting, during the period covered by this report, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 
66

Item 9B.
Other Information
None.
 
Item 9C.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not Applicable.
PART III
 
Item
 
10
Directors, Executive Officers and Corporate Governance
Directors and Executive Officers
As of March 22, 2022, our directors and officers are as follows:
 
NAME
   AGE   
POSITION
Rajiv Shukla    47    Chief Executive Officer and Chairman
Patrick A. Sturgeon
   46    Chief Financial Officer and Secretary
Darlene T. DeRemer
   66    Director
Eugene L. Podsiadlo
   65    Director
William Woodward
   62    Director
Rajiv S. Shukla
 has been our Chairman and Chief Executive Officer since inception and has two decades of buyouts, investments and operations experience in the healthcare industry. Since August 2021, Mr. Shukla has served as a director of Humacyte, Inc. (“HUMA”). Mr. Shukla also served as Chairman and Chief Executive Officer of Constellation Alpha Capital Corp. (“CNAC”), a Nasdaq-listed special purpose acquisition company, from June 2017 to August 2019. Since August 2019, Mr. Shukla has served as an independent director on the board of directors of InflammX Therapeutics, formerly known as Ocunexus Therapeutics, a clinical stage biotech company. From June 2013 to May 2015, Mr. Shukla served as Chief Executive Officer of Pipavav Defence & Offshore Engineering Company (now Reliance Naval and Engineering Ltd.), an Indian listed shipbuilding and defense manufacturing company. In this role, he successfully implemented an extensive financial restructuring project and sold control to the Reliance ADA Group. Between 2008 and 2013, Mr. Shukla worked as an investor at ICICI Venture, Morgan Stanley Investment Management and Citi Venture Capital International. Throughout his investment career, Mr. Shukla has been involved with numerous investments in healthcare companies. As a private equity investor, Mr. Shukla was involved with numerous control and minority healthcare investments including a hospital
roll-up platform
comprising multiple control investments and significant minority stakes in tertiary care hospitals and outpatient treatment centers, a
roll-up of
specialty chemicals and animal health businesses, a U.S. based clinical research organization, a vaccine company, and three specialty pharma companies. From 2001 to 2006, Mr. Shukla served as Senior Director at Pfizer, Inc. (NYSE:PFE). In this role, he played a key role in several acquisitions including Pharmacia in 2003, Meridica in 2004, Vicuron Pharmaceuticals and Idun Pharmaceuticals in 2005, and Rinat Neuroscience in 2006. Mr. Shukla also led the operational integration of these organizations into Pfizer across multiple sites around the world. Mr. Shukla graduated from Harvard University with a Masters in Healthcare Management and Policy and received a Bachelors in Pharmaceutics from the Indian Institute of Technology. We believe Mr. Shukla is well qualified to serve as one of our directors due to his extensive operations, finance and investment experience.
Patrick A. Sturgeon
 has been our Chief Financial Officer since inception and has nearly two decades of experience with M&A and equity capital market transactions in the healthcare and other sectors. Since May 2020, Mr. Sturgeon has served as Chief Financial Officer of Brookline Capital Acquisition Corp., a Nasdaq-listed special purpose acquisition company. He has also served as a Managing Director at Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”) since March 2016. At Brookline, Mr. Sturgeon focuses on mergers and acquisitions, public financing, private capital raising, secondary offerings, and capital markets. On the public financing front, he focuses on SPAC transactions, primarily underwritten initial public offerings and initial business combinations. From July 2013 to February 2016, Mr. Sturgeon served as a Managing Director at Axiom Capital Management. He worked at Freeman & Co. from October 2002 to November 2011, where he focused on mergers and acquisitions in the financial services sector. Mr. Sturgeon received his B.S. in Economics from the University of Massachusetts, Amherst and his M.B.A. in Finance from New York University.
 
67

Darlene T. DeRemer
 serves as one of our directors as of the date hereof. Mrs. DeRemer was a founding partner of Grail Partners LLC in 2005 until her retirement in 2019, where she served as a senior banker focusing on the asset management industry worldwide. Prior to founding Grail, Ms. DeRemer served as an investment banker at Putnam Lovell NBF from 2003 to 2005. Prior to becoming an investment banker at Putnam Lovell NBF, Ms. DeRemer Darlene spent twenty-five years. as a leading adviser to the financial services industry, specializing in strategic marketing, planning, product design and the implementation of innovative service strategies, including operating her own strategy firm in asset management, DeRemer + Associates, the first consultancy focused on the U.S. mutual fund industry. From 1985 to 1987 Ms. DeRemer was vice president and director in the Asset Management Division of State Street Bank & Trust Company (now State Street Global Advisors) where she managed the $4 billion Pension Real Estate Department and developed marketing communications and client service programs. Prior to joining State Street, Ms. DeRemer was a vice president at T. Rowe Price & Associates from 1982 to 1985. Ms. DeRemer’s career started in strategic planning, at Tiger International and its subsidiary, Flying Tiger Airlines. Ms. DeRemer currently serves on the Syracuse University Board of Trustees and Investment and Endowment Committee, the board of directors of Confluence Technologies, LLC and as the ARK Investment ETF Trust chairman. She has previously has served on the Congressional task force which was instrumental in the passage of the Pension Portable Act of 1998 and she provided testimony to the U.S. General Accounting Office’s 2000 Mutual Fund Fee and Expense Study. Ms. DeRemer earned a BS in finance and marketing summa cum laude and MBA degree with distinction from Syracuse University.
Eugene L. Podsiadlo
 serves as one of our directors as of the date hereof. Since 2019, Mr. Podsiadlo has been a shareholder and member of the board of advisors at The Singapore Forum, APAC Leadership Forum, Ltd. (London). From December 2020 to March 2021, Mr. Podsiadlo was a member of the board of trustees and chairperson of the audit committee for Esoterica Thematic ETF Trust. Mr. Podsiadlo was a member of the board of directors and partner at Wasatch Advisors, a privately-held global asset manager, with a focus on small- to
mid-cap public
companies around the world from 2001 to 2016, and a special advisor to its board of directors from 2017-2018. From 2001-2002, he was a director and audit committee member of American Capital Strategies (Nasdaq: ACAS), a mezzanine and senior debt financing company. Mr. Podsiadlo is a former partner/managing director of the global venture capital firm Warburg Pincus & Co. from 1991 to 2001. Mr. Podsiadlo was also partner of Warburg Pincus Asset Management, and president of Warburg Pincus Funds until the sale of the asset management division to Credit Suisse Group AG in 2000. Prior to the acquisition, Mr. Podsiadlo served as the
co-chief executive
officer of a joint venture with Credit Suisse Asset Management in Tokyo. Mr. Podsiadlo received a B.S. in Economics from The Wharton School, University of Pennsylvania and an M.B.A. from the University of Maryland.
William Woodword
 serves as one of our directors as of the date hereof. Mr. Woodward currently serves as the managing general partner of Anthem Venture Partners, a venture capital firm that he solely founded in 1999 where he raised their initial $120 million fund. Through Anthem. Mr. Woodward has made significant early-stage direct investments in privately held companies that have achieved significant enterprise values such as: Scopely, VideoAmp, Surfair, Jiko, DailyPay and Indie Semiconductor. Mr. Woodward has served on the board of directors or as an advisor to a number of other technology companies, including: TrueCar, InterMix “MySpace”, Cognet Microsystems, Android (acquired by Google), Advanced Cell Technologies, Celenex, Launch Music and NevenVision. Prior to founding Anthem, Mr. Woodward was a part of Avalon, a $100 million venture capital fund where he served as a general partner managing the West Coast in the late 1990’s. Mr. Woodward founded Celenex, a gene-therapy company with a mission to cure neurodegenerative disorders in pediatrics in 2017 which was acquired by Amicus Therapeutics in 2018. In addition to Celenex, Mr. Woodward founded ImmunoVec Inc, a venture-backed gene-therapy company with a focus on curing rare pediatric genetic disorders of the immune system. Prior to Celenex and ImmunoVec, Mr. Woodward was also a
co-founder Cognet
Microsystems, a company building fiberoptic networks based on technology from the University of California Los Angeles, prior to its sale to Intel in 2001. Mr. Woodward also
co-founded NevenVision
in 2003 which was acquired by Google in 2006. In 1994 Mr. Woodward founded Pulse Entertainment, a maker of 3D games and character authoring software. Mr. Woodward served as the chief executive officer and chairman of the board through 1998. In addition to Pulse Entertainment, Mr. Woodward
co-founded Launch
Media Inc, which went public in 1999 and was later acquired by Yahoo in 2001 and became Yahoo Music. Mr. Woodward began his career in technology as the sole founder of Paracomp, a San Francisco based software publisher that was known for developing early desktop multimedia software applications, which he created in 1986. In 1991 Paracomp merged with Macromind to form MacroMedia. Mr. Woodward served as the chairman of the board and ran business development for the company prior to their acquisition by Adobe in in 2005.
 
68

We believe our board of directors and management team are well positioned to take advantage of the growing set of investment opportunities focused on the biotechnology sector, and that our contacts, relationships and investment and operating experience will allow us to generate an attractive transaction for our shareholders.
There are no family relationships between any director, executive officer, or person nominated or chosen to become a director or officer.
Number and Terms of Office of Officers and Directors
Our board of directors is divided into three classes, with only one class of directors being elected in each year, and with each class (except for those directors appointed prior to our first annual meeting of stockholders) serving a three-year term. The term of office of the first class of directors, consisting of William Woodward expires at our first annual meeting of stockholders. The term of office of the second class of directors, consisting of Darlene T. DeRemer and Eugene Podsiadlo expires at our second annual meeting of stockholders. The term of office of the third class of directors, consisting of Rajiv Shukla will expire at our third annual meeting of stockholders.
Prior to the completion of an initial business combination, any vacancy on the board of directors may be filled by a nominee chosen by holders of a majority of our founder shares. In addition, prior to the completion of an initial business combination, holders of a majority of our founder shares may remove a member of the board of directors for any reason.
Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our amended and restated certificate of incorporation as it deems appropriate. Our amended and restated certificate of incorporation provides that our officers may consist of one or more chairman of the board, chief executive officer, president, chief financial officer, vice presidents, secretary, treasurer and such other offices as may be determined by the board of directors.
Director Independence
Applicable rules of the Nasdaq require a majority of a listed company’s board of directors to be comprised of independent directors within one year of listing. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. We have “independent directors” as defined in Nasdaq’s listing standards and applicable SEC rules. Our board of directors has determined that Darlene T. DeRemer, Eugene Podsiadlo and William Woodward are “independent directors” as defined in the Nasdaq listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are, subject to the transition rules described above for newly listed companies present.
Executive Officer and Director Compensation
None of our executive officers or directors have received any cash compensation for services rendered to us. Our sponsor, executive officers and directors, or any of their respective affiliates will be reimbursed for any
out-of-pocket expenses
incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to our sponsor, executive officers or directors, or our or their affiliates. Any such payments prior to an initial business combination will be made from funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their
out-of-pocket expenses
incurred in connection with our activities on our behalf in connection with identifying and consummating an initial business combination. On July 27, 2021, our sponsor transferred 25,000 founder shares to each of Darlene DeRemer, Eugene Podsiadlo, and William Woodward. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on the Company’s board of directors through the closing of such initial business combination. Other than that discussed above, no compensation of any kind, including finder’s and consulting fees, will be paid by the company to our sponsor, executive officers and directors, or any of their respective affiliates, prior to completion of our initial business combination.
 
69

After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to stockholders, to the extent then known, in the proxy solicitation materials or tender offer materials furnished to our stockholders in connection with a proposed business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed business combination, because the directors of the post-combination business will be responsible for determining executive officer and director compensation. Any compensation to be paid to our executive officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors.
We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our executive officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment.
Committees of the Board of Directors
Our board of directors has three standing committees: an audit committee, a nominating committee and a compensation committee. Subject to
phase-in rules
and a limited exception, the rules of Nasdaq and Rule 10A of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors. Subject to
phase-in rules
and a limited exception, the rules of Nasdaq require that the compensation committee of a listed company be comprised solely of independent directors. Each committee will operate under a charter that has been approved by our board and will have the composition and responsibilities described below.
Audit Committee
We have established an audit committee of the board of directors. Darlene DeRemer, Eugene Podsiadlo and William Woodward serve as members of our audit committee. Our board of directors have determined that each of Ms. DeRemer, Mr. Podsiadlo and Mr. Woodward are independent. Mr. Podsiadlo serves as the Chairman of the audit committee. Each member of the audit committee meets the financial literacy requirements of Nasdaq and our board of directors has determined that Ms. DeRemer qualifies as an “audit committee financial expert” as defined in applicable SEC rules and has accounting or related financial management expertise.
We have adopted an audit committee charter, which details the principal functions of the audit committee, including:
 
 
meeting with our independent registered public accounting firm regarding, among other issues, audits, and adequacy of our accounting and control systems;
 
 
monitoring the independence of the independent registered public accounting firm;
 
 
verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law;
 
 
inquiring and discussing with management our compliance with applicable laws and regulations;
 
 
pre-approving all
audit services and permitted
non-audit services
to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed;
 
 
appointing or replacing the independent registered public accounting firm;
 
70

 
determining the compensation and oversight of the work of the independent registered public accounting firm (including resolution of disagreements between management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work;
 
 
establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies;
 
 
monitoring compliance on a quarterly basis with the terms of our initial public offering and, if any noncompliance is identified, immediately taking all action necessary to rectify such noncompliance or otherwise causing compliance with the terms of our initial public offering; and
 
 
reviewing and approving all payments made to our existing stockholders, executive officers or directors and their respective affiliates. Any payments made to members of our audit committee will be reviewed and approved by our board of directors, with the interested director or directors abstaining from such review and approval.
Nominating Committee
We have established a nominating committee of the board of directors. Darlene DeRemer, Eugene Podsiadlo and William Woodward serve as members of our nominating committee. Our board of directors have determined that each of Ms. DeRemer, Mr. Podsiadlo and Mr. Woodward are independent. Mr. Woodward serves as the Chairman of the audit committee.
The nominating committee is responsible for overseeing the selection of persons to be nominated to serve on our board of directors. The nominating committee considers persons identified by its members, management, stockholders, investment bankers and others.
Guidelines for Selecting Director Nominees
The guidelines for selecting nominees, as specified in our charter, generally provide that persons to be nominated:
 
 
should have demonstrated notable or significant achievements in business, education or public service;
 
 
should possess the requisite intelligence, education and experience to make a significant contribution to the board of directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and
 
 
should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the stockholders.
The nominating committee will consider a number of qualifications relating to management and leadership experience, background and integrity and professionalism in evaluating a person’s candidacy for membership on the board of directors. The nominating committee may require certain skills or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The nominating committee does not distinguish among nominees recommended by stockholders and other persons.
Compensation Committee
We have established a compensation committee of the board of directors. Darlene DeRemer, Eugene Podsiadlo and William Woodward serve as members of our compensation committee. Ms. DeRemer serves as chairman of the compensation committee. Our board of directors have determined that each of Ms. DeRemer, Mr. Podsiadlo and Mr. Woodward are independent.
We have adopted a compensation committee charter, which details the principal functions of the compensation committee, including:
 
71

 
reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation, evaluating our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation; 
 
 
reviewing and approving the compensation of all of our other Section 16 executive officers;
 
 
reviewing our executive compensation policies and plans;
 
 
implementing and administering our incentive compensation equity-based remuneration plans;
 
 
assisting management in complying with our proxy statement and annual report disclosure requirements;
 
 
approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees;
 
 
producing a report on executive compensation to be included in our annual proxy statement; and
 
 
reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.
Notwithstanding the foregoing, as indicated above, other than the payment to an affiliate of our sponsor of $10,000 per month, for up to 24 months, for office space, utilities and secretarial and administrative support, no compensation of any kind, including finders, consulting or other similar fees, will be paid to any of our existing stockholders, officers, directors or any of their respective affiliates, prior to, or for any services they render in order to effectuate the consummation of an initial business combination. Accordingly, it is likely that prior to the consummation of an initial business combination, the compensation committee will only be responsible for the review and recommendation of any compensation arrangements to be entered into in connection with such initial business combination.
The charter also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC.
Compensation Committee Interlocks and Insider Participation
None of our executive officers currently serves, and in the past year has not served, as a member of the compensation committee of any entity that has one or more executive officers serving on our board of directors.
Code of Ethics
We have adopted a Code of Ethics applicable to our directors, officers and employees. We have filed a copy of our Code of Ethics as an exhibit to the registration statement in connection with our initial public offering. This document may be reviewed by accessing our public filings at the SEC’s web site at www.sec.gov. In addition, a copy of the Code of Ethics will be provided without charge upon request from us. We intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report on Form
8-K.
Conflicts of Interest
Subject to
pre-existing fiduciary
or contractual duties as described below, our officers and directors have agreed to present any business opportunities presented to them in their capacity as a director or officer of our company to us. Certain of our officers and directors presently have fiduciary or contractual obligations to other entities pursuant to which such officer or director is or will be required to present a business combination opportunity. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such opportunity to such entity. We believe, however, that the fiduciary duties or contractual obligations of our officers or directors will not materially affect our ability to complete our initial business combination. Our amended and restated certificate of incorporation provides that we renounce our interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of our company and such opportunity is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue, and to the extent the director or officer is permitted to refer that opportunity to us without violating another legal obligation.
 
72

Our officers and directors may become officers or directors of another special purpose acquisition company with a class of securities intended to be registered under the Exchange Act, even prior to us entering into a definitive agreement for our initial business combination.
In general, officers and directors of a corporation incorporated under the laws of the State of Delaware are required to present business opportunities to a corporation if:
 
 
the corporation could financially undertake the opportunity;
 
 
the opportunity is within the corporation’s line of business; and
 
 
it would not be fair to our company and its stockholders for the opportunity not to be brought to the attention of the corporation.
Accordingly, as a result of multiple business affiliations, our officers and directors may have similar legal obligations relating to presenting business opportunities meeting the above-listed criteria to multiple entities. Furthermore, our amended and restated certificate of incorporation provides that we renounced our interest in any corporate opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of our company and such opportunity is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue, and to the extent the director or officer is permitted to refer that opportunity to us without violating another legal obligation.
Below is a table summarizing the entities to which our executive officers and directors = currently have fiduciary duties or contractual obligations:
 
Individual
(1)
  
Entity
  
Entity’s Business
  
Affiliation
Rajiv Shukla    Constellation Alpha Holdings    Investments, advisory and research for the SPAC industry    Chief Executive Officer
  
InflammX Therapeutics
(formerly known as OcuNexus Therapeutics, Inc.)
   Biotech    Board Member
   Humacyte, Inc.    Biotech    Board Member
Patrick Sturgeon    Brookline Capital Markets    Mergers and acquisitions, public financing, private capital raising, secondary offerings, and capital markets    Managing Director
   Brookline Capital Acquisition Corp.    SPAC    Chief Financial Officer
Darlene DeRemer    Syracuse University    Education    Board of Trustees and Investment and Endowment Committee
   ARK Invest ETF Trust    Investment Fund    Chairman
   Confluence Technologies LLC    Software    Chairman of Compensation Committee
Eugene Podsiadlo    The Singapore Forum    Thought Leadership    Board of Advisors
William Woodward    Anthem Venture Partners    Venture Capital    Managing General Partner
 
(1)
Each person has a fiduciary duty with respect to the listed entities next to their respective names.
 
73

Potential investors should also be aware of the following other potential conflicts of interest:
 
 
None of our officers or directors is required to commit his or her full time to our affairs and, accordingly, may have conflicts of interest in allocating his or her time among various business activities.
 
 
In the course of their other business activities, our officers and directors may become aware of investment and business opportunities which may be appropriate for presentation to us as well as the other entities with which they are affiliated. Our management may have conflicts of interest in determining to which entity a particular business opportunity should be presented.
 
 
Our sponsor and its transferees, if any, have agreed to waive their redemption rights with respect to any founder shares and placement shares and any public shares held by them in connection with the consummation of our initial business combination. Additionally, our sponsor has agreed to waive its redemption rights with respect to any founder shares and placement shares held by it if we fail to consummate our initial business combination within 24 months after the closing of our initial public offering. However, if our sponsor acquires public shares in or after our initial public offering, it will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to consummate an initial business combination within 24 months from the closing of our initial public offering. If we do not complete our initial business combination within such applicable time period, the proceeds of the sale of the placement units held in the trust account will be used to fund the redemption of our public shares, and the placement warrants will expire worthless. With certain limited exceptions, the founder shares will not be transferable, assignable by our sponsor or certain of our directors that hold founder shares (or any other permitted assigns, if any) until the earlier of: (A) one year after the completion of our initial business combination or (B) subsequent to our initial business combination, (x) if the last sale price of our shares of Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 trading day period commencing at least 150 days after our initial business combination, or (y) the date on which we complete a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange their shares of common stock for cash, securities or other property. With certain limited exceptions, the placement units, placement shares and placement warrants and the shares of Class A common stock underlying such placement warrants, will not be transferable, assignable or salable by our sponsor or its permitted transferees until 30 days after the completion of our initial business combination. Since our sponsor and officers and directors may directly or indirectly own common stock and warrants following our initial public offering, our officers and directors may have a conflict of interest in determining whether a particular target business is an appropriate business with which to complete our initial business combination.
 
 
Our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial business combination.
 
 
Our sponsor, officers or directors may have a conflict of interest with respect to evaluating a business combination and financing arrangements as we may obtain loans from our sponsor or an affiliate of our sponsor or any of our officers or directors to finance transaction costs in connection with an intended initial business combination. Up to $1,500,000 of such loans may be convertible into placement units, at a price of $10.00 per placement unit at the option of the lender, upon consummation of our initial business combination. The placement units would be identical to the units.
 
74

The conflicts described above may not be resolved in our favor.
We are not prohibited from pursuing an initial business combination with a business combination target that is affiliated with our sponsor, officers or directors or completing the business combination through a joint venture or other form of shared ownership with our sponsor, officers or directors. In the event we seek to complete our initial business combination with a business combination target that is affiliated with our sponsor, executive officers or directors, we, or a committee of independent directors, would obtain an opinion from an independent investment banking which is a member of FINRA or a valuation or appraisal firm, that such initial business combination is fair to our company from a financial point of view. We are not required to obtain such an opinion in any other context. Furthermore, in no event will our sponsor or any of our existing officers or directors, or any of their respective affiliates, be paid by the company any finder’s fee, consulting fee or other compensation prior to, or for any services they render in order to effectuate, the completion of our initial business combination. Our office space and administrative and support services will be provided to us by an affiliate of our sponsor for a monthly fee of $10,000.
In the event that we submit our initial business combination to our public stockholders for a vote, our sponsor has agreed to vote any founder shares held by it and any public shares purchased during or after the initial public offering in favor of our initial business combination and our officers and directors have also agreed to vote any public shares purchased during or after the initial public offering in favor of our initial business combination.
Limitation on Liability and Indemnification of Officers and Directors
Our amended and restated certificate of incorporation provides that our officers and directors will be indemnified by us to the fullest extent authorized by Delaware law, as it now exists or may in the future be amended. In addition, our amended and restated certificate of incorporation provides that our directors will not be personally liable for monetary damages to us or our stockholders for breaches of their fiduciary duty as directors, unless they violated their duty of loyalty to us or our stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized unlawful payments of dividends, unlawful stock purchases or unlawful redemptions, or derived an improper personal benefit from their actions as directors.
We will enter into agreements with our officers and directors to provide contractual indemnification in addition to the indemnification provided for in our amended and restated certificate of incorporation. Our bylaws also permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit such indemnification.
We have purchased a policy of directors’ and officers’ liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. Except with respect to any public shares they may acquire in our initial public offering or thereafter (in the event we do not consummate an initial business combination), our officers and directors have agreed to waive (and any other persons who may become an officer or director prior to the initial business combination will also be required to waive) any right, title, interest or claim of any kind in or to any monies in the trust account, and not to seek recourse against the trust account for any reason whatsoever, including with respect to such indemnification (although our officers and directors will be entitled to liquidating distributions from the trust account with respect to any public shares they hold if we fail to complete our initial business combination within the prescribed time frame).
These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions.
 
75

We believe that these provisions, the directors’ and officers’ liability insurance and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors.
 
Item 11
Executive Compensation
Executive Officer and Director Compensation
None of our officers has received any cash or
in-kind
compensation for services rendered to us. We have agreed to pay an affiliate of our sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees. No compensation of any kind, including any finder’s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, will be paid by us to our sponsor, officers or directors or any affiliate of our sponsor, officers or directors, prior to, or in connection with any services rendered in order to effectuate, the consummation of our initial business combination (regardless of the type of transaction that it is). However, these individuals will be reimbursed for any
out-of-pocket expenses
incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to our sponsor, officers or directors or our or their affiliates. Any such payments prior to an initial business combination will be made using funds held outside the trust account. Other than quarterly audit committee review of such payments, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their
out-of-pocket expenses
incurred in connection with identifying and consummating an initial business combination.
After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to stockholders, to the extent then known, in the tender offer materials or proxy solicitation materials furnished to our stockholders in connection with a proposed initial business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed initial business combination, because the directors of the post-combination business will be responsible for determining officer and director compensation. Any compensation to be paid to our officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors.
We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our officers and directors that provide for benefits upon termination of employment.
 
Item 12
Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters
The following table sets forth information regarding the beneficial ownership of our shares of common stock as of December 31, 2021 based on information obtained from the persons named below, with respect to the beneficial ownership of our shares of common stock, by:
 
   
each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock;
 
   
each of our executive officers and directors that beneficially owns our shares of common stock; and
 
 
76

   
all our executive officers and directors as a group.
In the table below, percentage ownership is based on 15,907,985 shares of Class A common stock and 3,861,026 shares of Class B common stock outstanding as of December 31, 2021. Voting power represents the combined voting power of Class A common stock and Class B common stock owned beneficially by such person. On all matters to be voted upon, the holders of the Class A common stock and the Class B common stock vote together as a single class. Currently, all of the Class B common stock are convertible into Class A common stock on a
one-for-one
basis. The table below does not include the Class A common stock underlying the private placement warrants held by our sponsor because these securities are not exercisable within 60 days of this Annual Report on Form
10-K.
 
    
Class B common stock
   
Class A common stock
       
Name of Beneficial Owners(1)
  
Number of
Shares
Beneficially
Owned(2)
    
Approximate
Percentage
of Class
   
Number of
Shares
Beneficially
Owned
    
Approximate
Percentage
of Class
   
Approximate
Percentage
of Voting
Control
 
AHAC Sponsor LLC (our sponsor) (3)
     3,786,026        98%       463,882        2.9     22.9
Rajiv Shukla (3)
     —          —         —          —         —    
Patrick A. Sturgeon (4)
     —          —         —          —         —    
Darlene DeRemer (4)
     25,000        *       —          —         —    
Eugene Podsiadlo (4)
     25,000        *       —          —         —    
William Woodward (4)
     25,000        *       —          —         —    
All officers and directors as a group (5 individuals)
     —          —         —          —         —    
Anchor Investors
            
Atlas Diversified Master Fund, Ltd. and affiliates (5)
     —          —         1,485,000        9.3     7.44
Linden Capital L.P. and its affiliates (8)
     —          —         1,485,000        9.3     7.44
Sculptor Capital LP and its affiliates (9)
     —          —         1,471,470        9.25     7.4
UBS O’Connor LLC(10)
     —          —         1,485,000        7.51     6
All Anchor Investors (4 Total)
     —          —         5,926,470        35.36     28.2
5% or Greater Holders
            
Millennium Management LLC and affiliates (12)
     —          —         957,229        6.2     4.96
 
*
Less than one percent.
 
(1)
Unless otherwise noted, the business address of each of the following entities and individuals is 1177 Avenue of the Americas, 5th Floor, New York, New York 10036.
(2)
Interests shown consist solely of founder shares, classified as 3,861,026 Class B common stock (of which a total of 825,900 Class B common stock have been transferred to certain Anchor Investors) owned prior to the initial public offering, and an additional 463,882 placement shares to sold in the private placement that closed simultaneously with the closing of our initial public offering.
(3)
AHAC Sponsor III LLC, our sponsor, is the record holder of the securities reported herein. Rajiv Shukla, our Chief Executive Officer, is the managing member of our sponsor. By virtue of this relationship, Mr. Shukla may be deemed to share beneficial ownership of the securities held of record by our sponsor. Mr. Shukla disclaims any such beneficial ownership except to the extent of his pecuniary interest.
(4)
Such individuals hold membership interests in our sponsor and disclaim any beneficial ownership other than to the extent of his or her pecuniary interests.
(5)
Includes common stock directly owned by Atlas Diversified Master Fund, Ltd. and its affiliates based solely on the Schedule 13G/A filed by the reporting persons with the SEC on February 14, 2022. Atlas Diversified Master Fund, Ltd. is a Cayman corporation (“ADMF”), Atlas Diversified Fund, Ltd. is a Cayman corporation (“ADF LTD”), Atlas Diversified Fund, L.P. is a Delaware limited partnership (“ADF LP”), Atlas Master Fund, Ltd. is a Cayman corporation (“AMF”), Atlas Global, LLC is a Delaware limited liability company (“AG”), Atlas Global Investments, Ltd. is a Cayman corporation (“AGI”), Atlas Enhanced Master Fund, Ltd. is a Cayman corporation (“AEMF”), Atlas Enhanced Fund, L.P. is a Delaware limited partnership (“AEF LP”), Atlas Enhanced Fund, Ltd. is a Cayman corporation (“AEF LTD”), Atlas Portable Alpha, LP is a Delaware limited partnership (“APA LP”), Atlas Terra Fund, Ltd. is a Cayman corporation (“ATF LTD”), Atlas Institutional Equity Fund, L.P. is a Delaware limited partnership (“AIEF LP”). Balyasny Asset Management L.P. (“BAM” or the “Advisor”) serves as the investment manager to each of ADMF, ADF LTD, ADF LP, AMF, AG, AGI, AEMF, AEF LP, AEF LTD, APA LP, ATF LTD and AIEF LP. Dmitry Balyasny is the Managing Partner and Chief Investment Officer of the Advisor. The business address of each of ADF LP, AG, AEF LP, APA LP, AIEF LP, the Advisor and Mr. Balyasny is 444 W. Lake Street, 50
th
 Floor Chicago, IL 60606. The business address for ADMF, ADF LTD, AMF, AGI, AEMF, AEF LTD, and ATF LTD is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand
Cayman KY1-1104, Cayman
Islands, British West Indies.
 
77

(6)
Includes common stock directly owned by Linden Capital L.P., a Bermuda limited partnership (“Linden Capital”), Linden Advisors LP, a Delaware limited partnership (“Linden Advisors”), Linden GP LLC, a Delaware limited liability company (“Linden GP”), and Mr. Siu Min (Joe) Wong (“Mr. Wong,” and collectively, the “Reporting Persons”) based solely on the Schedule 13G/A filed jointly with the SEC on February 3, 2022. Linden GP is the general partner of Linden Capital and, in such capacity, may be deemed to beneficially own the Shares held by Linden Capital. Linden Advisors is the investment manager of Linden Capital and trading advisor or investment advisor for the Managed Accounts. Mr. Wong is the principal owner and controlling person of Linden Advisors and Linden GP. In such capacities, Linden Advisors and Mr. Wong may each be deemed to beneficially own the Shares held by each of Linden Capital and the Managed Accounts. As of December 31, 2021, each of Linden Advisors and Mr. Wong may be deemed the beneficial owner of 1,485,000 Shares. This amount consists of 1,383,827 Shares held by Linden Capital and 101,173 Shares held by separately managed accounts. As of December 31, 2021, each of Linden GP and Linden Capital may be deemed the beneficial owner of the 1,383,827 Shares held by Linden Capital. The principal business address for Linden Capital is Victoria Place, 31 Victoria Street, Hamilton HM10, Bermuda. The principal business address for each of Linden Advisors, Linden GP and Mr. Wong is 590 Madison Avenue, 15th Floor, New York, New York 10022.
(7)
Includes common stock directly owned by Sculptor Capital LP and its affiliates based solely on the Schedule 13/A filed jointly with the SEC on February 14, 2022. The following represents the shares directly held by Sculptor Capital LP (“Sculptor”): (i) Sculptor Master Fund, Ltd. (“SCMF”), a Cayman Islands exempted limited partnership, is the beneficial owner of 750,450 shares; Sculptor is the investment adviser to SCMF. (ii) Sculptor Credit Opportunities Master Fund, Ltd. (“SCCO”), a Cayman Islands company, is the beneficial owner of 222,720 shares; Sculptor is the investment adviser to SCCO. (iii) Sculptor SC II LP (“NJGC”), a Delaware limited partnership, is the beneficial owner of 441,441 shares; Sculptor Capital II LP
(“Sculptor-II”),
a Delaware limited partnership that is wholly owned by Sculptor, is the investment adviser to NJGC. (iv) Sculptor Enhanced Master Fund, Ltd. (“SCEN”), a Cayman Islands Company, is the beneficial owner of 58,859 shares; Sculptor is the investment adviser to SCEN. (v)
 Sculptor Special Funding, LP (“NRMD”) is a Cayman Islands exempted limited partnership, is the beneficial owner of 750,450 shares, that is wholly owned by SCMF.
Sculptor and
Sculptor-II serve
as the principal investment managers and thus may be deemed beneficial owners of the shares in the accounts managed by Sculptor and
Sculptor-II.
Sculptor Capital Holding II LLC, a Delaware limited liability company
(“SCHC-II”)
serves as the sole general partner of
Sculptor-II and
is wholly owned by Sculptor. Sculptor Capital Holding Corporation, a Delaware corporation (“SCHC”), serves as the sole general partner of Sculptor. As such, SCHC and
SCHC-II may
be deemed to control Sculptor as well as
Sculptor-II and,
therefore, may be deemed to be the beneficial owners of the shares in the accounts managed by Sculptor and
Sculptor-II.
Sculptor Capital Management, Inc., a Delaware corporation (“SCU”) is the sole shareholder of SCHC, and may be deemed a beneficial owner of the shares in the accounts managed by Sculptor and
Sculptor-II.
The business address of Sculptor,
Sculptor-II,
SCHC,
SCHC-II,
and SCU is 9 West 57 Street, 39 Floor, New York, NY 10019. The business address of SCMF, SCEN, and SCCO is c/o State Street (Cayman) Trust, Limited, 1 Nexus Way — Suite #5203, PO Box 896, Helicona Courtyard, Camana Bay, Grand Cayman,
KY1-1103,
Cayman Islands. The business address of NJGC is c/o The Corporation Trust Company 1209 Orange Street, Wilmington DE 19801. The address of the registered office of NRMD is c/o MaplesFS Limited, P.O. Box 1093, Queensgate House, Grand Cayman,
KY1-1102,
Cayman Islands.
(8)
Kevin Russell is the Chief Investment Officer of UBS O’Connor LLC, the investment manager of Nineteen77 Global Multi-Strategy Alpha Master Limited, and may be deemed to have voting and dispositive power over the shares held by Nineteen77 Global Multi-Strategy Alpha Master Limited. The business address of UBS O’Connor LLC is 1 N. Wacker Drive, Chicago, IL 60606.
 
78

(9)
Includes common stock directly owned based solely upon a 13G filed by Millennium Management LLC with the SEC on August 4, 2021. The reporting persons beneficially owned an aggregate of 957,229 shares, as follows : i) Integrated Core Strategies (US) LLC, a Delaware limited liability company (“Integrated Core Strategies”), beneficially owns 400,000 shares; and ii) ICS Opportunities, Ltd., an exempted company organized under the laws of the Cayman Islands (“ICS Opportunities”), beneficially owns 557,229 shares. Millennium International Management LP, a Delaware limited partnership (“Millennium International Management”), is the investment manager to ICS Opportunities and may be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities. Millennium Management LLC, a Delaware limited liability company (“Millennium Management”), is the general partner of the managing member of Integrated Core Strategies and may be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies. Millennium Management is also the general partner of the 100% owner of ICS Opportunities and may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities. Millennium Group Management LLC, a Delaware limited liability company (“Millennium Group Management”), is the managing member of Millennium Management and may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies. Millennium Group Management is also the general partner of Millennium International Management and may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities. The managing member of Millennium Group Management is a trust of which Israel A. Englander, a United States citizen (“Mr. Englander”), currently serves as the sole voting trustee. Therefore, Mr. Englander may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies and ICS Opportunities. The business address of Millennium Management LLC is 399 Park Avenue, New York, New York, 10022.
Our sponsor and our directors and executive officers have agreed (a) to vote any founder shares owned by them in favor of any proposed business combination and (b) not to redeem any founder shares in connection with a stockholder vote to approve a proposed initial business combination.
Our sponsor is deemed to be our “promoter” as such term is defined under the federal securities laws.
Transfers of Founder Shares and Private Placement Units
The founder shares, placement units, placement shares, placement warrants and any shares of Class A common stock issued upon conversion or exercise thereof are each subject to transfer restrictions pursuant to
lock-up provisions
in the agreements entered into by our sponsor and directors and executive officers. Our sponsor and our directors and executive officers have agreed not to transfer, assign or sell (i) any of their founder shares until the earliest of (A) one year after the completion of our initial business combination and (B) upon consummation of our initial business combination, (x) if the closing price of our shares of Class A common stock equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any
30-trading day
period commencing at least 150 days after our initial business combination or (y) the date on which we complete a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange their shares of Class A common stock for cash, securities or other property, and (ii) any of their placement units, placement shares, placement warrants and Class A common stock issued upon conversion or exercise thereof are not transferable or salable until 30 days after the completion of our initial business combination. The foregoing restrictions are not applicable to transfers (a) to our officers or directors, any affiliates or family members of any of our officers or directors, to our sponsor, any members or partners of our sponsor or their affiliates, or any affiliates of our sponsor; (b) in the case of an individual, by gift to a member of one of the individual’s immediate family or to a trust, the beneficiary of which is a member of the individual’s immediate family, an affiliate of such person or to a charitable organization; (c) in the case of an individual, by virtue of laws of descent and distribution upon death of the individual; (d) in the case of an individual, pursuant to a qualified domestic relations order; (e) by private sales or transfers made in connection with the consummation of a business combination at prices no greater than the price at which the founder shares, placement warrants or Class A common stock, as applicable, were originally purchased; (f) by virtue of our sponsor’s organizational documents upon liquidation or dissolution of our sponsor; (g) to the Company for no value for cancellation in connection with the consummation of our initial business combination; (h) in the event of our liquidation prior to the completion of our initial business combination; or (i) in the event of our completion of a liquidation, merger, capital stock exchange or other similar transaction which results in all of our stockholders having the right to exchange their shares of Class A common stock for cash, securities or other property subsequent to our completion of our initial business combination; provided, however, that in the case of clauses (a) through (f) these permitted transferees must enter into a written agreement agreeing to be bound by these transfer restrictions and the other restrictions contained in the letter agreements.
 
79

Registration Rights
The holders of the founder shares, placement units, placement shares, placement warrants, Class A common stock underlying the placement warrants and warrants that may be issued upon conversion of working capital loans (and any Class A common stock issuable upon the exercise of the placement warrants and warrants that may be issued upon conversion of working capital loans) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of initial public offering. The holder of these securities, our sponsor, is entitled to make unlimited demands that we register such securities. In addition, the holders have certain “piggy back” registration rights with respect to registration statements filed subsequent to our completion of our initial business combination. We will bear the expenses incurred in connection with the filing of any such registration statements. However, the registration rights agreement provides that we will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable
lock-up period,
which occurs (i) in the case of the founder shares, and (ii) in the case of the placement warrants and the respective shares of Class A common stock underlying such warrants, 30 days after the completion of our initial business combination. We will bear the expenses incurred in connection with the filing of any such registration statements.
Changes in Control
None.
 
Item 13
Certain Relationships and Related Transactions, and Director Independence
On January 21, 2021, our sponsor subscribed to purchase 3,593,750 shares of our common stock. On January 25, 2021, our sponsor paid $25,000, or approximately $0.00696 per share, for certain expenses on behalf of us in exchange for issuance of the founder shares. On March 1, 2021, we effected a 1:1.2 stock split of our common stock which resulted in the 3,593,750 shares being converted into 4,312,500 shares of our Class B common stock. The number of founder shares issued was determined based on the expectation that such founder shares would represent 20% of the issued and outstanding shares (excluding the placement shares underlying the placement units) upon completion of our initial public offering. On July 27, 2021, our sponsor transferred 25,000 founder shares to each of Darlene DeRemer, Eugene Podsiadlo, and William Woodward. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on the Company’s board of directors through the closing of such initial business combination.
Our sponsor purchased 455,000 placement units for a purchase price of $4,550,000 in a private placement that occurred simultaneously with the closing of our initial public offering. The placement units (including the placement shares, placement warrants and Class A common stock issued upon the exercise or conversion thereof) may not, subject to certain limited exceptions, be transferred, assigned or sold by the holder.
As more fully discussed in the section of this annual report entitled “Management — Conflicts of Interest,” if any of our officers or directors becomes aware of a business combination opportunity that falls within the line of business of any entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such opportunity to such entity. Our officers and directors currently have certain relevant fiduciary duties or contractual obligations that may take priority over their duties to us.
We currently maintain our executive offices at 1177 Avenue of the Americas, 5
th
 Floor, New York, New York 10036. The cost for our use of this space is included in the $10,000 per month fee we will pay to an affiliate of our sponsor for office space, administrative and support services, commencing on the date that our securities are first listed on the Nasdaq. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees.
No compensation of any kind, including finder’s and consulting fees, will be paid to our sponsor, officers and directors, or any of their respective affiliates, for services rendered prior to or in connection with the completion of an initial business combination. However, these individuals will be reimbursed for any
out-of-pocket expenses
incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made by us to our sponsor, officers, directors or our or their affiliates and will determine which expenses and the amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of
out-of-pocket expenses
incurred by such persons in connection with activities on our behalf.
In addition, in order to finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete an initial business combination, we would repay such loaned amounts.
In the event that the initial business combination does not close, we may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into placement units at $10.00 per placement unit at the option of the lender. The placement units would be identical to the units, including as to exercise price, exercisability and exercise period. The terms of such loans by our officers and directors, if any, have not been determined and no written agreements exist with respect to such loans. We do not expect to seek loans from parties other than our sponsor or any of their affiliates as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account.
 
80

After our initial business combination, members of our management team who remain with us may be paid consulting, management or other fees from the combined company with any and all amounts being fully disclosed to our stockholders, to the extent then known, in the tender offer or proxy solicitation materials, as applicable, furnished to our stockholders. It is unlikely the amount of such compensation will be known at the time of distribution of such tender offer materials or at the time of a stockholder meeting held to consider our initial business combination, as applicable, as it will be up to the directors of the post-combination business to determine executive and director compensation.
In addition, our direct anchor investors have purchased membership interests in our sponsor entitling them to an economic interest in certain of the founder shares owned by our sponsor and in certain of the placement units to be purchased by our sponsor. Each of P. Schoenfeld Asset Management LP, Balyasny Asset Management L.P., and Antara Capital LP has entered into the risk capital subscription agreement with our sponsor. Each of Linden Capital L.P., Sculptor Capital LP, and UBS O’Connor LLC has entered into the
non-risk capital
subscription agreement with our sponsor. Pursuant to their subscription agreements with our sponsor, the direct anchor investors will not be granted any material additional stockholder or other rights, and will only be issued membership interests in our sponsor with no right to control our sponsor or vote or dispose of any founder shares, placement units or underlying securities (which will continue to be held by our sponsor until following our initial business combination).
We have granted to the direct anchor investors an option, in their sole discretion, to subscribe to a forward purchase agreement for up to an aggregate of 60% (up to 10% per direct anchor investor) of the securities sold in one or multiple private placements to close prior to or concurrently with the closing of our initial business combination. The aggregate proceeds from the sale of any securities pursuant to these forward purchase agreements will be used by us for purposes related to our initial business combination.
We have entered into a registration rights agreement pursuant to which our initial stockholders, and their permitted transferees, if any, will be entitled to certain registration rights with respect to the placement units, placement shares, the placement warrants, the securities issuable upon conversion of working capital loans (if any) and the shares of Class A common stock issuable upon exercise of the foregoing and upon conversion of the founder share
Related Party Policy
The audit committee of our board of directors had adopted a charter, providing for the review, approval and/or ratification of “related party transactions,” which are those transactions required to be disclosed pursuant to Item 404 of
Regulation S-K as
promulgated by the SEC, by the audit committee. At its meetings, the audit committee shall be provided with the details of each new, existing, or proposed related party transaction, including the terms of the transaction, any contractual restrictions that the company has already committed to, the business purpose of the transaction, and the benefits of the transaction to the company and to the relevant related party. Any member of the committee who has an interest in the related party transaction under review by the committee shall abstain from voting on the approval of the related party transaction, but may, if so requested by the chairman of the committee, participate in some or all of the committee’s discussions of the related party transaction. Upon completion of its review of the related party transaction, the committee may determine to permit or to prohibit the related party transaction.
 
Item 14
Principal Accountant Fees and Services
Our independent public accounting firm is Marcum LLP (“Marcum”), 6002 Rogerdale Road, Suite 300, Houston, TX 77072, PCAOB Auditor ID # 688. The following is a summary of fees paid or to be paid to Marcum for services rendered.
Audit Fees
. Audit fees consist of fees billed for professional services rendered for the audit of our
year-end
financial statements and services that are normally provided by Marcum in connection with regulatory filings. The aggregate fees billed by Marcum for professional services rendered for the audit of our annual financial statements, review of the financial information included in our Forms
10-Q
for the respective periods and other required filings with the SEC for the period from January 21, 2021 (inception) through December 31, 2021 totaled $39,385. The above amounts include interim procedures and audit fees, as well as attendance at audit committee meetings.
 
81

Audit-Related Fees.
 Audit-related services consist of fees billed for assurance and related services that are reasonably related to performance of the audit or review of our financial statements and are not reported under “Audit Fees.” These services include attest services that are not required by statute or regulation and consultations concerning financial accounting and reporting standards. We did not pay Marcum for consultations concerning financial accounting and reporting standards for the period from January 21, 2021 (inception) through December 31, 2021.
Tax Fees
. We did not pay Marcum for tax planning and tax advice for the period from January 21, 2021 (inception) through December 31, 2021.
All Other Fees
. We did not pay Marcum for other services for the period from January 21, 2021 (inception) through December 31, 2021.
Pre-Approval
Policy
Our audit committee was formed upon the consummation of our initial public offering. As a result, the audit committee did not
pre-approve
all of the foregoing services, although any services rendered prior to the formation of our audit committee were approved by our board of directors. Since the formation of our audit committee, and on a going-forward basis, the audit committee has and will
pre-approve
all auditing services and permitted
non-audit
services to be performed for us by our independent registered public accounting firm, including the fees and terms thereof (subject to the de minimis exceptions for
non-audit
services described in the Exchange Act which are approved by the audit committee prior to the completion of the audit).
PART IV
 
Item 15
Exhibits, Financial Statement Schedules
(a) The following documents are filed as part of this Annual Report:
(1) Financial Statements
(2) Exhibits
We hereby file as part of this Annual Report on Form
10-K
the exhibits listed in the attached Exhibit Index.
 
82

Exhibit
No.
  
Description
   
    1.1    Underwriting Agreement, dated July 26, 2021, by and among the Company, PJT Partners LP, and BofA Securities, Inc., as representatives of the underwriters. (2)
   
    3.1    Certificate of Incorporation. (1)
   
     3.2    Amended and Restated Certificate of Incorporation. (1)
   
    3.3    Second Amended and Restated Certificate of Incorporation. (2)
   
    3.4    Bylaws. (1)
   
    4.1    Specimen Unit Certificate. (1)
   
    4.2    Specimen Common Stock Certificate. (1)
   
    4.3    Specimen Warrant Certificate. (1)
   
    4.4    Warrant Agreement, dated July 26, 2021, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent. (2)
   
    4.5*   
   
  10.1    Investment Management Trust Agreement, dated July 26, 2021, by and between the Company and Continental Stock Transfer & Trust Company. (2)
   
  10.2    Registration Rights Agreement, dated July 26, 2021, by and among the Company, the Sponsor and the other Holders (as defined therein) signatory thereto.(2)
   
  10.3    Form of Indemnity Agreement. (1).
   
  10.4    Letter Agreement, dated July 26, 2021, by and among the Company, the Sponsor and each director and executive officer of the Company. (2)
   
  10.5    Unit Purchase Agreement, dated July 26, 2021, between the Company and the Sponsor. (2)
   
  14    Code of Ethics. (1)
   
  31.1*    Certification of the Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
   
  31.2*    Certification of the Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).
   
  32.1**    Certification of the Chief Executive Officer required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350.
   
  32.2**    Certification of the Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. 1350.
   
101.INS    Inline XBRL Instance Document
   
101.SCH    Inline XBRL Taxonomy Extension Schema
   
101.CAL    Inline XBRL Taxonomy Extension Calculation Linkbase
   
101.DEF    Inline XBRL Taxonomy Extension Definition Linkbase
   
101.LAB    Inline XBRL Taxonomy Extension Label Linkbase
   
101.PRE    Inline XBRL Taxonomy Extension Presentation Linkbase
   
104    Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
 
*
Filed herewith.
**
Furnished herewith.
(1)
Incorporated by reference to the Registrants Form
S-1,
filed with the Securities Exchange Commission on July 19, 2021.
(2)
Incorporated by reference to the Registrants Form
8-K,
filed with the Securities Exchange Commission on July 29, 2021
 
83

Item 16
Form 10-K Summary
Not applicable.
 
84

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this Annual Report on Form
10-K
to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: April 15, 2022
 
Alpha Healthcare Acquisition Corp. III
 
/s/ Rajiv Shukla
Name:   Rajiv Shukla
Title:   Chief Executive Officer and Chairman
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form
10-K
has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
Name
  
Position
  
Date
     
/s/ Rajiv Shukla
Rajiv Shukla
   Chief Executive Officer and Chairman
(Principal Executive Officer)
   April 15, 2022
     
/s/ Patrick A. Sturgeon
Patrick A. Sturgeon
   Chief Financial Officer
(Principal Financial and Accounting

Officer)
   April 15, 2022
     
/s/ Darlene T. DeRemer
Darlene T. DeRemer
   Director    April 15, 2022
     
/s/ Eugene L. Podsiadlo
Eugene L. Podsiadlo
   Director    April 15, 2022
     
/s/ William Woodward
William Woodward
   Director    April 15, 2022
 
 
85


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and Board of Directors of
Alpha Healthcare Acquisition Corp. III
Opinion on the Financial Statements
We have audited the accompanying balance sheet of Alpha Healthcare Acquisition Corp. III (the “Company”) as of December 31, 2021, the related statements of operations, shareholders’ equity (deficit) and cash flows for the period from January 21, 2021 through December 31, 2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the results of its operations and its cash flows for the period from January 21, 2021 through December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.
Explanatory Paragraph – Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide
s
a reasonable basis for our opinion.
/s/ Marcum LLP
Marcum LLP
We have served as the Company’s auditor since 2021.
Houston, TX
April 15, 2022
 
F-2

ALPHA HEALTHCARE ACQUISITION CORP. III
BALANCE SHEET
As of December 31, 2021
 
Assets
        
Current assets:
        
Cash
   $ 774,192  
Prepaid expenses
     198,983  
    
 
 
 
Total current assets
     973,175  
Marketable securities held in trust account
     154,449,121  
    
 
 
 
Total assets
  
$
155,422,296
 
    
 
 
 
Liabilities and Shareholders’ Equity (Deficit)
        
Current liabilities:
        
Accrued offering costs
   $ 112,485  
Accrued expenses
     215,247  
Due to related party
     2,275  
    
 
 
 
Total current liabilities
     330,007  
Deferred underwriting fees payable
     5,405,436  
    
 
 
 
Total liabilities
     5,735,443  
    
 
 
 
Commitments and Contingencies (Note 5)
     
Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 15,444,103 shares subject to possible redemption
 issued and outs
ta
nding
     154,449,121  
Shareholders’ equity (deficit):
        
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
         
Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 463,882 not subject to possible redemption issued and outstanding (excluding 15,444,103 shares subject to possible redemption)
     46  
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 3,861,026 shares issued and outstanding (1)
     386  
Additional
paid-in
capital
         
Accumulated deficit
     (4,762,700
    
 
 
 
Total shareholders’ deficit
     (4,762,268
    
 
 
 
Total Liabilities and Shareholders’ Deficit
  
$
155,422,296
 
    
 
 
 
 
(1)
An aggregate of 4,312,500 shares of Class B common stock were originally issued, of which 562,500 shares were subject to forfeiture depending on whether the over-allotment option was exercised in full or in part by the underwriters during the
45-day
option period. As a result of a partial over-allotment option exercise by the underwriters, an aggregate of 451,474 shares were forfeited at the end of the
45-day
option period.
The accompanying notes are an integral part of these financial statements.
 
F-3

ALPHA HEALTHCARE ACQUISITION CORP. III
STATEMENT OF OPERATIONS
FOR THE PERIOD FROM JANUARY 21, 2021 (INCEPTION) TO DECEMBER 31, 2021
 
Formation, general and administrative expenses
   $ 467,431  
    
 
 
 
Loss from operations
     (467,431
Other income:
        
Dividend and interest income
     8,091  
Change in fair value of overallotment liability
     2,923  
Gain on expiration of overallotment option
     127,035  
    
 
 
 
Net loss
   $ (329,382
    
 
 
 
Weighted average shares outstanding of Class A common stock subject to possible redemption
     6,973,122  
Basic and diluted net loss per share, Class A common stock subject to possible redemption (see Note 2)
     (0.03
Weighted average shares outstanding of Class A common stock
     209,549  
Basic and diluted net loss per share, Class A common stock (see Note 2)
     (0.03
Weighted average shares outstanding of Class B common stock
     3,797,628  
Basic and diluted net loss per share, Class B common stock (see Note 2)
     (0.03
The accompanying notes are an integral part of these financial statements.
 
F-4

ALPHA HEALTHCARE ACQUISITION CORP. III
STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT)
FOR THE PERIOD FROM JANUARY 21, 2021 (INCEPTION) TO DECEMBER 31, 2021
 
    
Common Stock Subject to
Possible Redemption
    
Common Stock
   
Additional

Paid-in

Capital
   
Accumulated

Deficit
   
Total

Shareholders’
Equity

(Deficit)
 
    
Class A
    
Class A
    
Class B
 
    
Shares
    
Amount
    
Shares
    
Amount
    
Shares
   
Amount
 
Balance - January 21, 2021 (inception)
  
 
  
 
  
$
 
 
  
 
  
 
  
$
   
 
  
 
  
 
 
$
   
 
 
$
  
 
 
$
  
 
 
$
    
 
Class B common stock issued to Sponsor
     —          —          —          —          4,312,500       431       24,569       —         25,000  
Issuance of Private Placement Units
     —          —          463,882        46        —         —         4,638,774       —         4,638,820  
Issuance of Class A Common stock, net of issuance costs of $9,905,857
     15,444,103        140,738,518        —          —          —         —         —         —         —    
Issuance of Public Warrants, net of issuance costs of $239,247
     —          —          —          —          —         —         3,399,132       —         3,399,132  
Capital contribution by the Sponsor through transfer of Class B shares
     —          —          —          —          —         —         1,186,448       —         1,186,448  
Fair value of underwriter’s overallotment options exercised
     —          —          —          —          —         —         28,317       —         28,317  
Accretion to redemption value of Class A Common stock subject to possible redemption
     —          13,702,512        —          —          —         —         (9,277,240     (4,425,272 )     (13,702,512
Forfeiture of Founder Shares related to unexercised portion of underwriter’s overallotment option
     —          —          —          —          (451,474     (45     —         45       —    
Change in redemption value of Class A Common stock subject to possible redemption due to dividend and interest income earned
     —          8,091        —          —          —         —         —         (8,091     (8,091
Net loss
     —          —          —          —          —         —         —         (329,382     (329,382
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance – December 
31
,
2021
  
 
15,444,103
 
  
$
154,449,121
 
  
 
463,882
 
  
$
46
 
  
 
3,861,026
 
 
$
386
 
 
$
  
 
 
$
(4,762,700
 
$
(4,762,268
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
(1)
An aggregate of 4,312,500 shares of Class B common stock were originally issued, of which 562,500 shares were subject to forfeiture depending on whether the over-allotment option was exercised in full or in part by the underwriters during the
45-day
option period. As a result of a partial over-allotment option exercise by the underwriters, an aggregate of 451,474 shares were forfeited at the end of the
45-day
option period.
The accompanying notes are an integral part of these financial statements.
 
F-5

ALPHA HEALTHCARE ACQUISITION CORP. III
STATEMENT OF CASH FLOWS
FOR THE PERIOD FROM JANUARY 21, 2021 (INCEPTION) TO DECEMBER 31, 2021
 
Cash Flows from Operating Activities:
        
Net loss
   $ (329,382
Adjustments to reconcile net loss to net cash used in operating activities
        
Interest earned in trust account
     (8,091
Change in fair value of overallotment liability
     (2,923
Gain on expiration of overallotment option
     (127,035
Changes in current assets and liabilities:
        
Prepaid expenses
     (198,983
Accrued expenses
     215,247  
    
 
 
 
Net cash used in operating activities
     (451,167
    
 
 
 
Cash Flows from Investing Activities:
        
Investment of cash into trust account
     (154,441,030
    
 
 
 
Cash Flows from Financing Activities:
        
Proceeds from related party
     56,922  
Payment to related party
     (54,647
Proceeds from issuance of Units
     154,441,030  
Proceeds from issuance of Private Units
     4,638,820  
Payment of offering costs
     (3,415,736
    
 
 
 
Net cash provided by financing activities
     155,666,389  
    
 
 
 
Net Change in Cash
     774,192  
Cash - January 21, 2021 (inception)
         
    
 
 
 
Cash - end of the period
   $ 774,192  
Supplemental Disclosure of cash flow information:
        
Deferred underwriting fee payable
   $ 5,405,436  
Capital contribution by the Sponsor through transfer of Class B shares
   $ 1,186,448  
Offering costs included in accrued offerings costs
   $ 112,485  
Offering costs paid by Sponsor in exchange for issuance of Class B common stock
   $ 25,000  
Accretion of the interest earned in trust account
   $ 8,091  
The accompanying notes are an integral part of these financial statements.
 
F-6

ALPHA HEALTHCARE ACQUISITION CORP. III
NOTES TO FINANCIAL STATEMENTS
Note 1 — Organization and Business Operations
Alpha Healthcare Acquisition Corp. III is a blank check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company has not selected any specific Business Combination target and the Company has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any Business Combination target. While the Company may pursue an initial Business Combination target in any business or industry, it intends to focus its search on companies in the healthcare industry.
The Company has selected December 31 as its fiscal year end.
As of December 31, 2021, the Company had not yet commenced any operations. All activity from January 21, 2021 (inception) through December 31, 2021, relates to the Company’s formation, the Public Offering (as defined below), and activities necessary to identify a potential target for a Business Combination. Since our Initial Public Offering, we have not generated any operating revenues, and do not expect to generate any operating revenues, until after completion of our initial Business Combination.
The registration statement for the Company’s Public Offering was declared effective on July 26, 2021. On July 29, 2021 (“IPO Date”), the Company consummated the Initial Public Offering of 15,000,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $150,000,000, which is described in Note 3. In connection with the IPO, the Company also granted the underwriters a
45-day
option to purchase an additional 2,250,000 Public Units at the initial public offering price.
Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 455,000 Units (each, a “Private Placement Unit” and, collectively, the “Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to AHAC Sponsor III LLC (the “Sponsor”), generating gross proceeds of $4,550,000, which is described in Note 4.
At the IPO Date, transaction costs amounted to $3,461,151, consisting of $3,000,000 of underwriting fees and $461,151 of other offering costs. The Company has also accrued underwriting fees of $5,250,000 that will be paid only if a business combination is entered into. In addition, cash of $1,550,000 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes.
At the IPO date, the Sponsor also transferred to certain investors a total of 225,000 of Founders shares (Note 4)
(“Non-Risk
Incentive Private Shares”) as a compensation for their commitment to purchase the Public Units sold in the IPO. The Company estimated the aggregate fair value of these shares to be $1,186,448, or $5.27 per share. The fair value of the
Non-Risk
Incentive Private Shares was determined to be a contribution from the Sponsor for offering costs in accordance with Staff Accounting Bulletin Topic 5T. These offering costs were allocated to the Units and charged to shareholder’s equity upon the completion of the Initial Public Offering.
At the IPO date, the Sponsor also transferred to certain other investors the total of 600,900 of Founders shares (“Risk Incentive Private Shares”) as a compensation for their commitment to acquire at least 9.9% of the Units sold in the IPO. These Risk Incentive Private Shares are subject to forfeiture if the investors sell their Units prior to the closing of the initial Business Combination. The fair value of these Risk Incentive Private
Shares of $5.27
is equal to the fair value of the
Non-Risk
Incentive Private Shares. Due to the high probability of forfeiture, the fair value of these Risk Incentive Private Shares will be recorded as a capital contribution from the Sponsor upon the closing of the initial Business Combination.
On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 additional Units for a total amount of $4,441,030 resulting from the partial over-allotment exercise. The Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds. Transaction costs related to the Underwriters’ partial over-allotment exercise amounted to $92,070, consisting of $88,820 of underwriting fees and $3,250 of other offering costs. The Company has also accrued underwriting fees of $155,436 that will be paid only if a business combination is entered into.
 
F-7

The total issuance costs of $10,145,105 were allocated to the Class A shares subject to possible redemption and the Public Warrants based on their relative fair values with $9,905,857 to the Class A shares subject to possible redemption and $239,247 to the Public Warrants.
Following the closing of the Initial Public Offering on July 29, 2021, an amount of $154,441,030 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering, including the Units sold upon the exercise of the over-allotment option, and the sale of the Private Placement Units was placed in a trust account (the “Trust Account”), invested in U.S. government securities, within the meaning set forth in Section 2(a) (16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule
2a-7
of the Investment Company Act of 1940, as amended (the “Investment Company Act”), as determined by the Company. Except for the withdrawal of interest income to pay the income taxes, the Company’s amended and restated certificate of incorporation and subject to the requirements of law and regulation, provides that none of the funds held in the Trust Account will be released from the Trust Account until the earliest of (a) the completion of the Company’s initial Business Combination, (b) the redemption of the public shares if the Company is unable to consummate an initial Business Combination within 24 months from the closing of the Public Offering (the “Combination Period”), subject to applicable law, and (c) the redemption of the Company’s public shares properly submitted in connection with a shareholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of its public shares if the Company has not consummated an initial Business Combination within the Combination Period or with respect to any other material provisions relating to shareholders’ rights or
pre-initial
Business Combination activity. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public shareholders.
The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds are intended to be generally applied toward consummating a Business Combination.
The Company’s Business Combination must be with one or more target businesses that together have an aggregate fair market value of at least 80% of the assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting discounts held in trust and taxes payable on the interest earned on the Trust Account) at the time of the signing an agreement to enter into a Business Combination. However, the Company will only complete an initial Business Combination if the post-business combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination.
The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the initial Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed initial Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The shareholders will be entitled to redeem their shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest (net of taxes payable), divided by the number of then outstanding public shares. The amount in the Trust Account is initially anticipated to be $10.00 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters.
The shares of common stock subject to redemption were recorded at a redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”
The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.
 
F-8

If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in each case, to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to consummate an initial Business Combination within the Combination Period.
The Sponsor has agreed (i) to waive its redemption rights with respect to any Founder Shares, private placement shares and public shares held by it in connection with the completion of the initial Business Combination, (ii) to waive its rights to liquidating distributions from the Trust Account with respect to any Founder Shares or private placement shares held by it if the Company fails to complete its Business Combination within the Combination Period, although the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any public shares it holds if the Company fails to complete its Business Combination within such time period, (iii) not to propose any amendment to the Company’s amended and restated certificate of incorporation that would modify the substance or timing of its obligation to redeem 100% of the public shares if the Company does not complete its initial Business Combination within the Combination Period or with respect to any other material provisions relating to shareholders’ rights or
pre-initial
Business Combination activity, unless the Company provides its public shareholders with the opportunity to redeem their shares, and (iv) to vote any Founder Shares held by it and any public shares purchased during or after the Public Offering in favor of the Company’s initial Business Combination.
The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per share due to reductions in the value of the trust assets, in each case less taxes payable, provided that such liability will not apply to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has it independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.
Liquidity and Going Concern
As of December 31, 2021, the Company had cash outside the Trust Account of $774,192 available for working capital needs. All remaining cash held in the Trust Account are generally unavailable for the Company’s use, prior to an initial business combination, and is restricted for use either in a Business Combination or to redeem common stock. As of December 31, 2021, none of the amount in the Trust Account was available to be withdrawn as described above.
Through December 31, 2021, the Company’s liquidity needs were satisfied through receipt of $25,000 from the sale of the founder shares and the remaining net proceeds from the sale of Private Placement Units held outside of the trust account, totaling $774,192 as of December 31, 2021.
For the period from January 21, 2021 (inception) through December 31, 2021, the Company had a net loss of $329,382, which consisted of formation and general and administrative costs.
The $774,192 held outside of the Trust Account as of December 31, 2021, may not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company may need to raise additional capital through loans or additional investments from its Sponsor, stockholders, officers, directors, or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern, assuming a Business Combination is not consummated. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
The Company believes that the proceeds raised in the initial public offering and the funds potentially available from loans from the sponsor or any of their affiliates will be sufficient to allow the Company to meet the expenditures required for operating its business. However, if the estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to the initial Business Combination. Moreover, the Company may need to obtain additional financing either to complete the Business Combination or because the Company becomes obligated to redeem a significant number of public shares upon completion of the Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination.

F-9

Note 2 — Significant Accounting Policies
Basis of Presentation
The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).
Emerging Growth Company Status
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Marketable Securities Held in Trust Account
At December 31, 2021, the assets held in the Trust Account were substantially held in U.S. Treasury Bills and U.S Treasury Coupons. During the period from January 21, 2021 (inception) through December 31, 2021, the Company did not withdraw any of interest income from the Trust Account to pay its tax obligations.
 
F-10

Common Stock Subject to Possible Redemption
The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as shareholders’ equity. The Company’s common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of December 31, 2021, 15,444,103 shares of Class A common stock subject to possible redemption are classified in temporary equity outside of the shareholders’ equity (deficit) section of the Company’s balance sheet and were immediately accreted to redemption value at the IPO date.
Derivative Financial Instruments
The Company issues warrants to its investors and accounts for warrant instruments as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification.
The Public Warrants (see Note 3) and Private Warrants (see Note 4) were accounted for as equity as these instruments meet all of the requirements for equity classification under ASC 815.
The over-allotment option (see Note 6) was deemed to be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to ASC 480.
The fair value of the overallotment liability at the IPO date of $158,275 was determined using the Black Scholes option pricing model based on the following assumptions:
 
Risk-free interest rate
  
 
0.05
Dividend rate
  
 
0
Volatility
  
 
5.00
Expected life (in years)
  
 
0.12
 
On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 Units (see Note 3). The fair value of the corresponding overallotment liability partially extinguished upon exercise of $28,317 was determined using the Black Scholes option pricing model based on the following assumptions:
 
Risk-free interest rate
     0.05
Dividend rate
     0
Volatility
     5.00
Expected life (in years)
     0.10  
Upon the expiration of the unexercised overallotment options on September 9, 2021, the Company recorded a gain on the expiration of the overallotment option of $127,035.
Net Loss per Common Stock share
The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” Net loss per share is computed by dividing net loss by the weighted average number of Common Stock shares outstanding during the period. Weighted average shares for the period from January 21, 2021 (inception) through December 31, 2021 were reduced for the effect of an aggregate of
562,500
Class B Common shares that were subject to forfeiture until the over-allotment option was partially exercised by the underwriters on August 3, 2021 (see Note 5), upon which date the forfeiture provision lapsed for 111,026 Class B Common shares. Subsequent to September 9, 2021, weighted average shares were reduced for the effect of an aggregate of 451,474 Class B Common shares which were ultimately forfeited upon the expiration of the
45-day
period reserved for the exercise of over-allotment option.
 
F-11

The Company’s statements of operations include a presentation of net loss per share subject to redemption in a manner similar to the
two-class
method of income per share. With respect to the accretion of the Class A Shares subject to possible redemption and consistent with ASC
480-10-S99-3A,
the Company deemed the fair value of the Class A Common shares subject to possible redemption to approximate the contractual redemption value and the accretion has no impact on the calculation of net income/(loss) per share.
The Company’s Public Warrants (see Note 3) and Private Warrants (see Note 4) could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. However, these warrants were excluded when calculating diluted loss per share because such inclusion would be anti-dilutive for the periods presented. As a result, diluted loss per share is the same as basic loss per share for the period presented.
A reconciliation of net loss per share is as follows for the period from January 21 (Inception) through December 31, 2021:
 
    
Class A subject to
possible redemption
    
Class A
    
Class B
 
Allocation of undistributable losses
     (209,176      (6,286      (113,920
    
 
 
    
 
 
    
 
 
 
Net income/(loss) to Common shares
  
$
(209,176
  
$
(6,286
  
$
(113,920
    
 
 
    
 
 
    
 
 
 
Weighted average shares outstanding, basic and diluted
     6,973,122        209,549        3,797,628  
    
 
 
    
 
 
    
 
 
 
Basic and diluted net loss per share
   $ (0.03    $ (0.03    $ (0.03
    
 
 
    
 
 
    
 
 
 
Offering Costs
Offering costs consist of underwriting, legal, accounting and other expenses incurred through the Initial Public Offering that are directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with the Public Shares were charged to shareholders’ equity upon the completion of the Initial Public Offering. Offering costs amounted to $9,897,599 at July 29, 2021, which were allocated between the Class A shares subject to possible redemption and the Public Warrants and charged to shareholders’ equity upon the completion of the Initial Public Offering. Under the guidance in Staff Accounting Bulletin 107 Topic 5.A, Accounting for Expenses or Liabilities Paid by Principal Stockholder(s), the Company included in these offering costs amounts incurred by the Sponsor through the transfer of
Non-Risk
Incentive Private Shares (see Note 4) to Anchor Investors on behalf of the Company in the amount of $1,186,448. The initial public offering costs as of the IPO date were allocated $9,664,188 and $233,411 between the Class A shares subject to possible redemption and the Public Warrants (see Note 6), respectively, based on their relative fair values at the issuance date. The Company incurred an additional $92,070 offering costs of upon the partial exercise of the overallotment option on August 3, 2021.
The total issuance costs of $10,145,105 were allocated to the Class A shares subject to possible redemption and the Public Warrants based on their relative fair values with $9,905,857 to the Class A shares subject to possible redemption and $239,247 to the Public Warrants.
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.
 
F-12

Fair Value Measurements
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
 
   
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
   
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
   
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
 
Description
  
Level
    
December 31,
2021
 
Assets:
                 
Marketable securities held in Trust Account
     1      $ 154,449,121  
The overallotment liability is measured at fair value using the Black Scholes Option Pricing Model with significant unobservable inputs. The fair value is based on the share price of the underlying shares and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. Therefore, the overallotment liability is considered to be a Level 3 financial instrument.
The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis:
 
    
Overallotment
liability
 
Balance at January 21, 2021 (inception)
   $     
Issuance of overallotment option
     158,275  
Partial exercise of overallotment option
     (28,316
Change in fair value of overallotment liability
     (2,924
Expiration of overallotment option
     (127,035
    
 
 
 
Balance at December 31, 2021
   $     
    
 
 
 
Income Taxes
The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
 
F-13

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to a concentration of credit risk consist of a cash account in a financial institution, which at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Recently Issued Accounting Standards
Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.
Note 3 — Initial Public Offering
On July 29, 2021, the Company sold 15,000,000 Units at $10.00 per Unit, generating gross proceeds of $150.0 million. Each unit consists of one share of Class A common stock and
one-fourth
of one redeemable warrant. Only whole warrants are exercisable. Each whole warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share.
Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 455,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement to the Sponsor, generating gross proceeds of $4,550,000, which is described further in Note 4.
On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units for the total amount of $4,441,030, received on August 6, 2021. Resulting from the partial over-allotment exercise, the Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds.
Note 4 — Related Party Transactions
Founder Shares
On January 21, 2021, the Sponsor subscribed to purchase 3,593,750 shares of the Company’s common stock, par value $0.0001 per share (the “Founder Shares”) for an aggregate price of $25,000. On January 25, 2021, the Sponsor paid $25,000, or approximately $0.00696 per share, to cover for certain offering and formation costs in consideration for 3,593,750 Founder Shares. On March 1, 2021, the Company effected a 1:1.2 stock split of its common stock which resulted in an aggregate of 4,312,500 shares of Class B common stock outstanding. All shares and associated amounts have been retroactively restated to reflect the stock split. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units out of the total 2,250,000 available under the over-allotments and the forfeiture provisions lapsed for 111,026 Founder Shares. The remaining 451,464 Founder Shares were forfeited upon the expiration of the
45-day
period reserved for the exercise of over-allotment option.
On July 27, 2021, our sponsor transferred 25,000 founder shares to each of Darlene DeRemer, Eugene Podsiadlo, and William Woodward. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on the Company’s board of directors through the closing of such initial business combination.
 

F-14

At the IPO date, the Sponsor also transferred to certain investors a total of 225,000 of Founders shares (Note 4)
(“Non-Risk
Incentive Private Shares”) as a compensation for their commitment to purchase the Public Units sold in the IPO. The Company estimated the aggregate fair value of these shares to be $1,186,448, or $5.27 per share. The fair value of the
Non-Risk
Incentive Private Shares was determined to be a contribution from the sponsor for offering costs in accordance with Staff Accounting Bulletin Topic 5T. These offering costs were allocated to the Units and charged to shareholder’s equity upon the completion of the Initial Public Offering.
At the IPO date, the Sponsor also transferred to certain other investors the total of 600,900 of Founders shares (“Risk Incentive Private Shares”) as a compensation for their commitment to acquire at least 9.9% of the Units sold in the IPO. These Risk Incentive Private Shares are subject to forfeiture if the investors sell their Units prior to the closing of the initial Business Combination. The fair value of these Risk Incentive Private Shares is equal to the fair value of the
Non-Risk
Incentive Private Shares. Due to the high probability of forfeiture, the fair value of these Risk Incentive Private Shares will be recorded as a capital contribution from the Sponsor upon the closing of the initial Business Combination.
The Sponsor, directors and executive officers have agreed not to transfer, assign or sell (i) any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Company’s shares of Class A common stock equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any
30-trading
day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of its public shareholders having the right to exchange their common stock for cash, securities or other property, and (ii) any of their Private Placement Units, placement shares, Private Placement Warrants and Class A common stock issued upon conversion or exercise thereof until 30 days after the completion of the initial Business Combination (the
“Lock-up”).
Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor and directors and executive officers with respect to any Founder Shares, Private Placement Units, placement shares, Private Placement Warrants and Class A common stock issued upon conversion or exercise thereof.
Private Placement
Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased 455,000 placement units, at a purchase price of $4,550,000, in a private placement. Each Private Placement Unit is identical to the Units sold in the Initial Public Offering except as described below. A portion of the proceeds from the Private Placement Units was added to the proceeds from the Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law).
As a result of the partial over-allotment exercise on August 3, 2021, the Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds.
The Private Placement Units (including the placement shares, the placement warrants and Class A common stock issuable upon exercise of such placement warrants) will not be transferable or salable until 30 days after the completion of our Business Combination (except, among other limited exceptions, to our officers and directors and other persons or entities affiliated with our Sponsor).
Promissory Note — Related Party
On January 25, 2021, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $300,000 to be used for a portion of the expenses of the Proposed Public Offering. This loan was
non-interest
bearing, unsecured, and was due at the earlier of (i) the date on which the Company consummates the initial public offering and (ii) the date on which the Company determines not to conduct an initial public offering of its securities, upon request from the Company the Sponsor. Through the date of the Initial Public Offering, the Company had no borrowings under the promissory note.
Due to Related Party
The balance of $2,275 as of December 31, 2021, represents general and administrative costs paid by the Sponsor on behalf of the Company.
 
F-15

Administrative Service Fee
The Company has agreed, commencing on the date that the Company’s securities are first listed on the Nasdaq, to pay an affiliate of the Sponsor a monthly fee of an aggregate of $10,000 for office space, administrative and support services. For the period from January 21, 2021 (inception) through December 31, 2021, administrative fees incurred and paid to the Sponsor totaled $51,000. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees.
Related Party Loans
In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon consummation of a Business Combination into warrants at a price of $1.50 per warrant. The warrants will be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of December 31, 2021, there were no written agreements in place for the Working Capital Loans.
In conjunction with the IPO activities, on July 14, 2021 (the “Inception Date”), the Company and its Sponsor entered into the Subscription Agreements with certain investors (see Note 5).

Forward Purchase Agreement
The Company granted to the direct anchor investors an option, in their sole discretion, to subscribe to a forward purchase agreement for up to an aggregate of 60% (up to 10% per direct anchor investor) of the securities sold in one or multiple private placements to close prior to or concurrently with the closing of the initial business combination. The aggregate proceeds from the sale of any securities pursuant to these forward purchase agreements will be used for purposes related to the initial business combination.
Since the issuance of the securities to the investors is contingent upon the closing of an equity financing in relation to the initial business combination, the terms of the forward purchase agreement will not create an obligation for either party until such financing occurs.
Note 5 — Commitments & Contingencies
Registration Rights
The holders of the Founder Shares, Private Placement Units, Private Placement Warrants, Class A common stock underlying the Private Placement Warrants and Private Placement Units that may be issued upon conversion of Working Capital Loans (and any shares or Class A common stock issuable upon the exercise of the Private Placement Warrants and Private Placement Units that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration rights agreement dated July 26, 2021. The holders of these securities are entitled to make unlimited demands that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable
lock-up
period, which occurs (i) in the case of the Founder Shares, as described in the following paragraph, and (ii) in the case of the Private Placement Warrants and the respective shares of Class A common stock underlying such warrants, 30 days after the completion of the Company’s initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriters Agreement
The Company granted the underwriters a
45-day
option from July 26, 2021, to purchase up to 2,250,000 additional Units to cover over-allotments, if any, at the Public Offering price less the underwriting discounts and commissions. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units for the total amount of $4,441,030.
The underwriters received a cash underwriting discount of two percent (2.0%) of the gross proceeds of the Public Offering, or $3,000,000, paid on July 29, 2021. Additionally, in connection with the partial over-allotment exercise, the underwriters received a cash underwriting discount of two percent (2.0%) of the gross proceeds, or $88,820, paid on August 6, 2021. In addition to the cash underwriting discounts, the underwriters will be entitled to a deferred underwriting fee of three and a half percent (3.5%), or $5,405,436 of the gross proceeds of the Public Offering and the underwriters’ partial over-allotment exercise upon the completion of the Company’s initial Business Combination.
 
F-16

Subscription Agreements
In conjunction with the IPO activities, on July 14, 2021 (the “Inception Date”), the Company and its Sponsor entered into the Subscription Agreements with certain investors. Under these Subscription Agreements, the investors, who received the At Risk Incentive Private Shares, received the right but not the obligation to subscribe, at their sole discretion, to any equity financing associated with the Closing of the initial Business Combination subject to a maximum of 10% of such offerings’ proceeds, and the right but not the obligation to subscribe, at their sole discretion, at the same terms in the next special purpose acquisition company or other similar entity sponsored by Constellation Alpha Holdings. The investors who received the Non Risk Incentive Private Shares also received the right but not the obligation to subscribe, at their sole discretion, to any equity financing associated with the Closing of the SPAC’s initial Business Combination subject to a maximum of 10% of such offerings’ proceeds if the Investor still holds their Public Shares at the business combination date. Since the number of shares or other instruments to be purchase by the investors is unknown, these rights to participate in future offerings do not meet definition of an equity contract.
Risks and Uncertainties
Management is currently evaluating the impact of the
COVID-19
pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Note 6 — Shareholder’s Equity
Common Stock —
On January 25, 2021, the Company issued 3,593,750 shares of common stock, including an aggregate of up to 468,750 shares of common stock that were subject to forfeiture, to the Company by the initial shareholders for no consideration to the extent that the underwriters’ over- allotment option is not exercised in full or in part, so that the initial shareholders will collectively own 20% of the Company’s issued and outstanding common stock after the Proposed Public Offering.
On March 1, 2021, the Company amended its charter to authorize issuance of 100,000,000 Class A common stock, with a par value of $0.0001 per share, 10,000,000 Class B common stock, with a par value of $0.0001 per share, and 1,000,000 preferred stock, with a par value of $0.0001 per share, and effected a 1:1.2 stock split of its common stock which resulted in an aggregate of 4,312,500 shares of Class B common stock outstanding All shares and per share amounts have been retroactively restated to reflect the stock split.
On July 29, 2021, the Company sold 15,000,000 Units, each unit consists of one share of Class A common stock and
one-fourth
of one redeemable warrant. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units.
On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units out of the total 2,250,000 available under the over-allotments and the forfeiture term lapsed for 111,026 Founder Shares. The remaining 451,464 Founder Shares were forfeited upon the expiration of the
45-day
period reserved for the exercise of over-allotment option.
At December 31, 2021, there were (i) 15,907,985 shares of Class A common stock issued and outstanding (including 15,444,103 shares subject to possible redemption) and (ii) 3,861,026 shares of Class B common stock issued and outstanding.
Both Class A and B shareholders vote together as a single class on all matters submitted to a vote of the Company shareholders, with each share of common stock entitling the holder to one vote.
The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the initial Business Combination on a
one-for-one
basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like), and subject to further adjustment as provided herein. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in the Proposed Public Offering and related to the closing of the Business Combination, including pursuant to a specified future issuance, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless our Sponsor agrees to waive such adjustment with respect to any such issuance or deemed issuance, including a specified future issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an
as-converted
basis, 20% of the sum of the total number of all shares of common stock outstanding upon completion of the Proposed Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with the Business Combination (after giving effect to any redemptions of shares of Class A common stock by public shareholders) (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the Business Combination and any Private Placement Units issued to our Sponsor, officers or directors upon conversion of Working Capital Loans). The Sponsor may also elect to convert their shares of Class B common stock into an equal number of shares of Class A common stock, subject to adjustment as provided above, at any time.
 
F-17

Preferred Stock –
The Company is authorized to issue 1,000,000 shares of preferred stock, with a par value of $0.0001 per share. At December 31, 2021, there were no shares of preferred stock issued or outstanding.
Warrants –
The warrants may only be exercised for a whole number of shares. The warrants included in the units sold in the Public Offering (the “Public Warrants”) will become exercisable 30 days after the completion of a Business Combination provided that the Company has an effective registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their Public Warrants on a cashless basis and such cashless exercise is exempt from registration under the Securities Act). The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of the initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC and have an effective registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. If a registration statement covering the issuance of the Class A common stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption.
The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional shares of Class A common stock or equity- linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance), or the Newly Issued Price, (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, respectively.
The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants and the shares of Class A common stock issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions.
Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00: Once the warrants become exercisable, the Company may redeem the outstanding warrants for cash:
 
   
in whole and not in part;
 
   
at a price of $0.01 per warrant;
 
   
upon a minimum of 30 days’ prior written notice of redemption; and
 
   
if, and only if, the closing price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like and for certain issuances of Class A common stock and equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination) for any 20 trading days within a
30-trading
day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”).
 
F-18

The Company will not redeem the warrants unless an effective registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A common stock is available throughout the
30-day
redemption period.
In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.
Note 7 — Income Taxes
The Company’s general and administrative expenses are generally considered
start-up
costs and are not currently deductible. During the period from January 21, 2021 (inception) to December 31, 2021, no income tax expense was recorded. The Company’s effective tax rate for the period from January 21, 2021 (inception) through December 31, 2021 was zero percent, which differs from the expected income tax rate due predominantly to the
start-up
costs which are not currently deductible.
The income tax provision consisted of the following as of December 31, 2021:
 
Federal
        
Current
   $     
Deferred
     (96,461
State
        
Current
         
Deferred
      
Change in valuation allowance
     96,461  
    
 
 
 
Income tax provision
  
$
  
 
    
 
 
 
The Company’s net deferred tax assets consist of the following as of December 31, 2021:
 
Deferred tax assets:
        
Net operating loss carryforwards
   $ 33,531  
Organizational costs/startup expenses
     62,930  
    
 
 
 
Total deferred tax asset
     96,461  
Valuation allowance
     (96,461 )
    
 
 
 
Deferred tax asset, net of valuation allowance
  
$
  
 
    
 
 
 
As of December 31, 2021, the Company has U.S. federal net operating loss carryovers of $159,673
 
that do not expire.
In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the year ended December 31, 2021, the change in the valuation allowance was $96,461.
There were no unrecognized tax benefits as of December 31, 2021. No amounts were accrued for the payment of interest and penalties at December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.
A reconciliation of the federal income tax rate to the Company’s effective tax rate at December 31, 2021 is as follows:
 
Statutory federal income tax rate
     21.0
Change in fair value of overallotment liability
     8.3  
Change in valuation allowance
     (29.3 )
    
 
 
 
Effective tax rate
       
    
 
 
 
 
F-19

The Company files U.S. federal income tax returns and is subject to examination since inception.
Note 8 — Stock-based Compensation
On July 27, 2021, the Sponsor transferred 25,000 shares of Class B common stock to each of the three independent director nominees as compensation for their service on the board of directors. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on the Company’s board of directors through the closing of such initial business combination. As such, the service period for these awards will start on the IPO date. As the share awards would vest only upon the consummation on a business combination, the compensation expense in relation to these grants would be not recognized until the closing of the initial business combination. As a result, the Company recorded no compensation expense for the period from January 21, 2021 (inception) through December 31, 2021.
The fair value of the Founder Shares on the grant date was approximately $5.26 per share. The valuation performed by the Company determined the fair value of the Founder Shares on the date of grant based on the fair value of the Class A shares discounted for a) the probability of a successful business combination, and b) the lack of marketability. The aggregate grant date fair value of the award amounted to approximately $394,000.
A summary of the restricted stock award and restricted unit activity for the period from January 21, 2021 (inception) through December 31, 2021 is as follows:
 
 
  
Number
of
Shares
 
Unvested Shares Outstanding at January 21, 2021 (inception)
  
 
  
 
Granted
  
 
75,000
 
Forfeited
  
 
  
 
Vested
  
 
  
 
 
  
 
 
 
Unvested Outstanding at December 31, 2021
  
 
75,000
 
 
  
 
 
 
Total
 
unrecognized compensation expense related to unvested Founder Shares at December 31, 2021 amounted to approximately $
394,000
and is expected to be recognized upon the initial business combination.
Note 9 — Subsequent Events
The Company did not identify any subsequent events that require adjustment or disclosure in the financial statements.
 
 
F-20
EX-4.5 2 d268885dex45.htm EX-4.5 EX-4.5

Exhibit 4.5

DESCRIPTION OF SECURITIES

The following summary of the material terms of the securities of Alpha Healthcare Acquisition Corp. III (“we,” “us,” “our” or “the company”) is not intended to be a complete summary of the rights and preferences of such securities and is subject to and qualified by reference to our amended and restated memorandum and articles of association incorporated by reference as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 of which this Exhibit 4.5 forms a part, and applicable Delaware law. We urge you to read our amended and restated memorandum and articles of association in their entirety for a complete description of the rights and preferences of our securities.

Certain Terms

Unless otherwise stated in this Annual Report on Form 10-K or the context otherwise requires, references to:

 

“common stock” are to our Class A common stock and our Class B common stock, collectively;

 

“founder shares” are to shares of our Class B common stock initially purchased by our sponsor in a private placement prior to our initial public offering, and the shares of our Class A common stock issuable upon the conversion thereof;

 

“initial public offering” are to our initial public offering of 15,000,000 units, at $10.00 per unit, which closed on July 29, 2021, and the partial over-allotment exercise of 444,103 units, at $10.00 per unit, which closed on August 3, 2021;

 

“initial stockholders” are to our sponsor and any other holders of our founder shares prior to our initial public offering (or their permitted transferees);

 

“management” or our “management team” are to our officers and directors;

 

“placement units” are to the units purchased by our sponsor in the private placement concurrent with our initial public offering, each placement unit consisting of one placement share and one-fourth of one placement warrant;

 

“placement shares” are to the shares of our common stock included within the placement units purchased by our sponsor in the private placement concurrent with our initial public offering;

 

“placement warrants” are to the warrants included within the placement units purchased by our sponsor in the private placement concurrent with our initial public offering;

 

“private placement” are to the private placement of 463,882 placement units at a price of $10.00 per unit, for an aggregate purchase price of $4,638,820, which occurred simultaneously with the completion of our initial public offering;

 

“public shares” are to shares of our Class A common stock sold as part of the units in our initial public offering;

 

“public stockholders” are to the holders of our public shares, including our initial stockholders and management team to the extent our initial stockholders and/or members of our management team purchase public shares, provided that each initial stockholder’s and member of our management team’s status as a “public stockholder” shall only exist with respect to such public shares;

 

“public warrants” are to our redeemable warrants sold as part of the units in our initial public offering;

 

“sponsor” are to AHAC Sponsor LLC, a Delaware limited liability company;


“warrants” are to our redeemable warrants, which includes the public warrants as well as the placement warrants and any warrants issued upon conversion of working capital loans; and

 

“we,” “us,” “company” or “our company” are to Alpha Healthcare Acquisition Corp. III

General

We are a blank check company formed under the laws of the State of Delaware on January 21, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this Annual Report on Form 10-K as our initial business combination. Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 100,000,000 shares of Class A common stock and 10,000,000 shares of Class B common stock, as well as 1,000,000 shares of preferred stock, $0.0001 par value each. The following description summarizes certain terms of our shares as set out more particularly in our amended and restated certificate of incorporation. Because it is only a summary, it may not contain all the information that is important to you.

Units

Each unit has an offering price of $10.00 and consists of one share of Class A common stock and one-fourth of one warrant. Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustments as described herein. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of the company’s Class A common stock. This means only a whole warrant may be exercised at any given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Accordingly, unless you purchase at least four units, you will not be able to receive or trade a whole warrant.

The shares of Class A common stock and warrants comprising the units began separate trading on or about September 15, 2021. Once the shares of Class A common stock and warrants commenced separate trading, holders had the option to continue to hold units or separate their units into the component securities. Holders will need to have their brokers contact our transfer agent in order to separate the units into shares of Class A common stock and warrants.

Additionally, the units will automatically separate into their component parts and will not be traded after completion of our initial business combination.

Placement Units

The placement units (including the placement shares, the placement warrants and Class A common stock issuable upon exercise of such placement warrants) will not be transferable or salable until 30 days after the completion of our initial business combination (except, among other limited exceptions to our officers and directors and other persons or entities affiliated with our sponsor). Holders of our placement units are entitled to certain registration rights. If we do not consummate an initial business combination within 24 months from the closing of our initial public offering, the proceeds from the sale of the placement units held in the trust account will be used to fund the redemption of our public shares (subject to the requirements of applicable law) and the placement units (and the underlying securities) will expire worthless. Further, if we seek stockholder approval, we will complete our initial business combination only if a majority of the common stock, represented in person or by proxy and entitled to vote thereon, voted at a stockholder meeting are voted in favor of the business combination. In such case, our sponsor and each member of our management team have agreed to vote their founder shares, placement shares and any public shares purchased during or after our initial public offering in favor of our initial business combination. Otherwise, the placement units are identical to the units sold in our initial public offering.

Except as described herein, our sponsor and our directors and executive officers have agreed not to transfer, assign or sell (i) any of their founder shares until the earliest of (A) one year after the completion of our initial business combination and (B) subsequent to our initial business combination, (x) if the closing price of our shares of Class A common stock equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, organizations,


recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination, or (y) the date on which we complete a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of our public stockholders having the right to exchange their common stock for cash, securities or other property, and (ii) any of their placement units, placement shares, placement warrants and Class A common stock issued upon conversion or exercise thereof until 30 days after the completion of our initial business combination. Any permitted transferees will be subject to the same restrictions and other agreements of our sponsor and directors and executive officers with respect to any founder shares, placement units, placement shares, placement warrants and Class A common stock issued upon conversion or exercise thereof. We refer to such transfer restrictions as the lock-up.

Common Stock

On July 29, 2021, we sold 15,000,000 Units at $10.00 per Unit, generating gross proceeds of $150.0 million. Each unit consists of one share of Class A common stock and one-fourth of one redeemable warrant. Only whole warrants are exercisable. Each whole warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share. Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 455,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement to the Sponsor, generating gross proceeds of $4,550,000.

On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units out of the total 2,250,000 available under the over-allotments and the forfeiture term lapsed for 111,026 Founder Shares. The remaining 451,464 Founder Shares were forfeited upon the expiration of the 45-day period reserved for the exercise of over-allotment option.

At December 31, 2021, there were :

 

  (i)

15,907,985 shares of Class A common stock issued and outstanding (including 15,444,103 shares subject to possible redemption); and

 

  (ii)

3,861,026 shares of Class B common stock issued and outstanding.

Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. With respect to any matter submitted to a vote of our stockholders, including any vote in connection with our initial business combination, except as required by law or the applicable rules of Nasdaq then in effect, holders of our shares of Class A common stock and shares of Class B common stock will vote together as a single class on all matters submitted to a vote of our stockholders. Unless specified in our amended and restated certificate of incorporation or bylaws, or as required by applicable provisions of the Delaware General Corporate Law, or the DGCL, or applicable stock exchange rules, the affirmative vote of a majority of our shares of Class A common stock, on an as converted basis, entitled to vote on any matters that are voted on such matter is required to approve any such matter. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares voted for the election of directors can elect all of the directors. Our stockholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor.

Because our amended and restated certificate of incorporation authorizes the issuance of up to 100,000,000 shares of Class A common stock, if we were to enter into a business combination, we may (depending on the terms of such a business combination) be required to increase the number of shares of Class A common stock which we are authorized to issue at the same time as our stockholders vote on the business combination to the extent we seek stockholder approval in connection with our business combination.

The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the initial Business Combination on a one-for-one basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like), and subject to further adjustment as provided herein. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in the initial public offering and related to the closing of the business combination, including


pursuant to a specified future issuance, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless our Sponsor agrees to waive such adjustment with respect to any such issuance or deemed issuance, including a specified future issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all shares of common stock outstanding upon completion of the Proposed Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with the Business Combination (after giving effect to any redemptions of shares of Class A common stock by public shareholders) (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the business combination and any private placement units issued to our Sponsor, officers or directors upon conversion of working capital loans). The Sponsor may also elect to convert their shares of Class B common stock into an equal number of shares of Class A common stock, subject to adjustment as provided above, at any time.

In accordance with Nasdaq corporate governance requirements, we are not required to hold an annual meeting until no later than one year after our first fiscal year end following our listing on Nasdaq. Under Section 211(b) of the DGCL, we are, however, required to hold an annual meeting of stockholders for the purposes of electing directors in accordance with our bylaws, unless such election is made by written consent in lieu of such a meeting.

We will provide our stockholders with the opportunity to redeem all or a portion of their public shares upon the completion of our initial business combination at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account as of two business days prior to the consummation of our initial business combination including interest earned on the funds held in the trust account and not previously released to us to pay our franchise and income taxes, divided by the number of then outstanding public shares, subject to the limitations described herein. The amount in the trust account is initially anticipated to be approximately $10.00 per public share. The per share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions we will pay to the underwriters. Our sponsor has entered into a letter agreement with us, pursuant to which it has agreed to waive its redemption rights with respect to any founder shares, placement shares and any public shares held by it in connection with the completion of our business combination. However, if our sponsor acquires public shares in or after our initial public offering, it will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to consummate an initial business combination within 24 months from the closing of our initial public offering. Unlike many blank check companies that hold stockholder votes and conduct proxy solicitations in conjunction with their initial business combinations and provide for related redemptions of public shares for cash upon completion of such initial business combinations even when a vote is not required by law, if a stockholder vote is not required by law and we do not decide to hold a stockholder vote for business or other legal reasons, we will, pursuant to our amended and restated certificate of incorporation, conduct the redemptions pursuant to the tender offer rules of the SEC, and file tender offer documents with the SEC prior to completing our initial business combination. Our amended and restated certificate of incorporation requires these tender offer documents to contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under the SEC’s proxy rules. If, however, stockholder approval of the transaction is required by law, or we decide to obtain stockholder approval for business or other legal reasons, we will, like many blank check companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If we seek stockholder approval, we will complete our initial business combination only if a majority of the outstanding shares of common stock voted are voted in favor of the business combination. A quorum for such meeting will consist of the holders present in person or by proxy of shares of outstanding capital stock of the company representing a majority of the voting power of all outstanding shares of capital stock of the company entitled to vote at such meeting. However, the participation of our sponsor or its advisors or affiliates in privately negotiated transactions, if any, could result in the approval of our business combination even if a majority of our public stockholders vote, or indicate their intention to vote, against such business combination. For purposes of seeking approval of the majority of our outstanding shares of common stock voted, non-votes will have no effect on the approval of our business combination once a quorum is obtained. We intend to give approximately 30 days (but not less than 10 days nor more than 60 days) prior written notice of any such meeting, if required, at which a vote shall be taken to approve our business combination. These quorum and voting thresholds, and the voting agreements of our initial stockholders, may make it more likely that we will consummate our initial business combination.


If we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our business combination pursuant to the tender offer rules, our amended and restated certificate of incorporation provides that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the shares of common stock sold in our initial public offering, which we refer to as the Excess Shares. However, we would not be restricting our stockholders’ ability to vote all of their shares (including Excess Shares) for or against our business combination. Our stockholders’ inability to redeem the Excess Shares will reduce their influence over our ability to complete our business combination, and such stockholders could suffer a material loss in their investment if they sell such Excess Shares on the open market. Additionally, such stockholders will not receive redemption distributions with respect to the Excess Shares if we complete the business combination. And, as a result, such stockholders will continue to hold that number of shares exceeding 15% and, in order to dispose such shares would be required to sell their stock in open market transactions, potentially at a loss.

If we seek stockholder approval in connection with our business combination, our sponsor and each member of our management team have agreed to vote their founder shares, placement shares and public shares purchased during or after our initial public offering in favor of our initial business combination. As a result, in addition to our sponsor’s founder shares, we would need 53,915,000, or 26.1%, of the 15,000,000 public shares sold in our initial public offering to be voted in favor of an initial business combination in order to have our initial business combination approved (assuming all issued and outstanding shares are voted, the placement shares to be issued to our sponsor are voted in favor of the transaction and the over-allotment option is not exercised). Additionally, each public stockholder may elect to redeem their public shares irrespective of whether they vote for or against the proposed transaction or vote at all (subject to the limitation described in the preceding paragraph).

Pursuant to our amended and restated certificate of incorporation, if we are unable to complete our business combination within 24 months from the closing of our initial public offering, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter subject to lawfully available funds therefor, redeem the public shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to us to pay our franchise taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. Our sponsor has entered into a letter agreement with us, pursuant to which it has agreed to waive its rights to liquidating distributions from the trust account with respect to any founder shares or placement shares held by it if we fail to complete our business combination within 24 months from the closing of our initial public offering. However, if our sponsor acquires public shares in or after our initial public offering, it will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete our business combination within the prescribed time period.

In the event of a liquidation, dissolution or winding up of the company after a business combination, our stockholders are entitled to share ratably in all assets remaining available for distribution to them after payment of liabilities and after provision is made for each class of stock, if any, having preference over the common stock. Our stockholders have no preemptive or other subscription rights. There are no sinking fund provisions applicable to the common stock, except that we will provide our stockholders with the opportunity to redeem their public shares for cash equal to their pro rata share of the aggregate amount then on deposit in the trust account, upon the completion of our initial business combination, subject to the limitations described herein.

Founder Shares

The founder shares are identical to the shares of Class A common stock included in the units being sold our initial public offering, and our sponsor has the same stockholder rights as public stockholders, except that (i) the founder shares are subject to certain transfer restrictions, as described in more detail below, (ii) our sponsor has entered into a letter agreement with us, pursuant to which it has agreed (A) to waive its redemption rights with respect to any


founder shares, placement shares and any public shares held by it in connection with the completion of our business combination, (B) to waive its rights to liquidating distributions from the trust account with respect to any founder shares or placement shares held by it if we fail to complete our business combination within 24 months from the closing of our initial public offering, although our sponsor will be entitled to liquidating distributions from the trust account with respect to any public shares it holds if we fail to complete our business combination within such time period, (C) not to propose any amendment to our amended and restated certificate of incorporation that would modify the substance or timing of our obligation to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering or with respect to any other material provisions relating to stockholders’ rights or pre-initial business combination activity, unless we provide our public stockholders with the opportunity to redeem their shares, (iii) the founder shares are shares of our Class B common stock that will automatically convert into shares of our Class A common stock at the time of our initial business combination, or at any time prior thereto at the option of our sponsor, on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, as described herein and (iv) are subject to registration rights. If we submit our business combination to our public stockholders for a vote, our sponsor has agreed to vote any founder shares held by it and any public shares purchased during or after our initial public offering in favor of our initial business combination.

The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of our initial business combination on a one-for-one basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like), and subject to further adjustment as provided herein. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in our Initial Public Offering and related to the closing of the business combination, including pursuant to a specified future issuance, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless our sponsor agrees to waive such adjustment with respect to any such issuance or deemed issuance, including a specified future issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20% of the sum of the total number of all shares of common stock outstanding upon completion of our initial public offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with the business combination (after giving effect to any redemptions of shares of Class A common stock by public stockholders) (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the business combination and any placement units issued to our sponsor, officers or directors upon conversion of working capital loans). Our sponsor may also elect to convert their shares of Class B common stock into an equal number of shares of Class A common stock, subject to adjustment as provided above, at any time.

Except as described herein, our sponsor and our directors and executive officers have agreed not to transfer, assign or sell any of their founder shares until the earliest of (A) one year after the completion of our initial business combination and (B) subsequent to our initial business combination, (x) if the closing price of our shares of Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination, or (y) the date on which we complete a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our public stockholders having the right to exchange their shares of common stock for cash, securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of our sponsor and management team with respect to any founder shares, placement units, placement shares, placement warrants and Class A common stock issued upon conversion or exercise thereof. We refer to such transfer restrictions as the lock-up.

Preferred Stock

There are no shares of preferred stock outstanding. We are authorized to issue 1,000,000 shares of preferred stock, with a par value of $0.0001 per share, with such designation, rights and preferences as may be determined from time to time by our board of directors. No shares of preferred stock have been issued or registered as of December 31, 2021. Accordingly, our board of directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights which could adversely affect the voting power or other rights of the holders of common stock. However, the underwriting agreement prohibits us, prior to a business combination, from issuing preferred stock which participates in any manner in the proceeds of the trust account, or which votes as a class with the common stock on our initial business combination. We may issue some or all of the


preferred stock to effect our initial business combination. In addition, the preferred stock could be utilized as a method of discouraging, delaying or preventing a change in control of us. Although we have not currently issued any shares of preferred stock, we reserve the right to do so in the future.

Warrants

Public Stockholders’ Warrants. Each whole warrant entitles the registered holder to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing 30 days after the completion of our initial business combination, provided that we have an effective registration statement under the Securities Act covering the shares of Class A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or we permit holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement) and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of Class A common stock. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Accordingly, unless you purchase at least four units, you will not be able to receive or trade a whole warrant. The warrants will expire five years after the completion of our initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

We will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of Class A common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect to registration. No warrant will be exercisable and we will not be obligated to issue a share of Class A common stock upon exercise of a warrant unless the share of Class A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will we be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of Class A common stock underlying such unit.

We have agreed that as soon as practicable, but in no event later than twenty business days after the closing of our initial business combination, we will use our commercially reasonable efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the shares of Class A common stock issuable upon exercise of the warrants. We will use our commercially reasonable efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants is not effective by the sixtieth day after the closing of the initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when we will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption.

In addition, if (x) we issue additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to our initial stockholders or their affiliates, without taking into account any founder shares held by our initial stockholders or such affiliates, as applicable, prior to such issuance including any transfer or reissuance of such shares (the “Newly Issued Price”)), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination, and (z) the volume weighted average trading price of our shares of Class A common stock during the 20 trading day period starting on the trading day prior to the day on which we consummate our initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of


the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described adjacent to “Redemption of Warrants When the Price Per Share of Class A Common Stock Equals or Exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, respectively.

Redemption of Warrants When the Price Per Share of Class A Common Stock Equals or Exceeds $18.00. Once the warrants become exercisable, we may call the warrants for redemption:

 

   

in whole and not in part;

 

   

at a price of $0.01 per warrant;

 

   

upon not less than 30 days’ prior written notice of redemption, or the 30-day redemption period, to each warrant holder; and

 

   

if, and only if, the reported closing price of the common stock equals or exceeds $18.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like and for certain issuances of Class A common stock and equity-linked securities for capital raising purposes in connection with the closing of our initial business combination as described elsewhere in this Annual Report on Form 10-K) for any 20 trading days within a 30-trading day period ending three business days before we send to the notice of redemption to the warrant holders (the “Reference Value”).

We will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of common stock is available throughout the 30-day redemption period. If and when the warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. As a result, we may redeem the warrants as set forth above even if the holders are otherwise unable to exercise the warrants.

We have established the last of the redemption criteria discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrant holder will be entitled to exercise their warrant prior to the scheduled redemption date. However, the price of the shares of Class A common stock may fall below the $18.00 redemption trigger price (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) as well as the $11.50 warrant exercise price, subject to adjustments as described herein, after the redemption notice is issued.

No fractional shares of Class A common stock will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, we will round up to the nearest whole number of the number of shares of Class A common stock to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the shares of Class A common stock pursuant to the warrant agreement (for instance, if we are not the surviving company in our initial business combination), the warrants may be exercised for such security.

Redemption Procedures. A holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the warrant agent’s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (as specified by the holder) of the shares of Class A common stock issued and outstanding immediately after giving effect to such exercise.

Anti-dilution Adjustments. If the number of outstanding shares of Class A common stock is increased by a share dividend payable in shares of Class A common stock, or by a split-up of common stock or other similar event, then, on the effective date of such share dividend, split-up or similar event, the number of shares of Class A common stock issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding common stock.


In addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of shares of Class A common stock on account of such shares of Class A common stock (or other securities into which the warrants are convertible), then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and the fair market value of any securities or other assets paid on each share of Class A common stock in respect of such event.

If the number of outstanding shares of Class A common stock is decreased by a consolidation, combination, reverse share split or reclassification of shares of Class A common stock or other similar event, then, on the effective date of such consolidation, combination, reverse share split, reclassification or similar event, the number of shares of Class A common stock issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding shares of Class A common stock.

Whenever the number of shares of Class A common stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of shares of Class A common stock purchasable upon the exercise of the warrants immediately prior to such adjustment and (y) the denominator of which will be the number of shares of Class A common stock so purchasable immediately thereafter.

In addition, if (x) we issue additional shares of Class A common stock or equity linked securities for capital raising purposes in connection with the closing of our initial business combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to our initial stockholders or their affiliates, without taking into account any founder shares held by our initial stockholders or such affiliates, as applicable, prior to such issuance including any transfer or reissuance of such shares (the “Newly Issued Price”)), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination, and (z) the volume weighted average trading price of our shares of Class A common stock during the 20 trading day period starting on the trading day prior to the day on which we consummate our initial business combination (the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described adjacent to “Redemption of Warrants When the Price Per Share of Class A Common Stock Equals or Exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, respectively.

In case of any reclassification or reorganization of the outstanding shares of Class A common stock (other than those described above or that solely affects the par value of such shares of Class A common stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our outstanding shares of Class A common stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the shares of Class A common stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of Class A common stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised their warrants immediately prior to such event.

The warrants will be issued in registered form under a warrant agreement between Continental, as warrant agent, and us. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 50% of the then outstanding public warrants to make any change that adversely affects the interests of the registered holders. You should review a copy of the warrant agreement, which will be filed as an exhibit to the Annual Report on Form 10-K, for a complete description of the terms and conditions applicable to the warrants.


The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of common stock and any voting rights until they exercise their warrants and receive shares of Class A common stock. After the issuance of shares of Class A common stock upon exercise of the warrants, each holder will be entitled to one vote for each share of Class A common stock issued to such holder upon exercise of the warrants on all matters to be voted on by stockholders.

No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number the number of shares of Class A common stock to be issued to the warrant holder.

Placement Warrants. The placement warrants have terms and provisions that are identical to those of the warrants being sold as part of the units in our initial public offering. However, the placement warrants (including the shares of Class A common stock issuable upon exercise of the placement warrants) will not be transferable, assignable or salable until 30 days after the completion of our initial business combination (except pursuant to limited exceptions to our officers and directors and other persons or entities affiliated with the initial purchasers of the placement warrants).

In order to fund working capital deficiencies or finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. Up to $1,500,000 of such loans may be convertible into placement units of the post-business combination entity at a price of $10.00 per placement unit at the option of the lender. Such placement units would be identical to the units sold in our initial public offering.

Dividends

We have not paid any cash dividends on our common stock to date and do not intend to pay cash dividends prior to the completion of a business combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of a business combination. The payment of any cash dividends subsequent to a business combination will be within the discretion of our board of directors at such time. If we increase the size of our initial public offering, then we will effect a share capitalization with respect to our founder shares immediately prior to the consummation of our initial public offering in such amount as to maintain the number of founder shares at 20% of our issued and outstanding shares of our common stock upon the consummation of our initial public offering. Further, if we incur any indebtedness, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith.

Our Transfer Agent and Warrant Agent

The transfer agent for our common stock and warrant agent for our warrants is Continental Stock Transfer & Trust Company. We have agreed to indemnify Continental Stock Transfer & Trust Company in its roles as transfer agent and warrant agent, its agents and each of its stockholders, directors, officers and employees against all claims and losses that may arise out of acts performed or omitted for its activities in that capacity, except for any claims and losses due to any gross negligence or intentional misconduct of the indemnified person or entity.

Amended and Restated Certificate of Incorporation

Our amended and restated certificate of incorporation contains certain requirements and restrictions relating to our initial public offering that will apply to us until the completion of our initial business combination. These provisions cannot be amended without the approval of the holders of a majority of our common stock. Our sponsor, who beneficially owns 20% of our common stock upon the closing of our initial public offering (assuming our sponsor does not purchase any units in our initial public offering), may participate in any vote to amend our amended and restated certificate of incorporation and will have the discretion to vote in any manner it chooses.


Specifically, our amended and restated certificate of incorporation provides, among other things, that:

 

   

If we do not complete our initial business combination within 24 months from the closing of our initial public offering, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to fund our working capital requirements (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, liquidate and dissolve, subject in each case to our obligations under Delaware law to provide for claims of creditors and in all cases subject to the requirements of other applicable law;

 

   

Prior to our initial business combination, we may not issue additional securities that would entitle the holders thereof to (i) receive funds from the trust account or (ii) vote as a class with our public shares (a) on our initial business combination or (b) to approve an amendment to our amended and restated certificate of incorporation to (x) extend the time we have to consummate a business combination beyond 24 months from the closing of our initial public offering or (y) amend the foregoing provisions;

 

   

Although we do not intend to enter into a business combination with a target business that is affiliated with our sponsor, our directors or our executive officers, we are not prohibited from doing so. In the event we enter into such a transaction, we, or a committee of independent directors, will obtain an opinion from an independent investment banking firm which is a member of FINRA or a valuation or appraisal firm that such a business combination is fair to our company from a financial point of view;

 

   

If a stockholder vote on our initial business combination is not required by law and we do not decide to hold a stockholder vote for business or other legal reasons, we will offer to redeem our public shares pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, and will file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about our initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act. Whether or not we maintain our registration under the Exchange Act or our listing on Nasdaq, we will provide our public stockholders with the opportunity to redeem their public shares by one of the two methods listed above;

 

   

We must complete one or more business combinations having an aggregate fair market value of at least 80% of the assets held in the trust account (excluding the deferred underwriting commissions and taxes payable on the income earned on the trust account) at the time of the agreement to enter into the initial business combination;

 

   

If our stockholders approve an amendment to our amended and restated certificate of incorporation to modify the substance or timing of our obligation to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of our initial public offering, or with respect to any other material provisions relating to stockholders’ rights or pre-initial business combination activity, we will provide our public stockholders with the opportunity to redeem all or a portion of their shares of Class A common stock upon such approval at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay our taxes and up to $100,000 of interest to pay dissolution expenses, divided by the number of then outstanding public shares, subject to the limitations described herein; and

 

   

We will not effectuate our initial business combination with another blank check company or a similar company with nominal operations.


In addition, our amended and restated certificate of incorporation provides that under no circumstances will we redeem our public shares in an amount that would cause our net tangible assets to be less than $5,000,001 upon consummation of our initial business combination and after payment of deferred underwriters’ commission.

Certain Anti-Takeover Provisions of Delaware Law and our Certificate of Incorporation and By-Laws

We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers upon completion of our initial public offering. This statute prevents certain Delaware corporations, under certain circumstances, from engaging in a “business combination” with:

 

   

a stockholder who owns 10% or more of our outstanding voting stock (otherwise known as an “interested stockholder”);

 

   

an affiliate of an interested stockholder; or

 

   

an associate of an interested stockholder, for three years following the date that the stockholder became an interested stockholder.

 

   

A “business combination” includes a merger or sale of more than 10% of our assets. However, the above provisions of Section 203 do not apply if:

 

   

our board of directors approves the transaction that made the stockholder an “interested stockholder,” prior to the date of the transaction;

 

   

after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of common stock; or

 

   

on or subsequent to the date of the transaction, the business combination is approved by our board of directors and authorized at a meeting of our stockholders, and not by written consent, by an affirmative vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder.

Exclusive Forum For Certain Lawsuits

Our amended and restated certificate of incorporation requires, unless we consent in writing to the selection of an alternative forum, that (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee to us or our stockholders, (iii) any action asserting a claim against us, our directors, officers or employees arising pursuant to any provision of the DGCL or our second amended and restated certificate of incorporation or bylaws, or (iv) any action asserting a claim against us, our directors, officers or employees governed by the internal affairs doctrine, may be brought only in the Court of Chancery in the State of Delaware, except any claim (A) as to which the Court of Chancery of the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, (C) for which the Court of Chancery does not have subject matter jurisdiction, or (D) any action arising under the Securities Act, as to which the Court of Chancery and the federal district court for the District of Delaware shall have concurrent jurisdiction. If an action is brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder’s counsel. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, a court may determine that this provision is unenforceable, and to the extent it is enforceable, the provision may have the effect of discouraging lawsuits against our directors and officers, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder.


Notwithstanding the foregoing, our amended and restated certificate of incorporation provides that the exclusive forum provision will not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.

Special Meeting of Stockholders

Our bylaws provide that special meetings of our stockholders may be called only by a majority vote of our board of directors, by our chief executive officer or by our chairman.

Advance Notice Requirements for Stockholder Proposals and Director Nominations

Our bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders must provide timely notice of their intent in writing. To be timely, a stockholder’s notice will need to be delivered to our principal executive offices not later than the close of business on the 90th day nor earlier than the opening of business on the 120th day prior to the scheduled date of the annual meeting of stockholders. Our bylaws also specify certain requirements as to the form and content of a stockholders’ meeting. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.

Authorized but Unissued Shares of Common Stock and Preferred Stock

Our authorized but unissued common stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

Securities Eligible for Future Sale

Immediately after our initial public offering we had 15,455,000 shares of Class A common stock (or 17,750,000 shares of Class A common stock if the underwriters’ over-allotment option was exercised in full) issued and outstanding on an as-converted basis. On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 additional Units for a total amount of $4,441,030 resulting from the partial over-allotment exercise. We also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds. Transaction costs related to the Underwriters’ partial over-allotment exercise amounted to $92,070, consisting of $88,820 of underwriting fees and $3,250 of other offering costs. The Company has also accrued underwriting fees of $155,436 that will be paid only if a business combination is entered into.

Of these shares, the shares of Class A common stock sold in our initial public offering is freely tradable without restriction or further registration under the Securities Act, except for any shares of Class A common stock purchased by one of our affiliates within the meaning of Rule 144 under the Securities Act. All of the outstanding founder shares and all of the outstanding placement units are restricted securities under Rule 144, in that they were issued in private transactions not involving a public offering.

Rule 144

Pursuant to Rule 144, a person who has beneficially owned restricted shares or warrants for at least six months would be entitled to sell their securities provided that (i) such person is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale and (ii) we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section 13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as we were required to file reports) preceding the sale.


Persons who have beneficially owned restricted shares or warrants for at least six months but who are our affiliates at the time of, or at any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of:

 

   

1% of the total number of shares of common stock then outstanding, which will equal 192,050 shares immediately after our initial public offering (or 220,625 shares if the underwriters exercise their over-allotment option in full); or

 

   

the average weekly reported trading volume of the shares of Class A common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.

Sales by our affiliates under Rule 144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information about us.

Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies

Rule 144 is not available for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are met:

 

   

the issuer of the securities that was formerly a shell company has ceased to be a shell company;

 

   

the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;

 

   

the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and

 

   

at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

As a result, our sponsor will be able to sell their founder shares and our sponsor will be able to sell its private placement warrants pursuant to Rule 144 without registration one year after we have completed our initial business combination.

Registration Rights

The holders of the founder shares, placement units, placement shares, placement warrants, Class A common stock underlying the placement warrants and placement units that may be issued upon conversion of working capital loans (and any shares or Class A common stock issuable upon the exercise of the placement warrants and placement units that may be issued upon conversion of working capital loans) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of our initial public offering. The holders of these securities are entitled to make unlimited demands that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to our completion of our initial business combination. However, the registration rights agreement provides that we will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lock-up period, which occurs (i) in the case of the founder shares, as described in the following paragraph, and (ii) in the case of the placement warrants and the respective shares of Class A common stock underlying such warrants, 30 days after the completion of our initial business combination. We will bear the expenses incurred in connection with the filing of any such registration statements.


Except as described herein, our sponsor and our directors and executive officers have agreed not to transfer, assign or sell (i) any of their founder shares until the earliest of (A) one year after the completion of our initial business combination and (B) subsequent to our initial business combination, (x) if the closing price of our shares of Class A common stock equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination, or (y) the date on which we complete a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of our public stockholders having the right to exchange their common stock for cash, securities or other property, and (ii) any of their placement units, placement shares, placement warrants and Class A common stock issued upon conversion or exercise thereof until 30 days after the completion of our initial business combination. Any permitted transferees will be subject to the same restrictions and other agreements of our sponsor and directors and executive officers with respect to any founder shares, placement units, placement shares, placement warrants and Class A common stock issued upon conversion or exercise thereof.

Listing of Securities

Our units, Class A common stock and warrants are each traded on the Nasdaq Capital Market under the symbols “ALPAU,” “ALPA” and “ALPAW,” respectively. Our units commenced public trading on July 29, 2021. Our Class A common stock and warrants began separate trading on or about September 15, 2021. The units will automatically separate into their component parts and will not be traded following the completion of our initial business combination.

EX-31.1 3 d268885dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CERTIFICATION

PURSUANT TO RULE 13a-14 AND 15d-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Rajiv Shukla, certify that:

1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2021 of Alpha Healthcare Acquisition Corp. III;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. [Paragraph intentionally omitted in accordance with SEC Release Nos. 34-47986 and 34-54942];

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: April 15, 2022     By:  

/s/ Rajiv Shukla

      Rajiv Shukla
     

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 4 d268885dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CERTIFICATION

PURSUANT TO RULE 13a-14 AND 15d-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Patrick A. Sturgeon, certify that:

1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2021 of Alpha Healthcare Acquisition Corp. III;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. [Paragraph intentionally omitted in accordance with SEC Release Nos. 34-47986 and 34-54942];

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: April 15, 2022     By:  

/s/ Patrick A. Sturgeon

      Patrick A. Sturgeon
     

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-32.1 5 d268885dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. 1350

(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the Annual Report of Alpha Healthcare Acquisition Corp. III (the “Company”) on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Rajiv Shukla, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: April 15, 2022      

/s/ Rajiv Shukla

      Name: Rajiv Shukla
     

Title:   Chief Executive Officer

            (Principal Executive Officer)

EX-32.2 6 d268885dex322.htm EX-32.2 EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. 1350

(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

In connection with the Annual Report of Alpha Healthcare Acquisition Corp. III (the “Company”) on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Patrick A. Sturgeon, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 15, 2022

 

/s/ Patrick A. Sturgeon

Name: Patrick A. Sturgeon

Title:   Chief Financial Officer

            (Principal Financial and Accounting Officer)

EX-101.SCH 7 alpau-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Balance Sheet link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Balance Sheet (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Statement of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Statement Of Changes In Shareholders' Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Statement Of Changes In Shareholders' Equity (Deficit) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Statement of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Organization and Business Operations link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Initial Public Offering link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Commitments & Contingencies link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Shareholder's Equity link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Stock-based Compensation link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Organization and Business Operations - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Significant Accounting Policies - Schedule of Fair Value of the Overallotment Liability (Detail) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Significant Accounting Policies - Schedule of Reconciliation of Net Loss per Share (Detail) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Significant Accounting Policies - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Detail) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Significant Accounting Policies - Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis (Detail) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Initial Public Offering - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Related Party Transactions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Commitments & Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Shareholder's Equity - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Income Taxes - Schedule of Income Tax Provision (Detail) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate To The Company's Effective Tax Rate (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Award and Restricted Unit Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Stock-based Compensation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 alpau-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 alpau-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 alpau-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 alpau-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page - USD ($)
$ in Thousands
11 Months Ended
Dec. 31, 2021
Apr. 15, 2022
Document Information [Line Items]    
Document Type 10-K  
Amendment Flag false  
Document Period End Date Dec. 31, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus FY  
Document Annual Report true  
Document Transition Report false  
Entity Registrant Name Alpha Healthcare Acquisition Corp. III  
Entity Central Index Key 0001842939  
Entity File Number 001-40228  
Entity Interactive Data Current Yes  
Entity Current Reporting Status Yes  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 1177 Avenue of the Americas  
Entity Address, Address Line Two 5th Floor  
Entity Address, City or Town New York  
Entity Address, Postal Zip Code 10036  
City Area Code 646  
Local Phone Number 494-3296  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company true  
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share  
Trading Symbol ALPA  
Security Exchange Name NASDAQ  
Entity Address, State or Province NY  
Current Fiscal Year End Date --12-31  
Entity Tax Identification Number 85-1645738  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Public Float $ 157,170  
ICFR Auditor Attestation Flag false  
Auditor Name Marcum LLP  
Auditor Firm ID 688  
Auditor Location Houston, TX  
Units, each consisting of one share of Class A Common Stock and one-fourth of one Redeemable Warrant [Member]    
Document Information [Line Items]    
Title of 12(b) Security Units, each consisting of one share of Class A Common Stock and one-fourth of one Redeemable Warrant  
Trading Symbol ALPAU  
Security Exchange Name NASDAQ  
Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 [Member]    
Document Information [Line Items]    
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50  
Trading Symbol ALPAW  
Security Exchange Name NASDAQ  
Common Class A [Member]    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   15,907,985
Common Class B [Member]    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   3,861,026
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheet
Dec. 31, 2021
USD ($)
Current assets:  
Cash $ 774,192
Prepaid expenses 198,983
Total current assets 973,175
Marketable securities held in trust account 154,449,121
Total assets 155,422,296
Current liabilities:  
Accrued offering costs 112,485
Accrued expenses 215,247
Due to related party 2,275
Total current liabilities 330,007
Deferred underwriting fees payable 5,405,436
Total liabilities 5,735,443
Commitments and Contingencies (Note 5)
Shareholders' equity (deficit):  
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding 0
Additional paid-in capital 0
Accumulated deficit (4,762,700)
Total shareholders' deficit (4,762,268)
Total Liabilities and Shareholders' Deficit 155,422,296
Common Class A [Member]  
Current liabilities:  
Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 15,444,103 shares subject to possible redemption issued and outstanding 154,449,121
Shareholders' equity (deficit):  
Common stock value 46
Common Class B [Member]  
Shareholders' equity (deficit):  
Common stock value $ 386 [1]
[1] An aggregate of 4,312,500 shares of Class B common stock were originally issued, of which 562,500 shares were subject to forfeiture depending on whether the over-allotment option was exercised in full or in part by the underwriters during the 45-day option period. As a result of a partial over-allotment option exercise by the underwriters, an aggregate of 451,474 shares were forfeited at the end of the 45-day option period.
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheet (Parenthetical)
11 Months Ended
Dec. 31, 2021
$ / shares
shares
Preferred stock par or stated value per share | $ / shares $ 0.0001
Preferred stock shares authorized 1,000,000
Preferred stock shares issued 0
Preferred stock shares outstanding 0
Shares Issued Share Based Payment Arrangement Shares Forfeited 451,474
Common Class A [Member]  
Temporary Equity, Par or Stated Value Per Share | $ / shares $ 0.0001
Temporary Equity, Shares Authorized 100,000,000
Temporary Equity, Shares Issued 15,444,103
Temporary Equity, Shares Outstanding 15,444,103
Common stock par or stated value per share | $ / shares $ 0.0001
Common stock shares authorized 100,000,000
Common stock shares issued 463,882
Common stock shares outstanding 463,882
Common Class B [Member]  
Common stock par or stated value per share | $ / shares $ 0.0001
Common stock shares authorized 10,000,000
Common stock shares issued 3,861,026
Common stock shares outstanding 3,861,026
Shares Issued Share Based Payment Arrangement Shares Forfeited 451,474
Over-Allotment Option [Member] | Common Class A [Member]  
Common stock shares issued 15,907,985
Common stock shares outstanding 15,907,985
Common Stock Shares Subject To Forfeiture 15,444,103
Over-Allotment Option [Member] | Common Class B [Member]  
Common stock shares issued 3,861,026
Common stock shares outstanding 3,861,026
Common Stock Shares Subject To Forfeiture 562,500
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Statement of Operations
11 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
shares
Formation, general and administrative expenses $ 467,431
Loss from operations (467,431)
Other income:  
Dividend and interest income 8,091
Change in fair value of overallotment liability 2,923
Gain on expiration of overallotment option 127,035
Net loss (329,382)
Common Class A [Member]  
Other income:  
Net loss $ (6,286)
Weighted average shares outstanding of Class A common stock subject to possible redemption | shares 6,973,122
Basic and diluted net loss per share, Class A common stock subject to possible redemption | $ / shares $ (0.03)
Basic and diluted weighted average shares outstanding | shares 209,549
Basic and diluted net loss per share | $ / shares $ (0.03)
Common Class B [Member]  
Other income:  
Net loss $ (113,920)
Basic and diluted weighted average shares outstanding | shares 3,797,628
Basic and diluted net loss per share | $ / shares $ (0.03)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Statement Of Changes In Shareholders' Equity (Deficit) - 11 months ended Dec. 31, 2021 - USD ($)
Total
Public Warrants [Member]
Private Placement [Member]
Class A Common Stock Subject To Possible Redemption [Member]
Common Class A [Member]
Common Class B [Member]
Common Stock [Member]
Class A Common Stock Subject To Possible Redemption [Member]
Common Stock [Member]
Common Class A [Member]
Common Stock [Member]
Common Class A [Member]
Private Placement [Member]
Common Stock [Member]
Common Class B [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Public Warrants [Member]
Additional Paid-in Capital [Member]
Private Placement [Member]
Accumulated Deficit [Member]
Beginning Balance at Jan. 20, 2021 $ 0             $ 0   $ 0 $ 0     $ 0
Beginning Balance (in Shares) at Jan. 20, 2021             0 0   0        
Class B common stock issued to Sponsor (in Shares)           25,000       4,312,500        
Class B common stock issued to Sponsor 25,000                 $ 431 24,569      
Issuance of private placement units (Value)     $ 4,638,820           $ 46       $ 4,638,774  
Issuance of private placement units (Shares)                 463,882          
Issuance of Class A Common stock, net of issuance costs of $9,905,857 (Value)             $ 140,738,518              
Issuance of Class A Common stock, net of issuance costs of $9,905,857 (Shares)             15,444,103              
Issuance of Public Warrants, net of issuance costs of $239,247   $ 3,399,132                   $ 3,399,132    
Capital contribution by the Sponsor through transfer of Class B shares 1,186,448                   1,186,448      
Fair value of underwriter's overallotment options exercised 28,317                   28,317      
Accretion to redemption value of Class A Common stock subject to possible redemption $ (13,702,512)     $ 13,702,512             (9,277,240)     (4,425,272)
Forfeiture of Founder Shares related to unexercised portion of underwriter's overallotment option (Value)                   $ (45)       45
Forfeiture of Founder Shares related to unexercised portion of underwriter's overallotment option (Shares) 451,474         451,474       (451,474)        
Change in redemption value of Class A Common stock subject to possible redemption due to dividend and interest income earned $ (8,091)           $ 8,091             (8,091)
Net loss (329,382)     $ (209,176) $ (6,286) $ (113,920)               (329,382)
Ending Balance at Dec. 31, 2021 $ (4,762,268)           $ 154,449,121 $ 46   $ 386 $ 0     $ (4,762,700)
Ending Balance (in Shares) at Dec. 31, 2021             15,444,103 463,882   3,861,026        
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Statement Of Changes In Shareholders' Equity (Deficit) (Parenthetical)
11 Months Ended
Dec. 31, 2021
USD ($)
shares
Shares Issued Share Based Payment Arrangement Shares Forfeited 451,474
Public Warrants [Member]  
Issuance costs of warrants | $ $ 239,247
Common Class A [Member]  
Temporary equity stock issuance costs | $ $ 9,905,857
Common stock shares outstanding 463,882
Common Class B [Member]  
Common stock shares outstanding 3,861,026
Shares Issued Share Based Payment Arrangement Shares Forfeited 451,474
Over-Allotment Option [Member] | Common Class A [Member]  
Common Stock Shares Subject To Forfeiture 15,444,103
Common stock shares outstanding 15,907,985
Over-Allotment Option [Member] | Common Class B [Member]  
Common Stock Shares Subject To Forfeiture 562,500
Common stock shares outstanding 3,861,026
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Statement of Cash Flows
11 Months Ended
Dec. 31, 2021
USD ($)
Cash Flows from Operating Activities:  
Net loss $ (329,382)
Adjustments to reconcile net loss to net cash used in operating activities  
Interest earned in trust account (8,091)
Change in fair value of overallotment liability (2,923)
Gain on expiration of overallotment option (127,035)
Changes in current assets and liabilities:  
Prepaid expenses (198,983)
Accrued expenses 215,247
Net cash used in operating activities (451,167)
Cash Flows from Investing Activities:  
Investment of cash into trust account (154,441,030)
Cash Flows from Financing Activities:  
Proceeds from related party 56,922
Payment to related party (54,647)
Proceeds from issuance of Units 154,441,030
Proceeds from issuance of Private Units 4,638,820
Payment of offering costs (3,415,736)
Net cash provided by financing activities 155,666,389
Net Change in Cash 774,192
Cash - January 21, 2021 (inception) 0
Cash - end of the period 774,192
Supplemental Disclosure of cash flow information:  
Deferred underwriting fee payable 5,405,436
Capital contribution by the Sponsor through transfer of Class B shares 1,186,448
Offering costs included in accrued offerings costs 112,485
Offering costs paid by Sponsor in exchange for issuance of Class B common stock 25,000
Accretion of the interest earned in trust account $ 8,091
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Business Operations
11 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Business Operations
Note 1 — Organization and Business Operations
Alpha Healthcare Acquisition Corp. III is a blank check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company has not selected any specific Business Combination target and the Company has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any Business Combination target. While the Company may pursue an initial Business Combination target in any business or industry, it intends to focus its search on companies in the healthcare industry.
The Company has selected December 31 as its fiscal year end.
As of December 31, 2021, the Company had not yet commenced any operations. All activity from January 21, 2021 (inception) through December 31, 2021, relates to the Company’s formation, the Public Offering (as defined below), and activities necessary to identify a potential target for a Business Combination. Since our Initial Public Offering, we have not generated any operating revenues, and do not expect to generate any operating revenues, until after completion of our initial Business Combination.
The registration statement for the Company’s Public Offering was declared effective on July 26, 2021. On July 29, 2021 (“IPO Date”), the Company consummated the Initial Public Offering of 15,000,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $150,000,000, which is described in Note 3. In connection with the IPO, the Company also granted the underwriters a
45-day
option to purchase an additional 2,250,000 Public Units at the initial public offering price.
Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 455,000 Units (each, a “Private Placement Unit” and, collectively, the “Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to AHAC Sponsor III LLC (the “Sponsor”), generating gross proceeds of $4,550,000, which is described in Note 4.
At the IPO Date, transaction costs amounted to $3,461,151, consisting of $3,000,000 of underwriting fees and $461,151 of other offering costs. The Company has also accrued underwriting fees of $5,250,000 that will be paid only if a business combination is entered into. In addition, cash of $1,550,000 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes.
At the IPO date, the Sponsor also transferred to certain investors a total of 225,000 of Founders shares (Note 4)
(“Non-Risk
Incentive Private Shares”) as a compensation for their commitment to purchase the Public Units sold in the IPO. The Company estimated the aggregate fair value of these shares to be $1,186,448, or $5.27 per share. The fair value of the
Non-Risk
Incentive Private Shares was determined to be a contribution from the Sponsor for offering costs in accordance with Staff Accounting Bulletin Topic 5T. These offering costs were allocated to the Units and charged to shareholder’s equity upon the completion of the Initial Public Offering.
At the IPO date, the Sponsor also transferred to certain other investors the total of 600,900 of Founders shares (“Risk Incentive Private Shares”) as a compensation for their commitment to acquire at least 9.9% of the Units sold in the IPO. These Risk Incentive Private Shares are subject to forfeiture if the investors sell their Units prior to the closing of the initial Business Combination. The fair value of these Risk Incentive Private
Shares of $5.27
is equal to the fair value of the
Non-Risk
Incentive Private Shares. Due to the high probability of forfeiture, the fair value of these Risk Incentive Private Shares will be recorded as a capital contribution from the Sponsor upon the closing of the initial Business Combination.
On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 additional Units for a total amount of $4,441,030 resulting from the partial over-allotment exercise. The Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds. Transaction costs related to the Underwriters’ partial over-allotment exercise amounted to $92,070, consisting of $88,820 of underwriting fees and $3,250 of other offering costs. The Company has also accrued underwriting fees of $155,436 that will be paid only if a business combination is entered into.
 
The total issuance costs of $10,145,105 were allocated to the Class A shares subject to possible redemption and the Public Warrants based on their relative fair values with $9,905,857 to the Class A shares subject to possible redemption and $239,247 to the Public Warrants.
Following the closing of the Initial Public Offering on July 29, 2021, an amount of $154,441,030 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering, including the Units sold upon the exercise of the over-allotment option, and the sale of the Private Placement Units was placed in a trust account (the “Trust Account”), invested in U.S. government securities, within the meaning set forth in Section 2(a) (16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule
2a-7
of the Investment Company Act of 1940, as amended (the “Investment Company Act”), as determined by the Company. Except for the withdrawal of interest income to pay the income taxes, the Company’s amended and restated certificate of incorporation and subject to the requirements of law and regulation, provides that none of the funds held in the Trust Account will be released from the Trust Account until the earliest of (a) the completion of the Company’s initial Business Combination, (b) the redemption of the public shares if the Company is unable to consummate an initial Business Combination within 24 months from the closing of the Public Offering (the “Combination Period”), subject to applicable law, and (c) the redemption of the Company’s public shares properly submitted in connection with a shareholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of its public shares if the Company has not consummated an initial Business Combination within the Combination Period or with respect to any other material provisions relating to shareholders’ rights or
pre-initial
Business Combination activity. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public shareholders.
The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds are intended to be generally applied toward consummating a Business Combination.
The Company’s Business Combination must be with one or more target businesses that together have an aggregate fair market value of at least 80% of the assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting discounts held in trust and taxes payable on the interest earned on the Trust Account) at the time of the signing an agreement to enter into a Business Combination. However, the Company will only complete an initial Business Combination if the post-business combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination.
The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the initial Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed initial Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The shareholders will be entitled to redeem their shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest (net of taxes payable), divided by the number of then outstanding public shares. The amount in the Trust Account is initially anticipated to be $10.00 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters.
The shares of common stock subject to redemption were recorded at a redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”
The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.
 
If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in each case, to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to consummate an initial Business Combination within the Combination Period.
The Sponsor has agreed (i) to waive its redemption rights with respect to any Founder Shares, private placement shares and public shares held by it in connection with the completion of the initial Business Combination, (ii) to waive its rights to liquidating distributions from the Trust Account with respect to any Founder Shares or private placement shares held by it if the Company fails to complete its Business Combination within the Combination Period, although the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any public shares it holds if the Company fails to complete its Business Combination within such time period, (iii) not to propose any amendment to the Company’s amended and restated certificate of incorporation that would modify the substance or timing of its obligation to redeem 100% of the public shares if the Company does not complete its initial Business Combination within the Combination Period or with respect to any other material provisions relating to shareholders’ rights or
pre-initial
Business Combination activity, unless the Company provides its public shareholders with the opportunity to redeem their shares, and (iv) to vote any Founder Shares held by it and any public shares purchased during or after the Public Offering in favor of the Company’s initial Business Combination.
The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per share due to reductions in the value of the trust assets, in each case less taxes payable, provided that such liability will not apply to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has it independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.
Liquidity and Going Concern
As of December 31, 2021, the Company had cash outside the Trust Account of $774,192 available for working capital needs. All remaining cash held in the Trust Account are generally unavailable for the Company’s use, prior to an initial business combination, and is restricted for use either in a Business Combination or to redeem common stock. As of December 31, 2021, none of the amount in the Trust Account was available to be withdrawn as described above.
Through December 31, 2021, the Company’s liquidity needs were satisfied through receipt of $25,000 from the sale of the founder shares and the remaining net proceeds from the sale of Private Placement Units held outside of the trust account, totaling $774,192 as of December 31, 2021.
For the period from January 21, 2021 (inception) through December 31, 2021, the Company had a net loss of $329,382, which consisted of formation and general and administrative costs.
The $774,192 held outside of the Trust Account as of December 31, 2021, may not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company may need to raise additional capital through loans or additional investments from its Sponsor, stockholders, officers, directors, or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern, assuming a Business Combination is not consummated. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
The Company believes that the proceeds raised in the initial public offering and the funds potentially available from loans from the sponsor or any of their affiliates will be sufficient to allow the Company to meet the expenditures required for operating its business. However, if the estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to the initial Business Combination. Moreover, the Company may need to obtain additional financing either to complete the Business Combination or because the Company becomes obligated to redeem a significant number of public shares upon completion of the Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies
11 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Significant Accounting Policies
Note 2 — Significant Accounting Policies
Basis of Presentation
The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).
Emerging Growth Company Status
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Marketable Securities Held in Trust Account
At December 31, 2021, the assets held in the Trust Account were substantially held in U.S. Treasury Bills and U.S Treasury Coupons. During the period from January 21, 2021 (inception) through December 31, 2021, the Company did not withdraw any of interest income from the Trust Account to pay its tax obligations.
 
Common Stock Subject to Possible Redemption
The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as shareholders’ equity. The Company’s common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of December 31, 2021, 15,444,103 shares of Class A common stock subject to possible redemption are classified in temporary equity outside of the shareholders’ equity (deficit) section of the Company’s balance sheet and were immediately accreted to redemption value at the IPO date.
Derivative Financial Instruments
The Company issues warrants to its investors and accounts for warrant instruments as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification.
The Public Warrants (see Note 3) and Private Warrants (see Note 4) were accounted for as equity as these instruments meet all of the requirements for equity classification under ASC 815.
The over-allotment option (see Note 6) was deemed to be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to ASC 480.
The fair value of the overallotment liability at the IPO date of $158,275 was determined using the Black Scholes option pricing model based on the following assumptions:
 
Risk-free interest rate
  
 
0.05
Dividend rate
  
 
0
Volatility
  
 
5.00
Expected life (in years)
  
 
0.12
 
On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 Units (see Note 3). The fair value of the corresponding overallotment liability partially extinguished upon exercise of $28,317 was determined using the Black Scholes option pricing model based on the following assumptions:
 
Risk-free interest rate
     0.05
Dividend rate
     0
Volatility
     5.00
Expected life (in years)
     0.10  
Upon the expiration of the unexercised overallotment options on September 9, 2021, the Company recorded a gain on the expiration of the overallotment option of $127,035.
Net Loss per Common Stock share
The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” Net loss per share is computed by dividing net loss by the weighted average number of Common Stock shares outstanding during the period. Weighted average shares for the period from January 21, 2021 (inception) through December 31, 2021 were reduced for the effect of an aggregate of
562,500
Class B Common shares that were subject to forfeiture until the over-allotment option was partially exercised by the underwriters on August 3, 2021 (see Note 5), upon which date the forfeiture provision lapsed for 111,026 Class B Common shares. Subsequent to September 9, 2021, weighted average shares were reduced for the effect of an aggregate of 451,474 Class B Common shares which were ultimately forfeited upon the expiration of the
45-day
period reserved for the exercise of over-allotment option.
 
The Company’s statements of operations include a presentation of net loss per share subject to redemption in a manner similar to the
two-class
method of income per share. With respect to the accretion of the Class A Shares subject to possible redemption and consistent with ASC
480-10-S99-3A,
the Company deemed the fair value of the Class A Common shares subject to possible redemption to approximate the contractual redemption value and the accretion has no impact on the calculation of net income/(loss) per share.
The Company’s Public Warrants (see Note 3) and Private Warrants (see Note 4) could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. However, these warrants were excluded when calculating diluted loss per share because such inclusion would be anti-dilutive for the periods presented. As a result, diluted loss per share is the same as basic loss per share for the period presented.
A reconciliation of net loss per share is as follows for the period from January 21 (Inception) through December 31, 2021:
 
    
Class A subject to
possible redemption
    
Class A
    
Class B
 
Allocation of undistributable losses
     (209,176      (6,286      (113,920
    
 
 
    
 
 
    
 
 
 
Net income/(loss) to Common shares
  
$
(209,176
  
$
(6,286
  
$
(113,920
    
 
 
    
 
 
    
 
 
 
Weighted average shares outstanding, basic and diluted
     6,973,122        209,549        3,797,628  
    
 
 
    
 
 
    
 
 
 
Basic and diluted net loss per share
   $ (0.03    $ (0.03    $ (0.03
    
 
 
    
 
 
    
 
 
 
Offering Costs
Offering costs consist of underwriting, legal, accounting and other expenses incurred through the Initial Public Offering that are directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with the Public Shares were charged to shareholders’ equity upon the completion of the Initial Public Offering. Offering costs amounted to $9,897,599 at July 29, 2021, which were allocated between the Class A shares subject to possible redemption and the Public Warrants and charged to shareholders’ equity upon the completion of the Initial Public Offering. Under the guidance in Staff Accounting Bulletin 107 Topic 5.A, Accounting for Expenses or Liabilities Paid by Principal Stockholder(s), the Company included in these offering costs amounts incurred by the Sponsor through the transfer of
Non-Risk
Incentive Private Shares (see Note 4) to Anchor Investors on behalf of the Company in the amount of $1,186,448. The initial public offering costs as of the IPO date were allocated $9,664,188 and $233,411 between the Class A shares subject to possible redemption and the Public Warrants (see Note 6), respectively, based on their relative fair values at the issuance date. The Company incurred an additional $92,070 offering costs of upon the partial exercise of the overallotment option on August 3, 2021.
The total issuance costs of $10,145,105 were allocated to the Class A shares subject to possible redemption and the Public Warrants based on their relative fair values with $9,905,857 to the Class A shares subject to possible redemption and $239,247 to the Public Warrants.
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.
 
Fair Value Measurements
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
 
   
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
   
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
   
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
 
Description
  
Level
    
December 31,
2021
 
Assets:
                 
Marketable securities held in Trust Account
     1      $ 154,449,121  
The overallotment liability is measured at fair value using the Black Scholes Option Pricing Model with significant unobservable inputs. The fair value is based on the share price of the underlying shares and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. Therefore, the overallotment liability is considered to be a Level 3 financial instrument.
The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis:
 
    
Overallotment
liability
 
Balance at January 21, 2021 (inception)
   $ —    
Issuance of overallotment option
     158,275  
Partial exercise of overallotment option
     (28,316
Change in fair value of overallotment liability
     (2,924
Expiration of overallotment option
     (127,035
    
 
 
 
Balance at December 31, 2021
   $ —    
    
 
 
 
Income Taxes
The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
 
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to a concentration of credit risk consist of a cash account in a financial institution, which at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Recently Issued Accounting Standards
Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Initial Public Offering
11 Months Ended
Dec. 31, 2021
Stockholders' Equity Note [Abstract]  
Initial Public Offering
Note 3 — Initial Public Offering
On July 29, 2021, the Company sold 15,000,000 Units at $10.00 per Unit, generating gross proceeds of $150.0 million. Each unit consists of one share of Class A common stock and
one-fourth
of one redeemable warrant. Only whole warrants are exercisable. Each whole warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share.
Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 455,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement to the Sponsor, generating gross proceeds of $4,550,000, which is described further in Note 4.
On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units for the total amount of $4,441,030, received on August 6, 2021. Resulting from the partial over-allotment exercise, the Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions
11 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions
Note 4 — Related Party Transactions
Founder Shares
On January 21, 2021, the Sponsor subscribed to purchase 3,593,750 shares of the Company’s common stock, par value $0.0001 per share (the “Founder Shares”) for an aggregate price of $25,000. On January 25, 2021, the Sponsor paid $25,000, or approximately $0.00696 per share, to cover for certain offering and formation costs in consideration for 3,593,750 Founder Shares. On March 1, 2021, the Company effected a 1:1.2 stock split of its common stock which resulted in an aggregate of 4,312,500 shares of Class B common stock outstanding. All shares and associated amounts have been retroactively restated to reflect the stock split. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units out of the total 2,250,000 available under the over-allotments and the forfeiture provisions lapsed for 111,026 Founder Shares. The remaining 451,464 Founder Shares were forfeited upon the expiration of the
45-day
period reserved for the exercise of over-allotment option.
On July 27, 2021, our sponsor transferred 25,000 founder shares to each of Darlene DeRemer, Eugene Podsiadlo, and William Woodward. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on the Company’s board of directors through the closing of such initial business combination.
 

At the IPO date, the Sponsor also transferred to certain investors a total of 225,000 of Founders shares (Note 4)
(“Non-Risk
Incentive Private Shares”) as a compensation for their commitment to purchase the Public Units sold in the IPO. The Company estimated the aggregate fair value of these shares to be $1,186,448, or $5.27 per share. The fair value of the
Non-Risk
Incentive Private Shares was determined to be a contribution from the sponsor for offering costs in accordance with Staff Accounting Bulletin Topic 5T. These offering costs were allocated to the Units and charged to shareholder’s equity upon the completion of the Initial Public Offering.
At the IPO date, the Sponsor also transferred to certain other investors the total of 600,900 of Founders shares (“Risk Incentive Private Shares”) as a compensation for their commitment to acquire at least 9.9% of the Units sold in the IPO. These Risk Incentive Private Shares are subject to forfeiture if the investors sell their Units prior to the closing of the initial Business Combination. The fair value of these Risk Incentive Private Shares is equal to the fair value of the
Non-Risk
Incentive Private Shares. Due to the high probability of forfeiture, the fair value of these Risk Incentive Private Shares will be recorded as a capital contribution from the Sponsor upon the closing of the initial Business Combination.
The Sponsor, directors and executive officers have agreed not to transfer, assign or sell (i) any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Company’s shares of Class A common stock equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any
30-trading
day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of its public shareholders having the right to exchange their common stock for cash, securities or other property, and (ii) any of their Private Placement Units, placement shares, Private Placement Warrants and Class A common stock issued upon conversion or exercise thereof until 30 days after the completion of the initial Business Combination (the
“Lock-up”).
Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor and directors and executive officers with respect to any Founder Shares, Private Placement Units, placement shares, Private Placement Warrants and Class A common stock issued upon conversion or exercise thereof.
Private Placement
Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased 455,000 placement units, at a purchase price of $4,550,000, in a private placement. Each Private Placement Unit is identical to the Units sold in the Initial Public Offering except as described below. A portion of the proceeds from the Private Placement Units was added to the proceeds from the Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law).
As a result of the partial over-allotment exercise on August 3, 2021, the Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds.
The Private Placement Units (including the placement shares, the placement warrants and Class A common stock issuable upon exercise of such placement warrants) will not be transferable or salable until 30 days after the completion of our Business Combination (except, among other limited exceptions, to our officers and directors and other persons or entities affiliated with our Sponsor).
Promissory Note — Related Party
On January 25, 2021, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $300,000 to be used for a portion of the expenses of the Proposed Public Offering. This loan was
non-interest
bearing, unsecured, and was due at the earlier of (i) the date on which the Company consummates the initial public offering and (ii) the date on which the Company determines not to conduct an initial public offering of its securities, upon request from the Company the Sponsor. Through the date of the Initial Public Offering, the Company had no borrowings under the promissory note.
Due to Related Party
The balance of $2,275 as of December 31, 2021, represents general and administrative costs paid by the Sponsor on behalf of the Company.
 
Administrative Service Fee
The Company has agreed, commencing on the date that the Company’s securities are first listed on the Nasdaq, to pay an affiliate of the Sponsor a monthly fee of an aggregate of $10,000 for office space, administrative and support services. For the period from January 21, 2021 (inception) through December 31, 2021, administrative fees incurred and paid to the Sponsor totaled $51,000. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees.
Related Party Loans
In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon consummation of a Business Combination into warrants at a price of $1.50 per warrant. The warrants will be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of December 31, 2021, there were no written agreements in place for the Working Capital Loans.
In conjunction with the IPO activities, on July 14, 2021 (the “Inception Date”), the Company and its Sponsor entered into the Subscription Agreements with certain investors (see Note 5).

Forward Purchase Agreement
The Company granted to the direct anchor investors an option, in their sole discretion, to subscribe to a forward purchase agreement for up to an aggregate of 60% (up to 10% per direct anchor investor) of the securities sold in one or multiple private placements to close prior to or concurrently with the closing of the initial business combination. The aggregate proceeds from the sale of any securities pursuant to these forward purchase agreements will be used for purposes related to the initial business combination.
Since the issuance of the securities to the investors is contingent upon the closing of an equity financing in relation to the initial business combination, the terms of the forward purchase agreement will not create an obligation for either party until such financing occurs.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments & Contingencies
11 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments & Contingencies
Note 5 — Commitments & Contingencies
Registration Rights
The holders of the Founder Shares, Private Placement Units, Private Placement Warrants, Class A common stock underlying the Private Placement Warrants and Private Placement Units that may be issued upon conversion of Working Capital Loans (and any shares or Class A common stock issuable upon the exercise of the Private Placement Warrants and Private Placement Units that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration rights agreement dated July 26, 2021. The holders of these securities are entitled to make unlimited demands that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable
lock-up
period, which occurs (i) in the case of the Founder Shares, as described in the following paragraph, and (ii) in the case of the Private Placement Warrants and the respective shares of Class A common stock underlying such warrants, 30 days after the completion of the Company’s initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriters Agreement
The Company granted the underwriters a
45-day
option from July 26, 2021, to purchase up to 2,250,000 additional Units to cover over-allotments, if any, at the Public Offering price less the underwriting discounts and commissions. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units for the total amount of $4,441,030.
The underwriters received a cash underwriting discount of two percent (2.0%) of the gross proceeds of the Public Offering, or $3,000,000, paid on July 29, 2021. Additionally, in connection with the partial over-allotment exercise, the underwriters received a cash underwriting discount of two percent (2.0%) of the gross proceeds, or $88,820, paid on August 6, 2021. In addition to the cash underwriting discounts, the underwriters will be entitled to a deferred underwriting fee of three and a half percent (3.5%), or $5,405,436 of the gross proceeds of the Public Offering and the underwriters’ partial over-allotment exercise upon the completion of the Company’s initial Business Combination.
 
Subscription Agreements
In conjunction with the IPO activities, on July 14, 2021 (the “Inception Date”), the Company and its Sponsor entered into the Subscription Agreements with certain investors. Under these Subscription Agreements, the investors, who received the At Risk Incentive Private Shares, received the right but not the obligation to subscribe, at their sole discretion, to any equity financing associated with the Closing of the initial Business Combination subject to a maximum of 10% of such offerings’ proceeds, and the right but not the obligation to subscribe, at their sole discretion, at the same terms in the next special purpose acquisition company or other similar entity sponsored by Constellation Alpha Holdings. The investors who received the Non Risk Incentive Private Shares also received the right but not the obligation to subscribe, at their sole discretion, to any equity financing associated with the Closing of the SPAC’s initial Business Combination subject to a maximum of 10% of such offerings’ proceeds if the Investor still holds their Public Shares at the business combination date. Since the number of shares or other instruments to be purchase by the investors is unknown, these rights to participate in future offerings do not meet definition of an equity contract.
Risks and Uncertainties
Management is currently evaluating the impact of the
COVID-19
pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Shareholder's Equity
11 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Shareholder's Equity
Note 6 — Shareholder’s Equity
Common Stock —
On January 25, 2021, the Company issued 3,593,750 shares of common stock, including an aggregate of up to 468,750 shares of common stock that were subject to forfeiture, to the Company by the initial shareholders for no consideration to the extent that the underwriters’ over- allotment option is not exercised in full or in part, so that the initial shareholders will collectively own 20% of the Company’s issued and outstanding common stock after the Proposed Public Offering.
On March 1, 2021, the Company amended its charter to authorize issuance of 100,000,000 Class A common stock, with a par value of $0.0001 per share, 10,000,000 Class B common stock, with a par value of $0.0001 per share, and 1,000,000 preferred stock, with a par value of $0.0001 per share, and effected a 1:1.2 stock split of its common stock which resulted in an aggregate of 4,312,500 shares of Class B common stock outstanding All shares and per share amounts have been retroactively restated to reflect the stock split.
On July 29, 2021, the Company sold 15,000,000 Units, each unit consists of one share of Class A common stock and
one-fourth
of one redeemable warrant. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units.
On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units out of the total 2,250,000 available under the over-allotments and the forfeiture term lapsed for 111,026 Founder Shares. The remaining 451,464 Founder Shares were forfeited upon the expiration of the
45-day
period reserved for the exercise of over-allotment option.
At December 31, 2021, there were (i) 15,907,985 shares of Class A common stock issued and outstanding (including 15,444,103 shares subject to possible redemption) and (ii) 3,861,026 shares of Class B common stock issued and outstanding.
Both Class A and B shareholders vote together as a single class on all matters submitted to a vote of the Company shareholders, with each share of common stock entitling the holder to one vote.
The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the initial Business Combination on a
one-for-one
basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like), and subject to further adjustment as provided herein. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in the Proposed Public Offering and related to the closing of the Business Combination, including pursuant to a specified future issuance, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless our Sponsor agrees to waive such adjustment with respect to any such issuance or deemed issuance, including a specified future issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an
as-converted
basis, 20% of the sum of the total number of all shares of common stock outstanding upon completion of the Proposed Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with the Business Combination (after giving effect to any redemptions of shares of Class A common stock by public shareholders) (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the Business Combination and any Private Placement Units issued to our Sponsor, officers or directors upon conversion of Working Capital Loans). The Sponsor may also elect to convert their shares of Class B common stock into an equal number of shares of Class A common stock, subject to adjustment as provided above, at any time.
 
Preferred Stock –
The Company is authorized to issue 1,000,000 shares of preferred stock, with a par value of $0.0001 per share. At December 31, 2021, there were no shares of preferred stock issued or outstanding.
Warrants –
The warrants may only be exercised for a whole number of shares. The warrants included in the units sold in the Public Offering (the “Public Warrants”) will become exercisable 30 days after the completion of a Business Combination provided that the Company has an effective registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their Public Warrants on a cashless basis and such cashless exercise is exempt from registration under the Securities Act). The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of the initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC and have an effective registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. If a registration statement covering the issuance of the Class A common stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption.
The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional shares of Class A common stock or equity- linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance), or the Newly Issued Price, (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, respectively.
The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants and the shares of Class A common stock issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions.
Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00: Once the warrants become exercisable, the Company may redeem the outstanding warrants for cash:
 
   
in whole and not in part;
 
   
at a price of $0.01 per warrant;
 
   
upon a minimum of 30 days’ prior written notice of redemption; and
 
   
if, and only if, the closing price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like and for certain issuances of Class A common stock and equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination) for any 20 trading days within a
30-trading
day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”).
 
The Company will not redeem the warrants unless an effective registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A common stock is available throughout the
30-day
redemption period.
In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
11 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes
Note 7 — Income Taxes
The Company’s general and administrative expenses are generally considered
start-up
costs and are not currently deductible. During the period from January 21, 2021 (inception) to December 31, 2021, no income tax expense was recorded. The Company’s effective tax rate for the period from January 21, 2021 (inception) through December 31, 2021 was zero percent, which differs from the expected income tax rate due predominantly to the
start-up
costs which are not currently deductible.
The income tax provision consisted of the following as of December 31, 2021:
 
Federal
        
Current
   $ —    
Deferred
     (96,461
State
        
Current
     —    
Deferred
      
Change in valuation allowance
     96,461  
    
 
 
 
Income tax provision
  
$
—  
 
    
 
 
 
The Company’s net deferred tax assets consist of the following as of December 31, 2021:
 
Deferred tax assets:
        
Net operating loss carryforwards
   $ 33,531  
Organizational costs/startup expenses
     62,930  
    
 
 
 
Total deferred tax asset
     96,461  
Valuation allowance
     (96,461 )
    
 
 
 
Deferred tax asset, net of valuation allowance
  
$
—  
 
    
 
 
 
As of December 31, 2021, the Company has U.S. federal net operating loss carryovers of $159,673
 
that do not expire.
In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the year ended December 31, 2021, the change in the valuation allowance was $96,461.
There were no unrecognized tax benefits as of December 31, 2021. No amounts were accrued for the payment of interest and penalties at December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.
A reconciliation of the federal income tax rate to the Company’s effective tax rate at December 31, 2021 is as follows:
 
Statutory federal income tax rate
     21.0
Change in fair value of overallotment liability
     8.3  
Change in valuation allowance
     (29.3 )
    
 
 
 
Effective tax rate
     —  
    
 
 
 
 
The Company files U.S. federal income tax returns and is subject to examination since inception.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation
11 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation
Note 8 — Stock-based Compensation
On July 27, 2021, the Sponsor transferred 25,000 shares of Class B common stock to each of the three independent director nominees as compensation for their service on the board of directors. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on the Company’s board of directors through the closing of such initial business combination. As such, the service period for these awards will start on the IPO date. As the share awards would vest only upon the consummation on a business combination, the compensation expense in relation to these grants would be not recognized until the closing of the initial business combination. As a result, the Company recorded no compensation expense for the period from January 21, 2021 (inception) through December 31, 2021.
The fair value of the Founder Shares on the grant date was approximately $5.26 per share. The valuation performed by the Company determined the fair value of the Founder Shares on the date of grant based on the fair value of the Class A shares discounted for a) the probability of a successful business combination, and b) the lack of marketability. The aggregate grant date fair value of the award amounted to approximately $394,000.
A summary of the restricted stock award and restricted unit activity for the period from January 21, 2021 (inception) through December 31, 2021 is as follows:
 
 
  
Number
of
Shares
 
Unvested Shares Outstanding at January 21, 2021 (inception)
  
 
—  
 
Granted
  
 
75,000
 
Forfeited
  
 
—  
 
Vested
  
 
—  
 
 
  
 
 
 
Unvested Outstanding at December 31, 2021
  
 
75,000
 
 
  
 
 
 
Total
 
unrecognized compensation expense related to unvested Founder Shares at December 31, 2021 amounted to approximately $
394,000
and is expected to be recognized upon the initial business combination.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events
11 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events
Note 9 — Subsequent Events
The Company did not identify any subsequent events that require adjustment or disclosure in the financial statements.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies (Policies)
11 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).
Emerging Growth Company Status
Emerging Growth Company Status
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Marketable Securities Held in Trust Account
Marketable Securities Held in Trust Account
At December 31, 2021, the assets held in the Trust Account were substantially held in U.S. Treasury Bills and U.S Treasury Coupons. During the period from January 21, 2021 (inception) through December 31, 2021, the Company did not withdraw any of interest income from the Trust Account to pay its tax obligations.
Common Stock Subject to Possible Redemption
Common Stock Subject to Possible Redemption
The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as shareholders’ equity. The Company’s common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of December 31, 2021, 15,444,103 shares of Class A common stock subject to possible redemption are classified in temporary equity outside of the shareholders’ equity (deficit) section of the Company’s balance sheet and were immediately accreted to redemption value at the IPO date.
Derivative Financial Instruments
Derivative Financial Instruments
The Company issues warrants to its investors and accounts for warrant instruments as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification.
The Public Warrants (see Note 3) and Private Warrants (see Note 4) were accounted for as equity as these instruments meet all of the requirements for equity classification under ASC 815.
The over-allotment option (see Note 6) was deemed to be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to ASC 480.
The fair value of the overallotment liability at the IPO date of $158,275 was determined using the Black Scholes option pricing model based on the following assumptions:
 
Risk-free interest rate
  
 
0.05
Dividend rate
  
 
0
Volatility
  
 
5.00
Expected life (in years)
  
 
0.12
 
On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 Units (see Note 3). The fair value of the corresponding overallotment liability partially extinguished upon exercise of $28,317 was determined using the Black Scholes option pricing model based on the following assumptions:
 
Risk-free interest rate
     0.05
Dividend rate
     0
Volatility
     5.00
Expected life (in years)
     0.10  
Upon the expiration of the unexercised overallotment options on September 9, 2021, the Company recorded a gain on the expiration of the overallotment option of $127,035.
Net Loss per Common Stock share
Net Loss per Common Stock share
The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” Net loss per share is computed by dividing net loss by the weighted average number of Common Stock shares outstanding during the period. Weighted average shares for the period from January 21, 2021 (inception) through December 31, 2021 were reduced for the effect of an aggregate of
562,500
Class B Common shares that were subject to forfeiture until the over-allotment option was partially exercised by the underwriters on August 3, 2021 (see Note 5), upon which date the forfeiture provision lapsed for 111,026 Class B Common shares. Subsequent to September 9, 2021, weighted average shares were reduced for the effect of an aggregate of 451,474 Class B Common shares which were ultimately forfeited upon the expiration of the
45-day
period reserved for the exercise of over-allotment option.
 
The Company’s statements of operations include a presentation of net loss per share subject to redemption in a manner similar to the
two-class
method of income per share. With respect to the accretion of the Class A Shares subject to possible redemption and consistent with ASC
480-10-S99-3A,
the Company deemed the fair value of the Class A Common shares subject to possible redemption to approximate the contractual redemption value and the accretion has no impact on the calculation of net income/(loss) per share.
The Company’s Public Warrants (see Note 3) and Private Warrants (see Note 4) could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. However, these warrants were excluded when calculating diluted loss per share because such inclusion would be anti-dilutive for the periods presented. As a result, diluted loss per share is the same as basic loss per share for the period presented.
A reconciliation of net loss per share is as follows for the period from January 21 (Inception) through December 31, 2021:
 
    
Class A subject to
possible redemption
    
Class A
    
Class B
 
Allocation of undistributable losses
     (209,176      (6,286      (113,920
    
 
 
    
 
 
    
 
 
 
Net income/(loss) to Common shares
  
$
(209,176
  
$
(6,286
  
$
(113,920
    
 
 
    
 
 
    
 
 
 
Weighted average shares outstanding, basic and diluted
     6,973,122        209,549        3,797,628  
    
 
 
    
 
 
    
 
 
 
Basic and diluted net loss per share
   $ (0.03    $ (0.03    $ (0.03
    
 
 
    
 
 
    
 
 
 
Offering Costs
Offering Costs
Offering costs consist of underwriting, legal, accounting and other expenses incurred through the Initial Public Offering that are directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with the Public Shares were charged to shareholders’ equity upon the completion of the Initial Public Offering. Offering costs amounted to $9,897,599 at July 29, 2021, which were allocated between the Class A shares subject to possible redemption and the Public Warrants and charged to shareholders’ equity upon the completion of the Initial Public Offering. Under the guidance in Staff Accounting Bulletin 107 Topic 5.A, Accounting for Expenses or Liabilities Paid by Principal Stockholder(s), the Company included in these offering costs amounts incurred by the Sponsor through the transfer of
Non-Risk
Incentive Private Shares (see Note 4) to Anchor Investors on behalf of the Company in the amount of $1,186,448. The initial public offering costs as of the IPO date were allocated $9,664,188 and $233,411 between the Class A shares subject to possible redemption and the Public Warrants (see Note 6), respectively, based on their relative fair values at the issuance date. The Company incurred an additional $92,070 offering costs of upon the partial exercise of the overallotment option on August 3, 2021.
The total issuance costs of $10,145,105 were allocated to the Class A shares subject to possible redemption and the Public Warrants based on their relative fair values with $9,905,857 to the Class A shares subject to possible redemption and $239,247 to the Public Warrants.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.
 
Fair Value Measurements
Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
 
   
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
 
   
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
 
   
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
 
Description
  
Level
    
December 31,
2021
 
Assets:
                 
Marketable securities held in Trust Account
     1      $ 154,449,121  
The overallotment liability is measured at fair value using the Black Scholes Option Pricing Model with significant unobservable inputs. The fair value is based on the share price of the underlying shares and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. Therefore, the overallotment liability is considered to be a Level 3 financial instrument.
The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis:
 
    
Overallotment
liability
 
Balance at January 21, 2021 (inception)
   $ —    
Issuance of overallotment option
     158,275  
Partial exercise of overallotment option
     (28,316
Change in fair value of overallotment liability
     (2,924
Expiration of overallotment option
     (127,035
    
 
 
 
Balance at December 31, 2021
   $ —    
    
 
 
 
Income Taxes
Income Taxes
The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
 
ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments that potentially subject the Company to a concentration of credit risk consist of a cash account in a financial institution, which at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Recently Issued Accounting Standards
Recently Issued Accounting Standards
Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies (Tables)
11 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Schedule of Fair Value of the Overallotment Liability
The fair value of the overallotment liability at the IPO date of $158,275 was determined using the Black Scholes option pricing model based on the following assumptions:
 
Risk-free interest rate
  
 
0.05
Dividend rate
  
 
0
Volatility
  
 
5.00
Expected life (in years)
  
 
0.12
 
 
Risk-free interest rate
     0.05
Dividend rate
     0
Volatility
     5.00
Expected life (in years)
     0.10  
Schedule of Reconciliation of Net Loss per Share
A reconciliation of net loss per share is as follows for the period from January 21 (Inception) through December 31, 2021:
 
    
Class A subject to
possible redemption
    
Class A
    
Class B
 
Allocation of undistributable losses
     (209,176      (6,286      (113,920
    
 
 
    
 
 
    
 
 
 
Net income/(loss) to Common shares
  
$
(209,176
  
$
(6,286
  
$
(113,920
    
 
 
    
 
 
    
 
 
 
Weighted average shares outstanding, basic and diluted
     6,973,122        209,549        3,797,628  
    
 
 
    
 
 
    
 
 
 
Basic and diluted net loss per share
   $ (0.03    $ (0.03    $ (0.03
    
 
 
    
 
 
    
 
 
 
Schedule of Fair Value Measurements, Recurring and Nonrecurring
The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
 
Description
  
Level
    
December 31,
2021
 
Assets:
                 
Marketable securities held in Trust Account
     1      $ 154,449,121  
Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis
The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis:
 
    
Overallotment
liability
 
Balance at January 21, 2021 (inception)
   $ —    
Issuance of overallotment option
     158,275  
Partial exercise of overallotment option
     (28,316
Change in fair value of overallotment liability
     (2,924
Expiration of overallotment option
     (127,035
    
 
 
 
Balance at December 31, 2021
   $ —    
    
 
 
 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Tables)
11 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Income Tax Provision
The income tax provision consisted of the following as of December 31, 2021:
 
Federal
        
Current
   $ —    
Deferred
     (96,461
State
        
Current
     —    
Deferred
      
Change in valuation allowance
     96,461  
    
 
 
 
Income tax provision
  
$
—  
 
    
 
 
 
Schedule of Net Deferred Tax Assets
The Company’s net deferred tax assets consist of the following as of December 31, 2021:
 
Deferred tax assets:
        
Net operating loss carryforwards
   $ 33,531  
Organizational costs/startup expenses
     62,930  
    
 
 
 
Total deferred tax asset
     96,461  
Valuation allowance
     (96,461 )
    
 
 
 
Deferred tax asset, net of valuation allowance
  
$
—  
 
    
 
 
 
Schedule of Reconciliation of the Federal Income Tax Rate To The Company's Effective Tax Rate
A reconciliation of the federal income tax rate to the Company’s effective tax rate at December 31, 2021 is as follows:
 
Statutory federal income tax rate
     21.0
Change in fair value of overallotment liability
     8.3  
Change in valuation allowance
     (29.3 )
    
 
 
 
Effective tax rate
     —  
    
 
 
 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation (Tables)
11 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Summary of Restricted Stock Award and Restricted Unit Activity
A summary of the restricted stock award and restricted unit activity for the period from January 21, 2021 (inception) through December 31, 2021 is as follows:
 
 
  
Number
of
Shares
 
Unvested Shares Outstanding at January 21, 2021 (inception)
  
 
—  
 
Granted
  
 
75,000
 
Forfeited
  
 
—  
 
Vested
  
 
—  
 
 
  
 
 
 
Unvested Outstanding at December 31, 2021
  
 
75,000
 
 
  
 
 
 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Business Operations - Additional Information (Detail) - USD ($)
11 Months Ended
Aug. 03, 2021
Jul. 29, 2021
Jul. 26, 2021
Dec. 31, 2021
Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Shares Issued, Price Per Share       $ 10.00 $ 10.00
Restricted Investments Term       185 days  
Lock In Period For Redemption Of Public Shares After Closing Of IPO       24 months  
Percentage of public shares to be redeemed in case business combination is not consummated       100.00%  
Equity Method Investment, Ownership Percentage       50.00%  
Minimum Net Worth Required for Compliance       $ 5,000,001  
Cash       774,192  
Net loss       (329,382)  
Public Warrants [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Stock issuance cost allocation based on derivative fair value       $ 239,247  
Sponsor [Member] | Private Placement Warrants [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Class of warrants and rights issued during the period       455,000  
Class Of Warrants and Rights Issued, Price Per Warrant       $ 10.00  
Proceeds from Issuance of Private Placement       $ 4,550,000  
IPO [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Shares Issued, Price Per Share   $ 10.00      
Proceeds from Issuance Initial Public Offering   $ 154,441,030      
Stock issuance costs       3,461,151  
Payments for Underwriting Expense       3,000,000  
Other Offering Costs       461,151  
Deferred Offering Costs Current And Noncurrent       1,550,000  
Accrued underwriting fees       5,250,000  
Over-Allotment Option [Member] | Private Placement Warrants [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Class of warrants and rights issued during the period 8,882        
Proceeds from Issuance of Private Placement $ 88,820        
Other Offering Costs 3,250        
Transaction costs incurred 92,070        
Underwriting fees incurred $ 88,820        
Underwriting fees payable upon the consummation of business combination       155,436  
Private Placement [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Cash       774,192  
Common Class A [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Stock shares issued during the period shares   15,000,000      
Net loss       $ (6,286)  
Common Class A [Member] | Sponsor [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Share Price       $ 12.00  
Common Class A [Member] | IPO [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Stock shares issued during the period shares   15,000,000      
Shares Issued, Price Per Share   $ 10.00      
Proceeds from Issuance Initial Public Offering   $ 150,000,000      
Overallotment option vesting period   45 days      
Common Class B [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Stock issued during the period shares for services       25,000  
Net loss       $ (113,920)  
Risk Incentive Private Shares [Member] | IPO [Member] | Sponsor [Member] | Founder [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Stock shares issued during the period shares   600,900      
Sale of Stock, Percentage of Ownership before Transaction   9.90%      
Share Price   $ 5.27      
NonRisk Incentive Private Shares [Member] | Sponsor [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Sale of Stock, Consideration Received on Transaction   $ 1,186,448      
NonRisk Incentive Private Shares [Member] | IPO [Member] | Sponsor [Member] | Founder [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Stock shares issued during the period shares   225,000      
Sale of Stock, Consideration Received on Transaction   $ 1,186,448      
Sale of Stock, Price Per Share   $ 5.27      
Class A Common Stock Subject To Possible Redemption [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Stock issuance cost allocation based on temporary equity fair value       9,905,857  
Net loss       (209,176)  
Class A Common Stock Subject To Possible Redemption [Member] | Public Warrants [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Stock issuance costs       $ 10,145,105  
Maximum [Member] | Common Class A [Member] | Over-Allotment Option [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Stock shares issued during the period shares   2,250,000      
Underwriting Agreement [Member] | Over-Allotment Option [Member]          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Stock shares issued during the period shares     2,250,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 444,103        
Stock Issued During Period, Value, Stock Options Exercised $ 4,441,030        
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies - Additional Information (Detail) - USD ($)
11 Months Ended
Sep. 09, 2021
Aug. 03, 2021
Jul. 29, 2021
Dec. 31, 2021
Unrecognized Tax Benefits       $ 0
Accrued for interest and penalties       0
FDIC Insured Amount       $ 250,000
Stock issued during the period share based compensation forfeited       451,474
Offering costs incurred       $ 92,070
Gain on expiration of overallotment option $ 127,035     127,035
Fair value of overallotment liability at the initial public offering date       158,275
Fair value of overallotment liability partially extinguished upon exercise of option   $ 28,317    
Over-Allotment Option [Member] | Underwriting Agreement [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   444,103    
IPO [Member]        
Stock issuance costs       $ 3,461,151
Common Class A [Member]        
Temporary equity shares outstanding       15,444,103
Common Class A [Member] | IPO [Member]        
Offering costs incurred       $ 233,411
Class A Common Stock Subject To Possible Redemption [Member]        
Stock issuance cost allocation based on temporary equity fair value       9,905,857
Class A Common Stock Subject To Possible Redemption [Member] | IPO [Member]        
Offering costs incurred       $ 9,664,188
Common Class B [Member]        
Weighted average shares subject to forfeiture       562,500
Common stock shares for which the forfeiture option expired   111,026    
Stock issued during the period share based compensation forfeited       451,474
NonRisk Incentive Private Shares [Member] | Sponsor [Member]        
Sale of Stock, Consideration Received on Transaction     $ 1,186,448  
Public Warrants [Member]        
Stock issuance cost allocation based on derivative fair value       $ 239,247
Public Warrants [Member] | Class A Common Stock Subject To Possible Redemption [Member]        
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs       9,897,599
Stock issuance costs       $ 10,145,105
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies - Schedule of Fair Value of the Overallotment Liability (Detail)
11 Months Ended
Aug. 03, 2021
Dec. 31, 2021
Risk-free interest rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value of overallotment liability measurement input 0.05 0.05
Dividend rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value of overallotment liability measurement input 0 0
Volatility    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value of overallotment liability measurement input 5.00 5.00
Expected life (in years)    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value of overallotment liability term 1 month 6 days 1 month 13 days
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies - Schedule of Reconciliation of Net Loss per Share (Detail)
11 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
shares
Schedule Of Earnings Per Share Basic And Diluted [Line Items]  
Allocation of undistributable losses/ Net income/(loss) to Common shares $ (329,382)
Class A Common Stock Subject To Possible Redemption [Member]  
Schedule Of Earnings Per Share Basic And Diluted [Line Items]  
Allocation of undistributable losses/ Net income/(loss) to Common shares $ (209,176)
Weighted average shares outstanding, basic and diluted | shares 6,973,122
Basic and diluted net loss per share | $ / shares $ (0.03)
Common Class A [Member]  
Schedule Of Earnings Per Share Basic And Diluted [Line Items]  
Allocation of undistributable losses/ Net income/(loss) to Common shares $ (6,286)
Weighted average shares outstanding, basic and diluted | shares 209,549
Basic and diluted net loss per share | $ / shares $ (0.03)
Common Class B [Member]  
Schedule Of Earnings Per Share Basic And Diluted [Line Items]  
Allocation of undistributable losses/ Net income/(loss) to Common shares $ (113,920)
Weighted average shares outstanding, basic and diluted | shares 3,797,628
Basic and diluted net loss per share | $ / shares $ (0.03)
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Detail)
Dec. 31, 2021
USD ($)
Fair Value, Recurring [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Marketable securities held in Trust Account $ 154,449,121
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies - Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Overallotment liability
11 Months Ended
Dec. 31, 2021
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Beginning balance $ 0
Issuance of overallotment option 158,275
Partial exercise of overallotment option (28,316)
Change in fair value of overallotment liability (2,924)
Expiration of overallotment option (127,035)
Ending balance $ 0
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Initial Public Offering - Additional information (Detail) - USD ($)
11 Months Ended
Aug. 03, 2021
Jul. 29, 2021
Jul. 26, 2021
Dec. 31, 2021
Jun. 30, 2021
Shares Issued, Price Per Share       $ 10.00 $ 10.00
Private Placement Warrants [Member] | Sponsor [Member]          
Class of warrants and rights issued during the period       455,000  
Class Of Warrants and Rights Issued, Price Per Warrant       $ 10.00  
Proceeds from Issuance of Private Placement       $ 4,550,000  
IPO [Member]          
Shares Issued, Price Per Share   $ 10.00      
Proceeds from Issuance Initial Public Offering   $ 154,441,030      
Over-Allotment Option [Member] | Private Placement Warrants [Member]          
Class of warrants and rights issued during the period 8,882        
Proceeds from Issuance of Private Placement $ 88,820        
Common Class A [Member]          
Stock shares issued during the period shares   15,000,000      
Common Class A [Member] | IPO [Member]          
Stock shares issued during the period shares   15,000,000      
Shares Issued, Price Per Share   $ 10.00      
Proceeds from Issuance Initial Public Offering   $ 150,000,000      
Exercise price of warrant   $ 11.50      
Underwriting Agreement [Member] | Over-Allotment Option [Member]          
Stock shares issued during the period shares     2,250,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 444,103        
Stock Issued During Period, Value, Stock Options Exercised $ 4,441,030        
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions - Additional Information (Detail) - USD ($)
11 Months Ended
Aug. 03, 2021
Jul. 29, 2021
Jul. 27, 2021
Jul. 26, 2021
Mar. 01, 2021
Jan. 25, 2021
Jan. 21, 2021
Dec. 31, 2021
Jun. 30, 2021
Stock Issued During Period, Value, Issued for Services               $ 25,000  
Shares Issued, Price Per Share               $ 10.00 $ 10.00
Shares Issued, Shares, Share-based Payment Arrangement, Forfeited               451,474  
Due to related party               $ 2,275  
Founder Shares [Member]                  
Common Stock, Shares Subscribed but Unissued             3,593,750    
Common stock par or stated value per share             $ 0.0001    
Stock Issued During Period, Value, Issued for Services           $ 25,000 $ 25,000    
Shares Issued, Price Per Share           $ 0.00696      
Stock Issued During Period, Shares, Issued for Services           3,593,750      
Office Space Administrative And Support Services [Member]                  
Expenses from Transactions with Related Party               10,000  
Working Capital Loan [Member]                  
Due to related party               0  
Debt Instrument, Convertible, Warrants issued               $ 1,500,000  
Warrants issued price per warrant               $ 1.50  
Sponsor [Member]                  
Administrative fees               $ 51,000  
Sponsor [Member] | Promissory Note [Member]                  
Debt Instrument, Face Amount           $ 300,000      
Note payable – related party               $ 0  
Sponsor [Member] | Darlene DeRemer [Member] | Founder Shares [Member]                  
Stock shares issued during the period shares     25,000            
Sponsor [Member] | Eugene Podsiadlo [Member] | Founder Shares [Member]                  
Stock shares issued during the period shares     25,000            
Sponsor [Member] | William Woodward [Member] | Founder Shares [Member]                  
Stock shares issued during the period shares     25,000            
Sponsor [Member] | Private Placement Warrants [Member]                  
Class of warrants and rights issued during the period               455,000  
Proceeds from Issuance of Private Placement               $ 4,550,000  
Over-Allotment Option [Member] | Founder Shares [Member]                  
Common Stock forfeiture provisions lapsed 111,026                
Shares Issued, Shares, Share-based Payment Arrangement, Forfeited 451,464                
Overallotment option vesting period 45 days                
Over-Allotment Option [Member] | Private Placement Warrants [Member]                  
Class of warrants and rights issued during the period 8,882                
Proceeds from Issuance of Private Placement $ 88,820                
IPO [Member]                  
Shares Issued, Price Per Share   $ 10.00              
Underwriting Agreement [Member] | Founder Shares [Member]                  
Stock shares issued during the period shares 2,250,000                
Underwriting Agreement [Member] | Over-Allotment Option [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 444,103                
Stock shares issued during the period shares       2,250,000          
Forward Purchase Agreement [Member]                  
Option granted to direct anchor investors to subscribe to agreement as percentage of aggregate securities sold in one or multiple private placements               60.00%  
Option granted to direct anchor investors to subscribe to agreement percentage of as aggregate securities sold in one or multiple private placements per each direct anchor investor               10.00%  
Common Class A [Member]                  
Common stock par or stated value per share         $ 0.0001     $ 0.0001  
Common stock shares outstanding               463,882  
Stock shares issued during the period shares   15,000,000              
Common Class A [Member] | Sponsor [Member]                  
Share price               $ 12.00  
Number of trading days for determining the share price               20 days  
Number of consecutive trading days for determining the share price               30 days  
Waiting period after which the share trading days are considered               150 days  
Common Class A [Member] | Over-Allotment Option [Member]                  
Common stock shares outstanding               15,907,985  
Common Class A [Member] | IPO [Member]                  
Shares Issued, Price Per Share   $ 10.00              
Stock shares issued during the period shares   15,000,000              
Common Class B [Member]                  
Common stock par or stated value per share         $ 0.0001     $ 0.0001  
Stock Issued During Period, Shares, Issued for Services               25,000  
Stockholders' Equity Note, Stock Split         1:1.2        
Common stock shares outstanding         4,312,500     3,861,026  
Shares Issued, Shares, Share-based Payment Arrangement, Forfeited               451,474  
Common Class B [Member] | Over-Allotment Option [Member]                  
Common stock shares outstanding               3,861,026  
NonRisk Incentive Private Shares [Member] | Sponsor [Member]                  
Sale of Stock, Consideration Received on Transaction   $ 1,186,448              
NonRisk Incentive Private Shares [Member] | IPO [Member] | Sponsor [Member] | Founder Shares [Member]                  
Stock shares issued during the period shares   225,000              
Sale of Stock, Consideration Received on Transaction   $ 1,186,448              
Sale of Stock, Price Per Share   $ 5.27              
Risk Incentive Private Shares [Member] | IPO [Member] | Sponsor [Member] | Founder Shares [Member]                  
Stock shares issued during the period shares   600,900              
Sale of Stock, Percentage of Ownership before Transaction   9.90%              
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments & Contingencies - Additional Information (Detail) - USD ($)
11 Months Ended
Aug. 06, 2021
Aug. 03, 2021
Jul. 29, 2021
Jul. 26, 2021
Dec. 31, 2021
Jul. 14, 2021
NonRisk Incentive Private Shares [Member] | Maximum [Member] | Sponsor [Member]            
Percentage of ownership shares through initial Business Combination           10.00%
Risk Incentive Private Shares [Member] | Minimum [Member] | Sponsor [Member]            
Percentage of ownership shares through initial Business Combination           10.00%
Over-Allotment Option [Member] | Underwriting Agreement [Member]            
Stock shares issued during the period shares       2,250,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   444,103        
Stock Issued During Period, Value, Stock Options Exercised   $ 4,441,030        
Cash underwriting discount percent 2.00%   2.00%      
Payment of underwriting discount $ 88,820   $ 3,000,000      
Deferred underwriting fee percent         3.50%  
Deferred underwriting commission         $ 5,405,436  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Shareholder's Equity - Additional Information (Detail) - $ / shares
11 Months Ended
Sep. 30, 2021
Aug. 03, 2021
Jul. 29, 2021
Mar. 01, 2021
Jan. 25, 2021
Dec. 31, 2021
Class of Stock [Line Items]            
Equity Method Investment, Ownership Percentage           50.00%
Preferred stock par or stated value per share           $ 0.0001
Preferred stock shares authorized           1,000,000
Preferred stock shares issued           0
Preferred stock shares outstanding           0
Volume weighted average price of shares           $ 9.20
Proceeds from equity used for funding business combination as a percentage of the total           60.00%
Warrant [Member]            
Class of Stock [Line Items]            
Class of Warrant or Right, Exercise Price of Warrants or Rights           $ 11.50
Warrants and rights outstanding term           5 years
Common Class A [Member]            
Class of Stock [Line Items]            
Stock shares issued during the period shares     15,000,000      
Common stock par or stated value per share       $ 0.0001   $ 0.0001
Common stock shares authorized       100,000,000   100,000,000
Common stock shares issued           463,882
Common stock shares outstanding           463,882
Common Class A [Member] | Founder [Member]            
Class of Stock [Line Items]            
Percentage of common stock issued and outstanding           20.00%
Common Class B [Member]            
Class of Stock [Line Items]            
Common stock par or stated value per share       $ 0.0001   $ 0.0001
Common stock shares authorized       10,000,000   10,000,000
Common stock shares issued           3,861,026
Common stock shares outstanding       4,312,500   3,861,026
Stockholders' Equity Note, Stock Split       1:1.2    
Stock Issued During Period, Shares, Stock Splits       4,312,500    
Preferred Stock [Member]            
Class of Stock [Line Items]            
Preferred stock par or stated value per share       $ 0.0001    
Preferred stock shares authorized       1,000,000    
Redemption of warrants equals or exceeds $18.00 [Member]            
Class of Stock [Line Items]            
Adjusted exercise price of warrants as a percentage of newly issued price           180.00%
Share price           $ 18.00
Class of warrants or rights redemption price per unit           $ 0.01
Notice period of redemption warrant           30 days
Securities for capital with closing of initial business combination           20 days
Third trading day prior to date on which company notice of redemption           30 days
Redemption of warrants equals or exceeds $18.00 [Member] | Common Class A [Member]            
Class of Stock [Line Items]            
Notice period of redemption warrant           30 days
Redemption of warrants below $9.20 [Member]            
Class of Stock [Line Items]            
Adjusted exercise price of warrants as a percentage of newly issued price           115.00%
Share price           $ 9.20
Over-Allotment Option [Member]            
Class of Stock [Line Items]            
Number of additional shares purchased 444,103 444,103        
Number of shares available for purchase   2,250,000        
Number of shares lapsed   111,026        
Number of founder shares forfeited   451,464        
Over-Allotment Option [Member] | Common Class A [Member]            
Class of Stock [Line Items]            
Common Stock Shares Subject To Forfeiture           15,444,103
Common stock shares issued           15,907,985
Common stock shares outstanding           15,907,985
Over-Allotment Option [Member] | Common Class B [Member]            
Class of Stock [Line Items]            
Common Stock Shares Subject To Forfeiture           562,500
Common stock shares issued           3,861,026
Common stock shares outstanding           3,861,026
Over-Allotment Option [Member] | Common Stock [Member]            
Class of Stock [Line Items]            
Stock shares issued during the period shares         3,593,750  
Common Stock Shares Subject To Forfeiture         468,750  
Equity Method Investment, Ownership Percentage         20.00%  
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes - Schedule of Income Tax Provision (Detail)
11 Months Ended
Dec. 31, 2021
USD ($)
Federal  
Current $ 0
Deferred (96,461)
State  
Current 0
Deferred 0
Change in valuation allowance 96,461
Income tax provision $ 0
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes - Schedule of Net Deferred Tax Assets (Detail)
Dec. 31, 2021
USD ($)
Deferred tax assets:  
Net operating loss carryforwards $ 33,531
Organizational costs/startup expenses 62,930
Total deferred tax asset 96,461
Valuation allowance (96,461)
Deferred tax asset, net of valuation allowance $ 0
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate To The Company's Effective Tax Rate (Detail)
11 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Statutory federal income tax rate 21.00%
Change in fair value of overallotment liability 8.30%
Change in valuation allowance (29.30%)
Effective tax rate 0.00%
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes - Additional Information (Detail)
11 Months Ended
Dec. 31, 2021
USD ($)
Income Tax Expense $ 0
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent 0.00%
Deferred Tax Assets, Valuation Allowance $ 96,461
Unrecognized tax benefits 0
Unrecognized tax benefits income tax penalties and interest accrued 0
Domestic Tax Authority [Member]  
Net operating loss carryovers $ 159,673
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation - Summary of Restricted Stock Award and Restricted Unit Activity (Detail)
11 Months Ended
Dec. 31, 2021
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unvested Shares Outstanding at January 21, 2021 (inception) 0
Granted 75,000
Forfeited 0
Vested 0
Unvested Outstanding at December 31, 2021 75,000
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation - Additional Information (Detail) - USD ($)
11 Months Ended
Jul. 27, 2021
Dec. 31, 2021
Disclosure Of Compensation Related Costs Share Based Payments [Line Items]    
Share based compensation   $ 0
Fair value of founder shares on the grant date   $ 5.26
Aggregate grant date fair value of the award   $ 394,000
Total unrecognized compensation expense related to unvested founder shares   $ 394,000
Three Independent Director Nominees [Member] | Common Class B [Member] | Sponsor [Member]    
Disclosure Of Compensation Related Costs Share Based Payments [Line Items]    
Stock Issued During Period, Shares, New Issues 25,000  
XML 48 d268885d10k_htm.xml IDEA: XBRL DOCUMENT 0001842939 2021-01-21 2021-12-31 0001842939 2021-12-31 0001842939 2021-06-30 0001842939 2021-09-09 2021-09-09 0001842939 2021-08-03 2021-08-03 0001842939 2021-01-20 0001842939 us-gaap:CommonClassBMember 2021-12-31 0001842939 us-gaap:CommonClassAMember 2021-12-31 0001842939 us-gaap:CommonClassBMember us-gaap:OverAllotmentOptionMember 2021-12-31 0001842939 us-gaap:IPOMember 2021-12-31 0001842939 alpau:PrivatePlacementWarrantsMember us-gaap:OverAllotmentOptionMember 2021-12-31 0001842939 alpau:SponsorMember us-gaap:CommonClassAMember 2021-12-31 0001842939 alpau:PromissoryNoteMember alpau:SponsorMember 2021-12-31 0001842939 alpau:WorkingCapitalLoanMember 2021-12-31 0001842939 us-gaap:OverAllotmentOptionMember alpau:UnderwritingAgreementMember 2021-12-31 0001842939 us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember 2021-12-31 0001842939 alpau:FounderMember us-gaap:CommonClassAMember 2021-12-31 0001842939 us-gaap:WarrantMember 2021-12-31 0001842939 alpau:RedemptionOfWarrantsBelowUsDollarNinePointTwoZeroMember 2021-12-31 0001842939 alpau:RedemptionOfWarrantsEqualsOrExceedsUsDollarEighteenPointZeroZeroMember 2021-12-31 0001842939 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001842939 us-gaap:PrivatePlacementMember 2021-12-31 0001842939 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001842939 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001842939 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001842939 us-gaap:DomesticCountryMember 2021-12-31 0001842939 us-gaap:WarrantMember 2021-01-21 2021-12-31 0001842939 us-gaap:CapitalUnitsMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-01-21 2021-12-31 0001842939 us-gaap:AdditionalPaidInCapitalMember 2021-01-21 2021-12-31 0001842939 us-gaap:PrivatePlacementMember 2021-01-21 2021-12-31 0001842939 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassAMember us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2021-01-21 2021-12-31 0001842939 alpau:ClassACommonStockSubjectToPossibleRedemptionMember us-gaap:CommonStockMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassAMember 2021-01-21 2021-12-31 0001842939 alpau:PublicWarrantsMember 2021-01-21 2021-12-31 0001842939 alpau:PrivatePlacementWarrantsMember alpau:SponsorMember 2021-01-21 2021-12-31 0001842939 us-gaap:IPOMember 2021-01-21 2021-12-31 0001842939 alpau:PublicWarrantsMember alpau:ClassACommonStockSubjectToPossibleRedemptionMember 2021-01-21 2021-12-31 0001842939 alpau:ClassACommonStockSubjectToPossibleRedemptionMember 2021-01-21 2021-12-31 0001842939 alpau:SponsorMember us-gaap:CommonClassAMember 2021-01-21 2021-12-31 0001842939 alpau:OfficeSpaceAdministrativeAndSupportServicesMember 2021-01-21 2021-12-31 0001842939 alpau:SponsorMember 2021-01-21 2021-12-31 0001842939 us-gaap:OverAllotmentOptionMember alpau:UnderwritingAgreementMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassAMember alpau:RedemptionOfWarrantsEqualsOrExceedsUsDollarEighteenPointZeroZeroMember 2021-01-21 2021-12-31 0001842939 alpau:RedemptionOfWarrantsEqualsOrExceedsUsDollarEighteenPointZeroZeroMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassBMember 2021-01-21 2021-12-31 0001842939 alpau:PublicWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2021-01-21 2021-12-31 0001842939 us-gaap:RetainedEarningsMember 2021-01-21 2021-12-31 0001842939 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-01-21 2021-12-31 0001842939 alpau:ClassACommonStockSubjectToPossibleRedemptionMember us-gaap:IPOMember 2021-01-21 2021-12-31 0001842939 us-gaap:MeasurementInputExpectedTermMember 2021-01-21 2021-12-31 0001842939 alpau:OverallotmentLiabilityMember 2021-01-21 2021-12-31 0001842939 alpau:ForwardPurchaseAgreementMember 2021-01-21 2021-12-31 0001842939 alpau:SponsorMember alpau:RiskIncentivePrivateSharesMember alpau:FounderMember us-gaap:IPOMember 2021-07-29 2021-07-29 0001842939 alpau:SponsorMember alpau:NonriskIncentivePrivateSharesMember alpau:FounderMember us-gaap:IPOMember 2021-07-29 2021-07-29 0001842939 srt:MaximumMember us-gaap:CommonClassAMember us-gaap:OverAllotmentOptionMember 2021-07-29 2021-07-29 0001842939 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-07-29 2021-07-29 0001842939 us-gaap:IPOMember 2021-07-29 2021-07-29 0001842939 alpau:SponsorMember alpau:NonriskIncentivePrivateSharesMember alpau:FounderSharesMember us-gaap:IPOMember 2021-07-29 2021-07-29 0001842939 alpau:SponsorMember alpau:RiskIncentivePrivateSharesMember alpau:FounderSharesMember us-gaap:IPOMember 2021-07-29 2021-07-29 0001842939 us-gaap:OverAllotmentOptionMember alpau:UnderwritingAgreementMember 2021-07-29 2021-07-29 0001842939 us-gaap:CommonClassAMember 2021-07-29 2021-07-29 0001842939 alpau:SponsorMember alpau:NonriskIncentivePrivateSharesMember 2021-07-29 2021-07-29 0001842939 us-gaap:CommonClassAMember us-gaap:IPOMember 2021-07-29 0001842939 us-gaap:IPOMember 2021-07-29 0001842939 alpau:SponsorMember alpau:NonriskIncentivePrivateSharesMember alpau:FounderSharesMember us-gaap:IPOMember 2021-07-29 0001842939 alpau:SponsorMember alpau:NonriskIncentivePrivateSharesMember alpau:FounderMember us-gaap:IPOMember 2021-07-29 0001842939 alpau:SponsorMember alpau:RiskIncentivePrivateSharesMember alpau:FounderMember us-gaap:IPOMember 2021-07-29 0001842939 alpau:PrivatePlacementWarrantsMember us-gaap:OverAllotmentOptionMember 2021-08-03 2021-08-03 0001842939 us-gaap:OverAllotmentOptionMember alpau:UnderwritingAgreementMember 2021-08-03 2021-08-03 0001842939 alpau:FounderSharesMember alpau:UnderwritingAgreementMember 2021-08-03 2021-08-03 0001842939 alpau:FounderSharesMember us-gaap:OverAllotmentOptionMember 2021-08-03 2021-08-03 0001842939 us-gaap:OverAllotmentOptionMember 2021-08-03 2021-08-03 0001842939 us-gaap:MeasurementInputExpectedTermMember 2021-08-03 2021-08-03 0001842939 us-gaap:CommonClassBMember 2021-08-03 0001842939 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-08-03 0001842939 us-gaap:MeasurementInputExpectedDividendRateMember 2021-08-03 0001842939 us-gaap:MeasurementInputPriceVolatilityMember 2021-08-03 0001842939 alpau:FounderSharesMember 2021-01-21 2021-01-21 0001842939 alpau:FounderSharesMember 2021-01-21 0001842939 alpau:FounderSharesMember 2021-01-25 2021-01-25 0001842939 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2021-01-25 2021-01-25 0001842939 alpau:FounderSharesMember 2021-01-25 0001842939 alpau:PromissoryNoteMember alpau:SponsorMember 2021-01-25 0001842939 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2021-01-25 0001842939 us-gaap:CommonClassBMember 2021-03-01 2021-03-01 0001842939 us-gaap:CommonClassBMember 2021-03-01 0001842939 us-gaap:CommonClassAMember 2021-03-01 0001842939 us-gaap:PreferredStockMember 2021-03-01 0001842939 us-gaap:OverAllotmentOptionMember alpau:UnderwritingAgreementMember 2021-07-26 2021-07-26 0001842939 us-gaap:OverAllotmentOptionMember alpau:UnderwritingAgreementMember 2021-08-06 2021-08-06 0001842939 srt:MaximumMember alpau:SponsorMember alpau:NonriskIncentivePrivateSharesMember 2021-07-14 0001842939 srt:MinimumMember alpau:SponsorMember alpau:RiskIncentivePrivateSharesMember 2021-07-14 0001842939 us-gaap:OverAllotmentOptionMember 2021-09-30 2021-09-30 0001842939 alpau:DarleneDeRemerMember alpau:SponsorMember alpau:FounderSharesMember 2021-07-27 2021-07-27 0001842939 alpau:EugenePodsiadloMember alpau:SponsorMember alpau:FounderSharesMember 2021-07-27 2021-07-27 0001842939 alpau:WilliamWoodwardMember alpau:SponsorMember alpau:FounderSharesMember 2021-07-27 2021-07-27 0001842939 alpau:ThreeIndependentDirectorNomineesMember alpau:SponsorMember us-gaap:CommonClassBMember 2021-07-27 2021-07-27 0001842939 us-gaap:CommonClassBMember 2022-04-15 0001842939 us-gaap:CommonClassAMember 2022-04-15 0001842939 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-01-20 0001842939 us-gaap:RetainedEarningsMember 2021-01-20 0001842939 us-gaap:AdditionalPaidInCapitalMember 2021-01-20 0001842939 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-01-20 0001842939 alpau:ClassACommonStockSubjectToPossibleRedemptionMember us-gaap:CommonStockMember 2021-01-20 0001842939 alpau:ClassACommonStockSubjectToPossibleRedemptionMember us-gaap:CommonStockMember 2021-12-31 0001842939 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001842939 us-gaap:RetainedEarningsMember 2021-12-31 0001842939 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001842939 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001842939 alpau:OverallotmentLiabilityMember 2021-01-20 0001842939 alpau:OverallotmentLiabilityMember 2021-12-31 iso4217:USD shares utr:Day pure utr:Year utr:Month iso4217:USD shares false FY 0001842939 false 10-K true 2021-12-31 --12-31 2021 false 001-40228 Alpha Healthcare Acquisition Corp. III DE 85-1645738 1177 Avenue of the Americas 5th Floor New York NY 10036 646 494-3296 Units, each consisting of one share of Class A Common Stock and one-fourth of one Redeemable Warrant ALPAU NASDAQ Class A Common Stock, par value $0.0001 per share ALPA NASDAQ Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 ALPAW NASDAQ No No Yes Yes Non-accelerated Filer true true false true 157170000 15907985 3861026 688 Marcum LLP Houston, TX 774192 198983 973175 154449121 155422296 112485 215247 2275 330007 5405436 5735443 0.0001 100000000 15444103 15444103 154449121 0.0001 1000000 0 0 0 0.0001 100000000 463882 463882 46 0.0001 10000000 3861026 3861026 386 0 -4762700 -4762268 155422296 4312500 562500 451474 467431 -467431 8091 2923 127035 -329382 6973122 -0.03 209549 -0.03 3797628 -0.03 0 0 0 0 0 0 0 0 4312500 431 24569 25000 463882 46 4638774 4638820 9905857 15444103 140738518 239247 3399132 3399132 1186448 1186448 28317 28317 13702512 -9277240 -4425272 -13702512 -451474 -45 45 8091 -8091 -8091 -329382 -329382 15444103 154449121 463882 46 3861026 386 0 -4762700 -4762268 4312500 562500 451474 -329382 8091 2923 127035 198983 215247 -451167 -154441030 56922 54647 154441030 4638820 3415736 155666389 774192 0 774192 5405436 1186448 112485 25000 8091 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1 — Organization and Business Operations</div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alpha Healthcare Acquisition Corp. III is a blank check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company has not selected any specific Business Combination target and the Company has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any Business Combination target. While the Company may pursue an initial Business Combination target in any business or industry, it intends to focus its search on companies in the healthcare industry. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has selected December 31 as its fiscal year end. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2021, the Company had not yet commenced any operations. All activity from January 21, 2021 (inception) through December 31, 2021, relates to the Company’s formation, the Public Offering (as defined below), and activities necessary to identify a potential target for a Business Combination. Since our Initial Public Offering, we have not generated any operating revenues, and do not expect to generate any operating revenues, until after completion of our initial Business Combination. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The registration statement for the Company’s Public Offering was declared effective on July 26, 2021. On July 29, 2021 (“IPO Date”), the Company consummated the Initial Public Offering of 15,000,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $150,000,000, which is described in Note 3. In connection with the IPO, the Company also granted the underwriters a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">45-day</div> option to purchase an additional 2,250,000 Public Units at the initial public offering price. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 455,000 Units (each, a “Private Placement Unit” and, collectively, the “Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to AHAC Sponsor III LLC (the “Sponsor”), generating gross proceeds of $4,550,000, which is described in Note 4. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the IPO Date, transaction costs amounted to $3,461,151, consisting of $3,000,000 of underwriting fees and $461,151 of other offering costs. The Company has also accrued underwriting fees of $5,250,000 that will be paid only if a business combination is entered into. In addition, cash of $1,550,000 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At the IPO date, the Sponsor also transferred to certain investors a total of 225,000 of Founders shares (Note 4) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(“Non-Risk</div> Incentive Private Shares”) as a compensation for their commitment to purchase the Public Units sold in the IPO. The Company estimated the aggregate fair value of these shares to be $1,186,448, or $5.27 per share. The fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Risk</div> Incentive Private Shares was determined to be a contribution from the Sponsor for offering costs in accordance with Staff Accounting Bulletin Topic 5T. These offering costs were allocated to the Units and charged to shareholder’s equity upon the completion of the Initial Public Offering. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At the IPO date, the Sponsor also transferred to certain other investors the total of 600,900 of Founders shares (“Risk Incentive Private Shares”) as a compensation for their commitment to acquire at least 9.9% of the Units sold in the IPO. These Risk Incentive Private Shares are subject to forfeiture if the investors sell their Units prior to the closing of the initial Business Combination. The fair value of these Risk Incentive Private <div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares of $5.27 </div></div>is equal to the fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Risk</div> Incentive Private Shares. Due to the high probability of forfeiture, the fair value of these Risk Incentive Private Shares will be recorded as a capital contribution from the Sponsor upon the closing of the initial Business Combination. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 additional Units for a total amount of $4,441,030 resulting from the partial over-allotment exercise. The Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds. Transaction costs related to the Underwriters’ partial over-allotment exercise amounted to $92,070, consisting of $88,820 of underwriting fees and $3,250 of other offering costs. The Company has also accrued underwriting fees of $155,436 that will be paid only if a business combination is entered into. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total issuance costs of $10,145,105 were allocated to the Class A shares subject to possible redemption and the Public Warrants based on their relative fair values with $9,905,857 to the Class A shares subject to possible redemption and $239,247 to the Public Warrants. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following the closing of the Initial Public Offering on July 29, 2021, an amount of $154,441,030 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering, including the Units sold upon the exercise of the over-allotment option, and the sale of the Private Placement Units was placed in a trust account (the “Trust Account”), invested in U.S. government securities, within the meaning set forth in Section 2(a) (16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-7</div> of the Investment Company Act of 1940, as amended (the “Investment Company Act”), as determined by the Company. Except for the withdrawal of interest income to pay the income taxes, the Company’s amended and restated certificate of incorporation and subject to the requirements of law and regulation, provides that none of the funds held in the Trust Account will be released from the Trust Account until the earliest of (a) the completion of the Company’s initial Business Combination, (b) the redemption of the public shares if the Company is unable to consummate an initial Business Combination within 24 months from the closing of the Public Offering (the “Combination Period”), subject to applicable law, and (c) the redemption of the Company’s public shares properly submitted in connection with a shareholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of its public shares if the Company has not consummated an initial Business Combination within the Combination Period or with respect to any other material provisions relating to shareholders’ rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> Business Combination activity. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public shareholders. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Public Offering, although substantially all of the net proceeds are intended to be generally applied toward consummating a Business Combination. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s Business Combination must be with one or more target businesses that together have an aggregate fair market value of at least 80% of the assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting discounts held in trust and taxes payable on the interest earned on the Trust Account) at the time of the signing an agreement to enter into a Business Combination. However, the Company will only complete an initial Business Combination if the post-business combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will provide its public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a shareholder meeting called to approve the initial Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed initial Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The shareholders will be entitled to redeem their shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination, including interest (net of taxes payable), divided by the number of then outstanding public shares. The amount in the Trust Account is initially anticipated to be $10.00 per public share. The per share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares of common stock subject to redemption were recorded at a redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible, but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in each case, to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to consummate an initial Business Combination within the Combination Period. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor has agreed (i) to waive its redemption rights with respect to any Founder Shares, private placement shares and public shares held by it in connection with the completion of the initial Business Combination, (ii) to waive its rights to liquidating distributions from the Trust Account with respect to any Founder Shares or private placement shares held by it if the Company fails to complete its Business Combination within the Combination Period, although the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any public shares it holds if the Company fails to complete its Business Combination within such time period, (iii) not to propose any amendment to the Company’s amended and restated certificate of incorporation that would modify the substance or timing of its obligation to redeem 100% of the public shares if the Company does not complete its initial Business Combination within the Combination Period or with respect to any other material provisions relating to shareholders’ rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> Business Combination activity, unless the Company provides its public shareholders with the opportunity to redeem their shares, and (iv) to vote any Founder Shares held by it and any public shares purchased during or after the Public Offering in favor of the Company’s initial Business Combination. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per share due to reductions in the value of the trust assets, in each case less taxes payable, provided that such liability will not apply to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Public Offering against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has it independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsor would be able to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2021, the Company had cash outside the Trust Account of $774,192 available for working capital needs. All remaining cash held in the Trust Account are generally unavailable for the Company’s use, prior to an initial business combination, and is restricted for use either in a Business Combination or to redeem common stock. As of December 31, 2021, none of the amount in the Trust Account was available to be withdrawn as described above.</div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Through December 31, 2021, the Company’s liquidity needs were satisfied through receipt of $25,000 from the sale of the founder shares and the remaining net proceeds from the sale of Private Placement Units held outside of the trust account, totaling $774,192 as of December 31, 2021. </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the period from January 21, 2021 (inception) through December 31, 2021, the Company had a net loss of $329,382, which consisted of formation and general and administrative costs. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The $774,192 held outside of the Trust Account as of December 31, 2021, may not be sufficient to allow the Company to operate for at least the next 12 months from the issuance of the financial statements, assuming that a Business Combination is not consummated during that time. The Company may need to raise additional capital through loans or additional investments from its Sponsor, stockholders, officers, directors, or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern, assuming a Business Combination is not consummated. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company believes that the proceeds raised in the initial public offering and the funds potentially available from loans from the sponsor or any of their affiliates will be sufficient to allow the Company to meet the expenditures required for operating its business. However, if the estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to the initial Business Combination. Moreover, the Company may need to obtain additional financing either to complete the Business Combination or because the Company becomes obligated to redeem a significant number of public shares upon completion of the Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. </div></div><br/></div> 15000000 10.00 150000000 P45D 2250000 455000 10.00 4550000 3461151 3000000 461151 5250000 1550000 225000 1186448 5.27 600900 0.099 5.27 444103 4441030 8882 88820 92070 88820 3250 155436 10145105 9905857 239247 154441030 10.00 P185D P24M 1 0.50 10.00 5000001 1 10.00 774192 25000 774192 -329382 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2 — Significant Accounting Policies</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company Status </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable Securities Held in Trust Account </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December 31, 2021, the assets held in the Trust Account were substantially held in U.S. Treasury Bills and U.S Treasury Coupons. During the period from January 21, 2021 (inception) through December 31, 2021, the Company did not withdraw any of interest income from the Trust Account to pay its tax obligations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock Subject to Possible Redemption </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as shareholders’ equity. The Company’s common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of December 31, 2021, 15,444,103 shares of Class A common stock subject to possible redemption are classified in temporary equity outside of the shareholders’ equity (deficit) section of the Company’s balance sheet and were immediately accreted to redemption value at the IPO date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company issues warrants to its investors and accounts for warrant instruments as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Public Warrants (see Note 3) and Private Warrants (see Note 4) were accounted for as equity as these instruments meet all of the requirements for equity classification under ASC 815. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The over-allotment option (see Note 6) was deemed to be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to ASC 480. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the overallotment liability at the IPO date of $158,275 was determined using the Black Scholes option pricing model based on the following assumptions:</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 92%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.05</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend rate</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5.00</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life (in years)</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.12</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 Units (see Note 3). The fair value of the corresponding overallotment liability partially extinguished upon exercise of $28,317 was determined using the Black Scholes option pricing model based on the following assumptions: </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 91%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 91%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.00</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life (in years)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.10</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the expiration of the unexercised overallotment options on September 9, 2021, the Company recorded a gain on the expiration of the overallotment option of $127,035. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss per Common Stock share </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” Net loss per share is computed by dividing net loss by the weighted average number of Common Stock shares outstanding during the period. Weighted average shares for the period from January 21, 2021 (inception) through December 31, 2021 were reduced for the effect of an aggregate of <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">562,500</div></div> Class B Common shares that were subject to forfeiture until the over-allotment option was partially exercised by the underwriters on August 3, 2021 (see Note 5), upon which date the forfeiture provision lapsed for 111,026 Class B Common shares. Subsequent to September 9, 2021, weighted average shares were reduced for the effect of an aggregate of 451,474 Class B Common shares which were ultimately forfeited upon the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">45-day</div> period reserved for the exercise of over-allotment option. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company’s statements of operations include a presentation of net loss per share subject to redemption in a manner similar to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method of income per share. With respect to the accretion of the Class A Shares subject to possible redemption and consistent with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99-3A,</div></div></div> the Company deemed the fair value of the Class A Common shares subject to possible redemption to approximate the contractual redemption value and the accretion has no impact on the calculation of net income/(loss) per share. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s Public Warrants (see Note 3) and Private Warrants (see Note 4) could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. However, these warrants were excluded when calculating diluted loss per share because such inclusion would be anti-dilutive for the periods presented. As a result, diluted loss per share is the same as basic loss per share for the period presented. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of net loss per share is as follows for the period from January 21 (Inception) through December 31, 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A subject to<br/> possible redemption</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of undistributable losses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(209,176</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,286</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(113,920</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income/(loss) to Common shares</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(209,176</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,286</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(113,920</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding, basic and diluted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,973,122</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">209,549</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,797,628</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering Costs </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Offering costs consist of underwriting, legal, accounting and other expenses incurred through the Initial Public Offering that are directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with the Public Shares were charged to shareholders’ equity upon the completion of the Initial Public Offering. Offering costs amounted to $9,897,599 at July 29, 2021, which were allocated between the Class A shares subject to possible redemption and the Public Warrants and charged to shareholders’ equity upon the completion of the Initial Public Offering. Under the guidance in Staff Accounting Bulletin 107 Topic 5.A, Accounting for Expenses or Liabilities Paid by Principal Stockholder(s), the Company included in these offering costs amounts incurred by the Sponsor through the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Risk</div> Incentive Private Shares (see Note 4) to Anchor Investors on behalf of the Company in the amount of $1,186,448. The initial public offering costs as of the IPO date were allocated $9,664,188 and $233,411 between the Class A shares subject to possible redemption and the Public Warrants (see Note 6), respectively, based on their relative fair values at the issuance date. The Company incurred an additional $92,070 offering costs of upon the partial exercise of the overallotment option on August 3, 2021. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total issuance costs of $10,145,105 were allocated to the Class A shares subject to possible redemption and the Public Warrants based on their relative fair values with $9,905,857 to the Class A shares subject to possible redemption and $239,247 to the Public Warrants. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements</div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 77%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">154,449,121</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The overallotment liability is measured at fair value using the Black Scholes Option Pricing Model with significant unobservable inputs. The fair value is based on the share price of the underlying shares and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. Therefore, the overallotment liability is considered to be a Level 3 financial instrument. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Overallotment<br/> liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 21, 2021 (inception)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of overallotment option</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">158,275 </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partial exercise of overallotment option</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,316</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in fair value of overallotment liability</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,924</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expiration of overallotment option</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(127,035</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December 31, 2021</div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> </tr> </table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of a cash account in a financial institution, which at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Standards </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company Status </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable Securities Held in Trust Account </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December 31, 2021, the assets held in the Trust Account were substantially held in U.S. Treasury Bills and U.S Treasury Coupons. During the period from January 21, 2021 (inception) through December 31, 2021, the Company did not withdraw any of interest income from the Trust Account to pay its tax obligations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock Subject to Possible Redemption </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as shareholders’ equity. The Company’s common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, as of December 31, 2021, 15,444,103 shares of Class A common stock subject to possible redemption are classified in temporary equity outside of the shareholders’ equity (deficit) section of the Company’s balance sheet and were immediately accreted to redemption value at the IPO date. </div></div> 15444103 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company issues warrants to its investors and accounts for warrant instruments as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Public Warrants (see Note 3) and Private Warrants (see Note 4) were accounted for as equity as these instruments meet all of the requirements for equity classification under ASC 815. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The over-allotment option (see Note 6) was deemed to be a freestanding financial instrument indexed to the contingently redeemable shares and was accounted for as a liability pursuant to ASC 480. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the overallotment liability at the IPO date of $158,275 was determined using the Black Scholes option pricing model based on the following assumptions:</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 92%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.05</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend rate</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5.00</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life (in years)</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.12</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2021, the Underwriters partially exercised their overallotment option and purchased 444,103 Units (see Note 3). The fair value of the corresponding overallotment liability partially extinguished upon exercise of $28,317 was determined using the Black Scholes option pricing model based on the following assumptions: </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 91%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 91%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.00</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life (in years)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.10</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the expiration of the unexercised overallotment options on September 9, 2021, the Company recorded a gain on the expiration of the overallotment option of $127,035. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the overallotment liability at the IPO date of $158,275 was determined using the Black Scholes option pricing model based on the following assumptions:</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 92%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.05</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend rate</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5.00</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">% </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life (in years)</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.12</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 91%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.00</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected life (in years)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.10</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> 158275 0.05 0 5.00 P0Y1M13D 444103 28317 0.05 0 5.00 P0Y1M6D 127035 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss per Common Stock share </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company complies with accounting and disclosure requirements of ASC Topic 260, “Earnings Per Share.” Net loss per share is computed by dividing net loss by the weighted average number of Common Stock shares outstanding during the period. Weighted average shares for the period from January 21, 2021 (inception) through December 31, 2021 were reduced for the effect of an aggregate of <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">562,500</div></div> Class B Common shares that were subject to forfeiture until the over-allotment option was partially exercised by the underwriters on August 3, 2021 (see Note 5), upon which date the forfeiture provision lapsed for 111,026 Class B Common shares. Subsequent to September 9, 2021, weighted average shares were reduced for the effect of an aggregate of 451,474 Class B Common shares which were ultimately forfeited upon the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">45-day</div> period reserved for the exercise of over-allotment option. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company’s statements of operations include a presentation of net loss per share subject to redemption in a manner similar to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method of income per share. With respect to the accretion of the Class A Shares subject to possible redemption and consistent with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99-3A,</div></div></div> the Company deemed the fair value of the Class A Common shares subject to possible redemption to approximate the contractual redemption value and the accretion has no impact on the calculation of net income/(loss) per share. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s Public Warrants (see Note 3) and Private Warrants (see Note 4) could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. However, these warrants were excluded when calculating diluted loss per share because such inclusion would be anti-dilutive for the periods presented. As a result, diluted loss per share is the same as basic loss per share for the period presented. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of net loss per share is as follows for the period from January 21 (Inception) through December 31, 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A subject to<br/> possible redemption</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of undistributable losses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(209,176</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,286</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(113,920</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income/(loss) to Common shares</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(209,176</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,286</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(113,920</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding, basic and diluted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,973,122</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">209,549</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,797,628</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 562500 111026 451474 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of net loss per share is as follows for the period from January 21 (Inception) through December 31, 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A subject to<br/> possible redemption</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class A</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class B</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of undistributable losses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(209,176</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,286</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(113,920</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income/(loss) to Common shares</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(209,176</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(6,286</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(113,920</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding, basic and diluted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,973,122</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">209,549</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,797,628</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> -209176 -6286 -113920 -209176 -6286 -113920 6973122 209549 3797628 -0.03 -0.03 -0.03 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering Costs </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Offering costs consist of underwriting, legal, accounting and other expenses incurred through the Initial Public Offering that are directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with the Public Shares were charged to shareholders’ equity upon the completion of the Initial Public Offering. Offering costs amounted to $9,897,599 at July 29, 2021, which were allocated between the Class A shares subject to possible redemption and the Public Warrants and charged to shareholders’ equity upon the completion of the Initial Public Offering. Under the guidance in Staff Accounting Bulletin 107 Topic 5.A, Accounting for Expenses or Liabilities Paid by Principal Stockholder(s), the Company included in these offering costs amounts incurred by the Sponsor through the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Risk</div> Incentive Private Shares (see Note 4) to Anchor Investors on behalf of the Company in the amount of $1,186,448. The initial public offering costs as of the IPO date were allocated $9,664,188 and $233,411 between the Class A shares subject to possible redemption and the Public Warrants (see Note 6), respectively, based on their relative fair values at the issuance date. The Company incurred an additional $92,070 offering costs of upon the partial exercise of the overallotment option on August 3, 2021. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total issuance costs of $10,145,105 were allocated to the Class A shares subject to possible redemption and the Public Warrants based on their relative fair values with $9,905,857 to the Class A shares subject to possible redemption and $239,247 to the Public Warrants. </div></div> 9897599 1186448 9664188 233411 92070 10145105 9905857 239247 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements</div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 5%;"> </td> <td style="width: 3%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 77%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">154,449,121</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The overallotment liability is measured at fair value using the Black Scholes Option Pricing Model with significant unobservable inputs. The fair value is based on the share price of the underlying shares and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. Therefore, the overallotment liability is considered to be a Level 3 financial instrument. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Overallotment<br/> liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 21, 2021 (inception)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of overallotment option</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">158,275 </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partial exercise of overallotment option</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,316</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in fair value of overallotment liability</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,924</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expiration of overallotment option</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(127,035</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December 31, 2021</div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> </tr> </table> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 77%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">154,449,121</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> 154449121 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Overallotment<br/> liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 21, 2021 (inception)</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of overallotment option</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">158,275 </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Partial exercise of overallotment option</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,316</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in fair value of overallotment liability</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,924</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expiration of overallotment option</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(127,035</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December 31, 2021</div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> </tr> </table> 0 158275 28316 -2924 127035 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. </div></div> 0 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of a cash account in a financial institution, which at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div></div> 250000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Standards </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3 — Initial Public Offering </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July 29, 2021, the Company sold 15,000,000 Units at $10.00 per Unit, generating gross proceeds of $150.0 million. Each unit consists of one share of Class A common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-fourth</div> of one redeemable warrant. Only whole warrants are exercisable. Each whole warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 455,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement to the Sponsor, generating gross proceeds of $4,550,000, which is described further in Note 4. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units for the total amount of $4,441,030, received on August 6, 2021. Resulting from the partial over-allotment exercise, the Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds. </div></div> 15000000 10.00 150000000.0 11.50 455000 10.00 4550000 444103 4441030 8882 88820 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4 — Related Party Transactions </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Founder Shares </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On January 21, 2021, the Sponsor subscribed to purchase 3,593,750 shares of the Company’s common stock, par value $0.0001 per share (the “Founder Shares”) for an aggregate price of $25,000. On January 25, 2021, the Sponsor paid $25,000, or approximately $0.00696 per share, to cover for certain offering and formation costs in consideration for 3,593,750 Founder Shares. On March 1, 2021, the Company effected a 1:1.2 stock split of its common stock which resulted in an aggregate of 4,312,500 shares of Class B common stock outstanding. All shares and associated amounts have been retroactively restated to reflect the stock split. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units out of the total 2,250,000 available under the over-allotments and the forfeiture provisions lapsed for 111,026 Founder Shares. The remaining 451,464 Founder Shares were forfeited upon the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">45-day</div> period reserved for the exercise of over-allotment option.<br/></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 27, 2021, our sponsor transferred 25,000 founder shares to each of Darlene DeRemer, Eugene Podsiadlo, and William Woodward. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on the Company’s board of directors through the closing of such initial business combination. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><br/></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At the IPO date, the Sponsor also transferred to certain investors a total of 225,000 of Founders shares (Note 4) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(“Non-Risk</div> Incentive Private Shares”) as a compensation for their commitment to purchase the Public Units sold in the IPO. The Company estimated the aggregate fair value of these shares to be $1,186,448, or $5.27 per share. The fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Risk</div> Incentive Private Shares was determined to be a contribution from the sponsor for offering costs in accordance with Staff Accounting Bulletin Topic 5T. These offering costs were allocated to the Units and charged to shareholder’s equity upon the completion of the Initial Public Offering. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At the IPO date, the Sponsor also transferred to certain other investors the total of 600,900 of Founders shares (“Risk Incentive Private Shares”) as a compensation for their commitment to acquire at least 9.9% of the Units sold in the IPO. These Risk Incentive Private Shares are subject to forfeiture if the investors sell their Units prior to the closing of the initial Business Combination. The fair value of these Risk Incentive Private Shares is equal to the fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Risk</div> Incentive Private Shares. Due to the high probability of forfeiture, the fair value of these Risk Incentive Private Shares will be recorded as a capital contribution from the Sponsor upon the closing of the initial Business Combination. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor, directors and executive officers have agreed not to transfer, assign or sell (i) any of their Founder Shares until the earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Company’s shares of Class A common stock equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of its public shareholders having the right to exchange their common stock for cash, securities or other property, and (ii) any of their Private Placement Units, placement shares, Private Placement Warrants and Class A common stock issued upon conversion or exercise thereof until 30 days after the completion of the initial Business Combination (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“Lock-up”).</div> Any permitted transferees will be subject to the same restrictions and other agreements of the Sponsor and directors and executive officers with respect to any Founder Shares, Private Placement Units, placement shares, Private Placement Warrants and Class A common stock issued upon conversion or exercise thereof. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Placement </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased 455,000 placement units, at a purchase price of $4,550,000, in a private placement. Each Private Placement Unit is identical to the Units sold in the Initial Public Offering except as described below. A portion of the proceeds from the Private Placement Units was added to the proceeds from the Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the partial over-allotment exercise on August 3, 2021, the Company also issued 8,882 Private Placement Units, generating additional $88,820 in gross proceeds. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Units (including the placement shares, the placement warrants and Class A common stock issuable upon exercise of such placement warrants) will not be transferable or salable until 30 days after the completion of our Business Combination (except, among other limited exceptions, to our officers and directors and other persons or entities affiliated with our Sponsor). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Promissory Note — Related Party </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On January 25, 2021, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $300,000 to be used for a portion of the expenses of the Proposed Public Offering. This loan was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing, unsecured, and was due at the earlier of (i) the date on which the Company consummates the initial public offering and (ii) the date on which the Company determines not to conduct an initial public offering of its securities, upon request from the Company the Sponsor. Through the date of the Initial Public Offering, the Company had no borrowings under the promissory note. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to Related Party </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The balance of $2,275 as of December 31, 2021, represents general and administrative costs paid by the Sponsor on behalf of the Company. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative Service Fee</div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has agreed, commencing on the date that the Company’s securities are first listed on the Nasdaq, to pay an affiliate of the Sponsor a monthly fee of an aggregate of $10,000 for office space, administrative and support services. For the period from January 21, 2021 (inception) through December 31, 2021, administrative fees incurred and paid to the Sponsor totaled $51,000. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Loans </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon consummation of a Business Combination into warrants at a price of $1.50 per warrant. The warrants will be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of December 31, 2021, there were no written agreements in place for the Working Capital Loans. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the IPO activities, on July 14, 2021 (the “Inception Date”), the Company and its Sponsor entered into the Subscription Agreements with certain investors (see Note 5).</div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forward Purchase Agreement </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company granted to the direct anchor investors an option, in their sole discretion, to subscribe to a forward purchase agreement for up to an aggregate of 60% (up to 10% per direct anchor investor) of the securities sold in one or multiple private placements to close prior to or concurrently with the closing of the initial business combination. The aggregate proceeds from the sale of any securities pursuant to these forward purchase agreements will be used for purposes related to the initial business combination. </div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since the issuance of the securities to the investors is contingent upon the closing of an equity financing in relation to the initial business combination, the terms of the forward purchase agreement will not create an obligation for either party until such financing occurs. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> 3593750 0.0001 25000 25000 0.00696 3593750 1:1.2 4312500 444103 2250000 111026 451464 P45D 25000 25000 25000 225000 1186448 5.27 600900 0.099 12.00 P20D P30D P150D 455000 4550000 8882 88820 300000 0 2275 10000 51000 1500000 1.50 0 0.60 0.10 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5 — Commitments &amp; Contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration Rights </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The holders of the Founder Shares, Private Placement Units, Private Placement Warrants, Class A common stock underlying the Private Placement Warrants and Private Placement Units that may be issued upon conversion of Working Capital Loans (and any shares or Class A common stock issuable upon the exercise of the Private Placement Warrants and Private Placement Units that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration rights agreement dated July 26, 2021. The holders of these securities are entitled to make unlimited demands that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period, which occurs (i) in the case of the Founder Shares, as described in the following paragraph, and (ii) in the case of the Private Placement Warrants and the respective shares of Class A common stock underlying such warrants, 30 days after the completion of the Company’s initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underwriters Agreement </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company granted the underwriters a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">45-day</div> option from July 26, 2021, to purchase up to 2,250,000 additional Units to cover over-allotments, if any, at the Public Offering price less the underwriting discounts and commissions. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units for the total amount of $4,441,030. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters received a cash underwriting discount of two percent (2.0%) of the gross proceeds of the Public Offering, or $3,000,000, paid on July 29, 2021. Additionally, in connection with the partial over-allotment exercise, the underwriters received a cash underwriting discount of two percent (2.0%) of the gross proceeds, or $88,820, paid on August 6, 2021. In addition to the cash underwriting discounts, the underwriters will be entitled to a deferred underwriting fee of three and a half percent (3.5%), or $5,405,436 of the gross proceeds of the Public Offering and the underwriters’ partial over-allotment exercise upon the completion of the Company’s initial Business Combination. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subscription Agreements </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the IPO activities, on July 14, 2021 (the “Inception Date”), the Company and its Sponsor entered into the Subscription Agreements with certain investors. Under these Subscription Agreements, the investors, who received the At Risk Incentive Private Shares, received the right but not the obligation to subscribe, at their sole discretion, to any equity financing associated with the Closing of the initial Business Combination subject to a maximum of 10% of such offerings’ proceeds, and the right but not the obligation to subscribe, at their sole discretion, at the same terms in the next special purpose acquisition company or other similar entity sponsored by Constellation Alpha Holdings. The investors who received the Non Risk Incentive Private Shares also received the right but not the obligation to subscribe, at their sole discretion, to any equity financing associated with the Closing of the SPAC’s initial Business Combination subject to a maximum of 10% of such offerings’ proceeds if the Investor still holds their Public Shares at the business combination date. Since the number of shares or other instruments to be purchase by the investors is unknown, these rights to participate in future offerings do not meet definition of an equity contract. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management is currently evaluating the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> 2250000 444103 4441030 0.020 3000000 0.020 88820 0.035 5405436 0.10 0.10 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6 — Shareholder’s Equity </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock —</div></div> On January 25, 2021, the Company issued 3,593,750 shares of common stock, including an aggregate of up to 468,750 shares of common stock that were subject to forfeiture, to the Company by the initial shareholders for no consideration to the extent that the underwriters’ over- allotment option is not exercised in full or in part, so that the initial shareholders will collectively own 20% of the Company’s issued and outstanding common stock after the Proposed Public Offering. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 1, 2021, the Company amended its charter to authorize issuance of 100,000,000 Class A common stock, with a par value of $0.0001 per share, 10,000,000 Class B common stock, with a par value of $0.0001 per share, and 1,000,000 preferred stock, with a par value of $0.0001 per share, and effected a 1:1.2 stock split of its common stock which resulted in an aggregate of 4,312,500 shares of Class B common stock outstanding All shares and per share amounts have been retroactively restated to reflect the stock split. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July 29, 2021, the Company sold 15,000,000 Units, each unit consists of one share of Class A common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-fourth</div> of one redeemable warrant. On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On August 3, 2021, the Underwriters exercised their option to purchase 444,103 additional Units out of the total 2,250,000 available under the over-allotments and the forfeiture term lapsed for 111,026 Founder Shares. The remaining 451,464 Founder Shares were forfeited upon the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">45-day</div> period reserved for the exercise of over-allotment option. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December 31, 2021, there were (i) 15,907,985 shares of Class A common stock issued and outstanding (including 15,444,103 shares subject to possible redemption) and (ii) 3,861,026 shares of Class B common stock issued and outstanding. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Both Class A and B shareholders vote together as a single class on all matters submitted to a vote of the Company shareholders, with each share of common stock entitling the holder to one vote. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the initial Business Combination on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div> basis (subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like), and subject to further adjustment as provided herein. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in the Proposed Public Offering and related to the closing of the Business Combination, including pursuant to a specified future issuance, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless our Sponsor agrees to waive such adjustment with respect to any such issuance or deemed issuance, including a specified future issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, 20% of the sum of the total number of all shares of common stock outstanding upon completion of the Proposed Public Offering plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with the Business Combination (after giving effect to any redemptions of shares of Class A common stock by public shareholders) (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the Business Combination and any Private Placement Units issued to our Sponsor, officers or directors upon conversion of Working Capital Loans). The Sponsor may also elect to convert their shares of Class B common stock into an equal number of shares of Class A common stock, subject to adjustment as provided above, at any time. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Preferred Stock –</div></div> The Company is authorized to issue 1,000,000 shares of preferred stock, with a par value of $0.0001 per share. At December 31, 2021, there were no shares of preferred stock issued or outstanding. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants –</div></div> The warrants may only be exercised for a whole number of shares. The warrants included in the units sold in the Public Offering (the “Public Warrants”) will become exercisable 30 days after the completion of a Business Combination provided that the Company has an effective registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their Public Warrants on a cashless basis and such cashless exercise is exempt from registration under the Securities Act). The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of the initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC and have an effective registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. If a registration statement covering the issuance of the Class A common stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional shares of Class A common stock or equity- linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance), or the Newly Issued Price, (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, respectively. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants and the shares of Class A common stock issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00: Once the warrants become exercisable, the Company may redeem the outstanding warrants for cash: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 10%;"> </td> <td style="width: 2%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 10%;"> </td> <td style="width: 2%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 10%;"> </td> <td style="width: 2%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon a minimum of 30 days’ prior written notice of redemption; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 10%;"> </td> <td style="width: 2%; vertical-align: top;;text-align:left;">•</td> <td style="width: 1%; vertical-align: top;"> </td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the closing price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like and for certain issuances of Class A common stock and equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination) for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”). </div> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Company will not redeem the warrants unless an effective registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A common stock is available throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> redemption period. </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </div></div> 3593750 468750 0.20 100000000 0.0001 10000000 0.0001 1000000 0.0001 1:1.2 4312500 15000000 444103 444103 2250000 111026 451464 15907985 15907985 15444103 3861026 3861026 0.20 1000000 0.0001 0 0 11.50 P5Y 9.20 0.60 9.20 1.15 18.00 18.00 1.80 18.00 0.01 P30D 18.00 P20D P30D P30D <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7 — Income Taxes </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company’s general and administrative expenses are generally considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> costs and are not currently deductible. During the period from January 21, 2021 (inception) to December 31, 2021, no income tax expense was recorded. The Company’s effective tax rate for the period from January 21, 2021 (inception) through December 31, 2021 was zero percent, which differs from the expected income tax rate due predominantly to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> costs which are not currently deductible. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The income tax provision consisted of the following as of December 31, 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(96,461</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap; width: 7%; padding: 0pt 5pt 0pt 0pt;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96,461</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s net deferred tax assets consist of the following as of December 31, 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,531</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Organizational costs/startup expenses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,930</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax asset</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96,461 </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(96,461</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax asset, net of valuation allowance</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2021, the Company has U.S. federal net operating loss carryovers of $159,673<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">that do not expire. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the year ended December 31, 2021, the change in the valuation allowance was $96,461. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no unrecognized tax benefits as of December 31, 2021. No amounts were accrued for the payment of interest and penalties at December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the federal income tax rate to the Company’s effective tax rate at December 31, 2021 is as follows:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 92%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory federal income tax rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of overallotment liability</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">8.3 </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in valuation allowance</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(29.3</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)</td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective tax rate</div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company files U.S. federal income tax returns and is subject to examination since inception. </div></div> 0 0 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The income tax provision consisted of the following as of December 31, 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(96,461</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap; width: 7%; padding: 0pt 5pt 0pt 0pt;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96,461</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 0 -96461 0 0 -96461 0 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s net deferred tax assets consist of the following as of December 31, 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,531</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Organizational costs/startup expenses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,930</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax asset</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96,461 </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(96,461</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax asset, net of valuation allowance</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> 33531 -62930 96461 96461 0 159673 96461 0 0 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the federal income tax rate to the Company’s effective tax rate at December 31, 2021 is as follows:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 92%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory federal income tax rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of overallotment liability</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">8.3 </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Change in valuation allowance</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(29.3</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)</td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective tax rate</div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> </tr> </table> 0.210 0.083 -0.293 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8 — Stock-based Compensation </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 27, 2021, the Sponsor transferred 25,000 shares of Class B common stock to each of the three independent director nominees as compensation for their service on the board of directors. The awards will vest simultaneously with the closing of an initial business combination, provided the director has continuously served on the Company’s board of directors through the closing of such initial business combination. As such, the service period for these awards will start on the IPO date. As the share awards would vest only upon the consummation on a business combination, the compensation expense in relation to these grants would be not recognized until the closing of the initial business combination. As a result, the Company recorded no compensation expense for the period from January 21, 2021 (inception) through December 31, 2021. </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Founder Shares on the grant date was approximately $5.26 per share. The valuation performed by the Company determined the fair value of the Founder Shares on the date of grant based on the fair value of the Class A shares discounted for a) the probability of a successful business combination, and b) the lack of marketability. The aggregate grant date fair value of the award amounted to approximately $394,000. </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the restricted stock award and restricted unit activity for the period from January 21, 2021 (inception) through December 31, 2021 is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 90%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/> of<br/> Shares</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested Shares Outstanding at January 21, 2021 (inception)</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">75,000</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested Outstanding at December 31, 2021</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">75,000</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> </table> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total<div style="display:inline;"> </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px;;display:inline;">unrecognized compensation expense related to unvested Founder Shares at December 31, 2021 amounted to approximately $</div>394,000<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px;;display:inline;"> and is expected to be recognized upon the initial business combination.</div></div> 25000 0 5.26 394000 <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the restricted stock award and restricted unit activity for the period from January 21, 2021 (inception) through December 31, 2021 is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 90%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/> of<br/> Shares</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested Shares Outstanding at January 21, 2021 (inception)</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">75,000</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested Outstanding at December 31, 2021</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">75,000</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> </table> 0 75000 0 0 75000 394000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9 — Subsequent Events </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company did not identify any subsequent events that require adjustment or disclosure in the financial statements. </div></div></div> An aggregate of 4,312,500 shares of Class B common stock were originally issued, of which 562,500 shares were subject to forfeiture depending on whether the over-allotment option was exercised in full or in part by the underwriters during the 45-day option period. As a result of a partial over-allotment option exercise by the underwriters, an aggregate of 451,474 shares were forfeited at the end of the 45-day option period. EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 113 247 1 true 41 0 false 7 false false R1.htm 1001 - Document - Cover Page Sheet http://www.constellationalpha.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Balance Sheet Sheet http://www.constellationalpha.com/role/BalanceSheet Balance Sheet Statements 2 false false R3.htm 1003 - Statement - Balance Sheet (Parenthetical) Sheet http://www.constellationalpha.com/role/BalanceSheetParenthetical Balance Sheet (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Statement of Operations Sheet http://www.constellationalpha.com/role/StatementOfOperations Statement of Operations Statements 4 false false R5.htm 1005 - Statement - Statement Of Changes In Shareholders' Equity (Deficit) Sheet http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit Statement Of Changes In Shareholders' Equity (Deficit) Statements 5 false false R6.htm 1006 - Statement - Statement Of Changes In Shareholders' Equity (Deficit) (Parenthetical) Sheet http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical Statement Of Changes In Shareholders' Equity (Deficit) (Parenthetical) Statements 6 false false R7.htm 1007 - Statement - Statement of Cash Flows Sheet http://www.constellationalpha.com/role/StatementOfCashFlows Statement of Cash Flows Statements 7 false false R8.htm 1008 - Disclosure - Organization and Business Operations Sheet http://www.constellationalpha.com/role/OrganizationAndBusinessOperations Organization and Business Operations Notes 8 false false R9.htm 1009 - Disclosure - Significant Accounting Policies Sheet http://www.constellationalpha.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 1010 - Disclosure - Initial Public Offering Sheet http://www.constellationalpha.com/role/InitialPublicOffering Initial Public Offering Notes 10 false false R11.htm 1011 - Disclosure - Related Party Transactions Sheet http://www.constellationalpha.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 1012 - Disclosure - Commitments & Contingencies Sheet http://www.constellationalpha.com/role/CommitmentsContingencies Commitments & Contingencies Notes 12 false false R13.htm 1013 - Disclosure - Shareholder's Equity Sheet http://www.constellationalpha.com/role/ShareholderSEquity Shareholder's Equity Notes 13 false false R14.htm 1014 - Disclosure - Income Taxes Sheet http://www.constellationalpha.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 1015 - Disclosure - Stock-based Compensation Sheet http://www.constellationalpha.com/role/StockBasedCompensation Stock-based Compensation Notes 15 false false R16.htm 1016 - Disclosure - Subsequent Events Sheet http://www.constellationalpha.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 1017 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.constellationalpha.com/role/SignificantAccountingPolicies 17 false false R18.htm 1018 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.constellationalpha.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.constellationalpha.com/role/SignificantAccountingPolicies 18 false false R19.htm 1019 - Disclosure - Income Taxes (Tables) Sheet http://www.constellationalpha.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.constellationalpha.com/role/IncomeTaxes 19 false false R20.htm 1020 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.constellationalpha.com/role/StockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.constellationalpha.com/role/StockBasedCompensation 20 false false R21.htm 1021 - Disclosure - Organization and Business Operations - Additional Information (Detail) Sheet http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail Organization and Business Operations - Additional Information (Detail) Details 21 false false R22.htm 1022 - Disclosure - Significant Accounting Policies - Additional Information (Detail) Sheet http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail Significant Accounting Policies - Additional Information (Detail) Details 22 false false R23.htm 1023 - Disclosure - Significant Accounting Policies - Schedule of Fair Value of the Overallotment Liability (Detail) Sheet http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueOfTheOverallotmentLiabilityDetail Significant Accounting Policies - Schedule of Fair Value of the Overallotment Liability (Detail) Details 23 false false R24.htm 1024 - Disclosure - Significant Accounting Policies - Schedule of Reconciliation of Net Loss per Share (Detail) Sheet http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfReconciliationOfNetLossPerShareDetail Significant Accounting Policies - Schedule of Reconciliation of Net Loss per Share (Detail) Details 24 false false R25.htm 1025 - Disclosure - Significant Accounting Policies - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Detail) Sheet http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetail Significant Accounting Policies - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Detail) Details 25 false false R26.htm 1026 - Disclosure - Significant Accounting Policies - Schedule of Changes in Level&#160;3 Liabilities Measured at Fair Value on a Recurring Basis (Detail) Sheet http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueOnARecurringBasisDetail Significant Accounting Policies - Schedule of Changes in Level&#160;3 Liabilities Measured at Fair Value on a Recurring Basis (Detail) Details 26 false false R27.htm 1027 - Disclosure - Initial Public Offering - Additional information (Detail) Sheet http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail Initial Public Offering - Additional information (Detail) Details 27 false false R28.htm 1028 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 28 false false R29.htm 1029 - Disclosure - Commitments & Contingencies - Additional Information (Detail) Sheet http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail Commitments & Contingencies - Additional Information (Detail) Details 29 false false R30.htm 1030 - Disclosure - Shareholder's Equity - Additional Information (Detail) Sheet http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail Shareholder's Equity - Additional Information (Detail) Details 30 false false R31.htm 1031 - Disclosure - Income Taxes - Schedule of Income Tax Provision (Detail) Sheet http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail Income Taxes - Schedule of Income Tax Provision (Detail) Details 31 false false R32.htm 1032 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Detail) Sheet http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail Income Taxes - Schedule of Net Deferred Tax Assets (Detail) Details 32 false false R33.htm 1033 - Disclosure - Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate To The Company's Effective Tax Rate (Detail) Sheet http://www.constellationalpha.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanySEffectiveTaxRateDetail Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate To The Company's Effective Tax Rate (Detail) Details 33 false false R34.htm 1034 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 34 false false R35.htm 1035 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Award and Restricted Unit Activity (Detail) Sheet http://www.constellationalpha.com/role/StockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedUnitActivityDetail Stock-based Compensation - Summary of Restricted Stock Award and Restricted Unit Activity (Detail) Details 35 false false R36.htm 1036 - Disclosure - Stock-based Compensation - Additional Information (Detail) Sheet http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail Stock-based Compensation - Additional Information (Detail) Details 36 false false All Reports Book All Reports d268885d10k.htm alpau-20211231.xsd alpau-20211231_cal.xml alpau-20211231_def.xml alpau-20211231_lab.xml alpau-20211231_pre.xml d268885dex311.htm d268885dex312.htm d268885dex321.htm d268885dex322.htm d268885dex45.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d268885d10k.htm": { "axisCustom": 2, "axisStandard": 12, "contextCount": 113, "dts": { "calculationLink": { "local": [ "alpau-20211231_cal.xml" ] }, "definitionLink": { "local": [ "alpau-20211231_def.xml" ] }, "inline": { "local": [ "d268885d10k.htm" ] }, "labelLink": { "local": [ "alpau-20211231_lab.xml" ] }, "presentationLink": { "local": [ "alpau-20211231_pre.xml" ] }, "schema": { "local": [ "alpau-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 371, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 4, "total": 4 }, "keyCustom": 77, "keyStandard": 170, "memberCustom": 20, "memberStandard": 19, "nsprefix": "alpau", "nsuri": "http://www.constellationalpha.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.constellationalpha.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "alpau:InitialPublicOfferingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Initial Public Offering", "role": "http://www.constellationalpha.com/role/InitialPublicOffering", "shortName": "Initial Public Offering", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "alpau:InitialPublicOfferingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Related Party Transactions", "role": "http://www.constellationalpha.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Commitments & Contingencies", "role": "http://www.constellationalpha.com/role/CommitmentsContingencies", "shortName": "Commitments & Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Shareholder's Equity", "role": "http://www.constellationalpha.com/role/ShareholderSEquity", "shortName": "Shareholder's Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Income Taxes", "role": "http://www.constellationalpha.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Stock-based Compensation", "role": "http://www.constellationalpha.com/role/StockBasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Subsequent Events", "role": "http://www.constellationalpha.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "alpau:DerivativeFinancialInstrumentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Significant Accounting Policies (Tables)", "role": "http://www.constellationalpha.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "alpau:DerivativeFinancialInstrumentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Income Taxes (Tables)", "role": "http://www.constellationalpha.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Balance Sheet", "role": "http://www.constellationalpha.com/role/BalanceSheet", "shortName": "Balance Sheet", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Stock-based Compensation (Tables)", "role": "http://www.constellationalpha.com/role/StockBasedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Organization and Business Operations - Additional Information (Detail)", "role": "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "shortName": "Organization and Business Operations - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "lang": "en-US", "name": "alpau:RestrictedInvestmentsTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021", "decimals": "0", "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "alpau:DerivativeFinancialInstrumentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn08_03_2021_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis", "decimals": "2", "first": true, "lang": null, "name": "alpau:FairValueOfOverallotmentLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Significant Accounting Policies - Schedule of Fair Value of the Overallotment Liability (Detail)", "role": "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueOfTheOverallotmentLiabilityDetail", "shortName": "Significant Accounting Policies - Schedule of Fair Value of the Overallotment Liability (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "alpau:DerivativeFinancialInstrumentsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn08_03_2021_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis", "decimals": "2", "first": true, "lang": null, "name": "alpau:FairValueOfOverallotmentLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Significant Accounting Policies - Schedule of Reconciliation of Net Loss per Share (Detail)", "role": "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfReconciliationOfNetLossPerShareDetail", "shortName": "Significant Accounting Policies - Schedule of Reconciliation of Net Loss per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021_ClassACommonStockSubjectToPossibleRedemptionMemberusgaapStatementClassOfStockAxis", "decimals": "0", "lang": null, "name": "us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Significant Accounting Policies - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Detail)", "role": "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetail", "shortName": "Significant Accounting Policies - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn01_20_2021_OverallotmentLiabilityMemberusgaapFinancialInstrumentAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Significant Accounting Policies - Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis (Detail)", "role": "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueOnARecurringBasisDetail", "shortName": "Significant Accounting Policies - Schedule of Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn01_20_2021_OverallotmentLiabilityMemberusgaapFinancialInstrumentAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Initial Public Offering - Additional information (Detail)", "role": "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "shortName": "Initial Public Offering - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "alpau:InitialPublicOfferingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn07_29_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis", "decimals": "2", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Related Party Transactions - Additional Information (Detail)", "role": "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn01_21_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockSharesSubscribedButUnissued", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn07_14_2021_MaximumMembersrtRangeAxis_NonriskIncentivePrivateSharesMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis", "decimals": "2", "first": true, "lang": null, "name": "alpau:PercentageOfOwnershipSharesThroughInitialBusinessCombination", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Commitments & Contingencies - Additional Information (Detail)", "role": "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "shortName": "Commitments & Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn07_14_2021_MaximumMembersrtRangeAxis_NonriskIncentivePrivateSharesMemberusgaapStatementClassOfStockAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis", "decimals": "2", "first": true, "lang": null, "name": "alpau:PercentageOfOwnershipSharesThroughInitialBusinessCombination", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Balance Sheet (Parenthetical)", "role": "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "shortName": "Balance Sheet (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis", "decimals": "INF", "lang": null, "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Shareholder's Equity - Additional Information (Detail)", "role": "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "shortName": "Shareholder's Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021", "decimals": "2", "lang": null, "name": "alpau:VolumeWeightedAveragePriceOfShares", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Income Taxes - Schedule of Income Tax Provision (Detail)", "role": "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail", "shortName": "Income Taxes - Schedule of Income Tax Provision (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Detail)", "role": "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail", "shortName": "Income Taxes - Schedule of Net Deferred Tax Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate To The Company's Effective Tax Rate (Detail)", "role": "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanySEffectiveTaxRateDetail", "shortName": "Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate To The Company's Effective Tax Rate (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn01_20_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Award and Restricted Unit Activity (Detail)", "role": "http://www.constellationalpha.com/role/StockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedUnitActivityDetail", "shortName": "Stock-based Compensation - Summary of Restricted Stock Award and Restricted Unit Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn01_20_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Stock-based Compensation - Additional Information (Detail)", "role": "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail", "shortName": "Stock-based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "alpau:FormationGeneralAndAdministrativeExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Statement of Operations", "role": "http://www.constellationalpha.com/role/StatementOfOperations", "shortName": "Statement of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "alpau:FormationGeneralAndAdministrativeExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn01_20_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Statement Of Changes In Shareholders' Equity (Deficit)", "role": "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "shortName": "Statement Of Changes In Shareholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "PAsOn01_20_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Statement Of Changes In Shareholders' Equity (Deficit) (Parenthetical)", "role": "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical", "shortName": "Statement Of Changes In Shareholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis", "decimals": "0", "lang": null, "name": "alpau:IssuanceCostsOfWarrants", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - Statement of Cash Flows", "role": "http://www.constellationalpha.com/role/StatementOfCashFlows", "shortName": "Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Organization and Business Operations", "role": "http://www.constellationalpha.com/role/OrganizationAndBusinessOperations", "shortName": "Organization and Business Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Significant Accounting Policies", "role": "http://www.constellationalpha.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d268885d10k.htm", "contextRef": "P01_21_2021To12_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 41, "tag": { "alpau_AccretionOfInterestEarnedInTheTrustAccountAccruedToTemporaryEquityShareholders": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accretion of interest earned in the trust account accrued to temporary.", "label": "Accretion Of Interest Earned In The Trust Account Accrued To Temporary Equity Shareholders", "terseLabel": "Accretion of the interest earned in trust account" } } }, "localname": "AccretionOfInterestEarnedInTheTrustAccountAccruedToTemporaryEquityShareholders", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alpau_AccretionToRedemptionValueOfClassACommonStockSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accretion to redemption value of Class\u00a0A Common stock subject to possible redemption.", "label": "Accretion To Redemption Value Of Class A Common Stock Subject To Possible Redemption", "terseLabel": "Accretion to redemption value of Class\u00a0A Common stock subject to possible redemption" } } }, "localname": "AccretionToRedemptionValueOfClassACommonStockSubjectToPossibleRedemption", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "alpau_AccruedOfferingCosts": { "auth_ref": [], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued offering costs.", "label": "Accrued Offering Costs", "terseLabel": "Accrued offering costs" } } }, "localname": "AccruedOfferingCosts", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "alpau_AccruedUnderwritingFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued underwriting fees.", "label": "Accrued Underwriting Fees", "terseLabel": "Accrued underwriting fees" } } }, "localname": "AccruedUnderwritingFees", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjusted exercise price of warrants as a percentage of newly issued price.", "label": "Adjusted Exercise Price Of Warrants As A Percentage Of Newly Issued Price", "verboseLabel": "Adjusted exercise price of warrants as a percentage of newly issued price" } } }, "localname": "AdjustedExercisePriceOfWarrantsAsAPercentageOfNewlyIssuedPrice", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alpau_AdjustedExercisePriceOfWarrantsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjusted exercise price of warrants.", "label": "Adjusted Exercise Price Of Warrants [Axis]" } } }, "localname": "AdjustedExercisePriceOfWarrantsAxis", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alpau_AdjustedExercisePriceOfWarrantsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjusted exercise price of warrants.", "label": "Adjusted Exercise Price Of Warrants [Domain]" } } }, "localname": "AdjustedExercisePriceOfWarrantsDomain", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_AdjustmentsToAdditionalPaidInCapitalFairValueOfUnderwriterOverallotmentOptionsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital fair value of underwriter overallotment options exercised.", "label": "Adjustments To Additional Paid In Capital Fair Value Of Underwriter Overallotment Options Exercised", "terseLabel": "Fair value of underwriter's overallotment options exercised" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalFairValueOfUnderwriterOverallotmentOptionsExercised", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "alpau_AgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement.", "label": "Agreement [Axis]" } } }, "localname": "AgreementAxis", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alpau_AgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement.", "label": "Agreement [Domain]" } } }, "localname": "AgreementDomain", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_CapitalContributionByTheSponsorThroughTransferOfClassBShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Capital contribution by the Sponsor through transfer of Class B shares.", "label": "Capital contribution by the Sponsor through transfer of Class B shares" } } }, "localname": "CapitalContributionByTheSponsorThroughTransferOfClassBShares", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alpau_CashUnderwritingDiscountPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash underwriting discount percent.", "label": "Cash Underwriting Discount Percent", "verboseLabel": "Cash underwriting discount percent" } } }, "localname": "CashUnderwritingDiscountPercent", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alpau_ChangeInFairValueOfOverallotmentLiability": { "auth_ref": [], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.constellationalpha.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of overallotment liability.", "label": "Change In Fair Value Of Overallotment Liability", "negatedLabel": "Change in fair value of overallotment liability", "terseLabel": "Change in fair value of overallotment liability" } } }, "localname": "ChangeInFairValueOfOverallotmentLiability", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows", "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "alpau_ChangeInValueOfTemporaryEquityDueToDividendAndInterestEarned": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in value of temporary equity due to dividend and interest earned.", "label": "Change In Value Of Temporary Equity Due To Dividend And Interest Earned", "terseLabel": "Change in redemption value of Class\u00a0A Common stock subject to possible redemption due to dividend and interest income earned" } } }, "localname": "ChangeInValueOfTemporaryEquityDueToDividendAndInterestEarned", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "alpau_ClassACommonStockSubjectToPossibleRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class A Common Stock Subject To Possible Redemption [Member].", "label": "Class A Common Stock Subject To Possible Redemption [Member]", "terseLabel": "Class A Common Stock Subject To Possible Redemption [Member]" } } }, "localname": "ClassACommonStockSubjectToPossibleRedemptionMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfReconciliationOfNetLossPerShareDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "alpau_ClassOfWarrantsAndRightsIssuedDuringThePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants and rights issued during the period.", "label": "Class Of Warrants And Rights Issued During The Period", "verboseLabel": "Class of warrants and rights issued during the period" } } }, "localname": "ClassOfWarrantsAndRightsIssuedDuringThePeriod", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alpau_ClassOfWarrantsAndRightsIssuedPricePerWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants and rights issued price per warrant.", "label": "Class Of Warrants And Rights Issued Price Per Warrant", "verboseLabel": "Class Of Warrants and Rights Issued, Price Per Warrant" } } }, "localname": "ClassOfWarrantsAndRightsIssuedPricePerWarrant", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "alpau_ClassOfWarrantsOrRightsRedemptionPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrants or rights redemption price per unit.", "label": "Class Of Warrants Or Rights Redemption Price Per Unit", "verboseLabel": "Class of warrants or rights redemption price per unit" } } }, "localname": "ClassOfWarrantsOrRightsRedemptionPricePerUnit", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "alpau_CommonStockForfeitureProvisionsLapsed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock forfeiture provisions lapsed.", "label": "Common Stock Forfeiture Provisions Lapsed", "verboseLabel": "Common Stock forfeiture provisions lapsed" } } }, "localname": "CommonStockForfeitureProvisionsLapsed", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alpau_CommonStockSharesForWhichTheForfeitureOptionExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commonk shares for which the forfeiture option expired.", "label": "Common Stock Shares For Which The Forfeiture Option Expired", "verboseLabel": "Common stock shares for which the forfeiture option expired" } } }, "localname": "CommonStockSharesForWhichTheForfeitureOptionExpired", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alpau_CommonStockSharesSubjectToForfeiture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares subject to forfeiture.", "label": "Common Stock Shares Subject To Forfeiture", "verboseLabel": "Common Stock Shares Subject To Forfeiture" } } }, "localname": "CommonStockSharesSubjectToForfeiture", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical" ], "xbrltype": "sharesItemType" }, "alpau_CommonStockSubjectToPossibleRedemptionPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock subject to possible redemption [Policy text block].", "label": "Common Stock Subject To Possible Redemption [Policy Text Block]", "terseLabel": "Common Stock Subject to Possible Redemption" } } }, "localname": "CommonStockSubjectToPossibleRedemptionPolicyTextBlock", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "alpau_DarleneDeRemerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Darlene De Remer [Member]", "terseLabel": "Darlene DeRemer [Member]" } } }, "localname": "DarleneDeRemerMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_DeferredOfferingCostsCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs current and noncurrent.", "label": "Deferred Offering Costs Current And Noncurrent", "verboseLabel": "Deferred Offering Costs Current And Noncurrent" } } }, "localname": "DeferredOfferingCostsCurrentAndNoncurrent", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_DeferredTaxAssetsOrganizationalCostsStartupExpenses": { "auth_ref": [], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets organizational costs startup expenses.", "label": "Deferred Tax Assets Organizational Costs Startup Expenses", "negatedLabel": "Organizational costs/startup expenses" } } }, "localname": "DeferredTaxAssetsOrganizationalCostsStartupExpenses", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "alpau_DeferredUnderwritingFeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred underwriting fee percent.", "label": "Deferred Underwriting Fee Percent", "verboseLabel": "Deferred underwriting fee percent" } } }, "localname": "DeferredUnderwritingFeePercent", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alpau_DeferredUnderwritingFeesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting fees payable.", "label": "Deferred Underwriting Fees Payable", "terseLabel": "Deferred underwriting fee payable" } } }, "localname": "DeferredUnderwritingFeesPayable", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alpau_DeferredUnderwritingFeesPayableNoncurrent": { "auth_ref": [], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 10.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting fees payable noncurrent.", "label": "Deferred Underwriting Fees Payable Noncurrent", "terseLabel": "Deferred underwriting fees payable" } } }, "localname": "DeferredUnderwritingFeesPayableNoncurrent", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "alpau_DerivativeFinancialInstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative financial instruments.", "label": "Derivative Financial Instruments [Policy Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeFinancialInstrumentsPolicyTextBlock", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "alpau_DisclosureOfCompensationRelatedCostsShareBasedPaymentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Share Based Payments [Line Items]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsLineItems", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alpau_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Share Based Payments [Table]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTable", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alpau_EarningsPerShareStockSubjectToPossibleRedemptionBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings per share stock subject to possible redemption basic and diluted.", "label": "Earnings Per Share Stock Subject To Possible Redemption Basic And Diluted", "terseLabel": "Basic and diluted net loss per share, Class A common stock subject to possible redemption" } } }, "localname": "EarningsPerShareStockSubjectToPossibleRedemptionBasicAndDiluted", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "perShareItemType" }, "alpau_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfOverallotmentLiability": { "auth_ref": [], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanySEffectiveTaxRateDetail": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income fax rate reconciliation change in fair value of overallotment liability.", "label": "Effective Income Tax Rate Reconciliation Change In Fair Value Of Overallotment Liability", "terseLabel": "Change in fair value of overallotment liability" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfOverallotmentLiability", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanySEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "alpau_EmergingGrowthCompanyStatusPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for emerging growth company status.", "label": "Emerging Growth Company Status [Policy Text Block]", "verboseLabel": "Emerging Growth Company Status" } } }, "localname": "EmergingGrowthCompanyStatusPolicyTextBlock", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "alpau_EugenePodsiadloMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Eugene Podsiadlo [Member]", "terseLabel": "Eugene Podsiadlo [Member]" } } }, "localname": "EugenePodsiadloMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirationOfOverallotmentOption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability expiration of overallotment option.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Expiration Of Overallotment Option", "negatedLabel": "Expiration of overallotment option" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExpirationOfOverallotmentOption", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "alpau_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPartialExerciseOfOverallotmentOption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability partial exercise of overallotment option.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Partial Exercise Of Overallotment Option", "negatedLabel": "Partial exercise of overallotment option" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPartialExerciseOfOverallotmentOption", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "alpau_FairValueOfFounderSharesOnTheGrantDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value of founder shares on the grant date.", "label": "Fair Value Of Founder Shares On The Grant Date", "terseLabel": "Fair value of founder shares on the grant date" } } }, "localname": "FairValueOfFounderSharesOnTheGrantDate", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "alpau_FairValueOfOverallotmentLiabilityAtTheInitialPublicOfferingDate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of overallotment liability at the initial public offering date.", "label": "Fair Value Of Overallotment Liability At The Initial Public Offering Date", "terseLabel": "Fair value of overallotment liability at the initial public offering date" } } }, "localname": "FairValueOfOverallotmentLiabilityAtTheInitialPublicOfferingDate", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_FairValueOfOverallotmentLiabilityMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value of overallotment liability measurement input.", "label": "Fair Value Of Overallotment Liability Measurement Input", "terseLabel": "Fair value of overallotment liability measurement input" } } }, "localname": "FairValueOfOverallotmentLiabilityMeasurementInput", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueOfTheOverallotmentLiabilityDetail" ], "xbrltype": "decimalItemType" }, "alpau_FairValueOfOverallotmentLiabilityPartiallyExtinguishedUponExerciseOfOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of overallotment liability partially extinguished upon exercise of option.", "label": "Fair Value Of Overallotment Liability Partially Extinguished Upon Exercise Of Option", "terseLabel": "Fair value of overallotment liability partially extinguished upon exercise of option" } } }, "localname": "FairValueOfOverallotmentLiabilityPartiallyExtinguishedUponExerciseOfOption", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_FairValueOfOverallotmentLiabilityTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value of overallotment liability term.", "label": "Fair Value Of Overallotment Liability Term", "terseLabel": "Fair value of overallotment liability term" } } }, "localname": "FairValueOfOverallotmentLiabilityTerm", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueOfTheOverallotmentLiabilityDetail" ], "xbrltype": "durationItemType" }, "alpau_FormationGeneralAndAdministrativeExpenses": { "auth_ref": [], "calculation": { "http://www.constellationalpha.com/role/StatementOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Formation, general and administrative expenses.", "label": "Formation, General And Administrative Expenses", "terseLabel": "Formation, general and administrative expenses" } } }, "localname": "FormationGeneralAndAdministrativeExpenses", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "alpau_ForwardPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Forward Purchase Agreement [Member]" } } }, "localname": "ForwardPurchaseAgreementMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_FounderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Founder.", "label": "Founder [Member]" } } }, "localname": "FounderMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_FounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Founder shares.", "label": "Founder Shares [Member]" } } }, "localname": "FounderSharesMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_GainOnExpirationOfOverallotmentOption": { "auth_ref": [], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.constellationalpha.com/role/StatementOfOperations": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on expiration of overallotment option.", "label": "Gain On Expiration Of Overallotment Option", "negatedLabel": "Gain on expiration of overallotment option", "terseLabel": "Gain on expiration of overallotment option" } } }, "localname": "GainOnExpirationOfOverallotmentOption", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfCashFlows", "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "alpau_InitialPublicOfferingDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial public offering disclosure.", "label": "Initial Public Offering Disclosure [Text Block]", "verboseLabel": "Initial Public Offering" } } }, "localname": "InitialPublicOfferingDisclosureTextBlock", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/InitialPublicOffering" ], "xbrltype": "textBlockItemType" }, "alpau_InterestAndDividendIncomeNonOperating": { "auth_ref": [], "calculation": { "http://www.constellationalpha.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest and dividend income non operating.", "label": "Interest And Dividend Income Non Operating", "terseLabel": "Dividend and interest income" } } }, "localname": "InterestAndDividendIncomeNonOperating", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "alpau_InvestmentOfCashIntoTrustAccount": { "auth_ref": [], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment of cash into trust account.", "label": "Investment of Cash into Trust Account", "terseLabel": "Investment of cash into trust account" } } }, "localname": "InvestmentOfCashIntoTrustAccount", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alpau_IssuanceCostsOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance costs of warrants.", "label": "Issuance Costs Of Warrants", "terseLabel": "Issuance costs of warrants" } } }, "localname": "IssuanceCostsOfWarrants", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "alpau_LockInPeriodForRedemptionOfPublicSharesAfterClosingOfIpo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lock in period for redemption of public shares after closing of IPO.", "label": "Lock In Period For Redemption Of Public Shares After Closing Of IPO", "verboseLabel": "Lock In Period For Redemption Of Public Shares After Closing Of IPO" } } }, "localname": "LockInPeriodForRedemptionOfPublicSharesAfterClosingOfIpo", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alpau_NonriskIncentivePrivateSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-risk incentive private shares.", "label": "NonRisk Incentive Private Shares [Member]" } } }, "localname": "NonriskIncentivePrivateSharesMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_NoticePeriodOfRedemptionWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notice period of redemption warrant.", "label": "Notice Period Of Redemption Warrant", "terseLabel": "Notice period of redemption warrant" } } }, "localname": "NoticePeriodOfRedemptionWarrant", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alpau_NumberOfAdditionalSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares purchased.", "label": "Number Of Additional Shares Purchased", "verboseLabel": "Number of additional shares purchased" } } }, "localname": "NumberOfAdditionalSharesPurchased", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alpau_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of consecutive trading days for determining the share price.", "label": "Number Of Consecutive Trading Days For Determining The Share Price", "verboseLabel": "Number of consecutive trading days for determining the share price" } } }, "localname": "NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alpau_NumberOfFounderSharesForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of founder shares forfeited.", "label": "Number Of Founder Shares Forfeited", "verboseLabel": "Number of founder shares forfeited" } } }, "localname": "NumberOfFounderSharesForfeited", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alpau_NumberOfSharesAvailableForPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares available for purchase.", "label": "Number Of Shares Available For Purchase", "verboseLabel": "Number of shares available for purchase" } } }, "localname": "NumberOfSharesAvailableForPurchase", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alpau_NumberOfSharesLapsed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares lapsed.", "label": "Number Of Shares Lapsed", "verboseLabel": "Number of shares lapsed" } } }, "localname": "NumberOfSharesLapsed", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alpau_NumberOfTradingDaysForDeterminingTheSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of trading days for determining the share price.", "label": "Number Of Trading Days For Determining The Share Price", "verboseLabel": "Number of trading days for determining the share price" } } }, "localname": "NumberOfTradingDaysForDeterminingTheSharePrice", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alpau_OfferingCostsIncludedInAccruedOfferingsCostsAndExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering costs included in accrued offerings costs and expenses.", "label": "Offering Costs Included In Accrued Offerings Costs And Expenses", "terseLabel": "Offering costs included in accrued offerings costs" } } }, "localname": "OfferingCostsIncludedInAccruedOfferingsCostsAndExpenses", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alpau_OfferingCostsIncurred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering costs incurred.", "label": "Offering Costs Incurred", "verboseLabel": "Offering costs incurred" } } }, "localname": "OfferingCostsIncurred", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_OfferingCostsPaidBySponsorInExchangeForIssuanceOfClassBCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering costs paid by sponsor in exchange for issuance of class\u00a0B common stock.", "label": "Offering Costs Paid By Sponsor In Exchange For Issuance Of Class B Common Stock", "terseLabel": "Offering costs paid by Sponsor in exchange for issuance of Class B common stock" } } }, "localname": "OfferingCostsPaidBySponsorInExchangeForIssuanceOfClassBCommonStock", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alpau_OfferingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for offering costs.", "label": "Offering Costs [Policy Text Block]", "verboseLabel": "Offering Costs" } } }, "localname": "OfferingCostsPolicyTextBlock", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "alpau_OfficeSpaceAdministrativeAndSupportServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office space, administrative and support services.", "label": "Office Space Administrative And Support Services [Member]" } } }, "localname": "OfficeSpaceAdministrativeAndSupportServicesMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_OptionGrantedToDirectAnchorInvestorsToSubscribeToAgreementAsPercentageOfAggregateSecuritiesSoldInOneOrMultiplePrivatePlacements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option granted to direct anchor investors to subscribe to agreement as percentage of aggregate securities sold in one or multiple private placements.", "label": "Option Granted To Direct Anchor Investors To Subscribe To Agreement As Percentage Of Aggregate Securities Sold In One Or Multiple Private Placements", "terseLabel": "Option granted to direct anchor investors to subscribe to agreement as percentage of aggregate securities sold in one or multiple private placements" } } }, "localname": "OptionGrantedToDirectAnchorInvestorsToSubscribeToAgreementAsPercentageOfAggregateSecuritiesSoldInOneOrMultiplePrivatePlacements", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alpau_OptionGrantedToDirectAnchorInvestorsToSubscribeToAgreementPercentageOfAsAggregateSecuritiesSoldInOneOrMultiplePrivatePlacementsPerEachDirectAnchorInvestor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option granted to direct anchor investors to subscribe to agreement percentage of as aggregate securities sold in one or multiple private placements per each direct anchor investor.", "label": "Option Granted To Direct Anchor Investors To Subscribe To Agreement Percentage Of As Aggregate Securities Sold In One Or Multiple Private Placements Per Each Direct Anchor Investor", "terseLabel": "Option granted to direct anchor investors to subscribe to agreement percentage of as aggregate securities sold in one or multiple private placements per each direct anchor investor" } } }, "localname": "OptionGrantedToDirectAnchorInvestorsToSubscribeToAgreementPercentageOfAsAggregateSecuritiesSoldInOneOrMultiplePrivatePlacementsPerEachDirectAnchorInvestor", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alpau_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alpau_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alpau_OtherOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other offering costs.", "label": "Other Offering Costs", "verboseLabel": "Other Offering Costs" } } }, "localname": "OtherOfferingCosts", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_OverAllotmentOptionVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Over allotment option vesting period.", "label": "Over Allotment Option Vesting Period", "verboseLabel": "Overallotment option vesting period" } } }, "localname": "OverAllotmentOptionVestingPeriod", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alpau_OverallotmentLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Overallotment liability.", "label": "Overallotment Liability [Member]", "terseLabel": "Overallotment liability" } } }, "localname": "OverallotmentLiabilityMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "domainItemType" }, "alpau_OverallotmentOptionVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Over allotment option vesting period.", "label": "Overallotment Option Vesting Period", "verboseLabel": "Overallotment option vesting period" } } }, "localname": "OverallotmentOptionVestingPeriod", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alpau_PaymentOfUnderwritingDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of underwriting discount.", "label": "Payment Of Underwriting Discount", "verboseLabel": "Payment of underwriting discount" } } }, "localname": "PaymentOfUnderwritingDiscount", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_PercentageOfCommonStockIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of common stock issued and outstanding.", "label": "Percentage Of Common Stock Issued And Outstanding", "verboseLabel": "Percentage of common stock issued and outstanding" } } }, "localname": "PercentageOfCommonStockIssuedAndOutstanding", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alpau_PercentageOfOwnershipSharesThroughInitialBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership shares through initial business combination.", "label": "Percentage of ownership shares through initial Business Combination" } } }, "localname": "PercentageOfOwnershipSharesThroughInitialBusinessCombination", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alpau_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of public shares to be redeemed in case business combination is not consummated.", "label": "Percentage Of Public Shares To Be Redeemed In Case Business Combination Is Not Consummated", "verboseLabel": "Percentage of public shares to be redeemed in case business combination is not consummated" } } }, "localname": "PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alpau_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement warrants.", "label": "Private Placement Warrants [Member]" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Proceeds from equity used for funding business combination as a percentage of the total.", "label": "Proceeds From Equity Used For Funding Business Combination As A Percentage Of The Total", "verboseLabel": "Proceeds from equity used for funding business combination as a percentage of the total" } } }, "localname": "ProceedsFromEquityUsedForFundingBusinessCombinationAsAPercentageOfTheTotal", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alpau_ProceedsFromIssuanceOfPrivatePlacementUnit": { "auth_ref": [], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of private placement unit.", "label": "Proceeds From Issuance Of Private Placement Unit", "terseLabel": "Proceeds from issuance of Private Units" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacementUnit", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alpau_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory note.", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public warrants.", "label": "Public Warrants [Member]", "terseLabel": "Public Warrants [Member]" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "alpau_RedemptionOfWarrantsBelowUsDollarNinePointTwoZeroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption Of Warrants Below US Dollar Nine Point Two Zero [Member]", "terseLabel": "Redemption of warrants below $9.20 [Member]" } } }, "localname": "RedemptionOfWarrantsBelowUsDollarNinePointTwoZeroMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_RedemptionOfWarrantsEqualsOrExceedsUsDollarEighteenPointZeroZeroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption Of Warrants Equals Or Exceeds US Dollar Eighteen Point Zero Zero [Member]", "terseLabel": "Redemption of warrants equals or exceeds $18.00 [Member]" } } }, "localname": "RedemptionOfWarrantsEqualsOrExceedsUsDollarEighteenPointZeroZeroMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_RedemptionWarrantsTriggerPriceAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption Warrants Trigger Price [Axis]" } } }, "localname": "RedemptionWarrantsTriggerPriceAxis", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alpau_RedemptionWarrantsTriggerPriceDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption Warrants Trigger Price [Domain]" } } }, "localname": "RedemptionWarrantsTriggerPriceDomain", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_RestrictedInvestmentsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted investments term.", "label": "Restricted Investments Term", "verboseLabel": "Restricted Investments Term" } } }, "localname": "RestrictedInvestmentsTerm", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alpau_RiskIncentivePrivateSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk incentive private shares.", "label": "Risk Incentive Private Shares [Member]" } } }, "localname": "RiskIncentivePrivateSharesMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_ScheduleOfEarningsPerShareBasicAndDilutedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of earnings per share basic and diluted.", "label": "Schedule Of Earnings Per Share Basic And Diluted [Line Items]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedLineItems", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfReconciliationOfNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "alpau_ScheduleOfEarningsPerShareBasicAndDilutedTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of earnings per share basic and diluted.", "label": "Schedule Of Earnings Per Share Basic And Diluted [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTable", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfReconciliationOfNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "alpau_SecuritiesForCapitalWithClosingOfInitialBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities for capital with closing of initial business combination.", "label": "Securities For Capital With Closing Of Initial Business Combination", "terseLabel": "Securities for capital with closing of initial business combination" } } }, "localname": "SecuritiesForCapitalWithClosingOfInitialBusinessCombination", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alpau_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateGrantDateFairValueOfAward": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options aggregate grant date fair value of award.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Grant Date Fair Value Of Award", "terseLabel": "Aggregate grant date fair value of the award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateGrantDateFairValueOfAward", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_SponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sponsor.", "label": "Sponsor [Member]" } } }, "localname": "SponsorMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_StockIssuanceCostAllocationBasedOnDerivativeFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock issuance cost allocation based on derivative fair value.", "label": "Stock Issuance Cost Allocation Based On Derivative Fair Value", "terseLabel": "Stock issuance cost allocation based on derivative fair value" } } }, "localname": "StockIssuanceCostAllocationBasedOnDerivativeFairValue", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_StockIssuanceCostAllocationBasedOnTemporaryEquityFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock issuance cost allocation based on temporary equity fair value.", "label": "Stock Issuance Cost Allocation Based On Temporary Equity Fair Value", "terseLabel": "Stock issuance cost allocation based on temporary equity fair value" } } }, "localname": "StockIssuanceCostAllocationBasedOnTemporaryEquityFairValue", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_StockIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock issuance costs.", "label": "Stock Issuance Costs", "verboseLabel": "Stock issuance costs" } } }, "localname": "StockIssuanceCosts", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_TemporaryEquityStockIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issuance costs.", "label": "Temporary Equity Stock Issuance Costs", "terseLabel": "Temporary equity stock issuance costs" } } }, "localname": "TemporaryEquityStockIssuanceCosts", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "alpau_TemporaryEquityStockSharesIssuedDuringThePeriodShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock shares issued during the period shares.", "label": "Temporary Equity Stock Shares Issued During The Period Shares", "terseLabel": "Issuance of Class A Common stock, net of issuance costs of $9,905,857 (Shares)" } } }, "localname": "TemporaryEquityStockSharesIssuedDuringThePeriodShares", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "alpau_ThirdTradingDayPriorToDateOnWhichCompanyNoticeOfRedemption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third trading day prior to date on which company notice of redemption.", "label": "Third Trading Day Prior To Date On Which Company Notice Of Redemption", "terseLabel": "Third trading day prior to date on which company notice of redemption" } } }, "localname": "ThirdTradingDayPriorToDateOnWhichCompanyNoticeOfRedemption", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alpau_ThreeIndependentDirectorNomineesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Three Independent Director Nominees [Member]" } } }, "localname": "ThreeIndependentDirectorNomineesMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_TransactionCostsIncurred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transaction costs incurred.", "label": "Transaction Costs Incurred", "terseLabel": "Transaction costs incurred" } } }, "localname": "TransactionCostsIncurred", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_UnderwritingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriting agreement.", "label": "Underwriting Agreement [Member]" } } }, "localname": "UnderwritingAgreementMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_UnderwritingFeesIncurred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Underwriting fees incurred.", "label": "Underwriting Fees Incurred", "terseLabel": "Underwriting fees incurred" } } }, "localname": "UnderwritingFeesIncurred", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_UnderwritingFeesPayableUponTheConsummationOfBusinessCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Underwriting fees payable upon the consummation of business combination.", "label": "Underwriting Fees Payable Upon The Consummation Of Business Combination", "terseLabel": "Underwriting fees payable upon the consummation of business combination" } } }, "localname": "UnderwritingFeesPayableUponTheConsummationOfBusinessCombination", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alpau_VolumeWeightedAveragePriceOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Volume weighted average price of shares.", "label": "Volume Weighted Average Price Of Shares", "verboseLabel": "Volume weighted average price of shares" } } }, "localname": "VolumeWeightedAveragePriceOfShares", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "alpau_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Waiting period after which the share trading days are considered.", "label": "Waiting Period After Which The Share Trading Days Are Considered", "terseLabel": "Waiting period after which the share trading days are considered" } } }, "localname": "WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alpau_WeightedAverageNumberOfShareOutstandingStockSubjectToPossibleRedemptionBasic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average number of share outstanding stock subject to possible redemption basic.", "label": "Weighted Average Number Of Share Outstanding Stock Subject To Possible Redemption Basic", "terseLabel": "Weighted average shares outstanding of Class A common stock subject to possible redemption" } } }, "localname": "WeightedAverageNumberOfShareOutstandingStockSubjectToPossibleRedemptionBasic", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "sharesItemType" }, "alpau_WilliamWoodwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "William Woodward [Member]", "terseLabel": "William Woodward [Member]" } } }, "localname": "WilliamWoodwardMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alpau_WorkingCapitalLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Working capital loan.", "label": "Working Capital Loan [Member]" } } }, "localname": "WorkingCapitalLoanMember", "nsuri": "http://www.constellationalpha.com/20211231", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r388", "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r388", "r389", "r390" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r388", "r389", "r390" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r388", "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r388", "r389", "r390" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_MaximumMember": { "auth_ref": [ "r153", "r165", "r192", "r193", "r308", "r309", "r310", "r311", "r312", "r313", "r332", "r359", "r360", "r383", "r384" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r153", "r165", "r192", "r193", "r308", "r309", "r310", "r311", "r312", "r313", "r332", "r359", "r360", "r383", "r384" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r153", "r165", "r190", "r192", "r193", "r308", "r309", "r310", "r311", "r312", "r313", "r332", "r359", "r360", "r383", "r384" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r153", "r165", "r190", "r192", "r193", "r308", "r309", "r310", "r311", "r312", "r313", "r332", "r359", "r360", "r383", "r384" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r59", "r60", "r61", "r62", "r63", "r64", "r65", "r66", "r67", "r69", "r70", "r71", "r72", "r73", "r74", "r86", "r119", "r120", "r210", "r238", "r259", "r260", "r261", "r262", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r402", "r403" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r59", "r60", "r61", "r62", "r63", "r64", "r65", "r66", "r67", "r69", "r70", "r71", "r72", "r73", "r74", "r86", "r119", "r120", "r210", "r238", "r259", "r260", "r261", "r262", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r402", "r403" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r109", "r292" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r14", "r210", "r298" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "verboseLabel": "Additional\u00a0paid-in\u00a0capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r59", "r60", "r61", "r207", "r208", "r209", "r260" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Changes in current assets and liabilities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r194", "r196", "r212", "r213" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Capital contribution by the Sponsor through transfer of Class B shares" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r179", "r186" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "verboseLabel": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r150", "r179", "r186" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of Public Warrants, net of issuance costs of $239,247" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdministrativeFeesExpense": { "auth_ref": [ "r291" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.", "label": "Administrative Fees Expense", "terseLabel": "Administrative fees" } } }, "localname": "AdministrativeFeesExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r196", "r203", "r211" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r53", "r101", "r103", "r107", "r117", "r137", "r138", "r139", "r141", "r142", "r143", "r144", "r145", "r146", "r148", "r149", "r249", "r253", "r276", "r296", "r298", "r347", "r353" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r28", "r53", "r117", "r137", "r138", "r139", "r141", "r142", "r143", "r144", "r145", "r146", "r148", "r149", "r249", "r253", "r276", "r296", "r298" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Assets Held-in-trust, Noncurrent", "terseLabel": "Marketable securities held in trust account" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalUnitsMember": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Type of ownership interest in a corporation. Class of capital units or capital shares.", "label": "Capital Units [Member]", "terseLabel": "Units, each consisting of one share of Class A Common Stock and one-fourth of one Redeemable Warrant [Member]" } } }, "localname": "CapitalUnitsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r19", "r298", "r371", "r372" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r19", "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash - end of the period", "periodStartLabel": "Cash - January 21, 2021 (inception)" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net Change in Cash" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r9", "r48", "r346" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Marketable Securities Held in Trust Account" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "verboseLabel": "FDIC Insured Amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "verboseLabel": "Supplemental Disclosure of cash flow information:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r51", "r53", "r77", "r78", "r79", "r81", "r83", "r88", "r89", "r90", "r117", "r137", "r142", "r143", "r144", "r148", "r149", "r163", "r164", "r168", "r172", "r276", "r392" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet", "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/CoverPage", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfReconciliationOfNetLossPerShareDetail", "http://www.constellationalpha.com/role/StatementOfCashFlows", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical", "http://www.constellationalpha.com/role/StatementOfOperations", "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r188", "r195" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise price of warrant" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r25", "r135", "r349", "r356" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "Commitments and Contingencies (Note 5)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r132", "r133", "r134", "r136", "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments\u00a0& Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet", "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/CoverPage", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfReconciliationOfNetLossPerShareDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical", "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet", "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/CoverPage", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfReconciliationOfNetLossPerShareDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical", "http://www.constellationalpha.com/role/StatementOfOperations", "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r59", "r60", "r260" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock par or stated value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r179" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscribedButUnissued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock, Shares Subscribed but Unissued", "verboseLabel": "Common Stock, Shares Subscribed but Unissued" } } }, "localname": "CommonStockSharesSubscribedButUnissued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r298" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock value" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r93", "r352" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "verboseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r54", "r234", "r241" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Current" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r54", "r234", "r241" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "Current" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r155" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "verboseLabel": "Debt Instrument, Convertible, Warrants issued" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r152", "r156" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "verboseLabel": "Warrants issued price per warrant" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r151", "r157", "r158", "r284", "r285", "r286" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "verboseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "verboseLabel": "Deferred underwriting commission" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r54", "r235", "r241" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Deferred" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r54", "r235", "r241" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "Deferred" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r226" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax asset" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r228" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax asset, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r232", "r233" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r227" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance", "terseLabel": "Deferred Tax Assets, Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r21", "r57", "r140", "r142", "r143", "r147", "r148", "r149", "r290" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "verboseLabel": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "verboseLabel": "Basic and diluted net loss per share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfReconciliationOfNetLossPerShareDetail", "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r84", "r85" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Common Stock share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r55", "r219", "r242" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanySEffectiveTaxRateDetail": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanySEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r219", "r242" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanySEffectiveTaxRateDetail": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanySEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r219", "r242" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanySEffectiveTaxRateDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanySEffectiveTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r204" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation expense related to unvested founder shares" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r32", "r33", "r34", "r59", "r60", "r61", "r63", "r70", "r73", "r87", "r118", "r179", "r186", "r207", "r208", "r209", "r237", "r238", "r260", "r277", "r278", "r279", "r280", "r281", "r282", "r361", "r362", "r363", "r403" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CoverPage", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "verboseLabel": "Equity Method Investment, Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r263", "r264", "r265", "r274" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r263", "r264", "r265", "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of Fair Value Measurements, Recurring and Nonrecurring" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueOfTheOverallotmentLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueOfTheOverallotmentLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of Fair Value of the Overallotment Liability" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r263", "r264", "r267", "r268", "r275" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsQuantitativeInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]" } } }, "localname": "FairValueInputsQuantitativeInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r269", "r274" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r269", "r274" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Changes in Level\u00a03 Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r270" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value of overallotment liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r271" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Issuance of overallotment option" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r269" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r272", "r275" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Federal" } } }, "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r154", "r177", "r258", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r55", "r220", "r224", "r230", "r239", "r243", "r245", "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r56", "r72", "r73", "r100", "r218", "r240", "r244", "r358" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income Tax Expense", "totalLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r31", "r216", "r217", "r224", "r225", "r229", "r236" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r45" ], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r45" ], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r36" ], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "negatedLabel": "Interest earned in trust account" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r22", "r53", "r104", "r117", "r137", "r138", "r139", "r142", "r143", "r144", "r145", "r146", "r148", "r149", "r250", "r253", "r254", "r276", "r296", "r297" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r53", "r117", "r276", "r298", "r348", "r355" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Shareholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities and Shareholders' Equity (Deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r24", "r53", "r117", "r137", "r138", "r139", "r142", "r143", "r144", "r145", "r146", "r148", "r149", "r250", "r253", "r254", "r276", "r296", "r297", "r298" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Dividend rate" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueOfTheOverallotmentLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected life (in years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueOfTheOverallotmentLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueOfTheOverallotmentLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueOfTheOverallotmentLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueOfTheOverallotmentLiabilityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueOfTheOverallotmentLiabilityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MinimumNetWorthRequiredForCompliance": { "auth_ref": [ "r376", "r377", "r378", "r379" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of minimum net worth required for mortgage banking as defined by regulatory framework.", "label": "Banking Regulation, Mortgage Banking, Net Worth, Minimum", "verboseLabel": "Minimum Net Worth Required for Compliance" } } }, "localname": "MinimumNetWorthRequiredForCompliance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r42" ], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r42", "r44", "r46" ], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r29", "r30", "r34", "r35", "r46", "r53", "r62", "r64", "r65", "r67", "r68", "r72", "r73", "r80", "r101", "r102", "r105", "r106", "r108", "r117", "r137", "r138", "r139", "r142", "r143", "r144", "r145", "r146", "r148", "r149", "r262", "r276", "r350", "r357" ], "calculation": { "http://www.constellationalpha.com/role/StatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Allocation of undistributable losses/ Net income/(loss) to Common shares", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfReconciliationOfNetLossPerShareDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r20", "r57", "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, Related Parties, Current", "verboseLabel": "Note payable \u2013 related party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r101", "r102", "r105", "r106", "r108" ], "calculation": { "http://www.constellationalpha.com/role/StatementOfOperations": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryovers" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r58", "r75", "r99", "r257" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "verboseLabel": "Organization and Business Operations" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForUnderwritingExpense": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.", "label": "Payments for Underwriting Expense", "verboseLabel": "Payments for Underwriting Expense" } } }, "localname": "PaymentsForUnderwritingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r40" ], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12", "r163" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock par or stated value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12", "r163" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12", "r298" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r130", "r131" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "verboseLabel": "Proceeds from Issuance Initial Public Offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits": { "auth_ref": [ "r37" ], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common limited partners units during the period.", "label": "Proceeds from Issuance of Common Limited Partners Units", "terseLabel": "Proceeds from issuance of Units" } } }, "localname": "ProceedsFromIssuanceOfCommonLimitedPartnersUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "verboseLabel": "Proceeds from Issuance of Private Placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r38" ], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "verboseLabel": "Proceeds from related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r29", "r30", "r34", "r41", "r53", "r62", "r72", "r73", "r101", "r102", "r105", "r106", "r108", "r117", "r137", "r138", "r139", "r142", "r143", "r144", "r145", "r146", "r148", "r149", "r248", "r251", "r252", "r255", "r256", "r262", "r276", "r351" ], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r191", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r191", "r289", "r290", "r293" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "verboseLabel": "Expenses from Transactions with Related Party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r191", "r289", "r293", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r287", "r288", "r290", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r39" ], "calculation": { "http://www.constellationalpha.com/role/StatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Payment to related party", "negatedLabel": "Payment to related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r374", "r375", "r380", "r381" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "verboseLabel": "Marketable securities held in Trust Account" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfFairValueMeasurementsRecurringAndNonrecurringDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r186", "r210", "r298", "r354", "r365", "r370" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 12.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r59", "r60", "r61", "r63", "r70", "r73", "r118", "r207", "r208", "r209", "r237", "r238", "r260", "r361", "r363" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.", "label": "Sale of Stock, Percentage of Ownership before Transaction" } } }, "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Income Tax Provision" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Net Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Net Loss per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Reconciliation of the Federal Income Tax Rate To The Company's Effective Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r197", "r206" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedUnitActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Award and Restricted Unit Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r26", "r51", "r88", "r89", "r159", "r161", "r162", "r163", "r164", "r165", "r166", "r168", "r172", "r177", "r180", "r181", "r182", "r183", "r184", "r185", "r186" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Disclosure [Abstract]" } } }, "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested Outstanding at December 31, 2021", "periodStartLabel": "Unvested Shares Outstanding at January 21, 2021 (inception)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StockBasedCompensationSummaryOfRestrictedStockAwardAndRestrictedUnitActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share Price", "verboseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "verboseLabel": "Shares Issued, Price Per Share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (in Shares)", "periodStartLabel": "Beginning Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r49", "r58" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "State" } } }, "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r11", "r12", "r13", "r51", "r53", "r77", "r78", "r79", "r81", "r83", "r88", "r89", "r90", "r117", "r137", "r142", "r143", "r144", "r148", "r149", "r163", "r164", "r168", "r172", "r179", "r276", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet", "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/CoverPage", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfReconciliationOfNetLossPerShareDetail", "http://www.constellationalpha.com/role/StatementOfCashFlows", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical", "http://www.constellationalpha.com/role/StatementOfOperations", "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r27", "r32", "r33", "r34", "r59", "r60", "r61", "r63", "r70", "r73", "r87", "r118", "r179", "r186", "r207", "r208", "r209", "r237", "r238", "r260", "r277", "r278", "r279", "r280", "r281", "r282", "r361", "r362", "r363", "r403" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CoverPage", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet", "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfCashFlows", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical", "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r59", "r60", "r61", "r87", "r333" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet", "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfCashFlows", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical", "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "disclosureGuidance": "Stock issued during the period shares for services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock Issued During Period, Shares, Issued for Services", "verboseLabel": "Class\u00a0B common stock issued to Sponsor (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r12", "r13", "r179", "r186" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of private placement units (Shares)", "verboseLabel": "Stock shares issued during the period shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Stock issued during the period share based compensation forfeited", "disclosureGuidance": "Forfeiture of Founder Shares related to unexercised portion of underwriter's overallotment option (Shares)", "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited", "terseLabel": "Shares Issued Share Based Payment Arrangement Shares Forfeited", "verboseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r12", "r13", "r179", "r186", "r198" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockSplits": { "auth_ref": [ "r12", "r13", "r179", "r186" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of a stock split.", "label": "Stock Issued During Period, Shares, Stock Splits", "verboseLabel": "Stock Issued During Period, Shares, Stock Splits" } } }, "localname": "StockIssuedDuringPeriodSharesStockSplits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Stock Issued During Period, Value, Issued for Services", "verboseLabel": "Class B common stock issued to Sponsor" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r12", "r13", "r179", "r186" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of private placement units (Value)" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": { "auth_ref": [ "r205" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, Forfeited", "terseLabel": "Forfeiture of Founder Shares related to unexercised portion of underwriter's overallotment option (Value)" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r27", "r179", "r186" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Stock Issued During Period, Value, Stock Options Exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r53", "r110", "r117", "r276", "r298" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total shareholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Shareholders' equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r52", "r164", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r186", "r189" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Shareholder's Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplit": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.", "label": "Stockholders' Equity Note, Stock Split", "verboseLabel": "Stockholders' Equity Note, Stock Split" } } }, "localname": "StockholdersEquityNoteStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r283", "r300" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r283", "r300" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r299", "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/CommitmentsContingenciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/InitialPublicOfferingAdditionalInformationDetail", "http://www.constellationalpha.com/role/OrganizationAndBusinessOperationsAdditionalInformationDetail", "http://www.constellationalpha.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit", "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r137", "r142", "r143", "r144", "r148", "r149" ], "calculation": { "http://www.constellationalpha.com/role/BalanceSheet": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 15,444,103 shares subject to possible redemption issued and outstanding" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r8", "r160" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Temporary Equity, Par or Stated Value Per Share" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Temporary Equity, Shares Authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Temporary Equity, Shares Issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Temporary Equity, Shares Outstanding", "verboseLabel": "Temporary equity shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/BalanceSheetParenthetical", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Class A Common stock, net of issuance costs of $9,905,857 (Value)" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/StatementOfChangesInShareholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115", "r154", "r177", "r258", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r215", "r223" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits", "verboseLabel": "Unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits income tax penalties and interest accrued", "verboseLabel": "Accrued for interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r91", "r92", "r94", "r95", "r96", "r97", "r98" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r228" ], "calculation": { "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedLabel": "Change in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/CoverPage", "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "verboseLabel": "Warrants and rights outstanding term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/ShareholderSEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average shares outstanding, basic and diluted", "verboseLabel": "Basic and diluted weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesScheduleOfReconciliationOfNetLossPerShareDetail", "http://www.constellationalpha.com/role/StatementOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).", "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation", "verboseLabel": "Weighted average shares subject to forfeiture" } } }, "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.constellationalpha.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r257": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r295": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Footnote 11(c)))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r385": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r386": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r387": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r388": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r389": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r390": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r391": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r392": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r393": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r394": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r395": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r396": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r397": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r398": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r399": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r400": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r401": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" } }, "version": "2.1" } ZIP 56 0001193125-22-106907-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-106907-xbrl.zip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end